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ABSTRACT 
 
DESIGN AND SYNTHESIS OF NOVEL BENZIMIDAZOLES AND 
AMINOTHIAZOLES AS SMALL MOLECULE INHIBITORS OF CDK5/p25 
 
 
 
 
By 
Prashi Jain 
December 2011 
 
Dissertation supervised by Dr. Patrick T Flaherty 
This dissertation describes the design, synthesis and biological evaluation of 
novel CDK5/p25 small molecule inhibitors.  Cyclin dependent kinase 5 (CDK5) is a 
proline-directed serine/threonine kinase which plays an important role in the pathology of 
Alzheimer's disease (AD). CDK5/p25 has been implicated in hyperphosphorylation of tau 
protein which forms neurofibrillary tangles (NFTs), a contributing factor to the pathology 
of Alzheimer's disease (AD). Based on the deposited X-ray crystal structure of 
CDK5/p25 with a non-selective CDK inhibitor R-Roscovitine (PDB ID: 1UNL), eight 
series of novel compounds with a benzimidazole core were designed, synthesized and 
tested as inhibitors of CDK5/p25.  An efficient synthesis of trisubtituted benzimidazoles 
was developed to explore the SAR at the 1-, 4-, and 6- positions of the benzimidazole 
core. X-ray crystal structure verification of an intermediate confirmed selective alkylation 
v 
of the N-1 position of the benzimidazole scaffold. Synthesis of N-1, N-4, C6-O, C6-N, 
C6-C and C-2 substituted benzimidazoles were achieved via Mitsunobu coupling, Suzuki 
Miyaura coupling, Buchwald coupling and reductive alkylation strategies. Aminothiazole 
scaffolds are an established class of CDK inhibitors including CDK5. A molecular 
hybridization technique was applied to the design of a series of 2-, 5- disubstituted 
aminothiazoles incorporating structural features of both the Meriolins, natural product 
CDK inhibitors, and known aminothiazole scaffolds. Synthetic techniques employed 
included aryl lithiation, deoxygenation and acylation. 
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CHAPTER ONE 
 
Biochemical Literature Review 
1.1 General review 
The ability of cells to receive and act on signals detected by specific receptors in the 
plasma membrane produces a cellular response. These cellular responses may include a 
chemical change or process alternative to transfer the cellular information within the 
cells. Most signaling pathways begin with the arrival of external cell stimuli usually in 
the form of a chemical signal, which is received by receptors at the cell periphery. These 
receptors then function to transfer information to a variety of transducers and amplifiers 
to produce intracellular messengers. These messengers stimulate the sensors and effectors 
responsible for activating cellular responses.1 (Fig. 1) 
 
Fig. 1: Overview of cell signaling mechanism 
Cell signaling system or signal transduction is important to elicit appropriate responses 
into the cells such as, transmission of nerve signals, responses to hormones and growth 
factors, the senses of sight, light, smell and control of cell cycle/ cell division. Generally, 
2 
cell signaling can be divided into 6 categories: gated ion channel, receptor enzymes, G-
protein coupled receptors, nuclear proteins which binds to steroid receptors, protein 
kinases, and adhesion receptors. The different stages involved in cell signaling include 
interaction of the receptor/enzyme with a signaling molecule, amplification of the signals, 
and integration with other receptor’s input transmission into the cells and finally 
desensitization/adaptation of the receptor to end the response. Desensitization or 
adaptation controls these signaling systems using posttranslational modification of 
receptors, negative feedback circuit and conformational changes in the molecule.2 
 
Cell signaling systems become uncoupled from their designed biological responses 
because of alteration of receptor proteins, alternate pathways activation, and constitutive 
changes of receptor activation and deregulation of signaling transduction by altered 
receptors/enzymes. These undesired variations can pose a serious deregulation of normal 
cellular processes.  
 
1.2 Broad overview of CDK  
1.2.1 Functional Biology: 
Protein phosphorylation regulates many aspects of cellular functions. Eukaryotic protein 
kinases make up an unusually large family of proteins related by a homologous catalytic 
domain (known as the protein kinase domain). The sequenced human genome revealed 
478 distinct kinase genes, offering a rich collection of potential targets for developing 
novel therapeutics for human diseases.3-5  
3 
Recently, the attention has been focused on the protein kinases that drive and control the 
cell cycle. A major class of cell cycle control proteins is the cyclin dependent kinases 
(CDKs). Cyclin dependent kinases (CDK) activate host proteins through phosphorylation 
of most commonly serine or threonine residues using ATP as a phosphate group donor.6 
Cyclin-dependent kinases (CDKs) are proline directed serine/threonine kinases that bind 
to a required cyclin activator protein to become catalytically active. The first CDK to be 
identified were the budding yeast cell cycle regulator CDC28 along with the orthologous 
fission yeast cell cycle regulator cdc2.7 Most CDK family members regulate cell division. 
Some have ancillary roles mediating cellular processes and the roles of several CDKs are 
yet unknown. CDKs 1,2,3,4 and 6 are involved in cell cycle progression and are 
consequently being pursued as therapeutic targets to treat cancer. It has been proposed 
that by blocking cell cycle progression, rapidly dividing cancer cells will hit a cell cycle 
halt and be directed towards apoptotic cell death. CDK5 is a neuronal kinase and its 
cytosolic activation is associated with neurodegeneration.8 CDKs 7-9 are components of 
gene transcription factors and activate RNA elongation by phosphorylating the carboxyl-
terminal domain of RNA polymerase II. The activation of CDK9 may facilitate HIV-1 
and HSV-1 infection and replication, while CDK7 and 8 are involved in gene 
modifications but specific functions are not yet understood.9,10 (Fig. 2) 
 
 
4 
 
 
Fig. 2: Biological functions of CDKs. a) CDKs involved in cell cycle. 6) CDK5 involved 
in neurodegeneration11 c) CDKs are involved in promoting efficient RNA elongation10 
CDK activity is controlled at many levels12, including: (a) association with activating 
cyclin subunits (b) synthesis and degradation of these cyclin subunits (c) posttranslational 
c) 
b) 
a) 
5 
modification on the CDK mediated by phosphorylation and dephosphorylation event (d) 
interaction with natural inhibitors/activators, and e)  autoinhibition by a ‘PSTAIRE’ 
autoinhibitory α-helix. The cyclin subunits association with CDKs result in structural 
changes at the active site and may play an important role in determining substrate 
specificity. CDK activity and cyclin activation or degradation are subject to control by 
activating or deactivating phosphorylations. Some members of the CDK associating 
kinases that may play a regulatory role in controlling the activity of cell cycle CDKs, are 
known as CDK-activating kinases (CAKs). Typically CAKs exert control by 
phosphorylation of the CDKs resulting in structural reorientation of residues near the 
active site. For example, phosphorylation of the Thr-160/161 residue of CDK1 results in 
marked increases in CDK1 activity. Other kinases may effect phosphorylation events that 
result in CDK inactivation. For example, the Wee1/myt1 family kinases modify CDK1 
by phosphorylation of Thr-14 and Tyr-15 resulting in CDK1 inactivation. Two small 
protein families are reported as natural inhibitors of cyclin/CDKs: the p21 gene family 
and p16 gene family6,13. These small α-helical proteins mimic the PSTAIRE auto 
inhibitory loop found within the CDK structure. 
 
CDKs can be viewed as biochemical switches that can adopt at least two extreme 
conformations: an ‘on’ state that is maximally active, and an ‘off’ state that has markedly 
attenuated activity. The catalytic domains of different kinases adopt strikingly similar 
structures when they are in their active form. By contrast, the crystal structures of 
inactive kinase forms have revealed remarkable variation in their inactive kinase domain 
as they adapt a unique conformation in response to specific regulatory proteins or 
6 
domains. Conformational plasticity allows reversible switching between the different 
activity states of kinases and is a central feature of their unique regulatory mechanism.14 
 
In the absence of cyclin, the deactivating helix of CDK (PSTAIRE loop) is rotated in 
such a manner that it is blocking the active site. This is an inhibitory conformation 
assisted by the activation loop. Association of CDKs with an appropriate cyclin subunit 
results in well characterized structural changes of the PSTAIRE loop allowing access to 
the ATP active site and permitting substrate binding. Likewise, activation of the T-loop 
permits adaptation of an active conformation upon cyclin binding. This requires 
phosphorylation of the Thr160 residue of T-loop to stabilize the active conformation of 
most CDKs15. (Fig. 3) 
 
Fig. 3: The regulation of cyclin-dependent kinase (CDK)11,15 
CDK 1, 2, 3, 4, and 6 require phosphorylation of T-loop mediated by CAKs to become 
catalytically active. In contrast, CDK5 and CDK9 do not require phosphorylation of T-
loop to become active. 
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1.2.2 Sequence homology at ATP binding site: The active site of CDK5 was compared 
to and contrasted with the active sites of related CDK’s (1, 2, 4, and 5) and GSK-3β. 
Amino acid residues of CDK2 within a 7.0 Å radius of bound ATP were identified. The 
primary protein sequences for mammalian CDK1, 2, 4, 5 and GSK-3β were then obtained 
and further analyzed.  Manual search of these proteins’ secondary structure followed by 
manual alignment of the primary sequence similarity is shown below. The similarity and 
the differences are highlighted. 
Comparison of the sequences indicates that significant differences exist in the ATP 
binding site residues of the compared CDKs. These differences can be exploited in the 
design of selective inhibitors for CDK5.  
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Sequence homology at ATP binding site: 
A: Glycine rich loop(i10-r24)   “Pstaire” helixloop(g43-l58)      B: Front hinge (61k-l70) 
CDK1    i gegtygvvyk grhkttgqvv amkk  pstair ei    pnivslqdvl     
CDK2    i gegtygvvyk arnkltgevv alkk  pstair ei    pnivklldvi    
CDK4    i gvgaygtvyk ardphsghfv alkv  pistvr ev    pnvvrlmdvc  
CDK5    i gegtygtvfk aknretheiv alkrv  pssalr ei   knivrlhdvl  
GSK3β  i gngsfgvvyq aklcdsgelv aikkv  no Pstaire loop   missing  
  
C: Back hinge (l78-y90)   D: Polar ribose / 3rd Pi site (h124-i134)  E: Non-Polar  ribose/(k141-a150) 
CDK1    ylif eflsmdlkky   rvlhrdlkpq nllidd      ikladfglara f  
CDK2    ylvf eflhqdlkkf  hrdlkpq nllinte         ikladfglara f 
CDK4   tlvf ehvdqdlrty  ivhrdlkpe nilvtsgg   vkladfglari y 
CDK5   lvf efcdqdlkky  hrdlkpq  nlli      klanfglara 
GSK3β dyvp(no correlation to CDK 5) ichrdikpq nllldpd   lklcdfgsak 
 
1.3 Relevance to human disease state 
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that causes 
progressive dementia 16. According to the World Health Organization, an estimated 37 
million people worldwide currently have dementia; Alzheimer’s disease affects about 18 
millions of them.17 Its prevalence approximately doubles every five years after the age of 
60, so one in 10 individuals over 65 years old and nearly half of those over 85 are likely 
to be affected by the disease. The Alzheimer’s Society estimates that the number of 
individuals with Alzheimer disease will approximately double to 34 million by 2025 
worldwide, with approximately 1 million new cases reported per year by 205016.  
Memory loss is often the first sign of cognitive impairment in Alzheimer’s disease, 
followed by aphasia, agnosia, apraxia, and behavioral disturbances. These symptoms are 
explained by a severe and progressive neuronal loss and the progressive appearance of 
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two brain lesions: senile plaques and neurofibrillary tangles (NFTs) 18,19. The appearances 
of these two lesions are diagnostic for post-mortem confirmation of Alzheimer’s disease. 
 
1.3.1 Senile Plaques: Amyloid precursor protein (APP) is not normally neurotoxic, but 
aberrant proteolytic cleavage of amyloid precursor protein (APP) generates Aβ.  The first 
toxic cleavage is carried out by the aspartyl protease β-secretase to generate soluble APP 
(β-APPs) plus a 99-residue membrane associated C-terminal fragment, C99.  
Alternatively, APP can be cleaved by α-secretase, a membrane-associated 
metalloprotease.  This second path generates α-APPs plus an 83-residue membrane 
associated C-terminal fragment, C-83.  A third enzyme, γ-secretase, cleaves the C-99 
generated by β-secretase and produces the neurotoxic peptide Aβ.  Alternatively, γ-
secretase converts C-83 to a benign peptide, p3 (Fig. 4). Known genetic mutations in 
sAPP can result in an increase in aberrant proteolysis, greater amounts of insoluble Aβ, 
faster deposition of β-amyloid plaques, and an earlier onset of cognitive decline. These 
mutations are the Dutch and Swedish double mutations.20,21 Aβ plaques consist of 
precipitated antiparallel beta sheets of the 42 kDa β-amyloid protein. Deposition of the β-
amyloid occurs outside of the neurons.22 Recent evidence suggests that protofibrils of Aβ 
may act via glutamate receptors, cause an influx of Ca+2 and increase tau 
hyperphosphorylation.23 
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Fig. 4. Formation of amyloid plaques (Aβ) 
 
1.3.2 NFTs: Intraneuronally formed neurofibrillary tangles consist predominantly of 
hyperphosphorylated tau protein.  Microtubules are strong cylindrical polymers 
composed of α- and β-tubulin heterodimers that provide structural support to the axons of 
neurons. Tau is the major microtubule-associated protein in neurons and stabilizes 
microtubules via tubulin-binding motifs consisting of an 18 amino-acid residue separated 
by flexible linkers of 13 variable amino acid residues.  Phosphorylation at a number of 
serine/threonine sites on the microtubule-binding repeats of tau protein by certain 
affinity-regulating kinases, including GSK3β, CDK5 and ERK2, reduces tau binding, 
which results in dramatic destabilization of the microtubules. Abnormally phosphorylated 
tau protein becomes dissociated from neuronal microtubules and accumulates in paired 
helical filaments (PHFs). Partial proteolytic processing of tau leads to the formation of 
tau oligomers and insoluble aggregates called neurofibrillary tangles (NFTs).24 (Fig. 5) 
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Fig. 5. Formation of NFTs. 
 
1.3.3 Tau Pathology: Tau is a microtubule-associated protein expressed throughout the 
central nervous system, but predominantly in neuronal axons. In the adult brain, tau 
proteins constitute a family of six isoforms of with 352-441 amino acid length. Tau has 0, 
1 or 2 N-terminal inserts and either 3 or 4 microtubule-binding domains. Tau proteins 
bind primarily to microtubules through repetitive regions in the C-terminal portion. By 
regulating microtubule assembly, tau proteins have a critical role in modulating the share 
and function of neurons  particularly axonal morphology, growth, and polarity25. 
Phosphorylation of the KXGS motifs within the microtubule-binding repeats of tau 
strongly reduces the binding of tau to microtubules in vitro and these studies suggest that 
phosphorylation of Ser262 alone is sufficient to significantly attenuate the ability of tau 
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to bind to microtubules.26 Phosphorylation of two or more KXGS motifs (especially 
Ser262 and Ser356) is required to decrease microtubule binding and facilitate the 
formation of axonal processes in vivo.27 
 
Fig. 6: Isoforms of tau protein28 
Recently, it has been reported that when a specific cyclin-like subunit p25 (present in 
post mitotic neurons), associated with CDK5, hyperphosphorylation of tau and in paired 
helical filament depositions as neurofibrillary tangles (NFTs) result.29 It has been shown 
that CDK5 co-precipitates with the product as NFT’s are formed and deposited.30 
 
1.4 Cyclin Dependent Kinase 5 
1.4.1. Introduction:  Cyclin-dependent kinase 5 (CDK5) was identified almost twenty 
years ago from a bovine brain extract and has since emerged to be unique and different 
than other CDKs with respect to both its function and regulation.31 CDK5 is a unique 
member of the CDKs family. CDK5 is a serine/threonine kinase that phosphorylates its 
substrates at residues immediately upstream of a proline. Although it shares high 
sequence homology (60%) with CDK1 and CDK2, it is not a classic mediator of cell-
cycle transitions but rather controls neuronal development, function, and disease. 30 
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CDK5 may have additional yet uncharacterized roles in nonneuronal cells, including 
endothelial, epithelial, immune, and transformed cancerous  cells.29  
 
1.4.2. Activation: CDK5, like the other CDKs, is primarily regulated by its association 
with a catalytic subunit. In contrast to the classic CDKs, however, the activating subunits 
of CDK5 do not belong to the cyclin family: CDK5 binds to the two non-cyclin proteins 
p35 or p39 as well as to their proteolytically truncated forms p25 and p29.  p35/p25 were 
purified from brain extracts and initially identified as neuron specific 32-34. Although the 
amino acid sequence of p35 markedly differs from that of the cyclins, p35/p25 adopts a 
conformation similar to these conventional activators of CDKs 35. p35 has a short half-
life (20–30 min) and undergoes proteasomal degradation rapidly following 
ubiquitination. Phosphorylation of p35 by CDK5 inhibits its degradation, suggesting an 
autoregulatory feedback loop.36 p39 is also degraded in the proteasome, but at a much 
slower rate than p35.37 In neurons, p35 is present throughout the entire cell including the 
tips of the neuronal processes. The calpain proteolytic product, p25 lacks the 
myristoylation site of its parent p35 and as a result is concentrated in the cell body and 
nucleus of neurons. These properties of p25 have been proposed to cause deregulation of 
CDK5 kinase activity in vivo under high Ca++ influx and cause tau hyperphosphorylation, 
cytoskeletal disruption, and apoptotic death of neurons. Together, these observations 
suggest that excitotoxicity causes calpain-mediated cleavage of p35 to p25 and may be an 
essential event in the pathogenesis of Alzheimer’s disease. It is conceivable that 
CDK5/p25 may be involved in a broad spectrum of other neurodegenerative diseases 
specifically prefrontal dementia and Neiman-Pick disease.35 
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1.4.3. Substrates: CDK5 substrates include the neuron-specific cytoskeletal proteins 
neurofilament and tau, the LIS1- and dynein-associated protein Nudel, the synaptic 
protein Synapsin 1, and the Munc18/Syntaxin1A complex.35,38 
 
1.4.4. Pathological role: CDK5 knock outs in mice result in neuronal abnormalities and 
perinatal death. However, while there is evidence that CDK5 activation promotes cell 
death; the CDK5/p35 complex is neuro-protective. This suggests a conceivable dual role 
for CDK5. Interestingly, abnormal accumulation of p25 occurs as a result of the 
proteolytic cleavage of p35 by calpain, a calcium dependent protease, which is activated 
in AD brains by neurotoxic stimuli. Additionally, CDK5 immunoreactivity is elevated in 
neurons with early NFT deposition. Post-mortem examination of AD patient’s brains 
were also shown to display increased CDK5 activity39.  
The spatial and temporal pattern of CDK5 activation matches that of p35 and p39 
expression, which are primarily present in postmitotic neurons of the central nervous 
system. Targeted disruption of the mouse CDK5 locus results in lethality around birth, 
with severe defects in the lamination of the cerebral cortex, hippocampus, cerebellum 40. 
Disruption of the p35 locus results in a milder phenotype, with inverted lamination of 
neurons in the cortex, defects in fasciculation of axon fibers, and sporadic seizures in the 
adult mice.41 
CDK5 regulates actin dynamics, microtubule stability, cell adhesion, axon guidance, and 
membrane transport through the phosphorylation of a large number of substrates. 
Recently it has been shown that CDK5 can regulate the survival of adult hippocampal 
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neurons and can negatively regulate GSK3β activity through neuregulin/ErbB signaling. 
CDK5 plays a critical role in spinal and cranial motor neuron development. 
 
1.4.5. Activation mechanism: Other CDKs have an inhibitory phosphorylation site at 
Thr14 and Tyr15 targeted by the dual-specific with kinases Wee1 and Myt1. CDK1/2 is 
activated by phosphorylation at Thr161/160 by CAK. In contrast CDK5,  is not 
phosphorylated by Wee1, although the Thr14 residue is conserved and phosphorylation 
of CDK5 at Tyr15 moderately increases CDK5 activity. This is mediated by upstream 
kinases including c-Abelson (c-Abl), and Fyn, which also activates Sema3A signaling. 
(Fig. 7) The functional consequence of CDK5 phosphorlyation at Ser159, which is 
equivalent to Thr161/160 (CDK1/2) is controversial and is under current debate. No clear 
correlation between pSer159 state and observed kinase activity exists at this time.29 An 
important difference between the activation mechanism of CDK5 and that of other 
proline directed Ser/Thr kinases such as ERK2 and CDK2 is that the active loop 
conformation of CDK5 is not stabilized by a requisite phosphorylation of Tyr15 of the T-
loop but by extensive interactions with the regulatory subunit.35 The p25 protein can 
tether the unphosphorylated T loop of CDK5 in the active conformation. Ser159 of 
CDK5, equivalent to the Thr160 from CDK2, contributes to this specificity for the 
CDK5/p35 interaction. Mutation of Ser159 to Thr prevents p35 subunit binding to the 
CDK5. Mutation to Ala159 affects neither binding nor kinase activity. Interaction of p25 
with CDK5 involve Ile153 and Ser159 from the kinase and are critical for activation of 
the enzyme.35 
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Fig. 7: Regulation of CDK5 and CDK2 by phosphorylation.42 
 
1.4.6 Mechanism of CDK5/P25 binding by CDK inhibitors: An improved crystal 
structure has been reported by Mapelli et. al.43 showing the complex of CDK5/p25/with 
roscovitine and aloisine at a resolution of 2.2 Å and 2.3 Å respectively. (Fig. 8) 
Roscovitine stabilizes the unusual collapsed conformation of the glycine rich loop, an 
important site of CDK regulation.  The classical dual mechanism of CDK activation 
consists of the binding of the cyclin box fold (CBF) region of the cyclins and the 
phosphorylation of the activation T-loop by cyclin activating kinases. p25 contains a 
highly divergent CBF domain, which elicit an active conformation of CDK5 in the 
absence of phosphorylation. Deregulation of CDK5 is likely due to the release of 
CDK5/p25 from a membranous compartment, and subsequent hyperphosphorylation of 
substrates most notably tau contributes to the disease state. In particular, abnormal 
phosphorylation of the microtubule-binding protein Tau by regulated CDK5 results in 
formation and deposition of NFTs. 
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Fig 8: Ribbon diagram of CDK5/p25 complex with (R)-roscovitine.43 
 
(R)-Roscovitine, aloisine-A, and indirubin-3-oxime are planar substituted heterocyclic 
rings, highly complementary to the ATP-binding cavity and deriving their affinity mainly 
by burial of their hydrophobic side chains the ATP-binding pocket as well as by 
formation of specific essential hydrogen bonds with the kinase (Figs. 9 and 10). In 
CDK5, the H-bond partners are found on the backbone carbonyl and the amide backbone 
of Cys83, which acts as hydrogen bond acceptor and donor, respectively. This pattern of 
hydrogen bonding is also found in the complexes of CDK2 with several inhibitors, 
including among others purvalanol B, olomoucine, and roscovitine44,45. 
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Fig. 9: Structures of CDK5/p25 Inhibitors 
Roscovitine is a purine derivative (2-(1-ethyl-2-hydroxy-ethylamino)-6-benzylamino- 9-
isopropylpurine) containing an asymmetric carbon (Fig. 9) on the 2-amino linked side 
chain. The R isomer displays higher CDK1 inhibitory activity than the S isomer46. In the 
CDK5/p25 complex, the oxygen of the chiral hydroxyethyl substituent of (R)-roscovitine 
is an hydrogen bond donor to the main chain carbonyl oxygen of Gln130, whereas the 
ethyl group is engaged in hydrophobic interaction with the side chain of Ile10 and Val18. 
Due to its flexibility, the glycine-rich loop of unliganded CDK5 is poorly visualized in 
the x-ray structure with aloisine A and indirubin-3-oxime. Although binding of aloisine-
A and indirubin-3’-oxime do not dramatically move the structure of the glycine-rich loop, 
(R)-roscovitine uniquely induces a restructuring of this mobile element, inducing 
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excellent electron density and results in better glycine rich loop structural resolution over 
this entire segment (Fig. 11). This results from the sidechains of Ile10, Gly11, and Glu12 
participating in hydrophobic interactions with roscovitine, and reduction of solvent 
access to the ATP-binding pocket. The large benzyl substituent of roscovitine protrudes 
into a hydrophobic pocket defined by Ile10 and Phe82 and proximal to the solvent and 
further limits mobility of the glycine rich loop.43. 
 
 
Fig 10: (A) The orientation of (R)-roscovitine (yellow), aloisine-A (orange), and 
indirubin-3’-oxime (blue) in the CDK5 active site after superposition of residues in the 
kinase small lobe. (B) Schematic drawing of CDK5 interaction with the inhibitors 
generated by LIGPLOT 
 
The well-defined structure of the glycine-rich loop also allows the visualization of the 
exact orientation of the Tyr15 aromatic side chain. It fits into the cleft between the 
catalytic site of the kinase and the PSSALRE helix, hydrogen bonding with Lys33 and 
Glu51 (Fig. 11). This position is essentially identical to that adopted by an equivalent 
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CDK2 residue Tyr15 in the crystal structure of the ATP bound CDK2/CyclinA complex 
containing either unphosphorylated  Thr160 (inactive CDK2) or phosphorylated Thr 160 
(active CDK2). 
 
 
 
 
 
 
 
 
 
Fig. 11: Effect of (R)-roscovitine binding on Glycine rich loop. The glycine-rich loop is 
colored in magenta 
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1.5 CDK5 Inhibitors 
1.5.1 Review of prior CDK inhibitors 
Several CDKs inhibitors have been reported in literature. 4,47 
 
Table 1: Pharmcological CDKs Inhibitors48-50 
Inhibitor 
CDK1/Cyclin B 
(µM) 
CDK2/Cyclin A, E 
(µM) 
CDK5/P25
(µM) 
CDK4/Cyclin D 
(µM) 
R-roscovitine 0.45 0.7 0.16 >100 
Aloisine-A 0.15 0.12 0.2 - 
Indirubin-3’-
oxime 0.08 - 0.1 - 
Olomoucine 7 7 3 >1000 
Kenpaullone 0.4 0.68 0.85 - 
Purvanolol A 0.004 0.07 0.075 0.85 
 
1.5.2 CDK inhibitors: Prior medicinal chemistry knowledge 
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Several small molecule CDK inhibitors are known in the literature.6,51-53  Many were 
described in drug-design strategies and include the following feature:  (a) low molecular 
weight (<600); (b) flat, hydrophobic heterocycles; (c) competition for the ATP binding 
site; (d) essential backbone carbonyl H-bond acceptor and H-bond donor motifs utilized 
by the adenine portion of ATP, and (e) optimized hydrophobic interactions. 
 
A high degree of homology within the ATP binding domain of all protein kinases would 
seemingly make the design of selective ATP competitive agents challenging. Indeed 
selectivity over other kinases is and continues to be a major challenge in the kinase arena. 
Replacement of the purine core with other scaffolds has shown promise in obtaining 
selectivity against other kinases. Scaffold modification, particularly, the development of 
new scaffolds is an established strategy to achieve this selectivity. 51,54 
1.5.2.1 Staurosporine and analogs: The ATP-competitive inhibitor staurosporine as a 
natural product isolated from Strepromyces staurosporeus.  Cocrystallization of 
staurosporine with CDK2 provided an insight for key interactions with the backbone of 
hinge region of ATP binding pocket. 55 Additional non-ATP hydrophobic binding region 
were identified where the bis-indole ring binds. (CDK2/cyclin A IC50 = 7 nM, 
CDK4/cyclin D IC50 = 3-10 µM, cAPK IC50 = 8.2 nM.)56 
Problem: Significant CDK inhibitory activities at all CDKs (non-selectivity) have been 
identified. 
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Fig.12: 1) Binding mode of staurosporine. 2) Binding of staurosporine to CDK-2. 
Residues within a 4 Å radius of the staurosporine nucleus in CDK-2 are displayed51 
The hydroxystaurosporine analogue UCN-01 is currently being evaluated in phase 1 
clinical trials as a preferential inhibitior of CDK2 (Fig. 13). It has been shown to induce 
apoptosis in malignant glioma cells, and in gastric and/or breast cancer cells. 
 
Fig. 13: Staurosporine analogues57 
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1.5.2.2 Flavonoids: Several flavonoids have proven to be effective at inhibiting CDKs, 
including the natural products quercetin, flavopiridol, and 2-thioflavopiridol. Quercetin is 
a naturally occurring flavonoid which has shown cardiovascular, anticancer, and 
analgesic effects. Flavopiridol (NSC-649890, L86-8275) utilizes the flavone core while 
introducing additional interaction sites with the incorporation of the piperidine at the 8-
position of the quinoline and by the modification of the pendant 2-aryl group.58 This 
flavone is the most advanced CDK inhibitor, currently in phase II clinical trials for 
refractory myeloma, advanced gastric carcinoma, and highgrade non-Hodgkin’s and 
mantle cell lymphoma. The compound is a nonselective kinase inhibitor showing in vitro 
activity against CDK4, CDK2, CAK (CDK4/cyclin D IC50 = 0.4 µM, CDK2/cyclin A 
IC50 = 0.1 µM, CAK IC50 = 0.3 µM), CDK1 (IC50 = 0.4 µM), and PKC with very slight 
activity for EGF-receptor tyrosine kinase (IC50 = 21 µM) and PKA (IC50 = 122µM).59 
Flavopyiridol has recently been co-crystallized with CDK9 and the basic nitrogen resides 
in the Mg2+ site associated with ATP.60 
Problem: The flavonoids series lack the specificity for CDKs and this causes concern for 
possible undesired side effects in the clinical setting. 
                       
 
Fig. 14: Flavones derivatives 
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1.5.2.3 Purines: The purine ring system is the most common scaffold used in designing 
inhibitors of CDKs as ATP mimics. The initial purine analog olomoucine was showed 
modest potency for CDK1/cyclin B (IC50 = 7 µM), CDK2/cyclin A (IC50 = 7 µM), 
CDK2/cyclin E (IC50 = 7 µM), and CDK5/p35 (IC50 = 3 µM). A second-generation 
purine in which the 2- and 9-substituents were increased in size resulted in roscovitine. 
The SAR around the purine core which led to the discovery of roscovitine is described 
below. This compound showed a 10-fold improved potency for CDK1, CDK2, and 
CDK5. The s Modifications at the 2-, 6-, and 9-positions in an attempt to enhance the 
binding affinity within this series, yielded the purvalanols. Purvalanol A was shown to be 
active at CDK2/cylin E (IC50 = 9 nM) and CDK5/p35 (IC50 = 6 nM). This compound 
displayed selectivity for CDK4/cyclin D1, erk1, PKC, and RAF and other kinases. For 
these purine inhibitors, the 6-amino and N7 ring nitrogen were shown to interact with the 
hinge region in the ATP binding pocket as an H-bond donor and H-bond acceptor 
respectively.  
N
1
2
N
3
4
5
6
N 9
8
N
7
HN
R2
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R= benzyl or 3-hydroxy benzyl is active
dimethyl or 5-hydroxy pentyl maintain the activity
removal of -NH group results in complete loss of activity
R'
R' = Chloro or amino group improvs the activity
2-hydroxyethylamino side chain enhaces the activity by 3-5 fold
2-hydroxyisobutylamino side chain maintains the activity
2-dimethylaminoethylamino or 2-methylamino abolishes activity
R2 = H maintains the activity
methyl, ethyl or isopropyl improves the activity
3-hydroxypropyl reduces the activity by 2 fold
 
Other series also explored variation at the 2, 6, and 9 positions. NU2058 and NU6102 
(Fig. 15) have an oxygen at the 6 position instead of the NH group, thus this series 
presents a flipped binding mode, with N3 and N9 acting as the H-bond acceptor and 
26 
donor. 
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Fig. 15: Purine analogs 
1.5.4 Purine isomers and bioisosteres as CDK inhibitiors: Many interesting 
modifications have been reported from the purine scaffold that maintain CDK-binding 
orientation similar to roscovitine.  These include Pyrazolo [4,3-d]pyrimidine, Pyrazolo 
[1,5-a]pyrimidine, Triazolo[1,5-a]pyrimidine, Pyrazolo[1,5-a]-1,3,5- triazines, 
Imidazo[1,2-a]pyrazines, Imidazo[2,1-f]-1,2,4-triazines. 
1. Pyrimidines: The pyrimidine scaffold can be viewed as a truncated purine scaffold.  
2-Aminopyrimidine retains the capacity to form the multiple hydrogen bonds observed in 
purines. Thus, donor-acceptor-donor motifs can be retained with this scaffold.  NU6027 
is an ATP-competitive inhibitor of both CDK-1 (Ki = 2.5 µM) and CDK-2 (Ki = 2.5 µM) 
HO
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5
Fig. 16: Pyrimidine derivatives
Fig. 17: Analysis of the x-ray structure of NU6027 in CDK
 
The 5-nitroso group of NU6027 was proposed to exhibit an internal hydrogen bond to the 
the 6-NH2 group, resulting in the remaining hydrogen of the 6
geometry for interactions with the hinge backbone.  Based on the x
of NU6027 in CDK-2, the 6-NH
17) 
 
2. Oxyindoles: Indirubin-3-
leukemia treatment Danggui Longhui Wan. Indirubin
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(Fig. 
of CDK5/p25 (IC50 = 0.10 µM) and GSK3
derivatives consistently occupy the ATP binding site
CDK5/p25 complexed with indirubin. 
bond to the carbonyl group oxygen of Glu81.  Also, the carbonyl
the NH of indole exhibit a hydrogen bond donor/acceptor pair with the backbone Leu83.  
N
H
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NH
O
R2
indirubin-3'-monoxide (R1 = NOH, R2 = H)
indirubin-5-sulfonate (R1 = O, R2 = SO3H)
 
Fig. 18: Oxyindole derivatives
 
Fig. 19: Ligand interaction analysis of Indirubin 3
 
 
3. Paullones:   Kenopaullone (9
6(5H)-one) is clearly structurally divergent from previously presented CDK inhibitors.  It 
is of natural product origin. Ketopaullone is a potent inhibitor of CDKs with selectivity 
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-β (IC50 = 0.022 µM).52,53,59 . Indirubin 
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for CDK1, CDK2, and CDK5. It was shown through kinetic analysis that ketopaullone 
exhibits its activity as an ATP competitive inhibitor. 
 
Fig. 20: Paullones derivatives 
4. Aminothiazoles: Several groups have been working on the aminothiazole scaffold to 
develop selective and potent CDK5 inhibitors. 4-Acylamino-1,3-thiazole based inhibitors 
were explored by Larsen, et al.63  Compound 1 was obtained as a lead with HTS from 
known tyrosine protein kinase II inhibitors. Substitutions were explored from this 
scaffold. Compound 2 was identified as having improved potency and selectivity for 
CDK5 (Fig. 21).  
 
Fig. 21 4-acylamino-1,3-thiazole based inhibitors 63 
SAR studies have shown that 5-(1,1-disubstituted benzyl) derivatives are required for 
inhibitory activity and selectivity at CDK5 versus CDK2.  Although the replacement of 
the benzyl group with an aliphatic side chain resulted in loss of activity (IC50 = >100 
µM), larger side chains (PhSCH2, 4-MeO-PhOCH2) were tolerated. Molecular modeling 
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analysis suggests a co-planar arrangement of the thiazole ring and the urea moiety, with 
the thiazole nitrogen situated anti to the urea carbonyl as the preferred orientation (Fig. 
22). This effectively directs the lone pair of the ring nitrogen and the 2-NH hydrogen in 
the same direction. The orientation of this HBA and HBD has been demonstrated to be a 
very effective mimic of the 1-N and 2-NH2 of adenine. 
 
  
Fig. 22: SAR highlights of the 4-acylamino-1,3-thiazole based inhibitors 
   
 
Fig. 23. Low energy conformation of the urea side chain of the 1,3-aminothiazole 3. (2,6-
dichloro benzyl omitted for clarity)63 
 
31 
Helal, et al. 64,65 reported two scaffolds as CDK5/p25 inhibitors: 2-aminothiazole based 
inhibitors and 4-aminoimidazole based inhibitors. The 2- aminothiazole inhibitor 4 was 
discovered through a HTS for CDK5 and was used as the lead compound for the further 
development of a potent and selective CDK5 inhibitor 5 (Fig. 24).64  
 
Fig. 24. 2-Aminothiazole inhibitors 
 
SAR studies identified that cyclobutyl-substitution (IC50 = 25 ± 12 nM) at the C-5 
position of aminothiazole was 3 times more potent than the corresponding isopropyl 
analog (IC50 = 64 ± 12 nM).  Other groups such as cyclohexyl, methyl, and phenyl 
resulted in a marked loss of activity.  Improved potency and selectivity was observed 
with fused heteroaryl acetamide analogs. Moreover, aryl or heteroaryl ureas exhibited 
further improvement in activity (Fig. 25). Possible explanations for this increase in 
potency include contribution of both additional hydrogen bond donor/acceptor 
interactions and additional hydrophobic interactions. 
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Fig. 25. SAR of the 2-aminothiazole inhibitors 
A parallel scaffold utilizing an alternative scaffold 4-aminoimidazole was examined 
based on the observed activity of 4-aminothiazoles.  The key hydrogen bond acceptor and 
donor interactions with Cys83 in the hinge region were retained as shown below (Fig. 
26).65 
 
Fig. 26. 4-Aminoimidazole inhibitors by Pfizer 
 
Similarly, SAR variations were explored for the 4-aminoimidazoles analogous to the 2-
aminothiazoles.  It was observed that the 1-cyclobutyl group was the best substitution for 
4-aminoimidazoles. Based upon molecular modeling, polar functional groups were 
explored at the C-3 position of the 1-cyclobutyl group.  These polar groups were 
proposed to have interactions with the amino side chains Lys33 and Asp144 present in 
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CDK5. The amide group of the 3 position of the cyclobutyl ring resulted in increased 
activity. Also, the cis conformation was shown to be required for potency. The presence 
of 1-naphthyl acetamide side chain afforded the best potency for CDK5 inhibition (Fig. 
27).  
 
 
Fig. 27. SAR of the 4-aminoimidazole inhibitors65 
 
The most recent development in the aminothiazole field is analysis of the X-ray crystal 
structure of 2-aminothiazole (8) with CDK5/p25 as presented by Kosik et. al.66 67 
Analysis of the interactions suggest that the 2,4-diaminothiazole can form 
HBD/HBA/HBD triad with the backbone of Cys83 and Glu81. Subsequent SAR studies 
suggested that the pyridines on the 2-amino group and addition of substituents to the 2- or 
3-position of the phenyl ketone have shown to improve the CDK5 inhibitory activity.  
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Fig. 28: 2,4-Diaminothiazole derivatives 
 
5. Quinazolinones: The 3,4-dihydro-1H-quinazolin-2-ones scaffold is derived 
conceptually from an acyclic urea and was used as the lead structure as detailed below. It 
was proposed that ring-constrained quinazoline inhibitors might mimic the intramolecular 
hydrogen bond between N1 and N3-H of the acyclic urea 9, providing a pre-organization 
of the inhibitor into a U-shaped binding conformation (Fig. 29).68 This would properly 
orient the HBD/HBA functions of the quinazolinones toward the hinge region and mimic 
the adenine moiety of ATP. 
 
 
 
Fig. 29. Quinazolinones as CDK5 inhibitors  
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Initial SAR findings based on this previous hypothesis for the 3,4-dihydro-1H-
quinazolin-2-one derivatives provided validation. Different substitutions at the R1, R2 and 
R3 position of the phenyl ring were subsequently examined.  Aminothiazole side chain 
variations resulted in improved potency compared against heteroaryl groups.  Potency 
was also affected by the position of the nitrogen atom of the pyridyl ring (Fig. 30). Of 
note for this compound is that in this molecule the aminothiazole has a tertiary 2-amino 
substituent. This represents a very different role for the aminothiazole group than in the 
previous class of compounds; here this ring is effectively a spacer remote from the hinge 
region. 
 
Fig. 30. SAR of the 3,4-dihydro-1H-quinazolin-2-one derivatives. 
6. Quinolinones: The quinolin-2(1H)-ones derivatives were also examined as CDK/p25 
inhbitors. The SAR of the ring-constrained quinolin-2(1H)-one scaffold have shown the 
effect of different substitution at the R2, R3, R4 positions of the carbocyclic ring and their 
resultant improvement of activity by a 5-10 fold increase in activity. Amino substitution 
at the R1 position resulted in improved potency compared to the unsubstituted analog. 
Arylsulfone and heteroarysulfone derivatives were more potent than the analogous 4-
pyridyl derivative (Fig. 31).69 
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Fig. 31. SAR of the quinolin-2(1H)-one derivatives. 
7. Diaminopyrimidines: R547 is a diaminopyridine derivative that shows a sub-
nanomolar inhibitory activity for CDK 1, 2, 3, 5 and a nanomolar activity for CDK6 and 
7. X-ray crystallographic analysis of R547 in CDK 2 displayed critical hydrogen bond 
formation of diaminopyrimidine scaffold with Leu83 and Glu81. This compound is 
currently in Phase I clinical trials.70 The orientation the HBD/HBA features for this 2,6-
diaminopyrimidine display that the N-1 pyrimidine nitrogen and 2-NH2 adequately 
mimicks the adenine core of ATP. 
 
Fig. 32: Interactions of R547  
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8. Pyrazole Scaffold: A fragment-based screening technique of  cyclin dependent 
kinase 2 (CDK2) identified that the indazole scaffold can form HBD/HBA pair with 
backbone of Leu83 and Glu81. Further modification of this scaffold led to the 
identification of the multiple kinase inhibitor AT7519 (CDK1-9, GSK3β) , which 
captalizing on the pyrazole scaffold. SAR studies showed that the 1’,1’-disubstituted 
phenyl ring is important for activity and the 3-piperidinyl nitogen increses the activity by 
almost 10-fold.71 (CDK5/p35 IC50 = 13 nM, CDK2/Cyclin A IC50 = 47 nM) 
      
Fig. 33: Structural analysis of AT7519 71,72 
 
9. Pyrazolopyrimidine : SCH 727965 is a pyrazolo[1,5-a]pyrimidine derivative , 
developed by Schering- Plough, that selectively inhibits CDK 1, 2, 5 and 9 with IC50 of 
less than 5 nM. SCH-727965 is highly active in broad spectrum of cancer cell lines, 
causing cell cycle arrest and subsequent apoptosis. The utility of the pyrazolo[1,5-
a]pyrimidine scaffold as a basis for the development of CDK inhibitors that led to the 
discovery of Dinaciclib (SCH 727965), a novel CDK2 inhibitor developed by Merck, 
which was effective at reducing tumor burden in vivo upon oral delivery. Another group 
NHO
HN N
O
N
H
NH
ClCl
AT7519
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at Cephalon73 has reported some work on a series of pyrazolopyrimidines against 
CDK5/p35 and GSK3-β. Compound 10 showed IC50 under 300 nM for CDK5/p35 
complex.73-75 
 
Fig. 34: Pyrazolopyrimidine Derivatives 
10. Pyrrolopyridine:  Meriolins, a series of natural products are pyrrolo[2,3-b]pyridines 
that are structurally related to Variolin B and are highly potent inhibitors of CDKs. 
Meriolins display potent inhibitory activity against multiple cyclin-dependent kinases 
(CDKs) and, to a lesser extent, other kinases (GSK-3β, DYRK1A). The crystal structure 
of Meriolin 5 with CDK2-cyclin A provided insight regarding binding interactions of the 
azaindole moiety in forming critical HBD/HBA pair with backbone of Leu83 and Glu81. 
The pyrimidine moiety interacts with polar cleft formed by Glu51 and Lys33. Subsequent 
SAR studies on the Meriolins led to the discovery of the very potent CDK9 inhibitor 12. 
Some of the meriolins derivatives such as Meriolin 9 were more than 100 fold selective 
for CDK5 compared to CDK2.76 
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Fig. 35: Pyrrolopyridine derivatives 
11. 6-Phenyl[5H]pyrrolo[2,3-b]pyrazines: Aloisine A is a pyrrolo-[2,3-b]pyrazine-
based inhibitor and is a potent inhibitor of CDK-1, 2, and 5 and GSK-3α/β.  It is 1.5 times 
more potent for CDK-2/cyclin A, E versus CDK-5/p25.49 Aloisine A is the most potent 
CDK5/p25 inhibitor in this this class (IC50= 0.16-0.20 µM). It behaves as an ATP-
competitive inhibitor. An x-ray crystal structure of aloisine A with CDK5/p25 is 
known.43 The N4 and N5 of purine ring interact with the backbone amide and oxygen 
atoms of the Cys83, respectively. Additionally, the N1 nitrogen is engaged in an 
hydrogen bonding network involving the side chains of Lys33, Glu51, Asn144, and two 
water molecules.            
 
 
 
 
 
 
 
Fig. 36: Alosine A and interactions with CDK5/p2543 
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CHAPTER TWO 
 
Chemical Literature Review 
 
2.1 Benzimidazole Chemical Class 
2.1.1 Physical properties of benzimidazole 
1H-Benzimidazole (14) is a planar, bicyclic molecule with a benzene ring fused with at 
the 4- and 5- positions of the imidazole core.77 The heterocycle is numbered as indicated 
below:  
 
Fig. 37: 1H-Benzimidazole 
The melting and boiling point characteristics of benzimidazoles closely parallel those of 
the uncondensed imidazoles. In general benzimidazoles are high melting solids (1H-
benzimidazole (14), MP = 170 oC, 1-methyl-1H-benzimidazole, MP = 66 oC). Molecules 
with a free NH proton can display intermolecular hydrogen bonding. This is no longer 
possible when that proton is replaced by an alkyl group as the NH donor is absent. The 
melting and boiling points are therefore lower for N-substituted derivatives. Implicitly 
this confirms the ability of the N3 nitrogen to behave as an H-bond donor.  
Benzimidazoles are much less soluble in water than imidazoles. Benzimidazoles have 
high thermal stability, high aromatic stability, and are resistant to acids, bases, heat, 
oxidation and reduction. The annular NH proton exchange is so fast that only one species 
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is observable on the NMR timescale at ordinary temperatures. As a result 4(7)- and 5(6)- 
substituted benzimidazoles appear to be a single compound until NH substitution by an 
alkyl or other non-exchangeable group blocks the N1, N3 prototropic equilibrium.77-79  
 
Fig. 38: Protonation and deprotonation of benzimidazoles79 
 
The HMO calculation shows that benzimidazole ring is electron deficient as a result the 
following observations follow below.80 
    
Fig. 39: HMO calculated π-electron charges in benzimidazoles and imidazoles. 
 
Electrophilic substitution is favored at the 5- and 7- positions and nucleophilic attack is 
favored at the C2- position. The C2 position of benzimidazole ring is less prone to 
electrophilic attack by a factor of 500 compared with an imidazole ring. Benzimidazole 
has an increased positive charge at 2-position in contrast to the imidazole nucleus, which 
favors the 2-position displacement with hard nucleophile. With increasing aza 
substitution, increases the positive charge on nitrogen and makes the ring more electron 
deficient.  
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Like imidazole, unsubstituted benzimidazole is amphoteric, forming salts with both acids 
and bases. The fused benzene ring decreases the basicity of the aromatic nitrogens by 
(about 1.5 pKa units) and electron withdrawing groups on the carbocyclic portion can 
further reduce the pKa. Benzimidazoles are able to form salts with strong acids such as 
picric acid and HCl, unless there is considerable electron withdrawal effect by 
substituents in which case the pKa of the hetero ring nitrogen drops even lower.81 
 
Table 2: pKa values of Benzimidazoles81 
Substituent pKa in H2O Substituent pKa in 50% aq EtOH 
H 5.53 H 4.98 
1-Me 5.57 1-Me 4.88 
2-Me 6.19 2-NH2 3.37 
4-Me 5.67 5-Cl 3.92 
5-Me 5.81 5-OMe 5.07 
2-Et 6.19 4-OMe 4.98 
5-NH2 6.11 2-Ph 4.51 
5-OH, 1-Me 5.94 4-NO2 3.33 
1-oxide 2.90 5-NO2 2.67 
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2.1.2 Prior use in medicinal chemistry 
The benzimidazole nucleus is common in fungicides, herbicides, and a number of 
veterinary applications. Specific examples include anthelmintics, thiabendazole and 
cambendazole. The benzimdazol-2-amines have potent biological activity (e.g. 
mebendazole, oxfendazole, and benomyl)82,83 and other benzimidazoles are used as 
anticonvulsants, sedatives, immunosuppressants, antitumor agents and antihistamines. In 
particular, benzimidazoles with quinone functionality have marked antitumor activity. 
The compounds are also widely used as dyes and as high temperature polymers.83  One of 
the in vivo naturally ocuuring benzimidazoles is Vitamin B12 or cobalamin, which is a 
water soluble vitamin. The benzimidazole moiety in this vitamin acts as a lone pair donor 
to the cobalt ion cofactor in Vitamin B12.84  
 
2.1.3 Benzimidazole core synthesis77 overview: 
1. Ring closure reactions: This is the most common method to synthesize the 
benzimidazole core and has been extensively surveyed. The common ring synthesis 
method involves cyclization of N-C-C-N and C, N-C-N-C-C, or N-C-C-N-C synthons.   
 
A. Reactions with 1,2-diaminoarenes : Scheme 1 describes the utilization of two N-C 
bond formations to synthesize the benzimidazole core form 1,2- diaminoarenes  and 
carboxylic acid derivatives or equivalents. Reaction conditions include heating the 
diamine with the carboxylic acid (Phillips conditions (HCl)) 85 or use of polyphosphoric 
acid and/or boric acid, with heating under pressure and use of basic conditions.86 
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Scheme 1: Formation of 1-2 and 2-3 bonds 
The major limitation with Phillips conditions is the competition of the amino group with 
the carbonyl group for the acid-catalyst proton, consequently inhibiting the nucleophilic 
addition to that carbonyl group. Replacement of carbonyl group with more reactive 
iminium functionality has been suggested as a possible solution to overcome this 
problem.87 
 
Scheme 2 : Reaction of 1,2- diamine with imidates87 
Ring closure reactions utilizing palladium catalyzed carbonylation of iodobenzene 
followed by base-induced coupling and cyclization with 1,2- diaminoarenes have been 
reported for the synthesis of 2-arylbenzimidazoles.88 
 
Scheme 3: Palladium catalyzed coupling of iodobenzene. 
There is extensive literature on the ring closure synthesis using aldehydes, ketones, β-
diketones, unsaturated species with 1,2-diaminoarenes.77,89 
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B. Reactions with 2-nitroanilines: It is often convenient to use 2-nitroaniline in place of 
1,2-diaminoarene as a substrate in cyclizations, mostly because of the commercial 
availability and ease of handling. 2-Nitroanilines can either be sequentially reduced or 
hydrogenated, then cyclized, or the reduction and cyclization step can be combined into a 
single step to synthesize benzimidazoles. Reported methods include reactions of 2-
nitroanilines with carboxylic acids, alcohols, aldehydes and alkyl halides.90  
 
Scheme 4: Reaction of 2-nitroaniline with orthoesters 
 
C. Formation of one N-C bond: Ring-closure reaction with formation of one N-C bond 
is a common method for the synthesis of benzimidazoles.  Reactions involve formation of 
1-2 or 2-3 bonds are very similar to that form both the 1-2 and 2-3 bonds.  The most 
common reaction type cyclizes a 1,2-diaminoarene in which one of the amino groups has 
been acylated (Scheme 5).91 
 
Scheme 5: Benzimidazole synthesis from 1-(Aroylamino)-2-aminoarene 
D. Formation of 1-5 or 3-4 bonds: These types of reactions are almost entirely restricted 
to arylamidines, arylguanidines, or arylthioureas.92 
46 
 
Scheme 6: Amidine and guanidine cyclization 
2. Ring transformation: Synthetic efforts utilizing benzo-fused five-membered ring 
transformation include the thermolysis of indazoles, rearrangement of benzoxazol-4-
amines, and transformations of benzofuroxan.93 
 
Scheme 7: Conversion of a Benzoxazol-4-amine into a benzimidazole 
There are few examples of ring contraction of benzofused six- and seven-membered 
nitrogen heterocycles to benzimidazoles. Quinoxaline and their N-oxides have been 
utilized frequently in reactions to generate a benzimidazole core. 
 
3. Aromatization: Complete aromatizations of dihydrobenzimidzoles have been 
reported to generate the benzimidazole core. For example, the reaction of 1,2-
diaminoarene with a ketone initially gives the dihydrobenzimidaole, which aromatizes 
fully to a 1H-benzimidazole when heated to elevated temperatures. Usual reagents for 
aromatizations include Raney Nickel, platinum, palladium, and oxidants including MnO2, 
S, Se, CuO. 
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2.1.4 Substituent modification:  
The benzimidazole ring is very stable, resistant to treatment with strong acids, and alkali. 
Catalytic hydrogenation will reduce the fused benzene ring to provide 4,5,6,7-
tetrahydrobenzimidazole. Electrophilic substitutions also occur in the fused benzene ring, 
first, most commonly at the 5(6)- positions. Substituents on the benzimidazole ring can 
substantially modify the substitution orientation. A strong electron donating group at 5-
position will direct electrophiles to the 4-position through mesomeric effects, while a 
strong electron withdrawing group at C5-position will make the C4 or C6 positions more 
prone to nucleophilic attacks. Halogenations at either 1H- benzimidazole or 2-Me 
benzimidazole provide multiple sites for halogenations. 
 
1. Addition reactions: Catalytic hydrogenation normally leads to nonaromatic 
benzimidazole compounds by reducing the fused benzene ring while electrophilic 
additions could lead to salt formation, quaternization, and/or coordination with transition 
metals. 
 
2. Substitution of existing substituents on benzimidazole: Substitution by metals such 
as n-BuLi or tert-BuLi of N1-substituted benzimidazole at low temperatures will provide 
the 2-lithio benzimidazole derivatives, which can react with electrophiles to yield 2-
substituted benzimidazoles.94 
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Scheme 8: Introduction of 2-substituent via Lithiation 
 
Substitution by alkyl or aryl groups via electrophilic substitution is only possible when 
the benzimidazole ring is activated by electron donating groups. Friedel-Crafts alkylation 
does not occur on the benzimidazole ring, because of deactivation of the entire ring 
synthon by the obligate Lewis acid catalyst. There are few examples which deal with 
radical reaction of benzimidazoles for the substitution at the C2 carbon. The alkyl radical 
generated by silver-catalyzed oxidative decarboxylation of a 2-carboxylic acid (initiated 
by ammonium persulfate and followed by homolytic cleavage) can generate 2-alkyl 
substituted benzimidazoles. 
 
 
Scheme 9: 2-Substitution on benzimidaozle core by homolytic methods 
 
Substitution by halogens can be obtained at the most electrophilic C5 position of the 
benzimidazole, but it is difficult to get mono-halogenated benzimidazole products. 
Multiple brominations follow the order of bromination as 5>7>6, 4>2. The fused benzene 
ring makes benzimidazole about 5000 times less reactive to 2-bromination than in the 
case of imidazole.95 
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Scheme 10: Bromination at benzimidazole core 
 
Amination of N1-substituted benzimidazoles at the 2-position can be obtained via 
nucleophilic amination with sodium amide under Tschitschibabin like reaction 
conditions.  
 
Scheme 11: Amination of benzimidazoles 
 
 
 
 
 
 
 
2.1.5 Our Applications 
The chemistry related to (R) roscovitine and analogs will be reviewed and includes the 
reported synthetic schemes for the following: 
1. 4,6- Disubstituted benzimidazoles 
2. 1-Substituted bezimidazole 
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A. 4,6- Disubstituted benzimidazoles 
Sharma and coworkers96 reported the synthesis of 5,7-dibromo-1H-benzo[d]imidazole-2-
thiol, 46 (Scheme 12) and related compounds. Reduction of 45 (Scheme 12) with Raney 
nickel and hydrazine hydrate and subsequent treatment of the resulting diamine with 
carbon disulfide gave the 46 in 50% yield. 
 
Scheme 12:  Synthesis of 5,7-disubstitued 1H-benzo[d]imidazole-2-thiol 
 
Gillespie and colleagues97 reported the synthesis of 6-methoxy-4-nitro-1H-
benzo[d]imidazole 48 (Scheme 13) using 3,4-diamino-5-nitro anisole, 47, formic acid, 
concentrated sulfuric acid and sodium nitrite followed by washing by hot ethanol.   
 
Scheme 13:  Synthesis of 6-methoxy-4-nitro-1H-benzo[d]imidazole. 
Hoover and colleagues98 synthesized 4,6-dichloro-1H-benzo[d]imidazole 52 (Scheme 14)  
by refluxing 5-chloro-3-nitrobenzene-1,2-diamine 49 in formic acid with hydrochloric 
acid for 15-20 minutes, followed by reduction of compound 50 to 51. Diazotization 
followed by chlorination of the amino group of 51 gave 52. 
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Scheme 14:  Synthesis of 4,6-dichloro-1H-benzo[d]imidazole 
 
Knochel and coworkers99 reported a mild synthesis of polyfunctional benzimidazoles by 
the reaction of functionalized nitroarenes with phenylmagnesium chloride (Scheme 15).  
The 4-iodo-2,6-dinitroaniline 54, was prepared by iodination of  2,6-dinitroaniline 53 
with silver sulfate and iodine in ethanol. Compound 54 was treated with (MeO)2CHNMe2 
in toluene at 140 oC to give 55. The resulting protected ortho nitro substituted aniline 55 
was treated with phenylmagnesium chloride to yield the functionalized benzimidazole 56.  
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Scheme 15:  Synthesis of 6-iodo-N,N-dimethyl-4-nitro-1H-benzo[d]imidazol-2-amine 
 
B. 1-substituted Benzimidazoles 100 
Holen and coworkers101 reported the synthesis of N-1 substituted benzimidazoles. 
Appropriate 1,2-diaminoarenes, for example, 57 (Scheme 16) was dissolved in a protic 
solvent and then methyl trichloroacetimidate 58 was added slowly to the solution to give 
compound 59. 
 
Scheme 16:  Synthesis of 1-methyl-2-(trichloromethyl)-1H-benzo[d]imidazole 
 
Leonard and colleagues90 reported the synthesis of benzimidazoles using carboxylic acids 
and ortho esters. N-(2-acetyl-5-(benzylamino)-4-nitrophenyl)acetamide 60 (Scheme 17) 
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was reduced to 61 using Raney Nickel in DMF and ammonia. After reduction, the 
intermediate was taken up in triethyl orthoformate and formic acid then refluxed for 3 h. 
 
Scheme 17:  Reaction of 2-nitroanilines with carboxylic acids and ortho esters 
 
Suschitzky and coworkers102 reported another method for the synthesis of N-1 substituted 
benzimidazoles. Acylation of 62 (Scheme 18) with acetic anhydride gave the acylated 
precursor 63. Heating with phosphoric acid converted 63 to the 1,2-disubstitued 
benzimidazole 64. 
 
Scheme 18:  Benzimidazole formation from N1, N1-disubstitued 1,2-diaminoarenes. 
Confirmation of structure: 
Confirmation of the benzimidazole structures isolated in the course of this work was 
determined by using spectroscopic methods including 1H NMR, 13C NMR, mass 
spectroscopy and by elemental analysis. Melting points of the novel benzimidazole 
analogs synthesized will also be reported. Potentially equivalent products have been 
additionally verified by either x-ray crystallization analysis, or by synthesis by parallel 
non-equivalent routes. 
2.2  Aminothiazole Chemical Class:  
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2.2.1. Biochemical properties of 1,3-thiazole: IUPAC uses the name 1,3-thiazole for the 
heterocycle 65, although the term thiazole is recommended by CAS and is more 
commonly used. All three dihydrothiazoles (thiazolines) 66, 67, and 68 are known. 
Thiazolidine (69) is also known as 2,3,4,5-tetrahydrothiazole. 
 
Fig. 40: Thiazoles and their reduced forms 
Thiazole is a colorless liquid, bp 118.2 °C, with high thermal stability (pyrolysis occurs at 
530°C) which correlates well with theoretical predictions. The heterocycle forms salts 
with acids (e.g., hydrochloride, MP = 138 °C) and is soluble in water and many organic 
solvents.103 
 
Fig. 41: Bond Lengths (nm) and Bond Angles (°) of Thiazole104 
The general conclusions about the electronic structure of thiazole can be made based on 
different theoretical and experimental methods are: (i) the net distributions of a electrons 
at the sulfur atom is positive, whereas the net σ-charge at the sulfer atom is sometimes 
positive or sometimes negative depending on substitution (ii) the total net electron 
distribution on the nitrogen atom is negative, but on C2 the differential  electron 
distribution is slowly positive or close to zero, (iii) the net π-charge is negative. The 
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acidity of the protons bound to the thiazole ring are in the order: H4 < H5 ≤ H2, as 
predicted from their net σ-charges.105 
 
2.2.2. Biochemical properties of 2-Aminothiazole core 
 
When compared with thiazole ring, the main effects of the amino group of 2-
aminothaizole are: to decrease the partial positive character of C-2, increase the electron 
density at N-3, and to increase the electron density C-5. The 5- position has higher 
electron density for 2-aminothiazole than for the thiazoles, resulting in good reactivity at 
5- position by electrophiles.106 
 
Scheme 19: pKa values of 1,3-thiazole 
 
2-aminothiazole is more basic (pKa = 5.28) than thiazole (pKa = 2.52). Ultraviolet 
absorption properties suggest that protonation occurs on the ring nitrogen first. In 
strongly acidic media, the exocyclic nitrogen may preferentially also be protonated. 
Acylation of the 2-amino group lowers the pKa of 2-aminothiazole heterocyclic nitrogen 
by approximately two units. Alkyl substituents at the 4- and 5- position of the ring 
increases the pKa by 1-2 units.106-108 
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Amino–imino tautomerism of 2-aminothiazoles in different solvents has been studied by 
UV spectroscopy. The 2-arylamino derivatives 74  (R1 = Ar) exist in aqueous solution as 
the amine forms, but in the solid state, 2-aryl-substituted thiazol-2-imines 75 (R1 = Ar) 
are preferred. Both thiazol-4-amine and thiazol-4-imine derivatives are known, but 
thiazole-2,4-diamine exists exclusively as the 2-amino-4-imino form 77.103,109 (Scheme 
20) 
 
Scheme 20: Tautomerism in 2-Aminothiazole. 
 
Quantum chemical calculations have been used to evaluate the reactivity of thiazole 
derivatives; the results agree well with those determined experimentally.108The 
conclusions can be summarized as follows: 
Electrophilic reactions: C2<<C4 < C5 
Nucleophilic reactions: C4<<C5 < C2 
Radical reactions: C4 < C5 < C2 
Other electrophiles (e.g., alkyl halides and tosylates) also attack at nitrogen, although the 
rates of such reactions are substituent dependent. However, hydroxy-, sulfanyl-, or 
amino-substituted thiazoles undergo alkylation, depending on reaction conditions, both at 
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the exocyclic or the endocyclic heteroatoms. When the reactions are conducted in the 
absence of a strong base thiazolamines react with alkyl halides to yield mainly 3-
alkylated products. However, in the reaction with acyl or sulfonyl halides, the exocyclic 
amino group behaves as the preffered nucleophile. Thiazol-2-amines substituted at the 
exocyclic nitrogen may arise from 3-substituted thiazol-2-amines by subsequent 
equilibrations that occur under thermodynamic control.103,110 
 
When C2 is substituted, deprotonation by strong organic bases occurs at C5. Thiazolium 
salts can be deprotonated at C2 to form thiazolium-2-ylides which, due to the influence of 
the sulfur atom, are more stable than comparable imidazole or oxazole derivatives. 
Thiazole can be deprotonated at the C2 position using lithium 2,2,6,6-
tetramethylpiperidide. Other organobases have been used and the resulting 
organometallic derivatives react with electrophiles. Some allylic organometallic 
reagents,however,  afford adducts which can react further resulting in ring opened 
products.103,111,112 
 
2.2.3 Prior use in Medicinal Chemistry: 
Although unsubstituted thiazole is not naturally occuring, the thiazole ring occurs in 
many natural products including peptide alkaloids and cyclopeptides incorporating 
unusual amino acids. The biosynthetic origin of this functional group is predominately 
from cyclo dehydration of cysteine and has been extensively explored by Walsh113 as 
often arising from a non-ribosomal peptide synthesis origin. Some thiazoles containing 
natural products exhibit important antibiotic, antifungal properties, antineoplastic, and/or 
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cytotoxic activity. Many thiazoles containing natural products have been isolated from 
marine species.103 Cyclopeptides incorporating thiazole and dihydrothiazole rings also 
have cytotoxic activity and several total syntheses of these compounds have been 
described.114 Related natural products include a powerful cell growth inhibitor, and others 
that have an unusual mechanism of interaction with microtubules. The most important 
natural product containing a thiazole ring is thiamine (vitamin B1, 78, Thiamine 
pyrophosphate) (Scheme 2). Vitamin B1 is most notably employed by transketolase in 
the reversible portion of the pentose phosphate pathway. Its mode of action involve 
thiazole ylide adducts.109 Conformational analyses of some thiamine-related compounds 
have also been performed with the aim of establishing the relationship between their 
topological and biochemical properties.115  
 
Fig. 42: Thiamine pyrophosphate (vitamin B1) 
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2.2.4 Categories for the synthesis of Aminothiazole:  
A. Synthesis by ring closure reaction 
I. Formation of three heteroatom- carbon bonds :  
a. Only a few examples are exist in the literature addressing three heteroatom-
carbon bond formation and one C-C bond formation. 5-aminothiazole-2-carbothioamide 
81 (Scheme 21) is obtained in very low yield by passing gaseous hydrogen sulfide in 
saturated aqueous solution of potassium cyanide.116 
 
Scheme 21: Synthesis of 5-aminothiazole-2-carbothiamide 
b. Enamine 82 can react with sulfur and cyanamide in ethanol at room temperature 
to afford thaizol-2-amines.103 
 
Scheme 22: Thiazol-2-amine from enamines and cyanamide 
 
c. The reaction of an α-bromoketimine with ammonium thiocyanate in acetonitrile 
gave 4-tert-buthylthaizol-2-amine in 90% yield.117 
tBuiPrN
Br
NH4SCN
MeCN
tBuiPrHN
SCN
NH2
NH
S NH
tBuiPrHN
- iPrNH2 N
S
NH2
tBu
86 87 88 89
 
60 
Scheme 23: Synthesis of 4-tert-buthylthaizol-2-amine 
 
II. Formation of two heteroatom- carbon bonds :  
a. Fragments C-C-N-C and S : Fragments C-C-N-C appropriately functionalized at 
the terminal carbon and can undergo ring closure on sulfur using reagents such as 
phosphorus pentasulfide, or Lawesson’s reagent. Other reagents for introducing the sulfur 
atom include elemental sulfur, sulfur dioxide, hydrogen sulfide, thiobenzoic acid, 
thiourea and Davy’s reagent.103 
 
Scheme 24: Synthesis of thiazol-5-amines from 2-isocyanoalkanenitriles. 
b. Fragments S-C-N and C-C: The reaction of α-halo substituted aldehyde or ketones 
with thiourea in polar solvents provide 5- or 4- substituted thiazol-2-amine compounds. 
This is the most common synthetic method of choice for thiazoles ring synthesis. 
Variations utilizing thioamide instead of thiourea exist,118 but danger of explosion on 
larger scale due to the highly exothermic nature of this reaction recommends against this 
specific variation.64,108 
 
Scheme 25: Synthesis of thiazoles from α-substituted aldehydes and thiourea 
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c. Fragments C-C-S and C-N : The cyclization of a C-C-S fragment with a C-N 
reagent is also a convenient method of synthesizing thiazoles. One example includes the 
synthesis of 2,4,5- trisubstituted aminothiazoles from α-sulfanyl ketones with substituted 
nitriles.103 
 
Scheme 26: Synthesis from α-sulfanyl ketones and substituted nitriles 
d. Additional methods : Reactions of α-aminonitriles with carbonyl sulfide, carbon 
disulfide or isothiocyanates afford 5-aminothiazol-2-ols, 5-aminothiazol-2-thiols, 5-
aminothiazol-2-amines respectively.109 This pathway is of good synthetic utility and 
typically is only limited by functional group compatibility during formation of the 
isothiocyanate. 
 
Scheme 27: Synthesis of thiazoles from α-aminonitriles. 
1. Synthesis by ring transformation: Ring transformation can be utilized in the 
synthesis of thiazoles by either ring enlargement of three- or four-membered 
heterocycles, formal exchange of ring atoms with retention of the 5-membered ring size 
and/or ring contraction of 6- or 7- atom heterocycles. This transformation is less common 
due to the preffered ring synthesis presented above. 
2. Aromatization: Many mild ring closure reactions provide a dihydro or tetrahydro 
thiazole, which can be aromatized by dehydration, dehydroamination or aromatization by 
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appropriate oxidization reagents. For example, manganese dioxide is a convenient and 
high yielding reagent as shown in Scheme 28.103 This has been used in more complex 
aromatic compounds in total synthesis of natural products.119,120 Burgess salt has also 
been used for this same conversion. 
 
Scheme 28: Aromatization of thiazolidines. 
B. Synthetic transformations on preformed thiazoles:  
I. Addition reactions to the thiazole scaffold can be converted to quaternary salts 
by N-alkyalation with alkyl halides or alkyl sufonates. The addition of hetero atoms to 
the preformed thiazoles core can readily oxidized to thiazole-3-oxides and thiazole 
ammonium salts.103 
II. Synthesis by substituent modification:  
a. Replacement of hydrogen with deuterium: Thiazoles can be deuterated by 
direct hydrogen-deuterium exchange driven by the primary isotope effect or by full 
deprotonation with organobases followed by anion quench with deuterium oxide.121 
 
Scheme 29: Deuteration of 4-substituted thiazoles 
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Scheme 30: Deuteration of thiazol-2-amines 
b. Replacement of hydrogen with metals: The metallation of thiazoles is an 
important step to functionalize the preformed thiazoles ring with different substituents. 
Replacement of 2-position hydrogen with various metal such as lithium, sodium, or 
potassium, aluminium or zinc has been known in the literature. Lithiation at 5- or 2- 
positions of thiazoles have been discussed later in this review. 
 
c. Replacement of hydrogen with carbon electrophiles: The reactivity of 
thiazoles towards the electrophile has been extensively studied and follow the 
decreasing order of 5>4≥2. The low electron density of the thiazoles ring impedes the 
direct electrophilic attack on the ring, but electron donating substituents on thiazoles 
ring may undergo electrophilic substitutions.103,122 
 
Scheme 31: Reaction of carbon electrophile with thiazoles. 
III. Modification of substituents: This specific section discusses about the 
modification on preformed thiazoles ring, which serves as a synthon for synthesis of 2-
aminothiazole scaffold. 
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a. Tchichibabin reaction: Tchichibabin reaction can be employed to the synthesis 
of 2-aminothiazole. 2-Amino-4-methyl thiazole is formed when 4-methylthiazole is 
heated with sodium amide for 15 h.108 
 
Scheme 32: Tchichibabin reaction 
b. Ammonolysis of 2-halothiazole:  Ammonolysis can be used sometimes for the 
synthesis of 2-aminothiazole derivatives. For example, 2-bromothiazole was used in the 
synthesis of 2-(α-pyridinylamino)thiazoles shown in Scheme 33.123 
 
Scheme 33: Synthesis from 2-halothiazoles 
c. Replacement of a 2-mercapto group:  The reaction of 2-mercapto-4-
phenylthiazole with morpholine yields 2-morpholino-4-phenylthiazole.108 This reaction 
proceeds via attack on the 2-thione, conversion to the imine intermediate, and with 
reversion to the fully aromatized thiazoles. 
 
Scheme 34: Replacement of 2-mercapto group of thiazole 
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d. Mitsunobu coupling: Mitsunobu coupling of 2-amino-5-bromothiazole can be 
utilized to prepare the 2-subtituted aminothiazoles. This demonstrates the acidity of the 
proton of a 2-carbamino group. (Scheme 35) 
e. Suzuki coupling: 5-bromo of aminothiazole can be converted to a boronate salt 
120a using n-BuLi and 2-isoprpoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane, which 
can then participate in  Suzuki-Miyaura cross coupling reactions with a variety of 
appropriate substituted aryl halide.124 
 
Scheme 35: Organometallic coupling of 2-aminothiazole scaffold. 
e. Alternate methods to synthesize 2-amino-substituted thiazoles:  
Hetero- Heck cross coupling reaction: The amino group of 2-aminothiazole can be 
protected with pivalyl group and subsequent hetero-Heck coupling reaction with 
substituted aryl halide can provide 5-substituted 2-aminothiazole. 125 
 
Scheme 36: Hetero-heck cross coupling reaction. 
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f. Metalation: Metalation of the 2-aminothiazoles has been reported in the 
literature64,108,112 and is a very useful strategy for the synthesis of substituted thiazoles. 
In this case, lithiation of the N-substituted 2-aminothizaoles with n-BuLi provided 2 
and 5- lithiated thiazoles, which is quenched into the electophile, in this case substituted 
benzaldehyde. Deoxygenation of the tertiary alcohol with trifluoroacetic acid and 
triethylsilane provided the 2-amino-5-subtitutedbenzyl thiazole products.126 
 
Scheme 37: Metalation of the thiazoles 
g. Halogen Dance: In 2-substituted thiazoles, halogens can be transferred via 
halogen transfer from the 5-position to the 4-position of the thiazole moiety. This 
halogen exchange can be facilitated by selecting strong bases specifically, NaNH2, 
alkoxides, BuLi or LDA. Metal-halogen exchange followed by reaction with 
electrophiles or transition metal cross-coupling reaction has been successfully utilized 
to prepare a variety of 2,4,5-trisubstituted thiazoles as shown in Scheme 38.127 
 
Scheme 38: Halogen dance on thiazole ring 
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h. 2-Amino-4-substituted thiazole:  Reaction of ketones with thiourea in the 
presence of I2 can provide 2-amino-4-substituted aminothiazole.128,129 Presumably this 
proceeds via transient halogenation of methyl of the acetophenone. 
 
Scheme 39: 2-amino-4-substituted thiazole 
i. 2-amino-5-arylthiazole: These can be prepared via bromination of 5-position 
followed by Suzuki coupling with phenyl boronic acid derivative.130 
 
Scheme 40: 2-amino-5-arylthiazole synthesis 
j. Halogenation : The thiazole ring can be halogenated at the 2- and/or 5- positions 
with CCl4 or CBr4.131 The observed reactivity is that the more electron rich 2-carbon 
reacts preferentially with the halogen electrophile first. The next more electron rich 
position, C5, can then be halogenated either by proton abstraction and quenching with 
halide (Scheme 41) or by electrophilic bromination. (not shown) 
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Scheme 41: Halogenation of thiazole at the 2- or 2- and 5- positions 
 
k. 5-Bromo-2-aminothiazole can be replaced with the phenol to provide 5-aryl 
aminothiazoles via a SNAr reaction mechanism. This is facilitated by the presence of a 
strong electron withdrawing group on the phenol.132 
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Scheme 42: Sythesis of 5-aryl aminothiazoles via a SNAr reaction 
 
2.3. Diketopiperazine Scaffold 
Peptides and peptide like structures have an important role in drug discovery process, but 
often suffer poor physical and metabolic properties. Diketopiperazines retain some of the 
structural similarity to peptides yet are relatively stable. As a consequence, their 
appearance in biologically active natural products has inspired medicinal chemist to use 
diketopiperazines to circumvent some of the limitations of peptides. Diketopiperazines 
are easily accessible, chiral, and naturally occurring heterocycles.133 
Diketopiperazine contains a keto piperazine core which are reported in the literature as 
three isomers, 2,3-diketopiperazine (139), 2,5-diketopiperazine (140) and 2,6-
diketopiperazine (141) in all cases they are actually a amide. In this literature review, 
only 2,5-diketopiperazines will be presented.134 
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Scheme 43: Diketopiperazine isomers 
2,5-diketopiperazines (140) are head to tail dipeptide dimers and are a common naturally 
occurring motif. They arise biosynthetically from cycloaddition of di-peptide precurssors. 
Synthetic efforts to synthesize these molecules have utilized a wide range of natural and 
unnatural enantiopure starting materials. 
2.3.1 Synthesis of Diketopiperazines 
 
Scheme 44: 2,5- Diketopiperazine synthesis strategies. 
2.3.1.1 Intramolecular formation of N1-C2 : 2,5-DKP formation via intramolecular 
cyclization of the N1-C2 bond is well represented in the literature and is the preffered 
synthetic strategy as it arises from α-amino acids. One representative example is 
synthesis of compound 147, where the intermediate dipeptide 145 was prepared by 
coupling of two precursor amino acids, N-Boc deprotection under acidic conditions and 
nucleophillic attack of the liberated amino into the methyl ester to give the desired 2,5-
diketopiperazine, in this compound as a 1-hydroxamic acid. 
 
Scheme 45: Intramolecular formation of N1-C2 
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Another example includes the construction of pyrrolopyrazine-1,4-diones as cis-peptidyl 
proline amide mimetics. Bromoester 148 can react with hydrazine to form a seven 
membered complex 149. Dissolving metal reductive cleavage of 149 provided acyl 
hydrazone, an intermediate amino amide, which underwent spontaneous cyclization with 
extrusion of ammonia to provide the desired 2,5-diketopiperazine 150. 
 
Scheme 46: Intramolecular cyclization of 150. 
2.3.1.2. Intramolecular formation of N1-C6 : This is a less common mode of 2,5-
Diketopiperazine  scaffold synthesis. A representative transformation of this sort was 
reported as an oxidative byproduct of proline amide 153. When the prolyl acrylamide 151 
was treated with benzeneselenyl bromide and silver triflate, both the acyclic and cyclic 
selenium adducts resulted from the single electron oxidation. 
 
Scheme 47: Oxidative byproduct of proline amide 
A recent report by Marcaccini et al.135 suggested a rapid two step assembly of 2,5-DKPs, 
in which an acyclic α-haloacetamide amide was prepared via Ugi four component 
coupling strategy. Sonication in presence of alkali provided 2,5-DKPs in an excellent 
86% yield. 
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Scheme 48: Utilization of Ugi reaction136 
2.3.1.3 Tandem formation of N1-C2/C3-N4 : This is the most efficient strategy to 
combine two substituted α-amino acids to form 2,5-diketopiperazines. Ottenheijim et 
al.137 has reported a tandem acylation-condensation reaction of glycinamide with 
pyruvoyl chloride in one pot to provided substituted 2,5-diketopiperazine in 58% yield. 
 
Scheme 49: Tandem formation of N1-C2/C3-N4 
2.3.1.4 Tandem formation of N1-C2/C5-N4 : Another tandem bond-forming strategy with 
simultaneous formation of both amide bonds of a 2,5-diketopiprazine can occur as a one 
pot reaction from an α-amino ester derivative, commonly suffers from low yields and 
yields only symmetrical 2,5-diketopiperazines. Taddei et al.138 reported the dimerization 
of aspartic acid dimethyl ester to produce the corresponding symmetric diketopiperazine 
in 25% yield. 
 
Scheme 50: Tandem formation of N1-C2/C5-N4 
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2.3.1.5 Tandem formation of C2-N1-C6 : Synthesis of 2,5-diketopiperazines  by 
simultaneous formation of the N1-C2 and N1-C6 bonds utilizes primary amine as 
reactants.  An exemplary application of this approach is tandem acylation-alkylation of 
an amine with a α-halo-amide to give the N-substituted diketopiperazines as shown in 
scheme 49. Tronche et al.139 reported the synthesis of 2,5-dioxo-1,4-
diazabicyclo[4.3.0]nonane from trans-hydroxyproline, chloroacetyl chloride and final 
cyclization with benzyl amine to give 167. 
 
Scheme 51: Tandem formation of C2-N1-C6 
 
2.3.1.6 Simultaneous formation of four C-N bonds: This is the most efficient way to 
synthesize of diketopiperazines. The limitation is that the mixture of diketopiperazine 
isomers is often formed. Recently reported literature133 showed that heating equimolar 
amounts of phenethylamine and ethyl chloroacetate generated several products which 
were temperature dependent.  
 
Scheme 52: Simultaneous formation of diketopiperazines 
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2.4 Organometallic coupling reactions: 
Organometallic reactions have found increasing utility as the reaction of choice for the 
formation of aryl and alkyl carbon-carbon and carbon-hetero bonds. This increase in the 
utilization of coupling reactions has been facilitated by rapid developments in ligands and 
catalyst design that aid these reactions.140 These developments have made it possible to 
couple otherwise unreactive haloarenes, and the development of ligand-free Pd catalyzed 
reactions have made it economical to run such reactions. The major issues that limit 
wide-spread usage of organometallic coupling reactions are issues with scalability, cost 
of catalysts, and sensitivity to moisture, ligand and catalyst stability, choice of solvents 
for the reaction and final removal of the metal catalyst from the product mixture.141 
 
2.4.1 Buchwald-Hartwig aminations of heterocycles: Palladium-catalyzed coupling 
reaction of aryl/vinylic halides with amines or amides, due to the Buchwald-Hartwig 
cross coupling reactions. 
 
Scheme 53: Buchwald – Hartwig coupling 
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Scheme 54: Mechanism of Buchwald-Hartwig reaction.89 
The general mechanism of the Buchwald-Hartwig reaction involves initial oxidative 
addition of the palladium (0) species to the aryl/vinyl halide bond to give a trans 
palladium(II)  intermediate X (Scheme 55). When a strong base, such as potassium t-
butoxide is used the t-butoxide anion replaces the halide from the palladium(II) complex 
to form Y1. The amine displaces t-butoxide to generate species Z. For electron deficit 
amines, the amine coordinates with the palladium (II) species in X to form the alternate 
species Y2. Trans- to cis- dehydrohalogenation by the base leads to Z. This intermediate 
then undergoes reductive elimination to regenerate the catalyst palladium(0) species and 
releases the amine containing product. 
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2.4.1.2 Applications: Benzimidazoles 
1. Monguchi142 et al. reported direct oxidative amination of azoles (benzothiazole or 
benzimidazole) via C-H activation by copper catalyst with substituted amines.  
 
Scheme 55: Oxidative amination via C-H activation 
 
2. Shen143 et al. decribed an air- and moisture- stable palladium catalyst, [(CyPF-
tBu)PdCl2], for coupling of heteroaryl halides with variety of primary amines. Reactions 
of aryl halides containing protic functional groups with LiHMDS base instead of NaOtBu 
greatly improve the yield and compatibilities of reactive functional groups. This 
observation presumably results from the stronger base property of LiHMDS with lower 
nucleophilicity. 
 
Scheme 56: Amination of functionalized aryl halide with primary amines. 
 
3. Demattei89 et al. described Buchwald-Hartwig coupling of the electron deficient 
benzimidazole ring with aryl iodide using Xantphos and Pd2(dba)3. 
Xantphos has been shown wide utility as a ligand in Buchwald-Hartwig coupling 
reactions. Xantphos has a bite angle of 111 o144 and belongs to a class of wide-bite angle 
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ligands and have demonstrated pronounced effects on the rate and selectivity of metal 
catalyzed coupling reactions.144 Xantphos is commercially available.  
 
Scheme 57: Buchwald-Hartwig coupling of the benzimidazole core. 
 
2.4.2 Suzuki Miyaura cross coupling : The Suzuki-Miyaura cross coupling reaction145 
is the Pd catalyzed coupling reaction of aryl or vinyl boronic acids with an aryl or vinyl 
halide. This reaction has found wide utility in modern synthetic chemistry due to its mild 
reaction conditions, functional group tolerance, low toxicity of the boronate starting 
materials and the ready availability of  organoboron compounds.146 The boronate 
coupling partners for Suzuki-Miyaura cross coupling reactions include boronic acids, 
boronate esters, and organoboranes. However, difficulties in purification of the boronic 
acids, uncertain stoichiometry, air and moisture instability of boronic acids and cost 
present limitations for the wide applicability of this method.147 
 
Scheme 58: Suzuki- Miyaura cross coupling reaction 
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In contrast to boronate reagents, potassium trifluoroborate salts are air- and moisture 
stable crystalline solids which show greater nucleophilicity than their corresponding 
organoboranes or boronic acid derivatives.147,148 Additionally, they are less easily 
protodeboronated during cross coupling reactions even at elevated temperatures. They are 
easily prepared by boration of a substituted benzyl bromide or by transmetallation from 
an organo-magnesium species in one pot.149  The utility of potassium trifluoroborate salts 
in organometallic coupling has been recently reviewed in the literature.146,148,150-152 
 
2.4.2.1 Applications: 
1. Molander153 et al. reported a Suzuki Miyaura cross coupling of primary boronic 
acids with aryl triflates. An example includes the reaction of p-nitrophenyl triflate with 
methyl boronic acid in the presence of catalytic quantities of PdCl2(dppf).CH2Cl2 with 
potassium carbonate as the base and a THF/H2O mixture as the solvent. The reactions 
proceeded with high yields (> 90%) for electron poor aryl bromides and triflates but 
failed to proceed as well for electron rich aryl bromides and triflates. In certain cases, the 
use of THF without water improved the reaction yields. 
 
Scheme 59: Cross coupling between primary boronic acid and aryl triflates 
 
2. Molander154 et al. also described an improved cross coupling using potassium 
alkyl trifluoroborates with aryl triflates. Reaction of these phenyl triflates with potassium 
benzyltrifluoroborate in presence of 9 mol% of PdCl2(dppf).CH2Cl2, Cs2CO3 as a base 
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and THF/H2O mixture as a solvent gave 91% yield. These reactions demonstrated the 
advantages of using trifluoroborates over boronates including improved yields and ease 
of synthesis of the trifluoroborates. 
 
Scheme 60: Potassium alkyltrifluoroborate with aryl triflates 
 
3. Suzuki155,156 et al. reported the first coupling of aryl triflates with carbon boranes 
in 1993.  Reaction of phenyl triflates with 9-octyl-9-BBN proceed readily in THF at 65 
oC with PdCl2(dppf).CH2Cl2 as the catalyst and K3PO4 as the base in 66 % overall yield. 
 
Scheme 61: Aryl triflate cross coupling with alkyl borate. 
Scope of aminomethylation via Suzuki-Miyaura cross coupling was first reported by 
Molander et al.157 using organotrifluoroborates. Molander et al.157 reported an 
improvement in the scope of coupling reactions using potassium trifluoroborates with 
reactions with aryl triflates, aryl bromides and previously unreactive aryl chlorides. The 
reactions tolerated electron rich and electron poor aryl and heteroaryl electrophiles 
containing various functional groups such as esters, nitriles and aldehydes. It was shown 
that the reaction with alkenyl bromides was extremely substrate dependent. 
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Scheme 62: Suzuki-Miyaura cross coupling of aryl triflate with Potassium N-
(trifluoroboratomethyl)-piperidine 
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CHAPTER THREE 
 
Statement of the Problem 
 
 
3.1 CDK5: Benzimidazole Scaffold 
3.1.1 Goal of the research:  
Our goal is to design and synthesize novel CDK5/p25 small molecule inhibitors with 
enhanced potency and/or selectivity for CDK5/p25 over CDK2 and related kinases. 
Novel CDK5/p25 inhibitors can explore the different scaffolds that would retain the 
critical HBD/HBA interactions with the backbone of the CDK5 displayed by (R)-
roscovitine, a purine analog. After establishing the hydrogen-bonding interactions as a 
basic set, subsequent optimization of the hydrophobic interactions with the glycine rich 
loop and ribose binding pocket of the putative ATP binding site of CDK5. 
 
3.1.2 Hypothesis:  
The conversion of a purine scaffold to a benzimidazole scaffold may retain the essential 
HBD/HBA interaction pair with Cys83 of CDK5/p25 displayed by roscovitine and 
provide a novel scaffold that may display selectivity over other members of the CDK 
family and facilitate exploration of interactions unique to this putative ATP binding 
pocket for CDK5/p25 identified in the x-ray crystal structure of roscovitine/CDK5/p25. 
Ultimately, potent small molecule CDK5/p25 inhibitors could selectively inhibit the 
CDK5/p25 complex, reduce tau hyperphosphorylation, reduce deposition of NFTs, and 
thereby reduce or reverse the neurodegeneration displayed in Alzheimer’s disease. 
81 
3.1.3 Rationale:  
The reported crystal structures of CDK5/p25/roscovitine53 (PDB ID:1UNL) and 
CDK2/cyclin B/roscovitine158 (PDB ID:2A4L) permitted an analysis of similarities and 
differences of CDK2 and CDK5. Analysis of the X-ray crystal structures of both, CDK5 
and CDK2 with MOE 2008.10159 suggest that the hydrogen bonding pattern of 
roscovitine in CDK5 is significantly different from its hydrogen bonding pattern in 
CDK2.160(Fig.46) Additionally, in CDK5 (PDB:1UNL) the floor and top of the purine 
binding region are derived from hydrophobic amino acids Leu133 and Ile10, respectively 
(Fig. 43). This suggests that replacement of the purine scaffold with a benzimidazole 
scaffold should retain key H-bonding patterns and add additonal hydrophobic interactions 
with Ile10 and Leu133.  
        
Fig 43: Roscovitine bound to CDK5/p25. (PDB ID: 1UNL) and (R)-Roscovitine 
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Fig 44: Interaction of (R)-roscovitine in the CDK5 active site. PDB ID: 1UNL. 
Visualized using MOE 2008.10 
 
Analysis of the interaction between R-roscovitine and CDK5 reveals the following 
interactions (Fig. 44): hydrophobic interactions including the interaction of the isopropyl 
moiety with a hydrophobic cleft formed by the phenyl of Phe80, the isopropyl of Val84, 
and the alkyl portion of Lys33.  The flat adenine core is retained within a very 
hydrophobic pocket composed of a top surface (Ile10, Val18, and Phe82) and a bottom 
surface (Val64, Cys83, Leu133, and Ala143).  The ethyl side chain forms a hydrophobic 
interaction with the side chains of Gly11 and Val18.  The benzyl portion of roscovitine 
makes hydrophobic interactions with the side chains of Phe82, Ile10, and the alkyl 
portion of Lys89. Hydrogen bonding interactions include the H-bond donor-acceptor pair 
to the backbone amide of Cys83 (2.81 Å and 3.25 Å respectively). The primary hydroxyl 
acts as a hydrogen bond donor to the backbone acyl of Gln130 (2.83 Å). 
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Fig 45: Structural Changes: (R)-roscovitine to Benzimidazole 
 
Our next strategy was to explore the importance of the exocyclic NH group at C2, which 
forms an essential H-bond with Glu131 of CDK2 but is devoid of well-characterized 
interactions with CDK5. This suggests that replacement of purine with benzimidazole 
and replacement of the exocylic NH at C-2 with O (Fig. 46) would retain H-bonding 
patterns required for CDK5/p25 inhibitory activity and omit an essential H-bonding 
required for CDK2 activity; the exocyclic NH at C-2 normally forms an important H-
bond with Glu131 in CDK2.   
 
 
 
 
 
 
 
Fig 46: Roscovitine bound to CDK2 (interaction chart) 
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3.1.4 Specific goal:  
The specific goal is to design and synthesize seven series of compounds based on the 
previous purine SAR from roscovitine. Topliss analysis and molecular modeling will 
explore the utility of variations at N6-, C6-, O6-, N4-, C2- and N1- positions of the 
benzimidazole core. 
Series 1: Synthesis of C6-O linked benzimidazole series. 
 
The C6-O linked benzimidazole series was designed to explore the proposed ribose 
binding region of the ATP binding pocket of CDK5/p25. Modification of the terminal 
hydroxyl group of 190a with a methoxy will explore the importance of presenting an H-
bond donor or H-bond acceptor to Gln 130. Modification of the ethyl side chain by 
omission or by changing its position or length will explore stepwise variation at this 
position. 
Analysis of these compounds with MOE.2008.10 may provide insight concerning 
interaction of these analogs with the putative ATP binding site. In order to assay the 
ribose binding pocket with new ligands derived from the trimeric complex of 
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CDK5/p25/roscovitine53(1UNL), computer-assisted analog approaches were selected. 
The designed ligands were energy minimized (MMFF94x) and docked using both ‘MOE 
DOCK’ and manual docking in MOE 2008.10159 into the putative ATP binding site from 
the X-ray crystal structure of roscovitine/CDK5/p25 (1UNL). The receptor/ ligand 
complex was brought to an overall local energy minimum (Amber 98) retaining the 
backbone conformation of 1UNL. Ligands were inspected for reasonable interactions 
with the enzyme surface and scored with a principal component analysis scoring 
algorithm developed by the Madura161lab. 
 
Fig. 47 Docked pose of 190a in CDK5 using the London dG scoring algorithm in MOE 
2008.10 (PDB ID: 1UNL) 
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Series 2: Synthesis of the C6-C linked benzimidazole series. 
 
Based on 1UNL, we concluded that the most significant contribution to the binding of 
roscovitine to CDK5 is due to hydrogen bonding between the purine N7 (H-bond 
acceptor) and the exocylic NH at C6 of roscovitine (H-bond donor) with the amide NH 
and the acyl of Cys83, respectively. However, the exocylic NH at C2 are not within 
hydrogen bonding distance of any polar functionality. This suggests that replacement of 
the exocylic NH at C2 with CH2 (Figure 3) could increase the selectivity because the 
exocylic NH at C2 forms an important H-bond with Glu131 of CDK2158 (Figure 4). The 
polar and non-polar ribose binding pocket could be further explored with various 
substitutions from the C6 position of the benzimidazole core. 
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Fig. 48 Docked pose of 191f in CDK-5 using the London dG scoring algorithm in MOE 
2008.10 (PDB ID: 1UNL) 
 
Molecular modeling studies suggested that the C6-phenyl group would have favorable 
van der Waals interactions with the enzyme. These studies indicated that the benzyl side 
chain occupies the pocket where the ethyl side chain of roscovitine normally resides. 
 
Series 3: Synthesis of C6-N linked benzimidazole series. 
 
 
 
 
 
The initial two series of compounds synthesized have shown moderate activity against 
the CDK5/p25 enzyme. From the initial biological data we concluded that the 
benzimidazole replacement of the purine core retains some CDK5/p25 inhibitory activity, 
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as elucidated by compound 190a. A polar group acting as an H-bond donor is essential at 
the 6-position of benzimidazole.  The 6-benzyl analogs 191 did not show appreciable 
activitiy against the CDK5/p25 complex.  Capping the terminal alcohol with a methyl 
(190b) was detrimental for the inhibitory activity. Compound 190b is 80 fold less potent 
than (R)-roscovitine.  To determine whether this loss of activity is due to the 
benzimidazole replacement of the purine or the 6-O replacement of 6-NH is we designed 
a series of 6-amino benzimidazoles (189), with retention of the ethyl side chain and 
terminal alcohol.   
 
Fig. 49: Docked pose of 189a in CDK5 using the London dG scoring algorithm in MOE 
2008.10 (PDB ID: 1UNL) 
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Series 4: Synthesis of N4-benzyl substituted benzimidazole series. 
 
 
 
 
 
 
 
 
 
 
 
Initial synthesis and in-vitro biological testing of 190a and 189a verified the 
benzimidazole scaffold as a promising core and led us to design a new series of 
compounds. Thus the benzimidazole core was maintained and new series of C6-O linked 
compounds were designed and synthesized. However, compounds with variations at C6 
position of benzimidazole showed no CDK5/p25 activity. Hence N-1 and N4-substituted 
benzimidazoles were developed to further increase the potency and selectivity. Topliss 
analysis at N4-position of benzimidazole core and molecular modeling analysis suggested 
that this series of compounds could make additional H-bond or hydrophobic interactions 
with the solvent exposed pocket of the putative ATP binding site of CDK5. 
Molecular modeling identified 192 as promising compounds, showing favorable 
interaction at putative ATP binding site of CDK5/p25. Compound 192h is proposed to 
N
N
HN
O
OH
R
192a 2-CH3
192b 3-CH3
192c 4-CH3
192d 2-OMe
192e 3-OMe
192f 4-OMe
192g 2-OH
192h 3-OH
192i 4-OH
192j 2-Cl
192k 3-Cl
192l 4-Cl
192m 2-F
192n 3-F
192o 4-F
192p 2-NO2
192q 3-NO2
192r 4-NO2
192s 2-CF3
192t 3-CF3
192u 4-CF3
192v 2-Pyrido
192w 3-Pyrido
192x 4-Pyrido
192y 3-OEt
192z 4-COOH
192z' 4-tBu
RSeries 4 I
Series 4 II: R = 
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binds in the adenine binding region in the ATP binding pocket and makes critical 
hydrogen bonding interactions from the 4-NH2 and N3 lone pair to the amide backbone of 
Cys83 and Glu130 from the hinge region of the enzyme. The N1-i-Pr group is oriented 
towards the non-polar portion of ribose binding pocket formed by the side chains of 
Val18, Lys33, Val64, Phe80 and Ala143. The 4-N-benzyl group is oriented towards the 
solvent and forms a hydrogen bond between the m-OH of 192h and Glu8 in the hinge 
region of the putative ATP binding site. Substitutions from the N4-benzyl ring are 
presented as compounds in series II and are proposed to form additional polar/ nonpolar 
interaction with amino acids present (Glu8, Lys33 or Asp44) in the putative ATP binding 
site. The terminal hydroxyl at the 2-position maintains the hydrogen bonding interactions 
with Gln130 and Asp144 as has been seen in the docked structures of compounds from 
the other series reported in this document. 
 
Fig. 50: Docked pose of 192h in CDK-5 using the London dG scoring algorithm in MOE 
2008.10  
 
Series 5: Synthesis of N4-phenyl substituted benzimidazole series. 
NH
N
N
192h
O
OH
OH
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The observed SAR of benzimidazole analogs is consistent with the benzimidazole core 
mimicking the purine core with micromolar inhibitory activity against CDK5/p25. The 
next step was to improve the potency of these compounds. Purvalanol A is a purine based 
CDK inhibitor with 75 nM and 70 nM inhibitory activity for CDK5/p35 and 
CDK2/cyclin A respectively.162,163 The only difference between roscovitine and 
purvalanol A is an N-6 phenyl substitution replacing the N-6 benzyl substitution at 
CDK5/p25. Structure activity relationship studies of purvalanol A identified that a 3-
chlorophenyl substitution provided the most potent compound. Based on our previous 
SAR of the benzimidazole core164 and purvalanol163, we proposed a series of compounds 
to further improve the potency of compounds utilizing benzimidazole core. 
 
Fig. 51: Purvalanol A and benzimidzole analog 194b  
In order to explore the ribose binding pocket with new ligands derived from purvalanol, a 
computer-assisted analog design approach was selected. The CDK2/cyclin A/ purvalanol 
N
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O
OH
R
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N
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R
R
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194d 3-OH
R
195a H
195b 3-Cl
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B trimeric structure was obtained (PDB ID 1CKP).162 The purvalanol A structure was 
energy minimized (MMFF94x), aligned with the reported ligand and docked in crystal 
structure of CDK2/cyclin A (1CKP) using MOE 2008.10.159  In a parallel manner the 
designed ligands were energy minimized (MMFF94x) and docked using MOE 2008.10  
into the putative ATP binding site on the X-ray crystal structure of CDK5/p25/roscovitne 
(1UNL)53. The receptor/ ligand complex was brought to an overall local energy minimum 
retaining the backbone conformation of 1UNL. Ligands were inspected for reasonable 
interactions with the enzyme surface. 
  
Fig. 52:  Purvalanol A docked into the structure of CDK5/p25 (Based on 1UNL) 
N
N
NH
N
N
Purvalanol A
Cl
N
H
OH
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Fig. 53: Benzimidaole analog 194b docked in to the structure of CDK5/p25 
Series 6: Synthesis of C2-N linked benzimidazole series. 
N
N
NH
O
NH N
N
NH
O
NH
OH
196a 196b
 
Compounds 196a-b in Series 6 contain stepwise variations at the 2-position. Literature165-
167
 reports indicate that a polar functionality specifically hydrogen bond donor at the 2-
position of a benzimidazole provides increased activity against its target kinase. Thus, we 
have introduced a 2-amino functionality which is expected to increase CDK5/p25 
potency and/or selectivity by forming a hydrogen bond with the kinase peptide backbone 
specifically Glu81.  
NH
N
N
194b
Cl
O
OH
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Series 7: Synthesis of N-1 substituted benzimidazole series. 
 
Molecular modeling studies suggest that substitutions at the N1-position of the 
benzimidazole scaffold occupy the ribose binding pocket in the kinase active site. This 
site is occupied by substitutions form the 9-position of roscovitine, which overlaps with 
the N1-substitution from the benzimidazole scaffold. Thus, compounds in Series 7, which 
vary at the N1-position, were designed to explore the influence of the N1-substitution on 
potency and/or selectivity against CDK5. The substitutions vary in their bulk and are 
expected to shed light on the importance of bulk at the N1 position of this scaffold. 
 
3.1.5 Results:  
The biological evaluation of Series 1-4 indicates that the terminal –OH group is critical 
for the activity. The position of the ethyl side is also important for CDK5/p25 inhibitory 
activity. The N4-position of benzimidazole is tolerant of different substitutions and favors 
a 3’-benzyl substitution.  At the N-1 position, a cyclopentyl group is better than an 
isopropyl group, while a benzyl group was completely inactive. Compounds from Series 
5-6 have been submitted for biological evaluation.  
Overall, the replacement of the purine core with a benzimidazole moiety has been 
successfully shown to be moderately active against CDK5/p25, while offering the 
95 
possibility for improving the selectivity against other CDKs. Analysis of the phenyl 
variations is pending. 
The absolute requirement for a hydrogen bond donor or terminal –OH group at 
benzimidazole core is consistent with binding at the proposed putative ATP binding site 
of CDK5.  The docking protocols used need essential revision to improve the predictive 
ability for this class of molecules against CDKs specifically CDK5/p25. We addressed 
the issue of improving potency against CDK5/p25 by using purvalanol A as a lead 
compound for Series 5 and replacing the N4-benzyl with N4 phenyl substitution on the 
benzimidazole core. Additional efforts include the introduction of an additional 
heteroatom on the benzimidazole core at 2-carbon in Series 6 to further improve the 
activity as 2-nitrogen may form additional interactions with the CDK5/p25 peptide 
backbone. 
 
 
 
 
 
 
 
 
        
 
Fig 54: Analysis of SAR of benzimidazole scaffold. 
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IC50 = 11 µM 
Selective over CDK1, 4, GSK3β 
 
96 
3.2 CDK5: Aminothiazole Scaffold:  
3.2.1 Goal of the research:  
Our goal is to design a series of compounds based on hybrid structure of known potent 
CDK5/p25 inhibitors with a 2-aminothiazole scaffold and known selective CDK5 
inhibitor the Meriolins, which can inhibit CDK5/p25 complex effectively and selectively. 
This represents an initial stepwise approach from known and validated inhibitors with the 
ultimate goal to replace the aminothiazole scaffold with a more novel central scaffold. 
 
3.2.2 Hypothesis:  
Helal et al.64 and Zong et al.69,168 investigated 2-aminothiazole scaffold as CDK5/p25 
inhibitors with single digit nanomolar inhibition. The phenacyl group was found to be the 
most potent substituent on the 2-amino group, with a cyclic or branched aliphatic groups 
at the 5-position of the aminothiazole scaffold. Meijer et. al.76 discovered the meriolins: 
natural products with pyridopyrrole scaffolds and an aminopyrimidine side chain. These 
were initially identification as CDK5 and CDK2 inhibitors. Some of the meriolin 
derivatives such as Meriolin 9 were more than 100 fold selective for CDK5/p25 
inhibition versus CDK2 inhibition. Based on these literature observations, we designed a 
series of hybrid molecules retaining the 2-aminothiazole core and adding a polar 
sidechain from the 5-position of aminothiazole scaffold to combine the potency of 
aminothiazoles and selectivity of Meriolins. The ribose binding pocket of CDK5/p25 
complex can be explored by polar substitution at 5-position of 2-aminothiazole, and have 
been shown to interact in a cavity formed by Leu33 and Glu51 in case of meriolins to 
provide selectivity to these molecules. 
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3.2.3 Specific Goals:  
The specific goal is to synthesize a series of compounds designed on the basis of 
molecular hybridization of aminothiazole and meriolins and biological evaluation of 
these series of compounds against CDK5 and CDK2 enzymes. Subsequent work is 
currently underway. 
Series 8: Hybridization of aminothiazole and meriolins 
 
 
3.2.4 Rationale:  
The molecular hybridization technique was employed to devise a series of compounds to 
explore the ribose binding portion of putative ATP-binding pocket. Aminothiazole 
compounds have been co-crystallized with the CDK5/p25 complex66,67 and analysis of 
the interactions between 199 and CDK5/p25 revealed that the 2-amino group, N3- and 4-
amino group of 199 form three HBD, HBA and HBD interactions with the backbone 
amides of Cys83 and Glu81 in the  hinge region and the 3-nitrophenyl moiety of 199 
points towards a polar pocket formed by Glu51, Lys33 and Asn144. The p-chlorophenyl 
moiety points towards a hydrophobic cleft formed by Gly11 and Val18 of the glycine rich 
loop which is the same position where the ethyl side chain of R-roscovitine binds. 
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Fig. 55: Interactions of aminothiazole B in the CDK5 active site. PDB ID: 3O0G.  
Meijer et al.76,169 has reported the co-crystallized X-ray crystal structure of meriolin 5 (3-
(Pyrimidin-4-yl)-7-azaindoles) with CDK2 complex. An analysis of interactions of 
meriolin 5 with the CDK2 complex revealed that the azaindole moiety forms critical 
HBD/HBA pair with the backbone of Leu83 and Glu81, while the pyrimidine moiety 
interacts with a polar cleft formed by Glu51 and Lys33.  
 
Fig. 56 Interaction of meriolin 5 in the CDK2 active site76 
Based on the above observations, we proposed molecular hybridization of 2-
aminothiazoles and meriolin 5 (Fig. 57) by retaining the 2-aminothiazole core and its 
199 IC50= 750nM 
Meriolin 5 
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pendant phenacyl moiety at the 2-position of the 2-aminothiazole scaffold and 
introducing the aminopyrimidine moiety or a mimic from meriolins at the 5-position of 
the aminothiazole scaffold to maintain the critical hydrogen bonds with the backbone of 
CDK5/p25 and exploit the polar cleft formed by Glu51, Lys33 and Glu144.  
 
Fig. 57: Molecular hybridization 
The proposed compounds were constructed, energy minimized, and docked using MOE 
2008.11159 into the putative ATP binding site from the X-ray crystal structure of 
CDK5/p25/roscovitne (1UNL)53 The receptor/compound complex was brought to an 
overall local energy minimum (Amber 98) while retaining the backbone conformation of 
1UNL. Ligands were inspected for reasonable interactions with the enzyme surface. The 
hybrid analog 198d docked into CDK5/p25 is shown in Fig. 58. The 2-aminothiazole 
portion of 198d interacts with the backbone of Cys83 while the aminopyrimidine portion 
shows hydrogen bond interactions with Lys33 and Asp144. 
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Fig. 58 Docked pose of 198d in CDK-5 using the  London dG scoring algorithm in MOE 
2008.11 (PDB ID: 1UNL) 
3.2.5 Results: Compounds in this series have been synthesized and characterized and are 
currently undergoing biological evaluation. The results from the biological evaluation 
studies will be reported. 
3.3 CDK5: Diketopiperazine Scaffold: 
3.3.1 Goal of the research: 
Diketopiperazines are a class of natural products and have shown involvement in the 
neuroprotection. The goal of this research is to identify specific target protein in the 
neurodegenration siganlling cascade, which affected by diketopiperazines or related 
structures.  
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3.3.2 Hypothesis: 
Diketopiperazines belong to class of natural products which have demonstrated 
neuroprotective features in cellular models of Alzhiemer’s disease and are implicated in 
neurite outgrowh. These molecules were proposed to function as calpain inhibitors. 
Calpain is involved in the cellular processing of p35 and causes lysis of p35 into p25. The 
synthesis of phevalin-2 has been reported in the literature.170 Enzymatic evaluation of 
phevalin-2 against isolated calpain indicated that phevalin is not a calpain inhibitor. This 
suggests that the neuroprotective actions of phevalin-2 occur due to interactions of 
phevalin-2 with other possibly downstream targets in the calpain signaling pathway. Thus 
CDK5/p25, a downstream target of the calpain pathway, appears to be a potential target 
for diketopiperazines and that has not yet been explored in the literature. Preliminary 
modeling studies suggest that the structure of diketopiperazine easily lends itself to 
binding in the kinase site (discussed below). Thus, it was of interest to synthesize 
dikeotpiperazines to elucidate its molecular target(s) responsible for its neuroprotective 
actions. 
 
3.3.3 Rationale: 
Neurite outgrowth is a key process during neuronal migration and differentiation. 
Complex intracellular signaling is involved in the initiation of neurite protrusion and 
subsequent elongation. Although, in general many constituents of the machinery involved 
in this multi-stage process are common for neurons in distinct brain areas, there are 
notable differences between specific neuronal subtypes.171 Defective regulation of 
neurite/dendrite outgrowth has been identified in multiple neurodevelopmental disorders 
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(Rett syndrome, autism), neurodegenerative disorders (Alzheimer's, Huntington's 
diseases), and disorders arising from mechanical and biochemical neuronal damage 
(stroke, ischemic damage).  A possible approach toward addressing these deficiencies is 
to restore or modify the processes of neurite/dendrite outgrowth.  Neurotrophins are 
endogenous proteins that promote nerve growth and function; these include nerve growth 
factor (NGF), brain-derived neurotrophic growth factor (BDNF), neurotrophin-3, and 
others.  These factors were identified initially by their ability to support or induce 
neuronal growth, differentiation, and plasticity.  The search for small molecules that can 
affect the same results have recently identified the following compounds as inducing 
neurite outgrowth.172,173   
 
 
 
 
 
 
 
 
 
 
Fig. 59: Small molecules as neurite outgrowth inducers 
DKP 101516 (200a) 172 was originally isolated from an uncharacterized bacterial culture 
originating from marine sediment by O'Connor and co-workers in 2001174 and was 
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identified as inducing neurite outgrowth at 32 mM.  Further analysis both, in cultured 
cells, and intact animals confirmed the initial finding and has suggested that 200a 
stimulates axon outgrowth and branching directly and effectively overrides the effects of 
myelin-associated inhibitory proteins (MAIPs) and chondrotin sulfate proteoglycans 
(CSPGs).  The most likely mechanism suggested was that 200a modify multiple PI3K 
signaling pathways including the resultant stabilization of microtubules by reducing 
CDK5 activity.  Phevalin-2 (200e)175,176 contains the same atomic structure found in 200a 
and has been postulated to arise from oxidative dehydration of 200a177.  Interestingly 
200e was shown to inhibit calpain in an isolated enzyme assay when derived from the 
natural source (Streptomyces # SC433, Winthrop Collection) but not when prepared 
synthetically in pure form170.  This contradiction often suggests bioactive impurities or 
metabolic conversion during in vivo analysis; both scenarios have occurred previously 
with other DKPs . 
 
Series 9: Target compounds of Diketopiperazine series 
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Manual docking of DKP-101516 into the putative ATP binding site of the X-ray crystal 
structure53 of CDK5 suggests a very complimentary fit.  Interestingly this analysis 
suggests that a diastereomer of DKP 101516, (3R, 6S)-3-benzyl-6-isopropylpiperazine-
2,5-dione 200b, would have a more favorable interaction and perhaps display greater 
inhibitory properties against CDK5. 
Docking studies in Fig. 60 showed that the ketopiperazine moiety of DKP makes a 
critical HBD/HBA pair with Cys83 in the hinge region. The isopropyl moiety is buried in 
the ribose binding pocket, analogous to the binding of the isopropyl moiety of R-
roscovitine. The benzyl moiety of DKP 200b points towards the solvent, similar to the 
bound conformation of the benzyl group of R-roscovitine. These observations encouraged 
us to design and synthesize these target compounds (Series 9) as proposed CDK5 
inhibitors. 
 
Fig. 60 Interactions of DKP in the CDK5 active site. PDB ID: 1UNL. Visualized using 
MOE 2008.11 
 
3.3.4 Results:  
All of these compounds have been submitted for the biological activity. 
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CHAPTER FOUR 
 
Chemical Discussion 
4.1 Synthesis of key intermediate 1-isopropyl-6-methoxy-4-nitrobenzimidazole 
(152a) : 
4.1.1 Initial attempts for synthesis of 1,4 and 6-substituted benzimidazole scaffold:   
Cl
Cl X
Y
NH2
Various
conditions
Cl
Cl NH
Y 1. Reduction
2. Phillips Cyclization
Cl
Cl N
N
201 X = Cl, Y = NO2
202 X = Cl, Y = NH2
203 X = l, Y = NH2
204 Y = NO2
205 Y = NH2
206
 
Scheme 63: Attempted synthesis of 204 and 205. 
The original strategy for the synthesis of a 1,4,6-trisubstituted benzimidazole scaffold 
from 2,4,6-trichloronitrobenzene was based on the following reasoning: 
First, activation of the ortho chloro atoms due to the ortho nitro group would activates the 
chloro towards SNAr displacement by electron rich amine of isopropyl amine. 
Second, equimolar addition of isopropyl amine could be used to limit the formation of di- 
or tri-substituted 204. This initial displacement of chlorine atom ortho to the nitro group 
of 201 desymmetrizes the compound, providing rapid entry into a highly functionalized 
differentially activated synthetic precursor and finally, commercial availability of 201 – 
203. 
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Initial attempts at displacement of the chlorine (201 or 203) or iodine (202 or 204) atoms 
of 201 – 204  (Scheme 63) with isopropylamine under various conditions178-180 
(summarized in table 3) failed to give the corresponding substituted compounds 205 or 
206 as expected. The isopropylamine was utilized as both the base and nucleophile for all 
strategies. Both Ullmann coupling strategies or ionic displacement were examined and 
were not found to be successful. 
Table 3: Various strategies screened for the synthesis of 4 and 5. 
 Starting material Catalyst Solvent Temp/time Result 
1 201 - DMF 50 oC, 15 h NR 
2 201 - DMSO 60 oC, 15 h NR 
3 201 - EtOH 80 oC, 17 h NR 
4 201 - EtOH 120 oC, 15 min MW CM 
5 202 - DMSO 60 oC, 17 h CM 
6 203 - DMSO 70 oC, 17 h CM 
7 203 CuI DMF 70 oC, 24 h CM 
8 203 CuI DMF 120 oC, 5h CM 
9 203 - EtOH 60 oC, 12 h CM 
         *NR= No reaction, CM= Complex mixture 
 
4.1.2 Alternate strategy for synthesis of 1,4 and 6-substituted benzimidazole 
scaffold: 
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Scheme 64. Synthesis of 5-methoxy-7-nitro-1H-benzo[d]imidazole 212  
The failure of the initial strategy prompted the development of an alternate strategy that 
involved the synthesis of a 4,6-disubstituted benzimidazole scaffold with subsequent 
introduction of the 1-substituent by regioselective N1 nitrogen alkylation. Acetylation of 
p-anisidine 206 with acetic anhydride followed by mono nitration gave 208 (Scheme 64) 
which was deprotected with Claisen’s alkali to give 4-methoxy-2-nitro aniline, 209, in 
quantitative yield.97,181 Compound 209 was nitrated using HNO3 to give the dinitrated 
210 in 47% yield.182 Nitration of 209 using HNO3 was expected to be a highly 
exothermic reaction or could give rise to an exothermic and unstable product. Hence prior 
to conducting this reaction in a large scale, a differential scanning calorimetric analysis of 
the product was performed (Dr. Wildfong). No exotherm upon heating nor during melting 
of the product was identified. This analysis indicated that the product was not 
intrinsically unstable and was safe to synthesize under carefully controlled laboratory 
conditions; compound 210 was safely synthesized in a gram scale, adequate for this 
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project, but then converted to 211 for storage of intermediate product. 4-methoxy-2,6-
dinitroaniline 210 was subjected to Zinin reduction conditions 183 to provide 5-methoxy-
3-nitrobenzene-1,2-diamine 211. The uniqueness of Zinin reduction of the dinitroarene 
contrasted with to iron or catalytic Pd/H2 reduction lies with its lower reduction potential 
of the sulfides, thus reduction normally stops at the mono-reduced nitroarene stage. 
Compound 211 can undergoes cyclization under Phillips cyclization conditions to 
provide benzimidazole 212 in 95% yield.184 (Scheme 64). We recently published our data 
on the trisubstituted benzimidazole synthesis.164 
 
Scheme 65. Synthesis of 5-methoxy-7-nitro-1H-benzo[d]imidazole.185 
While there are reported procedures for the regioselective N1 alkylation of 
benzimidazoles185, there were no reported methods for introduction of an isopropyl group 
at the N1 position. Thus, a direct N1-alkylation was attempted on the benzimidazole 212.  
Compound 212 was successfully deprotonated with NaH, and then methylated selectively 
at the N1 position with methyl iodide to give 213.185,186 However when isopropyl iodide 
was used as the electrophile, either a very low non- isolable yield of the desired 
compound 214 was obtained or no product was obtained.187,188  The low reaction yield 
could be a result of the bulk of the isopropyl group which could hinder the nucleophilic 
attack, or due to β-elimination of the iodide under basic conditions (Scheme 66) to 
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generate inert propene. Examination of other electrophiles such as 2-tosyl ester of 
propane gave equally dismal results.
 
Scheme 66. Direct N1-alkylation of preformed benzimidazole 212. 
Table 4: Reaction conditions for the regioselective N1-alkylation 
S.NO. Conditions Results Yield 
1 DMF, NaH in Paraffin, iPrI No reaction Multiple products, 
No isolable 
product, SM left. 
2 KOH, DMSO, iPrI 
MW , 30 min, 50 oC 
Mixture of compd 
214 and 215. 
Approx 40% 
Not feasible to 
isolate 
3 212, KOH, DMSO, iPrI 
MW, 45 min, 50 oC, 
Mixture of 
compounds 
Approx 30% 
Not feasible to 
isolate 
4 212, NMM, 1,2 dichloroethane 
MW,120 oC,  
2 min, iPrTs 
No reaction Not feasible to 
isolate 
 
Given these observations, it was decided to introduce the isopropyl group prior to 
cyclization under reductive alkylation conditions. Reductive alkylation of 211 using 
acetone and NaBH(HCOO)3 as a mild reducing agent (generated in situ) provided 216. 
Compound 216 was refluxed with formic acid and concentrated HCl under Phillips 
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cyclization conditions184 to provide the derived 1,4,6 trisubstituted benzimidazole 214. It 
was anticipated that the electron withdrawing effect of nitro group would result in the o-
amine as being more electron deficient and consequently less nucleophilic. As a result 
reductive alkylation should only occur at the m-amine of 211. An X-ray crystal structure 
of 214 (Fig 61) confirmed that correct regioisomer was isolated.189  The poor isolated 
yields and the necessity to generate NaBH(HCOO)3 in situ (a thermally unstable reducing 
agent at room temperature) prompted a search for better methods to generate 214.
Scheme 67. Initial synthesis of 214. 
 
Fig. 61: X-ray crystal structure of 214.190 
Optimization of reaction conditions to improve the yield of 214 included replacement of  
NaBH(HCOO)3 with commercially available and more stable NaBH(AcO)3, increasing 
the ratio of concentrated HCl to formic acid, and addition of a sub-stoichiometric amount 
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of BHT to prevent oxidation of the intermediate 216.  These changes improved the 
isolated yield to 78%. With the substitution of NaBH(AcO)3 there existed the possibility 
of cyclization with acetic acid, which would have given the 2-methyl variant of 214. 
However, studies with glacial acetic acid and NaBH(AcO)3 indicated that this conversion 
was slower by a factor of 10. Thus the faster cyclization rate with formic acid and the 
abundance of formic acid over acetic acid explains the preferred formation of 214. 
 
Scheme 68.  Improved synthesis of 1-isopropyl-6-methoxy-4-nitro-1H-
benzo[d]imidazole.164,191 
Compound 214 was envisioned to be a common synthetic intermediate for further 
functionalization at the 4- and/or the 6-positions to give the corresponding C6- O6-, N6- 
or N4-substituted target compounds.  
The N1-Cyclopentyl benzimidazole 219 was synthesized in an analogous manner 
(Scheme 69), but utilized cyclopentanone for the reductive alkylation step. 
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Scheme 69. Synthesis of 1-cyclopentyl benzimidazole 219.164 
4.2. Synthesis of C6 Benzyl compounds: 
The C-6 benzyl compounds were planned to be synthesized from the key intermediate 
214 by functionalization at the 4-position, introduction of a suitable leaving group at the 
6-position and subsequent transition metal coupling under a variety of standard coupling 
reactions.   
4.2.1 Method A: Synthesis of the key intermediate 4-(benzylamino)-1-isopropyl-1H-
benzo[d]imidazol-6-triflate 224a 
 
Scheme 70: Synthesis of intermediate 220a. 
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Catalytic hydrogenation of the N1-alkylated benzimidazole 214 was performed using 10% 
Pd/C at 50 psi for 6-8 h to reduce the nitro group of 214 to the corresponding amine in 
highly reproducible 90% yield and was isolated as its hydrochloride salt 220 (Scheme 
70).  Benzylation at the 4-position of 220 could be carried out by one of the two methods 
(Scheme 71). Compound 220 was either subjected to reaction with benzoyl chloride 
under basic conditions to give 221 which could be reduced using LAH to give the 4-
benzylated compound 222 in 40% yield. Compound 220 could alternatively be subjected 
to reductive alkylation with benzaldehyde (1.5 equivalents) using NaBH(OAc)3 in 1,2-
dichloroethane to give 222 in 55% yield along with the dibenzylated product 222a (45%). 
Reducing the amount of benzaldehyde in the reaction mixture to exactly 1.0 equivalent 
lead to exclusively to the desired mono benzylated compound 222 and did so with an 
improved 70% yield. 
HN
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N
N
O
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DCE
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Scheme 71. 4-Benzylation of 220 using two synthetic routes191 
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Several methods were attempted for the demethoxylation of 222 and are summarized in 
table 5.  Treatment of 222 with 48% HBr resulted exclusively in debenzylation at the 4-N 
position.164,192  Demethoxylation of 222 using BBr3 initially at -78 oC for 30 min then 
stirring at room temperature for an additional 6 h gave the desired phenol 223, but in low 
yield (30%). Further optimization of the reaction conditions using BBr3 at -78 oC for 30 
min then stirring at -20 oC for an additional 12 h gave 223 in 90% yield.193 
 
Scheme 72. Demethylation of 222 using various conditions 
Table 5: Various reaction conditions for demethylation of 222. 
 
S.No. Conditions Results Yield 
1 48% HBr, reflux Loss of benzyl none 
2 48% HBr, 23 oC Loss of benzyl none 
3 BBr3, -78 oC - 23 oC 
12 h 
223 ~30% 
4 BBr3, at -20 oC, 12 h 223 ~90% 
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For R = OTf
p-nitrophenyltriflate
DMF, K2CO3, 4 h, 23
oC
HN
HO N
N
HN
R N
N
BBr3, -78
oC to -20 oC
HN
O N
N
222, 60% 223,~80%
224a, R = OTf, 88%
224b, R = OTs, 60%
For R = OTs
tosyl chloride, DMAP
NaHCO3,CHCl3 12 h
23 oC
 
Scheme 73: Formation of triflate 224a or tosylate 224b 
Phenol 223 was then converted to its corresponding triflate 224a194  or tosylate 224b 
under basic conditions using p-nitrophenyl triflate 195 or tosyl chloride196, respectively, in 
good yields (Scheme 73). Compounds 224a and 224b failed to couple with either simple 
alkyl or benzyl magnesium bromide (Grignard reagents) with modern Fe(acac)3 coupling 
conditions.197 Several conditions examined for the Fe(acac)3 coupling reaction as 
summarized in table 6.198-201 
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Table 6: Attempts for Fe(acac)3 coupling of 224a-b with Grignard reagents 
S.No. Condition Results Yield 
1 Fe(acac)3, THF, NMP, 
BnMgCl,  
2 h 
No reaction NA 
2 Fe(acac)3, THF, NMP, 
BnMgCl, overnight 
No reaction NA 
3 Fe[Salen]Cl, THF, 
 i-Butyl MgBr 
Only 10% desired 
compound, Unreacted 
starting material 
recovered. 
~5% 
4 MnCl2, THF, Ethyl MgBr No reaction NA 
Key: NA: Not applicable 
4.2.2 Method B: Synthesis of key intermediate 1-isopropyl-1H-4-
nitrobenzo[d]imidazol-6-triflate 227a or 1-cyclopentyl-1H-4-nitrobenzo[d]imidazol-
6-triflate 227b 
An alternate route was devised for the synthesis of the 6-benzyl compounds which 
retained the 4-nitro group on the coupling partner (227).  The advantages of retaining a 4-
nitro group contrasted with a 4-amino or a 4-subsituted amine group were two fold: First: 
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48% HBr could be used for demethylation of 214  or 219 (Scheme 74) which reduced the 
reaction time required (1.5 h) for demethoxylation compared to demethoxylation using 
BBr3 (12 h). Thus, subjecting 214 or 219 to 48% HBr with heating under microwave 
conditions gave 226 or 226a respectively as desired, which precipitated from the solution 
upon neutralization. Compounds 226 and 226a were converted to their corresponding 
triflates 227 and 227a, respectively, under basic conditions. Second: the 4-nitro group 
aided in reducing the electron density on the phenyl ring of the triflates 227 and 227a 
which assisted subsequent oxidative insertion of the palladium during subsequent 
organometallic coupling reaction on the heterocycle.  
 
Scheme 74. Synthesis of 227 and 227a.   
4.2.3 Metal catalyzed cross-coupling reactions on 227 
Different transition metal catalyzed coupling reactions were examined on 227 and are 
summarized in Table 7. Initial Iron (Fe(acac)3) catalyzed cross coupling with EtMgBr as 
the organometallic coupling partner202 gave no product. Ni(0)-catalyzed Kumada 
coupling203 utilizing  Ni(dppp)Cl2 and PhCH2MgBr as the organometallic coupling 
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partner also yielded no product. Attempts at Stille coupling204 with tributyl(3-Me-2-
butenyl)tin  as the organometallic coupling partner also failed. Negishi205 cross coupling 
with PhCH2ZnBr as the organometallic coupling partner with a variety of  palladium 
ligands gave a complicated mixture with inseparable products. Heck coupling206 with 
ethyl methacrylate at 120 oC using microwave irradiation also did not provide any 
conversion to the desired product 228. 
Table 7. Coupling reaction for C6-C bond formation. 
 
 Organometallic coupling 
partner 
Catalyst/ligand Solvent Temp/time Result 
1 (CH3)2CHCH2MgBr Fe(acac)3 THF/NMP 23 oC, 2 h NR 
2 CH3CH2MgBr Fe[Salen] 
Complex 
THF 23 oC, 3 h NR 
3 PhCH2MgBr Ni(dppp)Cl2 THF 23 oC, 20 h NR 
4 Tributyl(3-Me-2-
butenyl)tin 
Pd(PPh3)4, LiCl Dioxane 101 oC, 7 h CM 
5 Ethyl methacrylate (PPh3)2.PdCl2 
NaHCO3 
DMF 120 oC, 2 h, 
MW 
NR 
NR= No reaction, CM= Complex mixture 
Failure of the above methods prompted us to explore a Suzuki-Miyaura cross-coupling 
strategy employing the very nucleophillic yet readily isolated potassium 
benzyltrifluoroborate salt. It is established 207-209 that potassium benzyltrifluoroborates 
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can react with aryl triflates generating a C-C bond. Previously, electron rich aryl triflates 
were identified as giving poor to no conversion. Thus Suzuki-Miyaura cross-coupling on 
the electron rich benzimidazole core was conceivable (Scheme 75) if not yet developed to 
the level of practical utility.  
  
Scheme 75: Suzuki-Miyaura cross coupling using potassium trifluoroborate salts 
 
When triflate 227 and the commercially available potassium benzyl trifluoroborate salt 
233 were treated under standard Suzuki-Miyaura coupling conditions207 with cesium 
carbonate, THF, water and PdCl2(dppf) at  reflux (68 oC) for 24 hours, the reaction did 
not proceed to completion and the coupled product could not be isolated (Scheme 75). 
When the reaction was heated with microwave irradiation at 100 oC for 20 minutes, the 
reaction proceeded and the product 229a was isolated in 20% yield (Scheme 76). 
Unreacted starting material 227 (50%) was recovered. Optimization of the reaction time 
and temperature again with microwave irradiation improved the yield for substituted 
benzyl variations. Microwave irradiation achieves higher internal temperatures (110 oC 
for microwave compared to 66 oC on the bench top) and this effect may have aided in 
accelerating the reaction rate. Thus it was demonstrated that palladium catalyzed cross-
coupling reaction of potassium aryltrifluoroborates with 6-benzimidazole triflates, 
normally unreactive under other examined coupling conditions or under standard Suzuki-
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Miyaura coupling conditions, was achievable under microwave irradiation conditions 
(Series 2).141 
Scheme 76. 6-Benzyl substitution of benzimidazole by Suzuki Miyaura cross coupling  
Non-commercially available potassium benzyltrifluoroborates 233a-b were prepared 
from their corresponding precursor Grignard reagent, using known literature methods.210  
(Scheme 77) 
 
Scheme 77: Synthesis of non-commercially available trifluoroborates 
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4.3. Synthesis of O6 Benzyl compounds: 
 
Scheme 78: Synthesis of O6-benzyl compound (Series 1). 
6-Hydroxy benzimidazole 226 was utilized for Mitsunobu coupling with various alcohols 
to form the C6-O linked benzimidazoles 190a-d (Scheme 78).  Addition of diisopropyl 
azodicarboxylate (DIAD) in two portions gave better yield.  A probable reason for this 
observation is that the instability of the DIAD generated electrophile over an extended 
time interval.211 Addition of the electrophile in two portions effectively prolonged the 
half-life of the generated transient electrophile.  This strategy provided an improved yield 
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by a factor of 10.  Isolation of the Mitsunobu coupling product 234 was problematic. The 
product co-eluted on the silica column chromatography with the side product 
triphenylphosphine oxide.  Consequently, the crude product was carried on directly to the 
next catalytic hydrogenation step and/or subsequent reductive alkylation using 
benzaldehyde and colcuded with careful isolation of pure target compounds 190a-d 
(Scheme 78).164 
 
4.3.1 Synthesis of protected alcohols 237. 
 
Scheme 79: Synthesis of protected alcohols 237 
The protected alcohols 237a-c required for Mitsunobu coupling with 226 as shown in 
Scheme 78, were synthesized from the corresponding alcohols 236 or 238 (Scheme 16) 
according to established  literature methods.212 
 
 
 
4.4. Synthesis of N6 Benzyl Benzimidazole (Series 3): 
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Scheme 80: Synthesis of N6-benzyl compounds 189b-c (Series 3) 
Desired N6-benzyl compounds were synthesized from the key intermediate 227 using 
methods previously established in our laboratory.213 The triflate 227 was coupled with the 
electron rich benzophone imine 239a under Buchwald coupling methods, followed by 
hydrolysis to afford the aniline 240 in 68% yield by two steps.214,215  To differentiate 
between the amino groups at the 4- and 6-positions during the subsequent reductive 
alkylation, the 6-amino group of 240 was protected as the trifluoroacetic amide with 
trifluoroacetic anhydride and pyridine prior to the reduction of the 4-nitro group (241) to 
242.  Reductive alkylation of the 4-amino group of 242 gave the 4-N-benzyl compound 
243. Treatment of 243 with sodium hydride selectively generated the N6 amido-sodium 
salt of 243, which could condense with triflate 244a or 244b to give 245a or 245b 
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respectively.216-218  Compounds 245a-b were subsequently treated with sodium 
borohydride.  Under this condition simultaneous deprotection to the 6-amine 219,220 and 
reduction of the side chain ester to its corresponding alcohol were achieved, and the 
desired final compounds 189b-c were obtained in one step in acceptable yield.   
4.4.1 Side chain synthesis:  
 
Scheme 81. Synthesis of 244a-b. 
Triflates 244a-b were prepared from the commercially available α-hydroxy esters 246a-b 
217,218
 by reaction with triflic anhydride and 2,6-lutidine as a base in 90% yield. 
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4.5. Synthesis of N4-Benzyl Benzimidazole series (Series 4): 
4.5.1 Synthesis of N4-(mono-substituted benzyl) compounds : Series 4.1 
Compounds with a mono-substitution at the N4-benzyl position (Series 4.1) were 
synthesized (Scheme 82) from the key intermediate 226 and required commercially 
available benzaldehydes using a variant of the scheme previously described for the O6-
benzimadazole compounds. (Scheme 78). As a modification, use of a benzoyl protected 
alcohol as the coupling partner in the synthesis of 246 (Scheme 82) permitted easier 
purification of the intermediates with silica gel column chromatography contrasted to the 
partially silica labile compounds using a TBS-protected side chain alcohol. This 
permitted characterization of the intermediates. This was not possible with analogous 
TBS-protected intermediates.164 
126 
 
Scheme 82: Synthesis of N4-(mono-substituted benzyl) benzimidazole series 
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Scheme 83: Synthesis of 192r 
 
Curiously deprotection of 249r gave the 4-imine intermediate 250 (Scheme 83) rather 
than the expected alcohol 192r. This reaction probably occurs due to a very acidic pKa of 
the 4-N benzylic proton resulting from the electron withdrawing effect of the 4-NO2 
group and mediated by deprotonation by KOH. This imine intermediate 250 was purified 
and characterized by elemental analysis and 1H NMR. However, intermediate 250 was 
easily converted into the target 192r by reduction with NaBH4 in a mixture of 1,2-DCE 
and EtOH. 
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4.5.2 Synthesis of N4-(di-substituted benzyl) benzimidazole (Series 4.2) 
 
Scheme 84: Synthesis of N4-(di-substituted benzyl) benzimidazole series 
The N4-(di-substituted benzyl) compounds 193a-e were synthesized from 248 and the 
appropriate commercially available di-substituted benzaldehydes (Scheme 84) using the 
method previously described in Scheme 82 for the mono substituted benzyl compounds.  
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4.6. Synthesis of N4-Phenyl Benzimidaozle series (Series 5) 
4.6.1 Retrosynthetic analysis 
 
The N4-phenyl benzimidazole compounds 195 were envisioned as being synthesized 
from the 4-amino benzimidazole 253 utilizing either Ullmann or Buchwald coupling 
reaction strategy with the appropriately substituted iodobenzene. 
4.6.2 Synthesis using Ullmann coupling 
 
 
 
 
 
 
 
Scheme 85: Attempted synthesis of N4-phenyl compounds using Ullmann reaction 
 
An initial unsuccessful attempt was made to couple iodobenzene with 253 under Ullmann 
coupling conditions to synthesize the required N4-phenyl compound 195a.221-223 The 
reaction however failed to proceed as expected under the conditions examined (Scheme 
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85). Possible reason for the lack of reaction could include the low nucleophilicity of the 
4-amino group of the electron deficient benzimidazole scaffold. 
 
4.6.3 Synthesis using Sandmeyer reaction 
 
Scheme 86: Synthesis of N4-phenyl compounds using Sandmeyer reaction 
 
Since the benzimidazole scaffold is electron deficient,77 a new synthetic route was 
examined which utilizes the observed electron deficiency to assist the reaction by 
reversing the synthons. Thus, Sandmeyer halogenation was used to convert the amino 
group of 254 (Scheme 86) to the corresponding bromide in 256, which successfully 
underwent a Pd-catalyzed Buchwald reaction with aniline to provide the target compound 
257 albeit in low yields.222,224  
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4.6.4 Synthesis using Buchwald reaction 
 
Scheme 87a: Buchwald reaction conditions for synthesis of N4-phenyl compounds 
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Scheme 87: Synthesis of N1-isopropyl-N4-phenyl compounds using Buchwald reaction 
Compounds 194a-e were synthesized from 248 with these modified Buchwald coupling 
conditions using a simplified procedure89 for similar benzimidazole compounds. This 
reaction used Pd2(dba)3 as the Pd source and Xanthphos as the ligand in toluene at 60 – 
70 oC to give 194a-e in 35 – 68 % yield. 
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Scheme 88: Synthesis of N1-cyclopentylN4-phenyl benzimidazoles 
 
The N1-cyclopentyl-N4-phenyl compounds 195a-b were synthesized from 260 (Scheme 
88) using the procedure reported for the synthesis of 194a-e (Scheme 87) in 42% and 
53% yield respectively. 
 
4.7. Synthesis of 2-((4-(benzylamino)-1-methyl-1H-benzo[d]imidazol-6-yl)oxy)butan-
1-ol (197b) 
 
Scheme 89: Synthesis of 197b 
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Compound 213 was synthesized in 40% yield (Scheme 26). Hydrolysis of the 2-methoxy 
group of 213  provided 259 in 65 % yield, followed by Mitsunobu coupling with the 
protected alcohol, reduction of the nitro group to the corresponding amine and 
subsequent reductive alkylation with benzaldehyde and NaBH(OAc)3 followed by 
deprotection of the benzoyl protecting groups with Claisen’s alkali provided 197b. 
4.8. Synthesis of 2-Phenacetamido-5-substituted thiazoles 
4.8.1 De novo synthesis of N-(5-cyclopentylthiazol-2-yl)-2-phenylacetamide 
 
Scheme 90: Synthesis of N-(5-cyclopentylthiazol-2-yl)-2-phenylacetamide 266 
Compound 266 has been reported to be a single digit nanomolar inhibitor of CDK5/p25.64 
A de-novo synthetic approach was adopted for synthesizing N-(5-cyclopentylthiazol-2-
yl)-2-phenylacetamide 266 (Scheme 27).64,225 Oxidation of commercially available 2-
cyclopentylethanol to the aldehyde was performed using PCC in DCM for 2h at room 
temperature in 68% yield. Selective α-bromination using bromine in dioxane gave the 
reactive intermediate 264 which was directly condensed with thiourea in refluxing EtOH 
to form 2-amino-5-cyclopentyl thiazoles, 265. Reaction of 265 with benzoyl chloride 
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under Schotten Baumann reaction conditions provided 266 in 45% yield. Schotten 
Baumann reaction conditions were utilized because of literature precedence226 and to 
suppress likely allene formation if a tertiary amine were used.227 Compound 46 was 
utilized as a standard for our assays. 
4.8.2 Synthesis of 5-Aryl aminothiazoles 
 
Scheme 91: Attempted synthesis of 268 
An attempt to develop an efficient synthetic route for the target 2-aminothiazole 
compounds, it was envisioned that conversion of commercially available 2-amino-5-
bromothiazole to a boronate intermediate would enable Suzuki coupling with the desired 
aryl halides. The first step in this approach was the synthesis of 2-phenyl-N-(5-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)thiazol-2-yl)acetamide 268 (Scheme 91). 
Commercially available 2-amino-5-bromothiazole was reacted with benzoyl chloride 
under basic conditions to provide the 2-phenacetamido-5-bromothiazole 267 in 56% 
yield. Attempts to convert 267 to the corresponding boronate under Pd-catalyzed 
conditions led to debromination of 267 to give 269.   
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Scheme 92: Attempted synthesis of 270 via hetero-Heck cross coupling 
An alternate approach was a precedented hetero-Heck approach228 for synthesis of 270 
(Scheme 92). This reaction involved Boc protection of 2-aminothiazole followed by 
addition of 4-bromopyridine to the 2-position with Pd(OAc)2 as a catalyst. This reaction 
failed to proceed and no product was identified. 
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4.8.3 Metallation and Displacement with Benzaldehyde 
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Scheme 93: Synthesis of 198f, 198i and 198l 
Treatment of Boc-protected 2-aminothiazole with 2 eq. of n-BuLi in THF and subsequent 
quenching of the resulting nucleophile with the corresponding benzaldehydes resulted in 
formation of tert-butyl (5-(hydroxy(phenyl)methyl)thiazol-2-yl)carbamates 271a-b in 51-
54% yield. Deoxygenation of the hydroxyl group and simultaneous Boc deprotection was 
carried out using triethylsilane in CF3COOH to give 272a-b in 75-86% yield.126 
Acylation of the 2-amino group with phenacetyl chloride under Schotten Baumann 
conditions gave compounds 198f and 198b in 57-75% yield. Pd/C catalyzed reduction of 
the 4-NO2 group of 198i gave the compound 198l in 57% yield.   
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Scheme 94: Alternate synthesis of 271a 
An attempt to quench the intermediate 5-lithiated thiazole generated by the reaction of 
Boc protected 2-aminothiazole 125 with benzyl bromide in an effort to shorten the 
synthetic sequence for 271a gave the target compound 271a as only the minor reaction 
product. The major product in this reaction was the self-coupling product of benzyl 
bromide, 1,2-diphenylethane 27e.  
 
4.8.3.1 De-novo synthesis of 82 to confirm the structure of 82 
 
Scheme 95: De-novo synthesis of 276229 
A de-novo synthesis of 276 was performed to confirm that benzylation occured at the 5-
position during lithiation.(Scheme 95) 3-Phenylpropanal 274 was α-brominated using 
bromine in DCM to provide α-bromo aldehyde 275 which was condensed with thiourea 
in ethanol at reflux to provide 276 for a 60% overall yield. The structure of 276 
regardless of synthetic route was confirmed by identical 1H-NMRs, melting points of the 
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products obtained by the two synthetic routes and finally by comparison with reported 
literature values.126,229 
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Scheme 96: Synthesis of 198m 
Lithiation of Boc-protected 2-aminothiazole 125 (Scheme 96) and subsequent reaction 
with Cbz-protected piperidine carboxaldehyde gave benzyl 4-((2-((tert-
butoxycarbonyl)amino)thiazol-5-yl)(hydroxy)methyl)piperidine-1-carboxylate 278 in 
45% yield. Cbz-protected piperidine carboxaldehyde was synthesized using a reported 
method.213,230 Deoxygenation and simultaneous deprotection of the Boc-group was 
carried out using triethylsilane in CF3COOH. The longer reaction time required for the 
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deoxygenation of the hydroxyl group in case of 278 compared favorably with the 
deoxygenation of 5-aryl compounds (Scheme 29) and could be accounted for by 
reduction in the stabilization of the intermediate carbocations formed during the reaction. 
Acylation of the 2-amino group of 278 with phenacetyl chloride 280 gave 281 in 75% 
yield. Cbz deprotection of 281 was attempted using 10%  Pd/C reduction with H2, but 
failed to provide the target 198m. Prolonged reduction led to the generation of insoluble 
degradation products that could not be dissolved even into DMSO. These physical 
properties were inconsistent with the desired product 198m. 
 
Scheme 97: Attempted synthesis of 283 
Lithiation of Boc-protected 2-aminothiazole 125 (Scheme 33) and then subsequent 
reaction with 3-pyridine carboxaldehye or 4-pyridine carboxaldehye gave tert-butyl (5-
(hydroxy(pyridin-3-yl)methyl)thiazol-2-yl)carbamate 282a in 50% yield or tert-butyl (5-
(hydroxy(pyridin-4-yl)methyl)thiazol-2-yl)carbamate 282b in 45% yield respectively. 
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However, the subsequent deoxygenation with triethylsilane failed to proceed under the 
various reaction conditions attempted. These attempts included use of stronger acids, 
alternate hydride sources and higher temperatures. The failure of the acid mediated 
deoxygenation could be explained by initial protonation of the pyridine nitrogen prior to 
protonation of the hydroxyl group. This could prevent formation of the intermediate 
carbocation, a required step for silane and reductive deoxygenation. Strong hydride 
sources provided complex mixtures without any evidence of product, most likely the 
result of partial pyridine ring reduction.
 
Scheme 98: Synthesis of 289 
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The failure of the acid mediated silane reductive deoxygenation prompted a search for an 
alternate, base catalyzed deoxygenation method. Weinreb-amide 285 was synthesized 
from isonicotinic acid 284 in 44% yield (Scheme 34). 231 Lithiation of Boc-protected 2-
aminothiazole 125 and subsequent reaction with the Weinreb amide 285 gave tert-butyl 
(5-isonicotinoylthiazol-2-yl)carbamate 286 in 49% yield. A Huang-Minlon modification 
of the Wolff-Kishner reduction232 using hydrazine in diglyme failed to produce the 
reduced 287. Although the intermediate hydrazone was formed as evidenced by loss of 
2,4-DNP positive spot, the subsequent high temperature led to degradation of the 
intermediate and loss of starting material, which could not be recovered. As an 
alternative, Boc deprotection of 286 gave 288 in 80% yield. Acylation of the 2-amino 
group of 288 with phenacetyl chloride gave target 289 in 60% yield. Subsequent 
conversion of 289 will follow. 
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Scheme 99: De-novo synthesis of 41e 
The failure of both the acid and/or base-mediated deoxygenations to generate 198k 
prompted a de-novo approach to synthesize 198k.233 Swern oxidation of 3-pyridyl 
propanol generated aldehyde 291 (Scheme 35) in 70% yield. α-Bromination of 291 using 
33% HBr in AcOH gave 292 which was condensed without purification with thiourea in 
ethanol at reflux to give 5-(pyridin-3-ylmethyl)thiazol-2-amine 283 in 50% yield from 
the precursor aldehyde. Acylation of 283 with phenacetylchloride under basic conditions 
gave target 198k in quantitative yield.   
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4.8.4 Synthesis of 2-phenacetamido-5-phenylaminothiazole. 
 
Scheme 100: Synthesis of 5-Phenyl-2-aminothiazole 
α-Bromination of phenacylaldehyde 294 gave crude α-bromoaldehyde 295 which was 
then condensed with thiourea in ethanol at 80 oC to give 296 in 60% yield.234 Acylation 
of 296 under Schotten-Baumann conditions using phenacetyl chloride in dioxane gave 
297 in 55% isolated yield. 
4.8.5 Synthesis of 2-phenacetamido-4-phenylaminothiazole 
 
Scheme 101: Synthesis of 298 
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Synthesis of the 4-phenyl regioisomer235 of 298 (Scheme 101) was performed by a one-
pot reaction of acetophenone, thiourea and stoichiometric excess of either iodine or 
bromine at 110 oC for 25 min in 20% yield. Acylation of 133 under Schotten Baumann 
conditions with phenacetyl chloride in dioxane gave 298 in 60% yield. 
4.9. Synthesis of diketopiperazines 
 
Scheme 102: Synthesis of diketopiperazine 200a. 
Boc protection of L-valine 299 gave 300 in 83% yield which was coupled with D-
phenylalanine 301 using EDCI and HOBt to give 302 in 88% isolated yield. Removal of 
the Boc protective group with TFA at room temperature for 30 minutes released the free 
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amino group which then participated in an acid catalyzed intramolecular cyclization with 
the carboxylic methyl ester of phenylalanine upon heating at 100 oC for 2 h to yield the 
desired diketopiperazine (S, S)-200a in 26% recrystallized yield.133,134 
Scheme 103: Synthesis of diketopiperazines 200b-d. 
Compounds 200b-d, the other stereoisomers of 200a (Scheme 102), were synthesized in 
an analogus manner by reacting the corresponding dipeptides stereoisomers of valine and 
phenylalanine under reaction conditions described in Scheme 102. 
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4.10. Synthesis of Phevalin 
 
 
 
 
 
 
 
Scheme 104: Synthesis of 200e 
Reduction of the ester of 302 (Scheme 38) with DIBAL-H in THF at 0 oC for 2 h 
provided the alcohol 304 in 69% yield. A previous literature reference170 had produced 
the partial reduction, but only full reduction to the alcohol was observed in practice. PCC 
oxidation of 304 in DCM at room temperature however gave aldehyde 305 in 67% yield. 
Heating 75 in TFA at 100 oC led to deprotection of the Boc group and subsequent 
intramolecular condensation with the aldehyde to provide the pyridazone core of phevalin 
200e in 35% yield.170 
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CHAPTER FIVE 
 
 
Experimental: 
All solvents and reagents were used as received unless noted otherwise.  Tetrahydrofuran 
(THF) was distilled from Na-benzophenone ketyl radical under a blanket of argon prior 
to use.  All reactions were conducted in dry glassware and under an atmosphere of argon 
unless otherwise noted.  Microwave reactions were conducted in sealed tube and utilized 
a multimode Milestone Start apparatus for irridation with power and control parameters 
as noted.  Melting points were determined on a MelTemp apparatus and are uncorrected.  
All proton NMR spectra were obtained with 500 MHz or 400 MHz Oxford spectrospin 
cryostat, controlled by a Bruker Avance system, and were acquired using Bruker 
TOPSPIN 2.0 acquisition software.  Acquired FIDs were analyzed using MestReC 3.2.  
Elemental analyses were conducted by Atlantic Microlabs and are ± 0.4 of theoretical.  
All HRMS mass spectral analyses were conducted at Duquesne University with a nano 
ESI chip cube TOF HRMS and are ± 0.004 of theoretical.  All 1H NMR spectra were 
taken in CDCl3 unless otherwise noted and are reported as ppm relative to TMS as an 
internal standard.  Coupling values are reported in Hertz. 
 
Series 1: C6-O LINKED BENZIMIDAZOLE SERIES 
1-Isopropyl-6-methoxy-4-nitro-1H-benzo[d]imidazole (214): A 500 mL one-neck flask 
was charged with 5-methoxy-3-nitrobenzene-1,2-diamine  (211; 5.0 g, 27.3 mmol), 
NaHB(OAc)3 (17.36 g, 81.9 mmol), THF (100 mL), acetone (7.93 g, 137 mmol), and 
formic acid (3.77 g, 81.9 mmol). The mixture was stirred overnight. The solvent was 
removed in vacuo, and the dark red residue was dissolved in formic acid (31 mL). BHT 
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(20.0 mg, 0.10 mmol) was added, and then the mixture was cooled to 0 °C. Concentrated 
HCl (87 mL) was added, and the mixture was quickly heated to reflux with a heating 
mantle. After maintaining reflux temperature for 15 min, the solvent was removed in 
vacuo at 80 °C. This solution was cooled to ambient temperature, neutralized with 50% 
NaOH (aq) to pH 8 then extracted with four times with 50 mL portions of EtOAc. The 
combined extracts were washed with three 10 mL portions of NaCl (aq, sat), dried over 
Na2SO4, decanted, and then the solvent was removed under reduced pressure to give a 
brown solid, which was subjected to SiO2 column chromatography (Hex/EtOAc 1:1) to 
afford 4.50 g (74%) of  as a yellow solid. Rf 0.32 (CH2Cl2/MeOH/NH4OH 100:10:0.1). 
MP 127.2–128.1 °C. 1H NMR (400 MHz, CDCl3): δ 8.12 (s, 1H), 7.21 (d, J = 2.3 Hz, 
1H), 7.79 (d, J = 2.3 Hz, 1H), 4.58–4.65 (m, 1H), 3.95 (s, 3H), 1.65 (d, J = 6.8 Hz, 6H). 
Anal. Calcd for C11H13N3O3: C, 56.16; H, 5.57; N, 17.86. Found: C, 56.45; H, 5.62; N, 
17.55. 
 
1-Isopropyl-4-nitro-1H-benzo[d]imidazol-6-ol (226): 1-Isopropyl-6-methoxy-4-nitro-
1H-benzo[d]imidazole (214; 1.00 g, 4.25 mmol) and 48% HBr (20 mL) were added to a 
50 mL microwave tube. The mixture was subjected to microwave irradiation (350 Watt) 
to maintain 120 ºC for 2.5 h. After cooling, the solvent was removed in vacuo. The 
resulting yellow solid was dissolved in minimum amount of H2O. NaHCO3 (sat, aq) was 
added with dropwise addition until the pH was equivalent to 6.0. The mixture was filtered 
and the yellow solid was collected on a #1 Whatman filter paper and washed with H2O 
and then dried under high vacuum (150 micron) to afford 0.92 g (97%) of product as a 
yellow solid. Rf 0.36 (CH2Cl2/MeOH/NH4OH 90:10:0.1). MP = 206 – 207 °C. 1H NMR 
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(400 MHz, DMSO-d6): δ 10.16 (s, 1H), 8.45 (s, 1H), 7.51 (d, J = 2.0 Hz, 1H), 7.40 (d, J = 
2.0 Hz, 1H), 4.68−4.75 (m, 1H), 1.50 (d, J = 6.8 Hz, 6H). Anal. Calcd for 
C10H11N3O3.0.131 % HBr: C, 51.81; H, 4.84; N, 18.12. Found: C, 51.84; H, 4.73; N, 
18.07.    
 
1-isopropyl-6-(1-methoxybutan-2-yloxy)-4-nitro-1H-benzo[d]imidazole (234b): 
A 100 mL oven dried one-neck flask was charged with 1-isopropyl-4-nitro-1H-
benzo[d]imidazol-6-ol (226; 334.0 mg, 1.5 mmol), 1-methoxybutan-2-ol (0.5 mL, 4.0 
mmol), triphenyl phosphine (985.0 mg, 3.8 mmol), and 4.0 mL of anhydrous DMF.  The 
solution was cooled to 0 oC.  Neat DIAD (0.4 mL, 2.8 mmol) was added with dropwise 
addition.  The solution was stirred for 30 min at 0 oC, the ice-bath was removed, and the 
reaction was stirred for an additional 2 h at 23 oC.  The reaction was then cooled to 0 oC 
and an additional quantity of DIAD (0.4 mL, 2.8 mmol) was added at 0 oC.  The reaction 
was stirred for 30 min at 0 oC then at 23 oC until the reaction was complete as determined 
by TLC. The reaction mixture was poured into 10 mL of EtOAc and 10 mL of K2CO3 
(sat, aq). This was extracted with three 10 mL portions of EtOAc and the combined 
organic extracts were washed with three 5 mL portions of NaCl (sat, aq) and dried 
(Na2SO4).  The solution was decanted and the solvent was removed in vacuo.  The crude 
material was carried on directly without any further purification. 1H NMR (400 MHz, 
CDCl3): δ 8.10 (s, 1H), 7.83 (d, J = 2.24 Hz,1H), 7.36 (d, J = 2.23 Hz,1H),  4.55-4.62 
(sept,  J= 6.7Hz, 1H ), 4.37−4.43 (m, 1H), 3.42-3.49 (m, 2H), 3.37(s, 3H),1.72-1.78 (m, 
2H), 1.61 (d, J = 6.78 Hz, 6H),  1.00 (t, J = 7.47 Hz, 3H).  
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1-isopropyl-6-(1-methoxybutan-2-yloxy)-1H-benzo[d]imidazol-4-amine (235b) : 
The crude material  from above (234b) was dissolved into 25 mL of EtOH and added to a 
Parr hydrogenation vessel previously charged with 90 mg of Pd/C (10 % w/w).  After 3 
vacuum/purge cycles with H2, the vessel was charged to 50 psi with H2 and shaken for 12 
h on a Parr hydrogenation apparatus; the reaction was monitored by TLC.  The mixture 
was filtered through a pad of Celite and the pad was then washed with an additional 10 
mL of EtOH.The solvent was removed in vacuo.  The resultant oil was treated with 50 
mL of 1 N HCl (aq) (pH<1) and washed with three 10 mL portions of EtOAc. The 
aqueous phase was neutralized and then basified with 5%  K2CO3 (aq) (pH~ 9-10) and 
then extracted with three 15 mL portions of EtOAc.  The combined EtOAc layers were 
extracted with three 10 mL portions of 1 N HCl, then basified with 50 % NaOH(aq) and 
back extracted with three 15 mL portions of Et2O. The combined Et2O layers were 
washed with three 10 mL portions of NaCl (sat, aq) and dried (Na2SO4).  The organic 
phase was decanted and the solvent was removed in vacuo to afford 220 mg of a brown 
semisolid product, which was carried out to the next step without further purification.  1H 
NMR (400 MHz, CDCl3): δ 7.75 (s, 1H), 6.38 (d, J = 2.07 Hz,1H), 6.25 (d, J = 2.07 Hz, 
1H),  4.42-4.52 (m, 1H ), 4.33 (broad s, 1H),  4.26−4.33 (td, J = 5.5 Hz,  J =10.9 Hz, 1H), 
3.52-3.62 (ddd, J = 4.91 Hz, J = 10.17 Hz, J = 24.31 Hz, 2H), 3.41 (s, 3H),1.73-1.82 (m, 
2H), 1.58 (d, J = 6.76 Hz, 6H),  0.96-1.01 (t, J = 7.47 Hz, 3H). 
N-benzyl-1-isopropyl-6-(1-methoxybutan-2-yloxy)-1H-benzo[d]imidazol-4-amine 
hydrochloride (190b):  A dry round bottom flask was charged with 1-isopropyl-6-(1-
methoxybutan-2-yloxy)-1H-benzo[d]imidazol-4-amine (235b; 200 mg, 0.72 mmol), 
NaBH(OAc)3 (307.31 mg, 1.45 mmol), benzaldehyde (80 µL, 0.80 mmol) and 5.0 mL of 
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1,2- dichloroethane. The mixture was stirred at 23 oC for 24 h. Additional NaBH(OAc)3  
(40.0 mg, 0.19 mmol) and benzaldehyde (25µL, 0.25 mmol) were added to the reaction 
mixture to drive the reaction to completion. The reaction mixture was stirred at 23 oC for 
additional 2 h. The reaction mixture was quenched with the addition of 10 mL of 5% 
K2CO3(aq)  (pH~ 9-10), the mixture was extracted with three 10 mL portions of EtOAc. 
The combined organic layers were washed with three 10 mL portions of NaCl (sat, aq) 
and dried (Na2SO4). The solution was decanted and the solvent was removed in vacuo to 
provide a brown solid, which was subjected to silica gel flash column chromatography 
(Hex/EtOAc/Et3N 1:1:0.005) to afford 200 mg of the product as a colorless oil in 76% 
yield.This colorless oil was treated with gaseous HCl in EtOAc.  The hydrochloride salt 
of the N-benzyl-1-isopropyl-6-(1-methoxybutan-2-yloxy)-1H-benzo[d]imidazol-4-amine 
(220 mg) was collected as white solid. Rf 0.7 (CH2Cl2/MeOH/NH4OH 100:10:0.1). MP = 
129-130oC. 1H NMR (400 MHz, CDCl3) : δ 7.27 (s, 1H), 7.41-7.43 (m, 2H), 7.31-7.34 
(m, 2H), 7.26 (m, 1H), 6.32 (d, J = 2.05 Hz,1H), 6.10 (d, J = 2.04 Hz,1H),  5.30 (broad 
peak, 1H), 4.45-4.52 (m, 3H ), 4.23−4.28 (m, 1H), 3.49-3.59 (dd, J = 4.85, 10.16, 23.14 
Hz, 2H), 3.37(s, 3H),1.70-1.74 (m, 2H), 1.59 (d, J = 6.76 Hz, 6H) 0.96-1.00 (t, J = 
7.47Hz, 3H). Anal. Calcd for C22H30ClN3O2: C, 65.41; H, 7.49; N, 10.40. Found: C, 
65.43; H, 7.35; N, 10.33.  
 
2-(1-isopropyl-4-nitro-1H-benzo[d]imidazol-6-yloxy)ethyl benzoate (234c): 
An  oven dried one-neck flask was charged with 1-isopropyl-4-nitro-1H-
benzo[d]imidazol-6-ol (226; 334.0 mg, 1.5 mmol), 2-hydroxyethyl benzoate (665 mg, 4.0 
mmol), triphenyl phosphine (985.0 mg, 3.8 mmol), and 4.0 mL of anhydrous DMF.  The 
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resulting solution was cooled to 0 oC.  Neat DIAD (0.4 mL, 2.8 mmol) was added 
dropwise at 0 oC.  The solution was stirred for 30 min at 0 oC and then stirred for 
additional 2 h at 23 oC.  The reaction was then cooled to 0 oC and additional DIAD (0.4 
mL, 2.8 mmol) was added dropwise at 0 oC. The reaction was stirred for 30 min at 0 oC 
then at 23 oC for 12 h. The reaction was followed by TLC.  After completion of the 
reaction, 10 mL of EtOAc and 10 mL of K2CO3 (sat, aq) were added to the reaction 
mixture.  The aqueous layer was extracted with three 10 mL portions of EtOAc and the 
organic layers were combined and washed with three 5 mL portions of NaCl (sat, aq), 
and dried (Na2SO4). The organic phase was decanted and the solvent was removed in 
vacuo. The crude material was carried onto the next step without further purification. 1H 
NMR (400 MHz, CDCl3): δ 8.13 (s, 1H), 8.01-8.02 (m, 5H), 7.85 (d, J = 2.29 Hz, 1H), 
7.29 (d, J = 2.29 Hz, 1H),  5.23 (m, 1H), 4.73-4.76 (dd, J = 4.13 Hz, 5.27 Hz, 2H), 3.81-
3.84 (dd, J = 5.25 Hz, J = 6.19 Hz, 2H), 1.62 (d, J = 6.74 Hz, 6H).  
 
2-(4-amino-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)ethyl benzoate (235c) : 
A Parr hydrogenation vessel was charged with 115 mg of Pd/C (10 % w/w) and a 
solution of starting material 234c (obtained from the previous step) in 20 mL of EtOH 
was added to the reaction vessel. After 3 vacuum/purge cycles with H2, the reaction 
vessel was shaken under 50 psi H2 for 12 h with a Parr hydrogenation apparatus. 
Completion of reaction was monitored by TLC.  The reaction mixture was filtered 
through a pad of Celite, the pad was washed with an additional 10 mL of EtOH and the 
solvent was removed in vacuo.  The resultant brown oil was treated with 50 mL of 1 N 
HCl (aq) and washed with three 10 mL portions of EtOAc. The aqueous layer was then 
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basified with 5% K2CO3 (aq) and then extracted with three 15 mL portions of EtOAc. 
The combined EtOAc layers were washed with three 10 mL portions of NaCl (sat, aq) 
and dried (Na2SO4).  The organic phase was decanted and the solvent was removed in 
vacuo to afford 110 mg of brown crude solid, which was subjected to the next step 
without further purification.  Rf 0.45 (CH2Cl2/MeOH/NH4OH 100:10:0.1). 1H NMR 
(400MHz, CDCl3): δ 8.075 (dd, J = 1.31 Hz, J = 8.37 Hz, 2H), δ 7.76 (s, 1H), 7.65-7.71 
(m, 2H), 7.54-7.59 (m, 2H), 7.42-7.51 (m, 4H), 6.33 (d, J = 2.12 Hz, 1H), 6.25(d, J = 
2.14 Hz, 1H),  5.00 (td, J = 6.3 Hz, J = 12.6 Hz, 1H), 4.62-4.71 (dd, J = 4.3 Hz, J = 5.4 
Hz, 2H), 4.37 (broad peak, 2H), 4.33−4.36 (dd,  J = 4.3 Hz, J = 5.3 Hz, 2H), 1.58 (d, J = 
6.76 Hz, 6H).  
 
2-(4-(benzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)ethyl benzoate (190c’):  
A 100 mL dry round bottom flask was charged with 2-(4-amino-1-isopropyl-1H-
benzo[d]imidazol-6-yloxy)ethyl benzoate (235c; 110 mg, 0.3 mmol), NaBH(OAc)3 
(127.16 mg, 0.6 mmol), benzaldehyde (33µL, 0.33 mmol) and 5.0 mL of 1,2-
dichloroethane. The mixture was stirred at 23 oC for 12 h. After 12 h, additional 
NaBH(OAc)3 (41.0 mg, 0.2 mmol), and benzaldehyde (11 µL, 0.11 mmol) were added to 
the reaction mixture to complete the consumption of starting material. The reaction 
mixture was stirred at 23 oC for an additional 3 h. The reaction was quenched with 10 mL 
of NaHCO3 (sat, aq) solution and the mixture was extracted with three 10 mL portions of 
EtOAc. The combined organic extracts were washed with three 10 mL portions of NaCl 
(sat, aq) and dried (Na2SO4). The solvent was decanted and in vacuo removal of the 
solvent provided a brown solid, which was subjected to silica gel flash column 
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chromatography (Hex/EtOAc 1:1) to afford 40 mg of a white solid in 31% yield. MP = 
141.5-142.8 oC.  Rf 0.7 (CH2Cl2/MeOH/NH4OH 100:10:0.1). 1H NMR (400MHz, 
CDCl3): δ 8.07 (dd, J = 1.3 Hz, J = 8.4 Hz, 1H), 7.73 (s, 1H), 7.55-7.60 (m, 1H), 7.40-
7.46 (m, 4H), 7.31-7.35 (m, 2H), 7.27 (m, 1H), 6.26 (d, J = 2.07 Hz, 1H), 6.10 (d, J = 
2.04 Hz, 1H),  5.29 (t, J = 5.76 Hz, 1H), 4.67 (dd, J = 4.33 Hz, J = 5.31 Hz, 2H) 4.45-
4.52 (m, 3H), 4.23−4.28 (dd, J = 3.70 Hz, J = 5.95 Hz, 2H), 1.58 (d, J = 6.76 Hz, 6H). 
HRMS (EI) Calcd for C26H27N3O3 : 430.2125 [M+H+], Found 430.2125 [M+H+].  
 
2-(4-(benzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)ethanol (190c): 2-(4-
(benzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)ethyl benzoate (190c’; 35 mg, 
0.081 mmol) was dissolved in 2 mL of 5% KOH (MeOH) and the reaction mixture was 
stirred for 12 h. The reaction was monitored by TLC. The reaction was quenched with 5 
mL of NH4Cl (sat, aq) and extracted with three 10 mL portions of EtOAc. The combined 
organic extracts were washed with three 10 mL portions of NaCl (sat, aq) and dried 
(Na2SO4). The organic layer was decanted and removal of the solvent in vacuo provided 
an off white solid, which was subjected to silica gel flash column chromatography (Hex: 
EtOAc; 1:1) to afford 18 mg of white solid as the product. Recrystallization of the solid 
with CH2Cl2/Hex (9:1) mixture provided 15 mg of product as white needles in 56% yield.  
Rf 0.65 (CH2Cl2/MeOH/NH4OH 90:10:0.1). MP =140-142oC. 1H NMR (400MHz, 
CDCl3): δ 7.74 (s, 1H), 7.41-7.43 (m, 2H), 7.31-7.36 (m, 2H), 7.25-7.29 (m, 1H), 6.23 (d, 
J = 2.11 Hz,1H), 6.06 (d, J = 2.07 Hz, 1H),  5.33 (broad peak, 1H), 4.45-4.55 (m, 3H ), 
4.08−4.14 (dd, 2H, J = 3.9Hz, J = 5.2Hz), 3.94-3.97 (dd, J = 3.4, 5.51 Hz, 2H), 1.59 (d, J 
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= 6.75 Hz, 6H). Anal. Calcd for C19H23N3O2. 0.6 % H2O: C, 67.87; H, 7.25; N, 12.49. 
Found: C, 67.88; H, 6.93; N, 12.34.  
 
1-((1-isopropyl-4-nitro-1H-benzo[d]imidazol-6-yl)oxy)butan-2-yl benzoate (234d): 
An  100 mL oven dried one-neck flask was charged with 1-isopropyl-4-nitro-1H-
benzo[d]imidazol-6-ol (266, 166.0 mg, 0.75 mmol), 1-hydroxybutan-2-yl benzoate (388 
mg, 2.0 mmol), triphenyl phosphine (493 mg, 1.9 mmol), and 4.0 mL of anhydrous DMF.  
The resulting solution was cooled to 0 oC.  Neat DIAD (0.2 mL, 1.4 mmol) was added 
with dropwise addition at 0 oC.  The solution was stirred for 30 min at 0 oC and then 
stirred at 23 oC for additional 2 h.  The reaction was then cooled to 0 oC and additonal 
DIAD (0.2 mL, 1.4 mmol) was added with dropwise addition at 0 oC.  The reaction was 
stirred for 30 min at 0 oC then at 23 oC for an additional 12 h. The reaction was monitored 
by TLC.  After completion of reaction, 10 mL of EtOAc and 10 mL of K2CO3 (sat, aq) 
were added to the reaction mixture.  The aqueous layer was extracted with three 10 mL 
portions of EtOAc and the combined organic layers were washed with three 5 mL 
portions of NaCl (sat, aq) and dried (Na2SO4).  The organic layer was decanted and the 
solvent was removed in vacuo to afford 3.3 g product as brown oil. The crude material 
was carried onto the next step without further purification. 1H NMR (400 MHz, CDCl3): δ 
8.10 (s, 1H), 7.99-8.03 (m, 5H), 7.79 (d, J = 2.27 Hz, 1H), 7.28 (d, J = 2.30 Hz,1H),  
5.38-5.44 (m, 1H), 4.55 (m, 1H), 4.20-4.40 (m, 2H ), 1.71-1.79 (m, 2H), 1.58 (dd, J = 
4.72 Hz, 6.73Hz,  6H),  1.05 (t, J = 7.46 Hz, 3H).  
 
1-((4-amino-1-isopropyl-1H-benzo[d]imidazol-6-yl)oxy)butan-2-yl benzoate (235d): 
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A Parr hydrogenation vessel was charged with 100 mg of Pd/C (10 % w/w) and a 
solution of starting material (234d; obtained from the previous step) in EtOH was added 
to the reaction vessel. After 3 vacuum/purge cycles with H2, the reaction vessel was 
shaken under 50 psi H2 for 12 h on a Parr hydrogenation apparatus. Completion of 
reaction was monitored by TLC.  The reaction mixture was filtered through a pad of 
Celite, the pad was washed with an additional 20 mL of EtOH, and the solvent was 
removed in vacuo.  The resultant brown oil was treated with 50 mL of 1 N HCl (aq) and 
washed with three 10 mL portions of EtOAc. The aqueous layer was basified with 5% 
K2CO3 (aq) (pH~ 9-10) and then extracted with three 15 mL portions of EtOAc.  The 
combined EtOAc layers were washed with three 10 mL portions of NaCl (sat, aq) and 
dried (Na2SO4).  The organic phase was decanted and the solvent was removed in vacuo 
to afford 280 mg of crude product, which was subjected to the next step without further 
purification.1H NMR (400 MHz, CDCl3): δ 8.06 (dd, J = 1.31 Hz, J = 8.45 Hz, 2H), 7.74 
(s, 1H), 7.55-7.57 (m, 1H),7.48-7.51 (m, 2H), 6.58 (broad s, 2H),  6.30 (d, J = 2.06 Hz, 
1H), 6.21 (d, J = 2.09 Hz, 1H),  5.34-5.41 (m, 1H), 4.43 (m, 1H), 4.14-4.23 (ddd, J = 4.46 
Hz, J = 10.26 Hz, J = 20.23 Hz, 2H ), 1.89-1.95 (m, 2H), 1.54 (dd, J = 3.67 Hz, J = 6.74 
Hz, 6H),  1.05 (t, J = 7.43 Hz, 3H).  
 
1-((4-(benzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yl)oxy)butan-2-yl benzoate 
(190d’):  A dry round bottom flask was charged with 2-(4-amino-1-isopropyl-1H-
benzo[d]imidazol-6-yloxy)ethyl benzoate (234d; 280 mg, 0.75 mmol), NaBH(OAc)3 
(317.91 mg, 1.5 mmol), benzaldehyde (85 µL, 0.85 mmol) and 5.0 mL of 1,2-
dichloroethane. The mixture was stirred at 23 oC for 12 h. Then reaction was quenched 
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with 10 mL of NaHCO3 (sat, aq) (pH~ 8-9) and the mixture was extracted with three 10 
mL portions of EtOAc. The combined organic layers were washed with three 5 mL 
portions of NaCl (sat, aq) and dried (Na2SO4). The organic layer was decanted and in 
vacuo removal of the solvent provided a brown solid, which was subjected to silica gel 
flash column chromatography (Hex/EtOAc 1:1) to afford 40 mg of a brown solid in 11% 
yield. MP = 116.1-116.9 oC. Rf  0.71 (CH2Cl2/MeOH/NH4OH 90:10:0.1). 1H NMR (400 
MHz, CDCl3): δ 8.07 (dd, J = 1.35 Hz, J = 8.39 Hz, 1H), δ 7.71 (s, 1H), 7.54-7.59 (m, 
1H), 7.39-7.46 (m, 4H), 7.29-7.35 (m, 2H),  7.26 (m, 1H), 6.26 (d, J = 2.07 Hz, 1H), 6.08 
(d, J = 2.05 Hz, 1H),  5.39 (m, 1H), 5.25 (t, J = 5.51 Hz, 1H), 4.45-4.52 (m, 4H), 
4.13−4.22 (ddd, J = 5.0 Hz, J = 10.3 Hz, J = 22.9 Hz, 2H), 1.89-1.94 (m, 2H), 1.59 (dd, J 
= 3.5 Hz, J = 6.8 Hz, 6H),  1.07 (t, J = 7.39 Hz, 3H). HRMS (EI) Calcd for C28H31N3O3: 
457.2438 [M+H+], Found 457.2438 [M+H+].  
 
1-((4-(benzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yl)oxy)butan-2-ol 
hydrochloride (190d): 2-(4-(benzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-
yloxy)ethyl benzoate (190d’; 36.0 mg, 0.079 mmol) was dissolved into 2 mL of 5% KOH 
(MeOH) and the reaction mixture was stirred for 12 h. Completion of the reaction was 
determined by TLC. The reaction was quenched with 5 mL of NH4Cl (sat, aq) and 
extracted with three10 mL portions of EtOAc. The combined EtOAc layers were washed 
with three 5 mL portions of NaCl (sat, aq) and dried (Na2SO4). The organic phase was 
decanted and evaporation of the solvent provided 30 mg of the off white solid, which was 
dissolved into Et2O and HCl (Et2O) was slowly added to precipitate HCl salt of the 
product. Recrystallization with EtOH provided 15 mg of a white solid in 65% yield. Rf 
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0.62 (CH2Cl2/MeOH/NH4OH 90:10:0.1). MP = 140-142oC. 1H NMR (400 MHz, MeOD-
d4): δ 9.23 (s, 1H), 7.42-7.46 (d, J =7.24 Hz, 2H), 7.38-7.35 (t, J = 7.4 Hz, 2H), 7.30 (t, J 
= 7.24 Hz, 1H), 6.67 (d, J = 1.71 Hz, 1H), 6.37 (d, J = 1.85 Hz, 1H),  4.92 (m, 1H), 4.49 
(s, 2H), 3.96−4.1 (ddd, J = 5.2 Hz, J = 9.6 Hz, J = 16.0 Hz, 2H), 3.80-3.86 (m, 1H), 1.68 
(d, J = 6.70 Hz, 6H), 1.50-1.65 (m, 2H), 1.00-1.05 (t, J = 7.44 Hz, 3H). Anal. Calcd for 
C21H28ClN3O2. 1.46 % H2O: C, 60.59; H, 7.48; N, 10.09. Found: C, 60.60; H, 7.10; N, 
9.90.  
 
Side chain Synthesis: 
2-Hydroxybutyl benzoate (237a): Butane-1,2-diol (5 g, 55.48 mmol) was dissolved into 
35 mL of toluene and TEA (8 mL, 55.48 mmol) was added to the reaction mixture. Then 
benzoyl chloride (6.4 mL, 55.48 mmol) was added with dropwise addition to the solution. 
The reaction mixture was stirred for 12 h at 23 oC; the reaction was monitored by TLC. 
The reaction was quenched with 15 mL of NaHCO3 (sat, aq) and extracted with three 10 
mL portions of EtOAc. The combined organic layers were washed with three 5 mL 
portions of NaCl (sat, aq) and dried (Na2SO4). The solvent was decanted and removal of 
solvent under pressure provided 7.0 g of colorless oil in 70 % yield.  
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Series 2: C6-N BENZIMIDAZOLE SERIES 
 
(R)-benzyl 2-(N-(4-(benzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yl)-2,2,2-
trifluoroacetamido)propanoate (245a): NaH, 60% dispersion in mineral oil (36 mg, 0.6 
mmol) was added to a solution of (N-(4-(benzylamino)-1-isopropyl-1H-
benzo[d]imidazol-6-yl)-2,2,2-trifluoroacetamide (243; 188.2 mg, 0.5 mmol) in 2 mL of 
THF.  This white suspension was stirred at 23 oC for 30 min.  A 0.25 M solution of 
triflate (244a, 0.75 mmol, 1.5 equiv) in 3 mL of THF was added, and the stirring was 
continued for an additional 90 min.  The mixture was then diluted with 30 mL of EtOAc, 
washed with two 5 mL portions of NaCl (sat, aq), and dried (Mg2SO4).  The mixture was 
filtered and evaporated in vacuo to provide a brown solid, which was subjected to silica 
gel column chromatography (Hex/EtOAc 1:1) to afford 245 mg (90%) of product as a 
white semisolid.  Rf 0.54 (CH2Cl2/MeOH/NH4OH 100:5:0.1).  1H NMR (500 MHz, 
CDCl3): δ 7.86 (d, J = 3.90 Hz, 1H), 7.25 – 7.40 (m, 10H), 6.86 (s, 0.5H), 6.63 (s, 0.5H), 
6.35 (s, 0.5H), 6.15 (s, 0.5H), 5.43 (m, 1H), 5.15-5.25 (m, 2H), 4.84 (q, J = 7.3 Hz , 
0.5H), 4.67(q, J = 7.3 Hz , 0.5H), 4.35 – 4.44 (m, 3H), 1.51-1.56 (m, 6H), 1.2-1.4 (dd, J = 
7.38 Hz, J = 63.57 Hz, 3H). Anal. Calcd for C29H29F3N4O3. 0.31% H2O: C, 63.99; H, 
5.48; N, 10.29. Found: C, 64.02; H, 5.37; N, 10.09. 
 
(R)-2-(4-(benzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-ylamino)propan-1-ol 
(189b): NaBH4 (68.5 mg, 1.81 mmol) was added to a solution of (R)-benzyl 2-(N-(4-
(benzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yl)-2,2,2-trifluoroacetamido) 
propanoate (245a; 195 mg, 0.36 mmol) in 5 mL of EtOH at 0 °C.  The mixture was 
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stirred at 23 oC for 12 h, then quenched with 5 mL of NH4Cl (sat, aq), and extracted with 
three 10 mL portions of EtOAc.  The combined organic extracts were washed with three 
10 mL of NaCl (sat, aq) and dried (Na2SO4).  The mixture was filtered and the solvent 
was removed in vacuo to provide a yellowish white solid, which was subjected to silica 
gel column chromatography (hex/EtOAc/ Et3N 1:1:0.1) to afford 70 mg (58%) of an 
offwhite foam.  Rf 0.2 (CH2Cl2/MeOH/NH4OH 100:5:0.1). MP = 135-137.1 ºC. 1H NMR 
(500 MHz, CDCl3): δ 7.66 (s, 1H), 7.44 (d, J = 7.02 Hz, 2H), 7.36-7.34 (t, J = 7.45 Hz, 
2H), 7.27 (m, 1H), 6.02 (d, J = 1.82 Hz, 1H), 5.78 (d, J = 1.83 Hz, 1H), 5.27 (broad s, 
1H), 4.44 – 4.48 (m, 3H), 3.73 (dd, J = 4.35 Hz, J = 10.68 Hz, 1H), 3.65-3.62 (m, 1H), 
3.49 (dd, J = 10.69, 6.29 Hz, 1H), 1.58 (dd, J = 1.34, 6.75 Hz, 6H), 1.20 (d, J = 6.47 Hz, 
3H). Anal. Calcd for  C20H26N4O. 0.14 % H2O: C, 70.44; H, 7.76; N, 16.42.  Found: C, 
70.52; H, 7.60; N, 16.05.  
 
(S)-methyl 2-(N-(4-(benzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yl)-2,2,2-
trifluoroacetamido)propanoate (245b): NaH, 60% dispersion in mineral oil (36 mg, 0.6 
mmol) was added to a solution of (N-(4-(benzylamino)-1-isopropyl-1H-
benzo[d]imidazol-6-yl)-2,2,2-trifluoroacetamide (243; 188.2 mg, 0.5 mmol) in 2 mL of 
THF.  This white suspension was stirred at 23 oC for 30 min.  A 0.25 M solution of 
triflate (244b; 177.12 mg, 0.75 mmol) in 3 mL of THF was added, and the stirring was 
continued for an additional 70 min.  The mixture was diluted with 30 mL of EtOAc, 
washed with three 5 mL portions of NaCl (sat, aq) and dried (Mg2SO4).  The mixture was 
filtered and the solvent was removed in vacuo to provide a brown solid, which was 
subjected to silica gel column chromatography (Hex/EtOAc 1:1) to afford 180 mg (78%) 
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of a white semisolid. Rf 0.54 (CH2Cl2/MeOH/NH4OH 95:5:0.1). 1H NMR (500 MHz, 
CDCl3): δ 7.90 (s, 1H), 7.40 (d, J = 7.38 Hz, 2H), 7.32-7.36 (t, J = 7.40 Hz, 2H), 7.27 (m, 
1H), 6.89 (s, 0.5H), 6.68 (s, 0.5H),  6.38 (s, 0.5H), 6.17 (s, 0.5H), 5.53 (broad s, 1H), 4.80 
(m, 1H), 4.48-4.58 (m, 3H), 3.76 (d, J = 25.05 Hz, 3H),  1.61-1.66 (dd, J = 6.61 Hz, 
12.12 Hz, 6H), 1.25-1.35 (dd, J = 7.35 Hz, J = 40.89 Hz, 3H). Anal. Calcd for 
C23H25F3N4O3: C, 59.73; H, 5.45; N, 12.11   Found: C, 59.57; H, 5.46; N, 11.83. 
 
(S)-2-(4-(benzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-ylamino)propan-1-ol 
(189c): NaBH4 (65.5 mg, 1.73 mmol) was added to a solution of (S)- methyl 2-(N-(4-
(benzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yl)-2,2,2-trifluoroacetamido) 
propanoate (245b; 160 mg, 0.35 mmol) in 5 mL of EtOH at 0 °C. The mixture was stirred 
at 23 oC for 12 h, then quenched with 5 mL of NH4Cl (sat, aq), and extracted with 10 mL 
portions of EtOAc.  The combined organic extracts were washed with three 10 mL 
portions of NaCl (sat, aq) and dried (Na2SO4). The mixture was filtered and the solvent 
was removed in vacuo to provide a pinkish white solid, which was subjected to silica gel 
column chromatography (Hex/EtOAc 1:1, 0.5% Et3N) to afford 50 mg (58%) of white 
foam. Rf 0.2 (CH2Cl2/MeOH/NH4OH 95:5:0.1). MP = 109.2-111 oC. 1H NMR (500 MHz, 
DMSO-d6): δ 7.81 (s, 1H), 7.37 (d, J = 7.46 Hz, 2H), 7.29-7.33 (t, J = 7.60 Hz, 2H), 7.21 
(t, J = 7.28 Hz, 1H), 5.94 (t, J = 6.78 Hz, 1H), 5.84 (d, J = 1.33 Hz, 1H), 5.63 (d, J = 1.37 
Hz, 1H), 4.78 (broad s, 1H), 4.56 (t, J = 5.61Hz, 1H), 4.45 (td, J = 6.78 Hz, J = 13.66 Hz, 
1H), 4.39 (d, J = 6.21 Hz, 2H), 3.47 (m, 1H), 3.21 (m, 1H), 1.47 (d, J = 6.71 Hz, 6H), 
1.06 (d, J = 6.31Hz, 3H). Anal. Calcd for  C20H26N4O. 0.29 % EtOAc: C, 69.82; H, 7.84; 
N, 15.39.  Found: C, 69.54; H, 7.74; N, 15.66. 
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Series 3 : C6-C BENZIMIDAZOLE SERIES 
1-Isopropyl-4-nitro-1H-benzo[d]imidazol-6-yl trifluoromethanesulfonate (227):  
Solid K2CO3 (608.1 mg, 4.4 mmol)  was added to a solution of 1-isopropyl-4-nitro-1H-
benzo[d]imidazol-6-ol (226; 486.7 mg, 2.2 mmol) and 4-nitrophenyl 
trifluoromethanesulfonate (656.5 mg, 2.42 mmol) in 11 mL of anhydrous DMF. This 
suspension was stirred at 23 oC for 2 h. The reaction mixture was diluted with CH2Cl2 
(250 mL) and then filtered through #1 Whatman filter paper. The filtrate was washed 
with four 100 mL portions of H2O, three 20 mL portions of NaCl (sat, aq), and dried 
(Na2SO4). The mixture was decanted and the solvent was removed in vacuo to provide a 
yellow oil, which was subjected to silica gel column chromatography (Hex/EtOAc/ Et3N 
1:1:0.005) to afford 673.0 mg of an off white solid (87% yield). Rf 0.42 
(CH2Cl2/MeOH/NH4OH 95:5:0.1). MP = 129.5-130.5 oC. 1H NMR (DMSO-d6): δ 8.33 
(s, 1H), 8.08 (d, J = 2.2 Hz, 1H), 7.70 (d, J = 2.6 Hz, 1H), 4.71 (d, J = 6.71 Hz, 1H), 1.70 
(d, J = 6.77 Hz, 6H). Anal. Calcd for C11H10F3N3O5S: C, 37.40; H, 2.85; N, 11.89. 
Found: C, 37.43; H, 2.79; N, 11.84.  
 
6-benzyl-1-isopropyl-4-nitro-1H-benzo[d]imidazole (229a): A dry 20 mL microwave 
tube was charged with 1-isopropyl-4-nitro-1H-benzo[d]imidazol-6-yl 
trifluoromethanesulfonate (227; 353.03 mg, 1.0 mmol), potassium benzyltrifluoroborate 
(198.03 mg, 1.0 mmol), Cs2CO3 (488.7 mg, 1.5 mmol) and PdCl2(dppf)·CH2Cl2 (81.66 
mg, 0.1 mmol). The microwave tube was capped with a septum and underwent three 
vaccum/ Ar purge cycles. A mixture of degassed deionized H2O (0.7 mL) and THF (7 
mL) was added via syringe. The rubber septum was quickly removed and replaced with a 
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microwave cap. The mixture was subjected to microwave irradiation at 250 Watt to 
maintain the reaction temperature at 110 ºC for 1.5 h.  After cooling to 23 oC the mixture 
was filtered through a pad of Celite and the pad was washed with an additional 10 mL of 
EtOAc. The combined organic layers were washed with three 5 mL portions of NaCl (sat, 
aq) and dried (Mg2SO4). Filtration, then removal of the solvent under reduced pressure, 
gave a brown solid, which was subjected to silica gel column chromatography 
(Hex/EtOAc/ Et3N 1:1:0.005) to afford 70.0 mg of an off white solid product in 32% 
yield. Rf 0.4 (CH2Cl2/MeOH/NH4OH 95:5:0.1). MP = 106-106.5oC. 1H NMR (CDCl3): δ 
8.18 (s, 1H), 8.05 (d, J = 1.26 Hz, 1H), 7.52 (d, J = 0.93 Hz, 1H), 7.34 (m, 2H), 7.27 (m, 
1H), 7.22 (d, J = 7.16 Hz, 2H), 4.64 (m, J = 6.75 Hz, 1H), 4.21 (s, 2H), 1.63 (d, J = 6.75 
Hz, 6H). Anal. Calcd for C17H17N3O2: C, 69.14; H, 5.80; N, 14.23. Found: C, 68.97; H, 
5.80; N, 14.23.   
 
6-benzyl-1-isopropyl-1H-benzo[d]imidazol-4-aminium chloride (230a): Solid 10% 
Pd/C (15 mg)  was added to an empty Parr hydrogenation vessel. A solution of 6-benzyl-
1-isopropyl-4-nitro-1H-benzo[d]imidazole (229a; 77 mg, 0.26 mmol) in EtOH (20 mL) 
and CHCl3 (1.5 mL) was added to the vessel. After three vaccum/ H2 purge cycles, the 
mixture was shaken at 50 psi of H2 for 12 h. After completion of the reaction (TLC), the 
mixture was filtered through a pad of Celite and the pad was washed with an additional 
10 mL of EtOH. The filtrate was concentrated in vacuo to afford 61.0 mg of a green 
semisolid in 90% yield. The crude was carried onto the next step without further 
purification. 1H NMR (500 MHz, DMSO-d6): δ 9.45 (s, 1H), 7.24 (m, , 4H), 7.14 (m, 
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1H), 6.64 (s, 1H), 6.19 (s, 1H), 5.28 (broad peak, 2H), 4.52−4.58 (m, 1H), 3.87 (s, 2H), 
1.48 (d, J = 6.73 Hz, 6H).  
 
N-benzyl-6-benzyl-1-isopropyl-1H-benzo[d]imidazol-4-amine (191a): A dry 100 mL 
round bottom flask was charged with 6-benzyl-1-isopropyl-1H-benzo[d]imidazol-4-
aminium chloride (230a; 60.0 mg, 0.22 mmol), NaBH(OAc)3 (95.3 mg, 0.44 mmol), 
benzaldehyde (24 µL, 0.242 mmol) and 5 mL of 1,2-dichloroethane. The mixture was 
stirred at 23 oC for 12 h. After quenching with 2 mL of deionized H2O and 2 mL of 1N 
NaOH (aq), the mixture was extracted with three 10 mL portions of Et2O. The combined 
extracts were washed with three 10 mL portions of NaCl (sat, aq), and dried (Mg2SO4). 
The mixture was filtered and the solvent was removed in vacuo to provide a brown solid, 
which was subjected to silica gel flash column chromatography (Hex/EtOAc/Et3N 
1:1:0.005) to afford 35 mg of an off white solid product in 38% yield. Rf 0.54 
(CH2Cl2/MeOH/NH4OH 95:5:0.1). MP = 74-78 oC. 1H NMR (400 MHz, CDCl3): δ 7.77 
(s, 1H), 7.18−7.41 (m, 10H), 6.57 (s, J = 0.84 Hz, 1H ), 6.27 (d, J = 1.12 Hz, 1H), 5.26 
(broad peak, 1H), 4.49−4.55 (m, 1H), 4.47 (s, 2H), 4.02 (s, 2H), 1.58 (d, J = 6.76 Hz, 
6H). Anal. Calcd for C24H25N3: C, 81.09; H, 7.09; N, 11.82. Found: C, 81.32; H, 7.09; N, 
11.80.  
 
Potassium (4-fluorobenzyl)trifluoroborate (233a): A dry single-neck round bottom 
flask with a nitrogen inlet was charged with trimethoxyborate (780 mg, 7.5 mmol) and 10 
mL of THF. The solution was cooled to -78 ºC and (4-fluorobenzyl) magnesium chloride 
0.75 M in THF (232a; 6.7 mL, 5 mmol) was added with dropwise addition over 15 min. 
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The mixture was stirred at -78 ºC for 1 h, and then allowed to warm to 23 oC over a 
period of 1 h. The resulting white slurry was cooled to 0 ºC and MeOH (5 mL) was added 
with dropwise addition over 5 min. Then the nitrogen inlet was removed and 4.5 M 
aqueous solution of KHF2 (6.5 mL, 30 mmol) was added dropwise at 0 ºC. After the 
addition, this mixture was stirred at 0 ºC for 1 h. The mixture was concentrated and 
residual water was removed with azeotropic distillation using three 10 mL aliquots of 
toluene (60 ºC in vacuo) and then dried under high vacuum (150 µM) for 12 h to afford a 
white solid. This solid was broken into a fine powder with a spatula and then suspended 
in 10 mL of acetone, and warmed on rotavap with rotation at atmosphere pressure for 5 
min at 40 ºC. The resulting suspension was filtered through a pad of Celite. An additional 
5 mL of acetone was added to the remaining solid in the flask and the procedure was 
repeated two additional times. The combined acetone filtrates were concentrated in 
vacuo. The solid obtained was suspended into 10 mL of Et2O, filtered through #1 
Whatman filter paper, and the collected solid was washed with 10 mL of Et2O and then 
finally dried under high vacuum (150 µM) to afford 399.6 mg of the desired salt (37%).  
The resultant white solid was carried to the next step further purification.1H NMR (400 
MHz, DMSO-d6): δ 6.94− 6.97 (m, 2H), 6.81−6.84 (m, 2H), 1.41 (br, 2H).  
 
6-(4-Fluorobenzyl)-1-isopropyl-4-nitro-1H-benzo[d]imidazole (229c): A dry 20 mL 
microwave tube with a stir bar was charged with 1-isopropyl-4-nitro-1H-
benzo[d]imidazol-6-yl trifluoromethanesulfonate (227; 176.6 mg, 0.50 mmol), potassium 
(2-fluorobenzyl)trifluoroborate (233a; 129.6 mg, 0.60 mmol), Cs2CO3 (485.7 mg, 1.50 
mmol) and PdCl2(dppf)·CH2Cl2 (41.0 mg, 0.05 mmol). The microwave tube was capped 
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with a rubber septum and subjected to 3 vacuum/Ar purge cycles. A mixture of degassed 
deionized H2O (0.5 mL) and THF (5 mL) was added via syringe.The rubber septum was 
quickly removed and replaced with the microwave tube cap, and the mixture was 
subjected to microwave irradiation at 250 Watt to maintain a temperature of 100 ºC for 3 
h. After cooling down to 23 oC, the mixture was filtered through a pad of Celite and the 
pad was washed with an additional 10 mL of EtOAc. The combined organic layers were 
washed with 5 mL of NaCl (sat, aq) and dried (Mg2SO4). Filtration and then removal of 
the solvent under reduced pressure gave a brown solid, which was subjected to silica gel 
column chromatography (Hex/EtOAc/Et3N 1:1:0.005) to afford 91.0 mg of an off white 
solid in 58% yield. Rf 0.42 (CH2Cl2/MeOH/NH4OH 95:5:0.1). 1H NMR (400 MHz, 
CDCl3): δ 8.18 (s, 1H), 7.99 (d, J = 2.0 Hz, 1H), 7.58 (s, 1H), 7.50 (d, J = 2.0 Hz, 1H), 
7.15−7.18 (m, 2H), 6.98−7.03 (m, 2H), 4.62−4.68 (m, 1H), 4.17 (s, 2H), 1.63 (d, J = 8.5 
Hz, 6H). HRMS (EI) calcd for C17H16FN3O2:  [M+1]+ 314.1260, Found 314.1311.  
 
6-(4-Fluorobenzyl)-1-isopropyl-1H-benzo[d]imidazol-4-amine (230c): Solid 10% 
Pd/C (20 mg) was added to an empty Parr hydrogenation vessel. A solution of 6-(4-
fluorobenzyl)-1-isopropyl-4-nitro-1H-benzo[d]imidazole (229c; 90 mg, 0.25 mmol) in 
EtOH (15 mL) and CHCl3 (1.5 mL) was added to the vessel. After 3 vaccum/H2 purge 
cycles, the mixture was shaken at 50 psi of H2 for 12 h. After completion of the reaction 
(TLC), the mixture was filtered through a pad of Celite and the pad was washed with an 
additional 10 mL of EtOH. The filtrate was concentrated in vacuo to give 90.0 mg of a 
greenish semisolid product (100% yield). This crude material was carried onto the next 
step without further purification.1H NMR (400 MHz, DMSO-d6): δ 8.47 (s, 1H), 7.24-
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7.26 (m, 2H), 7.06-7.10 (m, 2H), 6.76 (s, 1H), 6.28 (s, 1H), 4.63 (m, 1H), 3.89 (s, 2H), 
1.50 (d, J = 6.72 Hz, 6H).  
 
N-benzyl-6-(4-Fluorobenzyl)-1-isopropyl-1H-benzo[d]imidazol-4-amine (191c): A 
dry 100 mL round bottom flask was charged with 6-(4-fluorobenzyl)-1-isopropyl-1H-
benzo[d]imidazol-4-amine (230c; 100.0 mg, 0.35 mmol), NaBH(OAc)3 (148.35 mg, 0.70 
mmol), benzaldehyde (39 µL, 0.39 mmol) and 5.0 mL of 1,2-dichloroethane. The mixture 
was stirred at 23 oC for 24 h. The reaction was monitored by TLC. The reaction was 
quenched with 1 mL of NaHCO3 (sat, aq) and then extracted with three 5 mL portions of 
Et2O. The combined organic layers were washed with three 5 mL portions of NaCl (sat, 
aq) and dried (Mg2SO4). Filtration and then removal of the solvent under reduced 
pressure gave a brown solid, which was subjected to silica gel flash column 
chromatography (Hex/EtOAc/Et3N 1:1:0.005) to afford 60 mg of the brown solid product 
in 65% yield. Rf 0.6 (CH2Cl2/MeOH/NH4OH 90:10:0.1). MP = 93-95.5oC. 1H NMR (400 
MHz, CDCl3): δ 7.78 (s, 1H), 7.4 (dd, J = 7.26 Hz, 2H), 7.34-7.30 (m, 3H), 7.10-7.14 (m, 
2H), 6.91-6.96 (m, 2H), 6.53 (s, 1H), 6.20 (s, 1H), 5.30 (t, J = 5.29 Hz, 1H), 4.48−4.53 
(m, J = 6.76 Hz, 1H), 4.47 (d, J = 5.49 Hz, 2H), 3.97 (s, 2H), 1.58 (d, J = 6.76 Hz, 6H). 
Anal. Calcd for C24H24FN3: C, 77.18; H, 6.48; N, 11.25. Found: C, 76.89; H, 6.52; N, 
11.24.  
 
Potassium (4-methoxybenzyl)trifluoroborate (233b): A dry 100 mL single-neck round 
bottom flask with a nitrogen inlet was charged with trimethoxyborate (0.74 mL, 6.5 
mmol) and 10 mL of THF. The solution was cooled to -78 ºC and (4-methoxybenzyl) 
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magnesium chloride [0.217 M in THF] (232b; 20 mL, 4.34 mmol) was added with 
dropwise addition over 15 min. The mixture was stirred at -78 ºC for 1 h, and then 
allowed to warm to 23 oC over 1 h. The resulting white slurry was cooled to 0 ºC and 
MeOH (5 mL) was added dropwise over 5 min. The nitrogen inlet was removed and a 4.5 
M aqueous solution of KHF2 (5.78 mL, 26 mmol) was added dropwise at 0 ºC. After the 
addition, the mixture was stirred at 0 ºC for 1 h. The mixture was concentrated and the 
residual water was removed with azeotropic distillation with three 10 mL portions of 
toluene (60 ºC in vacuo) and then dried under high vacuum (150 µm) for 12 h to afford a 
white solid. This solid was broken into a fine powder with a spatula and then suspended 
in 10 mL of acetone and warmed on rotavap with rotation at atmosphere pressure for 5 
min at 40 ºC. The resulting suspension was filtered through a pad of Celite. A 5 mL 
portion of acetone was added to the solid remaining in the flask. This procedure was 
repeated an additional two times. The combined filtrates were concentrated in vacuo. The 
resultant white solid was dissolved into a minimum amount of hot acetone (4 mL) and 
then Et2O (5 mL) was added with dropwise addition to precipitate a white solid. The 
mixture was slowly cooled to 23 oC, placed in ice-bath for 1 h and then cooled in the 
refrigerator for another 2 h. The mixture was filtered through #1 Whatman filter paper 
and the collected white solid was dried under vacuum to afford 135 mg (14%) of the 
product. The crude material was carried onto the next step without further purification. 
1H NMR (400 MHz, DMSO-d6): δ 6.89− 6.90 (m, 2H), 6.62−6.64 (m, 2H), 3.65 (s, 3H), 
1.37 (br, 2H).  
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6-(4-Methoxy benzyl)-1-isopropyl-4-nitro-1H-benzo[d]imidazole (229b): A dry 20 
mL equipped microwave tube with a stir bar was charged with 1-isopropyl-4-nitro-1H-
benzo[d]imidazol-6-yl trifluoromethanesulfonate (227; 176.5 mg, 0.50 mmol), potassium 
(4-methoxybenzyl)trifluoroborate (233b; 135.0 mg, 0.60 mmol), Cs2CO3 (488.73 mg, 1.5 
mmol) and PdCl2(dppf)·CH2Cl2 (40.83 mg, 0.05 mmol). The microwave tube was capped 
with a rubber septum and subjected to vacuum /Ar purge cycles three times. A mixture of 
degassed deionized H2O (0.5 mL) and THF (5 mL) was added via syringe. The rubber 
septum was quickly removed and replaced with a microwave tube cap, and the mixture 
was subjected to microwave irradiation at 250 Watt to maintain a reaction temperature of 
110 ºC for 2.5 h. After cooling to 23 oC, the mixture was filtered through a pad of Celite 
and the pad was washed with an additional 10 mL of EtOAc. The combined organic 
layers were washed with three 5 mL portions of NaCl (sat, aq) and dried (MgSO4). 
Filtration and removal of the solvent under reduced pressure gave a brown solid, which 
was then subjected to silica gel column chromatography (Hex/EA/Et3N 1:1:0.005) to 
afford 80.0 mg of the brown solid in 50% yield. Rf 0.4 (CH2Cl2/MeOH/NH4OH 95:5:0.1). 
1H NMR (400 MHz, CDCl3): δ 8.16 (s, 1H), 8.01 (d, J = 1.38 Hz, 1H), 7.50 (d, J = 1.36 
Hz, 1H), 7.13 (d, J = 8.74 Hz, 2H), 6.87 (d, J = 8.71 Hz, 2H), 4.63 (m, 1H), 4.14 (s, 2H), 
1.63 (d, J = 6.75 Hz, 6H). HRMS (EI) calcd for C18H19N3O3: 326.1499 [M+H+], found 
326.1500 [M+H+], 348.1317 [M+Na+]. 
 
6-(4-Methoxybenzyl)-1-isopropyl-1H-benzo[d]imidazol-4-amine (230b): Solid 10% 
Pd/C (20 mg) was added to an empty Parr hydrogenation vessel. A solution of 6-(4-
methoxybenzyl)-1-isopropyl-4-nitro-1H-benzo[d]imidazole (229b; 80 mg, 0.25 mmol) in 
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EtOH (15 mL) and CHCl3 (1.5 mL) was added to the vessel. After 3 vaccum/ H2 purge 
cycles, the mixture was shaken at 50 psi for 12 h. After completion of the reaction (TLC), 
the mixture was filtered through a pad of Celite and washed with an additional 10 mL of 
EtOH. The filtrate was concentrated in vacuo to give 70.0 mg of a greenish semisolid in 
98% yield. This crude material was carried to the next step without further purification. 
1H NMR (400 MHz, DMSO-d6): δ 8.041 (s, 1H), 7.12 (d, J = 8.65 Hz, 2H), 6.81 (d, J = 
8.65 Hz, 2H), 6.61 (s, 1H), 6.17 (s, 1H), 5.24 (s, 2H), 4.55 (m, 1H), 3.80 (s, 2H), 3.68 (s, 
3H), 1.47 (d, J = 6.72 Hz, 6H). 
 
N-benzyl-6-(4-Methoxybenzyl)-1-isopropyl-1H-benzo[d]imidazol-4-amine (191b): A 
100 mL dry round bottom flask was charged with 6-(4-methoxybenzyl)-1-isopropyl-1H-
benzo[d]imidazol-4-amine (230b; 70.0 mg, 0.24 mmol), NaBH(OAc)3 (101.73 mg, 0.48 
mmol), benzaldehyde (27µL, 0.27 mmol) and 3.0 mL of 1,2-dichloroethane . The mixture 
was stirred at 23 oC for 24 h. The reaction was monitored by TLC. The reaction was 
quenched with 2 mL of NaHCO3 (sat, aq) and then extracted with three 5 mL portions of 
Et2O. The combined organic layers were washed with three 5 mL portions of NaCl (sat, 
aq) and dried (Mg2SO4). Filtration and removal of the solvent under reduced pressure 
gave a brown solid, which was subjected to silica gel flash column chromatography 
(Hex/EtOAc/Et3N 1:1:0.005) to afford 60 mg of the desired product in 65% yield. Rf 0.6 
(CH2Cl2/MeOH/NH4OH 90:10:0.1). MP = 83-84.5 oC. 1H NMR (CDCl3): δ 7.78 (s, 1H), 
7.40 (dd, J = 7.26 Hz, 2H), 7.34-7.30 (m, 2H), 7.26 (m, 1H), 7.11(m, 2H), 6.82-6.80 (m, 
2H), 6.54 (s, 1H), 6.24 (s, 1H), 5.30 (broad peak, 1H), 4.48−4.53 (m, 1H), 4.46 (s, 2H), 
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3.96 (s, 2H),3.80 (s, 3H), 1.57 (d, J = 6.75 Hz, 6H). Anal. Calcd for C25H27N3O: C, 
77.89; H, 7.06; N, 10.90. Found: C, 77.80; H, 7.09; N, 10.85.  
 
1-Cyclopentyl-6-methoxy-4-nitro-1H-benzo[d]imidazole (219):  A 500 mL one neck 
round bottom flask was charged with 5-methoxy-3-nitrobenzene-1,2-diamine (211, 3.67 
g, 20.0 mmol), NaBH(OAc)3 (12.71 g, 60.0 mmol), THF (60 mL), cyclopentanone (8.95 
mL, 100.0 mmol) and formic acid (2.26 mL, 60.0 mmol).  This mixture was stirred at 23 
oC for 12 h.  The solvent was removed in vacuo, and the dark red residue was dissolved 
into 60 mL of formic acid.  BHT (2,6-di-tert-butyl-4-hydroxytoluene) (20 mg, 0.09 
mmol) was added, and the mixture was cooled to 0 °C. An 80 mL of concentrated HCl 
was added, and the mixture was heated to reflux (~100 oC) with a heating mantle.  After 
maintaining reflux for 25 min, the solvent was removed in vacuo at 80 °C.  The residual 
acid was neutralized with K2CO3 (sat, aq) to a pH = 8 and then extracted with four 50 mL 
portions of EtOAc.  The combined organic extracts were washed with three 10 mL 
portions of NaCl (sat, aq) and dried (Na2SO4).  Filtration and removal of the solvent in 
vacuo gave a brown solid, which was subjected to silica gel column chromatography 
(Hex/EtOAc 1:1) to afford 2.1 g (40%) of the desired product as a yellow solid.  Rf 0.32 
(CH2Cl2/MeOH/NH4OH 90:10:0.1). MP = 107-108 °C.  1H NMR (400 MHz, CDCl3): δ 
8.08 (s, 1H), 7.79 (d, J = 2.32 Hz, 1H), 7.23(d, J = 2.3 Hz, 1H), 4.68 – 4.75 (m, 1H), 3.95 
(s, 3H), 2.35-2.30 (m, 2H), 1.83-2.05 (m, 6H). Anal. Calcd for C13H15N3O3: C, 59.76; H, 
5.79; N, 16.08. Found: C, 59.88; H, 5.84; N, 16.27.  
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1- Cyclopentyl-4-nitro-1H-benzo[d]imidazol-6-ol hydrobromide (226a):  A 50 mL 
microwave reactor tube was charged with 1-cyclopentyl-6-methoxy-4-nitro-1H-
benzo[d]imidazole (219; 0.75 g, 2.87 mmol) and 10 mL of 48% HBr and then subjected 
to microwave irradiation at 250 Watt to maintain a reaction temperature of 120 ºC for 2.5 
h. The solvent was removed in vacuo.  The resultant yellow solid was dissolved into a 
minimum amount of H2O (5 mL). Solid NaHCO3 was added in small portions until a pH 
= 6 was reached.  The resultant mixture was filtered and the yellow solid was collected 
on #1 Whatman filter paper, washed with additional 10 mL of H2O, and then dried under 
high vacuum (150 µM) to afford 0.6 g (85.7 %) of the yellow solid.  Rf 0.36 
(CH2Cl2/MeOH/NH4OH 90:10:0.1). MP = 118-121 oC. 1H NMR (400 MHz, DMSO-d6): 
δ 10.12 (s, 1H), 8.40 (s, 1H), 7.51 (d, J = 2.17 Hz, 1H), 7.38 (d, J = 2.21 Hz, 1H), 4.81 − 
4.87 (m, 1H), 2.15-2.21 (m, 2H), 1.70-1.96 (m, 6H). Anal. Calcd for C12H13N3O3 .1.18 % 
HBr: C, 42.09; H, 4.17; N, 12.27. Found: C, 42.13; H, 4.33; N, 12.12. 
 
1- Cyclopentyl-4-nitro-1H-benzo[d]imidazol-6-yl trifluoromethanesulfonate (227a):  
Solid K2CO3 (246.0 mg, 1.78 mmol)  was added to a solution of 1-Cyclopentyl-4-nitro-
1H-benzo[d]imidazol-6-ol (226a; 220.0 mg, 0.89 mmol) and 4-nitrophenyl 
trifluoromethanesulfonate (65.5 mg, 0.979  mmol) in 5 mL of anhydrous DMF. The 
suspension was stirred at 23 oC for 4 h.  The reaction mixture was then diluted with 30 
mL of EtOAc and filtered through #1 Whatman filter paper. The filtrate was washed with 
four 100 mL portions of H2O, three 20 mL portions of NaCl (sat, aq) and dried (Na2SO4). 
Evaporation of the solvent gave a yellow oil, which was then subjected to silica gel 
column chromatography (Hex/EtOAc/Et3N 1:1:0.005) to afford 290.0 mg of an off white 
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solid in 86% yield.  Rf 0.5 (CH2Cl2/MeOH/NH4OH 95:5:0.1). MP = 124-125 °C. 1H 
NMR (400 MHz, CDCl3): δ 8.30 (s, 1H), 8.10 (d, J = 2.26 Hz, 1H), 7.74 (d, J = 2.27 Hz, 
1H), 4.78 − 4.83 (m, 1H), 2.42-2.36 (m, 2H), 1.91-2.05 (m, 6H).  Anal. Calcd for 
C13H12F3N3O5S: C, 41.16; H, 3.19; F, 15.03; N, 11.08. Found: C, 41.21; H, 3.15; N, 
11.08. 
 
6-benzyl-1-cyclopentyl-4-nitro-1H-benzo[d]imidazole (229d):  A dry microwave tube 
equipped with a stir bar was charged with 1-cyclopentyl-4-nitro-1H-benzo[d]imidazol-6-
yl trifluoromethanesulfonate (227a; 500.0 mg, 1.31 mmol), potassium 
benzyltrifluoroborate (259.4 mg, 1.31 mmol), Cs2CO3 (640.2 mg, 1.9 mmol) and 
PdCl2(dppf)·CH2Cl2 (106.9 mg, 0.131 mmol). The microwave tube was capped with a 
rubber septum and subjected to three vacuum/Ar purge cycles. The mixture of degassed 
deionized H2O (0.8 mL) and THF (8 mL) was added via syringe. The rubber septum was 
quickly replaced with a microwave tube cap, and the mixture was subjected to microwave 
irradiation at 250 Watt to maintain 110 ºC for 1.8 h. After cooling to 23 oC, the mixture 
was filtered through a pad of Celite and the pad was washed with an additional 10 mL of 
EtOAc. The combined organic extracts were washed with three 10 mL portions of NaCl 
(sat, aq) and dried (MgSO4). Filtration and removal of the solvent under reduced pressure 
gave a brown solid, which was subjected to silica gel column chromatography 
(Hex/EA/Et3N 1:1:0.005) to afford 70.0 mg of an off white solid in 17% yield. Rf 0.45 
(CH2Cl2/MeOH/NH4OH 95:5:0.1). MP= 145-147 oC. 1H NMR (400 MHz, CDCl3): δ 
8.15 (s, 1H), 8.06 (d, J = 1.41 Hz, 1H), 7.55(d, J = 1.46 Hz, 1H), 7.36 (m, 2H), 7.28 (m, 
1H), 7.23 (dd, J = 1.41 Hz, J = 8.1 Hz, 2H),  4.75 (m, 1H), 4.22 (s, 2H), 2.29-2.36 (m, 
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2H), 1.85-2.02 (m, 6H). Anal. Calcd for  C19H19N3O2: C, 71.01; H, 5.96; N, 13.08. 
Found: C, 70.83; H, 5.88; N, 13.10.  
 
6-benzyl-1-cyclopentyl-1H-benzo[d]imidazol-4-aminium chloride (230d): Solid 10% 
Pd/C (20 mg) was added to an empty Parr hydrogenation vessel. A solution of 6-benzyl-
1-cyclopentyl-4-nitro-1H-benzo[d]imidazole (229d; 70 mg, 0.22 mmol) in EtOH (20 mL) 
and CHCl3 (1 mL) was added to the vessel. After 3 vaccum/ H2 purge cycles, the mixture 
was shaken at 50 psi for 12 h. After completion of the reaction (TLC), the mixture was 
filtered through a pad of Celite and the pad was washed with an additional 10 mL of 
EtOH. The filtrate was concentrated in vacuo to give 51.0 mg of a greenish semisolid 
product in 75 % yield. The crude material was carried to the next step without further 
purification. Rf 0.4 (CH2Cl2/MeOH/NH4OH 100:5:0.1). 1H NMR (400 MHz, DMSO-d6): 
δ 9.43 (s, 1H), 7.26 (m, , 4H), 7.17 (m, 1H), 7.01(s, 1H), 6.54 (s, 1H), 5.28 (broad peak, 
2H), 4.91−4.95 (m, 1H), 3.96 (s, 2H), 2.24-2.35 (m, 2H), 1.71-1.98 (m, 6H)).  
 
N-benzyl-6-benzyl-1-cyclopentyl-1H-benzo[d]imidazol-4-amine(191d): A dry round 
bottom flask was charged with 6-benzyl-1-cyclopentyl-1H-benzo[d]imidazol-4-aminium 
chloride (230d; 50.0 mg, 0.15 mmol), NaBH(OAc)3 (64.6 mg, 0.305 mmol), 
benzaldehyde (17.12 µL, 0.17 mmol) and  2.5 mL of 1,2-dichloroethane . The reaction 
mixture was stirred at 23 oC for 12 h. The reaction progress was monitored by TLC. The 
reaction was quenched with 2 mL of 1N of NaOH (aq) and then extracted with three 5 
mL portions of EtOAc. The combined organic extracts were washed with three 5 mL 
portions of NaCl (sat, aq) and dried (MgSO4). Filtration and removal of the solvent under 
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reduced pressure gave a brown solid, which was subjected to silica gel flash column 
chromatography (Hex/EtOAc/Et3N 1:1:0.005) to afford 30 mg of white needles in 51.5% 
yield. Rf 0.54 (CH2Cl2/MeOH/NH4OH 95:5:0.1). MP = 118-118.5 oC. 1H NMR (400 
MHz, CDCl3): δ 7.74 (s, 1H), 7.18−7.40 (m, 10H), 6.57 (d, J = 1.14 Hz, 1H ), 6.26 (d, J = 
1.12 Hz, 1H), 5.24 (t, J = 5.82 Hz, 1H), 4.6.0−4.64 (m, 1H), 4.46 (d, J = 5.60 Hz, 2H), 
4.02 (s, 2H), 2.24-2.35 (m, 2H), 1.78-2.02 (m, 6H). Anal. Calcd for C26H27N3. 0.29 % 
H2O: C, 80.75; H, 7.18; N, 10.86. Found: C, 80.73; H, 7.05; N, 10.86.  
 
Series 4: N4 BENZYL BENZIMIDAZOLE 
 
2-(1-isopropyl-4-nitro-1H-benzo[d]imidazol-6-yloxy)butyl benzoate (246): 
A dry one-neck 25 mL round bottom flask was charged with 1-isopropyl-4-nitro-1H-
benzo[d]imidazol-6-ol (226; 1.105 g, 5.0 mmol), 2-hydroxybutyl benzoate (237a; 2.427 
g, 12.5 mmol), Ph3P (3.278 g, 12.5 mmol), and 10 mL of anhydrous DMF.  This solution 
was cooled to 0 oC.  Neat DIAD (1.35 mL, 9.2 mmol) was added with dropwise addition 
over 5 min.The solution was stirred for 30 min at 0 oC. The ice-bath was removed and the 
reaction was stirred for an additional 2 h at 23 oC. The reaction was then cooled to 0 oC 
and an additional quantity of DIAD (1.35 mL, 9.2 mmol) was added at 0 oC.  The 
reaction was stirred for 30 min at 0 oC then at 23 oC for 12 h. Completion of reaction was 
determined by TLC. The reaction mixture was then poured into a mixture of 50 mL of 
EtOAc and 50 mL of K2CO3 (sat, aq) was added.  This mixture was extracted three 25 
mL portions of with EtOAc and the combined organic extracts were washed three 10 mL 
portions of  with NaCl
 
(sat, aq) and dried (Na2SO4).  The extract was decanted and the 
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solvent was removed under reduced pressure.  The brown colored crude material was 
subjected to silica gel flash column chromatography (Hex: EtOAc 1:1) to afford 1.6 g of 
product with 10% of triphenyl phosphine oxide impurity. Recrystallization from 
(Hex:EtOAc 1:0.5)  provided 1.2 g of the product as a desired bright yellow solid (60%).   
Rf 0.6 (CH2Cl2/MeOH/NH4OH 100:10:0.1). MP = 111.5-112.0 ºC. 1H NMR (400MHz, 
CDCl3): δ 8.1 (s, 1H), 7.92 (t, J = 2.08 Hz, 2H), 7.90 (d, J = 1.31 Hz, 1H), 7.51-7.55 (tt, J 
= 7.47 Hz, J = 1.33 Hz, 1H), 7.37 (t, J = 7.79 Hz, 3H), 4.48-4.68 (m, 4H), 1.90 (q, J = 
7.45 Hz, 2H), 1.58 (d, J = 6.76 Hz, 6H), 1.14 (t, J = 7.46 Hz, 3H). Anal. Calcd for  
C21H23N3O5: C, 63.46; H, 5.83; N, 10.57. Found: C, 63.48; H, 5.89; N, 10.44.  
 
2-(4-amino-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butyl benzoate hydrochloride 
(248): 2-(1-isopropyl-4-nitro-1H-benzo[d]imidazol-6-yloxy)butyl benzoate (246; 1.20 g, 
3.02 mmol) was dissolved into 70 mL of EtOH and added to a Parr hydrogenation vessel 
previously charged with 100 mg of Pd/C (10 % w/w).  After three vacuum/purge cycles 
with H2, the vessel was charged to 50 psi with H2 and shaken for 12 h on a Parr 
hydrogenation apparatus. The mixture was filtered through a pad of Celite and the pad 
was washed with an additional 10 mL of EtOH. The solvent was removed in vacuo. The 
resultant oil was dissolved into 10 mL of Et2O and HCl(g) in Et2O was added.  A white 
precipitate was obtained. The solid was collected on a #1 Whatman filter paper and 
washed with Et2O. Recrystallization from EtOH gave the 1.09 g of product as an off 
white solid (90%). Rf 0.52 (CH2Cl2/MeOH/NH4OH 90:10:0.1). MP = 170-175 ºC. 1H 
NMR (500 MHz, CDCl3): δ 9.2 (s, 1H), 7.95 (dd, J = 1.29 Hz, J = 8.27 Hz, 2H), 7.54-
7.59 (tt, J = 7.45 Hz, 1H), 7.39-7.42 (t, J = 7.82 Hz, 2H), 6.46 (d, J = 1.93 Hz, 1H), 6.42 
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(d, J = 1.90 Hz, 1H), 5.65 (s, broad peak, 2H), 4.55-4.62 (m, 3H), 4.64 (q, J = 6.98 Hz, 
1H), 1.82-1.90 (m, 2H), 1.67 (dd, J = 6.79 Hz, J = 8.20 Hz, 6H), 1.10 (t, J = 7.44 Hz, 
3H). Anal. Calcd for C21H26ClN3O3: C, 62.45; H, 6.49; N, 10.40, Cl, 8.78. Found: C, 
62.35; H, 6.39; N, 10.33; Cl, 8.86.  
 
2-(4-(benzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butyl benzoate 
(249aa): A dry 100 mL round bottom flask was charged with 2-(4-amino-1-isopropyl-
1H-benzo[d]imidazol-6-yloxy)butyl benzoate hydrochloride (248; 95 mg, 0.258 mmol), 
NaHB(OAc)3 (109.59 mg, 0.516 mmol), benzaldehyde (31.61 µL, 0.31 mmol) and 1,2- 
dichloroethane (2.0 mL). The mixture was stirred at 23 oC for 12 h. Completion of the 
reaction was judged by TLC. The reaction mixture was quenched with the addition of 10 
mL of NaHCO3 (sat, aq) (pH~ 9-10), the mixture was extracted with three 10 mL 
portions of EtOAc. The combined organic layers were washed with three 10 mL portions 
of NaCl (sat, aq) and dried (Na2SO4). Evaporation of the solvent gave a brown semisolid, 
which was subjected to silica gel flash column chromatography (Hex/EtOAc; 1:1) to 
afford the desired product in approximately 63.5% yield as oil. Rf 0.62 
(CH2Cl2/MeOH/NH4OH 90:10:0.1). 1H NMR (400MHz, CDCl3): δ 7.95-7.97 (dd, J = 
1.28 Hz, J = 8.31 Hz, 2H), 7.72(s, 1H), 7.52-7.56 (m, 1H), 7.36-7.41 (m, 4H), 7.31 (t, J = 
7.31 Hz, 2H), 7.23-7.27 (m, 1H),  6.36 (d, J = 2.05 Hz, 1H), 6.12 (d, J = 2.03 Hz, 1H), 
5.30 (s, broad peak, 1H), 4.38-4.51 (m, 6H), 1.80-1.84 (m, 2H), 1.53 (dd, J = 4.24 Hz, J = 
6.72 Hz, 6H), 1.06 (t, J = 7.46 Hz, 3H). The free base was dissolved into 5 mL of Et2O, 
cooled to 0 °C and treated with HCl(g) in 5mL of Et2O. After stirring for 15 min at 0 °C, 
the mixture was concentrated to a white solid. The solid was dissolved in a minimal 
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amount of hot EtOH and recrystallized at -20°C, to afford white needles. The desired 
product was characterized as the hydrochloride salt. MP = 115.5-116.7 oC.  1H NMR 
(400MHz, MeOD-d4): δ 9.19 (s, 1H), 7.82-7.85 (dd, J = 1.32 Hz, J = 8.38 Hz, 2H), 7.54-
7.58 (m, 1H), 7.26-7.43 (m, 7H),  6.77 (d, J = 1.96 Hz, 1H), 6.39(d, J = 1.97 Hz, 1H), 
4.81 (m, 1H), 4.77 (m, 1H), 4.5 (d, J = 1.47 Hz,1H), 4.49 (s, 1H), 4.45 (m, 1H), 1.80-1.84 
(m, 2H), 1.61 (t, J = 6.73 Hz, 6H), 1.06 (t, J = 7.45 Hz, 3H). Anal. Calcd for 
C28H32ClN3O3: C, 68.07; H, 6.53; N, 8.51. Found: C, 67.75; H, 6.46; N, 8.39.  
 
General procedure for synthesis of 2-(substituted 4-(benzylamino)-1-isopropyl-1H-
benzo[d]imidazol-6-yloxy)butyl benzoate):  A 100 mL dry round bottom flask was 
charged with 2-(4-amino-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butyl benzoate 
hydrochloride  (246; 160 mg, 0.396 mmol), NaHB(OAc)3 (167.91 mg, 0.792 mmol), the 
appropriate benzaldehyde (0.604 mmol, 1.2 equiv) and 4.0 mL of 1,2-dichloroethane.  
The mixture was stirred at room temperature for 12 h. Completion of the reaction was 
determined by TLC. The reaction mixture was quenched with the addition of 10 mL of 
NaHCO3 (sat. aq.) (pH~ 9-10) and the mixture was extracted with three 10 mL portions 
of EtOAc. The combined EtOAc extracts were washed with NaCl (sat, aq) and dried 
(Na2SO4). The solution was decanted and removal of the solvent gave a residue, which 
was subjected to silica gel flash column chromatography (Hex/EtOAc; 1:1) to afford the 
products in approximately 50-88% yield as indicated below typically as an oil.  
 
2-(1-isopropyl-4-(2-methylbenzylamino)-1H-benzo[d]imidazol-6-yloxy)butyl 
benzoate (249a): 180 mg of  an off-white semisolid (80%). Rf 0.75 
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(CH2Cl2/MeOH/NH4OH 100:10:0.1). MP = 149-154 ºC. 1H NMR (400MHz, CDCl3): δ 
7.95-7.97 (dd, J = 1.17 Hz, J = 8.29 Hz, 2H), 7.77 (s, 1H), 7.52-7.56 (tt, J = 7.47 Hz, 
1H), 7.35-7.41 (m, 3H), 7.14-7.20 (m, 3H), 6.37 (d, J = 2.03 Hz, 1H), 6.15 (d, J = 2.01 
Hz, 1H), 5.27 (s, broad peak, 1H), 4.42-4.55 (m, 4H), 4.40 (s, 2H), 2.38 (s, 3H), 1.82-
1.88 (m, 2H), 1.67 (dd, J = 5.16 Hz, J = 6.71 Hz, 6H), 1.09 (t, J = 7.45 Hz, 3H). Anal. 
Calcd for C29H33N3O3. 0.594 % H2O: C, 72.22; H, 7.14; N, 8.71. Found: C, 72.21; H, 
7.05; N, 8.74.  
 
2-(1-isopropyl-4-(3-methylbenzylamino)-1H-benzo[d]imidazol-6-yloxy)butyl 
benzoate (249b): 175 mg of an off-white semisolid (78%). Rf 0.73 
(CH2Cl2/MeOH/NH4OH 100:10:0.1). 1H NMR (400 MHz, CDCl3): δ 7.95-7.98 (dd, J = 
1.31 Hz, J = 8.36 Hz, 2H), 7.71 (s, 1H), 7.52-7.56 (tt, J = 7.43 Hz, 1H), 7.36-7.41 (t, J = 
7.72 Hz, 2H), 7.23 (m, 1H), 7.19-7.21 (m, 2H), 7.07 (m, 1H), 6.36 (d, J = 2.08 Hz, 1H), 
6.15 (d, J = 2.04 Hz, 1H), 5.22 (t, J = 5.55 Hz, 1H), 4.44-4.51 (m, 6H), 2.32 (s, 3H), 
1.82-1.86 (m, 2H), 1.53 (dd, J = 4.29 Hz, J = 6.74 Hz, 6H), 1.07 (t, J = 7.45 Hz, 3H). 
Anal. Calcd for C29H33N3O3: C, 73.86; H, 7.05; N, 8.91. Found: C, 73.81; H, 7.21; N, 
8.78.  
 
2-(1-isopropyl-4-(4-methylbenzylamino)-1H-benzo[d]imidazol-6-yloxy)butyl 
benzoate (249c): 150 mg of an off-white semisolid (78%). Rf 0.75 
(CH2Cl2/MeOH/NH4OH 100:10:0.1). 1H NMR (400 MHz, CDCl3): δ 7.95-7.98 (dd, J = 
1.13 Hz, J = 8.27 Hz, 2H), 7.71 (s, 1H), 7.52-7.56 (tt, J = 7.43 Hz, 1H), 7.36-7.41 (t, J = 
7.77 Hz, 2H), 7.23 (m, 1H), 7.29 (d, J = 7.99 Hz, 2H), 7.12 (d, J = 7.83 Hz, 2H), 6.36 (d, 
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J = 2.04 Hz, 1H), 6.14 (d, J = 2.03 Hz, 1H), 5.22 (t, J = 5.42 Hz, 1H), 4.40-4.50 (m, 6H), 
2.33 (s, 3H), 1.79-1.86 (m, 2H), 1.53 (dd, J = 4.18 Hz, J = 6.73 Hz, 6H), 1.07 (t, J = 7.46 
Hz, 3H). Anal. Calcd for C29H33N3O3. 0.3626 % H2O: C, 72.84; H, 7.10; N, 8.78. Found: 
C, 72.82; H, 7.16; N, 9.05.  
 
2-(1-isopropyl-4-(2-methoxybenzylamino)-1H-benzo[d]imidazol-6-yloxy)butyl 
benzoate (249d): 140 mg of an off-white semisolid (60%). Rf 0.70 
(CH2Cl2/MeOH/NH4OH 100:10:0.1). MP = 155-160 ºC 1H NMR (400 MHz, CDCl3): δ 
7.95-7.98 (dd,  J = 1.24 Hz, J = 8.31 Hz, 2H), 7.71(s, 1H), 7.51-7.56  (tt, J = 7.43 Hz, 
1H), 7.36-7.40 (t,  J = 7.90 Hz, 3H), 7.20-7.24 (dt, J = 1.71 Hz, J = 8.03 Hz , J = 8.15 Hz, 
1H), 6.85-6.90 (m, 2H), 6.33 (d, J = 2.06 Hz, 1H), 6.17 (d, J = 2.03 Hz, 1H), 5.33 (s, 
broad peak, 1H), 4.46-4.51 (m, 5H), 4.40 (m, 1H), 3.86 (s, 3H), 1.79-1.86 (m, 2H), 1.53 
(dd, J = 4.45 Hz, J = 6.73 Hz, 6H), 1.07 (t, J = 7.46 Hz, 3H). Anal. Calcd for 
C29H33N3O4. 0.367 % H2O: C, 70.47; H, 6.88; N,8.50. Found: C, 70.49; H, 6.88; N, 8.41.  
 
2-(1-isopropyl-4-(3-methoxybenzylamino)-1H-benzo[d]imidazol-6-yloxy)butyl 
benzoate (249e): 120 mg of  a brown semisolid (62%). Rf 0.72 (CH2Cl2/MeOH/NH4OH 
100:10:0.1). 1H NMR (400 MHz, CDCl3): δ 7.95-7.98 (dd, J = 1.33 Hz, J = 8.35 Hz, 2H), 
7.71 (s, 1H), 7.51-7.56 (tt, J = 7.43 Hz, 1H), 7.36-7.40 (t, J = 7.90 Hz, 2H), 7.20-7.24 (m, 
1H), 6.96-7.0 (m, 2H), 6.78-6.81 (dd, J = 2.57 Hz, J = 8.17 Hz, 1H), 6.36 (d, J = 2.05 Hz, 
1H), 6.13 (d, J = 2.03 Hz, 1H), 5.27 (t, J = 5.23 Hz, 1H), 4.38-4.53 (m, 6H), 3.77 (s, 3H), 
1.79-1.86 (m, 2H), 1.53 (dd, J = 4.31 Hz, J = 6.74 Hz, 6H), 1.07 (t, J = 7.46 Hz, 3H). 
181 
Anal. Calcd for C29H33N3O4. 0.239 % H2O: C, 70.808; H, 6.86; N, 8.54. Found: C, 70.81; 
H, 6.99; N, 8.59.  
 
2-(1-isopropyl-4-(4-methoxybenzylamino)-1H-benzo[d]imidazol-6-yloxy)butyl 
benzoate (249f): 120 mg of a brown semisolid (62%). Rf 0.74 (CH2Cl2/MeOH/NH4OH 
100:10:0.1). 1H NMR (400 MHz, CDCl3): δ 7.95-7.98 (dd, J = 1.33 Hz, J = 8.35 Hz, 2H), 
7.71 (s, 1H), 7.51-7.56 (tt, J = 7.43 Hz, 1H), 7.36-7.40 (t, J = 7.90 Hz, 2H), 7.32 (d, J = 
8.64 Hz, 2H), 6.84-6.86 (d, J = 8.69 Hz, 2H), 6.36 (d, J = 2.04 Hz, 1H), 6.15 (d, J = 2.03 
Hz, 1H), 5.23 (s, broad peak, 1H), 4.37-4.52 (m, 6H), 3.79 (s, 3H), 1.79-1.86 (m, 2H), 
1.53 (dd, J = 4.21 Hz, J = 6.74 Hz, 6H), 1.07 (t, J = 7.46 Hz, 3H). Anal. Calcd for 
C29H33N3O4. 0.263 % H2O: C, 70.74; H, 6.86; N, 8.53. Found: C, 70.74; H, 6.88; N, 8.59.  
 
2-(4-(2-hydroxybenzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butyl 
benzoate (249g): 150 mg of an off-white solid (80%). Rf 0.65 (CH2Cl2/MeOH/NH4OH 
100:10:0.1). MP = 62.5-65.5 oC. 1H NMR (400 MHz, CDCl3): δ 7.95-7.98 (dd, J = 1.24 
Hz, J = 8.31 Hz, 2H), 7.71 (s, 1H), 7.51-7.56 (tt, J = 7.43 Hz, 1H), 7.36-7.40 (t, J = 7.90 
Hz, 2H), 7.18 (m, 2H), 6.89-6.92 (dd, J = 1.13 Hz, J = 8.50 Hz, 1H), 6.82-6.87 (td, J = 
1.18 Hz, J = 7.40 Hz,  J = 7.39 Hz, 1H), 6.49 (d, J = 2.06 Hz, 1H), 6.36 (d, J = 2.03 Hz, 
1H), 5.03 (s, broad peak, 1H), 4.40-4.56 (m, 6H), 1.79-1.86 (m, 2H), 1.53 (dd, J = 4.03 
Hz, J = 6.73 Hz, 6H), 1.07 (t, J = 7.46 Hz, 3H). Anal. Calcd for C28H31N3O4: C, 71.01; H, 
6.60; N, 8.87. Found: C, 70.87; H, 6.53; N, 8.74.  
 
182 
2-(4-(3-hydroxybenzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butyl 
benzoate (249h): 160 mg of an off-white solid (85%). Rf 0.65 (CH2Cl2/MeOH/NH4OH 
100:10:0.1). MP =111-113.5 oC. 1H NMR (400 MHz, CDCl3): δ 7.96-7.98 (dd, J = 1.24 
Hz, J = 8.31 Hz, 2H), 7.79 (s, 1H), 7.51-7.56 (tt, J = 7.43 Hz, 1H), 7.36-7.40 (t, J = 7.90 
Hz, 2H), 7.01 (m, 1H), 6.82-6.84 (m, 2H), 6.77-6.79 (m, 1H), 6.37 (d, J = 2.06 Hz, 1H), 
6.19 (d, J = 2.03 Hz, 1H), 5.03 (s, broad peak, 1H), 4.49-4.55 (m, 3H), 4.44-4.48 (m, 
1H), 4.28 (s, 2H), 1.79-1.86 (m, 2H), 1.53 (dd, J = 4.03 Hz, J = 6.73 Hz, 6H), 1.07 (t, J = 
7.46 Hz, 3H). Anal. Calcd for C28H31N3O4: C, 71.01; H, 6.60; N, 8.87. Found: C, 70.81; 
H, 6.58; N, 8.69.  
 
2-(4-(4-hydroxybenzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butyl 
benzoate (249i): 210 mg of  a white solid (95%). Rf 0.66 (CH2Cl2/MeOH/NH4OH 
100:10:0.1). MP =136.5-138.1 oC. 1H NMR (400 MHz, CDCl3): δ 7.96-7.98 (dd, J = 1.24 
Hz, J = 8.31 Hz, 2H), 7.87 (s, 1H), 7.51-7.56 (tt, J = 7.43 Hz, 1H), 7.36-7.40 (t, J = 7.90 
Hz, 2H), 7.08 (d, J = 8.12 Hz, 2H),  6.73-6.76 (d, J = 8.47 Hz, 2H), 6.38 (d, J = 2.06 Hz, 
1H), 6.23 (d, J = 2.03 Hz, 1H), 5.29 (s, broad peak, 1H), 4.43-4.45 (m, 4H), 4.22 (s, 2H), 
1.79-1.86 (m, 2H), 1.53 (dd, J = 5.69 Hz, J = 6.46 Hz, 6H), 1.26 (s, broad peak, 1H), 1.07 
(t, J = 7.46 Hz, 3H). Anal. Calcd for C28H31N3O4: C, 71.01; H, 6.60; N, 8.87. Found: C, 
70.81; H, 6.58; N, 8.69.  
 
2-(4-(2-chlorobenzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butyl 
benzoate (249j): 140 mg of yellow semisolid (70%). Rf 0.70 (CH2Cl2/MeOH/NH4OH 
100:10:0.1). MP = 155-212 ºC. 1H NMR (400 MHz, CDCl3): δ 7.93-7.96 (dd, J = 1.18 
183 
Hz, J = 8.30 Hz, 2H), 7.73 (s, 1H), 7.51-7.56 (tt, J = 7.42 Hz, 1H), 7.45 (m, 1H), 7.37 (m, 
3H), 7.17 (m, 2H), 6.37 (d, J = 2.00 Hz, 1H), 6.06 (d, J = 1.96 Hz, 1H), 5.37 (t, J = 6.05 
Hz, 1H), 4.58 (d, J = 6.05 Hz, 2H), 4.38-4.50 (m, 4H), 1.79-1.85 (m, 2H), 1.54 (dd, J = 
4.53 Hz, J = 6.71 Hz, 6H), 1.06 (t, J = 7.46 Hz, 3H). Anal. Calcd for C28H30ClN3O3. 0.16 
% H2O: C, 67.95; H, 6.17; N, 8.49. Found: C, 67.95; H, 6.22; N, 8.58.  
 
2-(4-(4-chlorobenzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butyl 
benzoate (249l): 138 mg of an off-white semisolid (69%). Rf 0.70 
(CH2Cl2/MeOH/NH4OH 100:10:0.1). 1H NMR (400 MHz, CDCl3): δ 7.94-7.97 (dd, J = 
1.31 Hz, J = 8.45 Hz, 2H), 7.72 (s, 1H), 7.52-7.56 (tt, J = 7.42 Hz, 1H), 7.36-7.40 (t, J = 
7.99Hz, 2H), 7.33 (d, J = 8.70 Hz, 2H), 7.26 (d, J = 8.64 Hz, 2H), 6.37 (d, J = 2.04 Hz, 
1H), 6.06 (d, J = 2.03 Hz, 1H), 5.27 (t, J = 5.54 Hz, 1H), 4.38-4.53 (m, 6H), 1.79-1.85 
(m, 2H), 1.54 (dd, J = 4.39 Hz, J = 6.74 Hz, 6H), 1.07 (t, J = 7.47 Hz, 3H). Anal. Calcd 
for C28H30ClN3O3. 0.632 % H2O: C, 66.80; H, 6.26; N, 8.34. Found: C, 66.81; H, 6.10; N, 
8.22.  
 
2-(4-(2-fluorobenzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butyl 
benzoate (249m): 175 mg of an off-white semisolid (78%). Rf 0.72 
(CH2Cl2/MeOH/NH4OH 100:10:0.1). 1H NMR (400 MHz, CDCl3): δ 7.93-7.96 (dd, J = 
1.31 Hz, J = 8.43 Hz, 2H), 7.72 (s, 1H), 7.51-7.54 (tt,  J = 7.44 Hz, 1H), 7.43 (td,  J = 
1.79 Hz, J = 7.80 Hz, J = 7.68 Hz, 1H), 7.35-7.40 (t, J = 7.71 Hz, 2H), 7.20-7.22 (m, 1H),  
7.03-7.06 (m, 2H), 6.37 (d, J = 2.04 Hz, 1H), 6.15 (d, J = 2.02 Hz, 1H), 5.29 (t, J = 5.49 
Hz, 1H), 4.54 (d, J = 5.40 Hz, 2H), 4.43-4.50  (m, 4H), 1.79-1.84 (m, 2H), 1.53 (dd, J = 
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4.22 Hz, J = 6.74 Hz, 6H), 1.07 (t, J = 7.46 Hz, 3H). Anal. Calcd for C28H30FN3O3. 0.289 
% H2O: C, 69.95; H, 6.41; N, 8.74. Found: C, 69.96; H, 6.35; N, 8.62. 
 
2-(4-(3-fluorobenzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butyl 
benzoate (249n): 150 mg of a white semisolid (66%). Rf 0.71 (CH2Cl2/MeOH/NH4OH 
100:10:0.1). 1H NMR (400 MHz, CDCl3): δ 7.96 (dd, J = 1.3 Hz, J = 8.5 Hz, 1H), 7.72 
(s, 1H), 7.51-7.56 (tt, J = 7.44 Hz, 1H), 7.36-7.40 (t, J = 7.88 Hz, 2H), 7.27 (m, 1H), 7.17 
(d, J = 7.17 Hz, 1H),  7.12 (d, J = 9.62 Hz, 1H), 6.91-6.96 (dt, J = 2.6Hz, J = 8.4Hz, 1H), 
6.37 (d, J = 2.01 Hz, 1H), 6.06 (d, J = 1.98 Hz, 1H), 5.29 (t, J = 5.82 Hz, 1H), 4.43-4.54 
(m, 6H), 1.79-1.84 (m, 2H), 1.54 (dd, J = 4.46 Hz, J = 6.73 Hz, 6H), 1.07 (t, J = 7.46 Hz, 
3H). Anal. Calcd for C28H30FN3O3. 0.377 %  H2O: C, 69.72; H, 6.42; N, 8.71. Found: C, 
69.76; H, 6.60; N, 8.49. 
 
2-(4-(4-fluorobenzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butyl 
benzoate (249o): 210 mg of an off-white semisolid (95%). Rf 0.73 
(CH2Cl2/MeOH/NH4OH 100:10:0.1). 1H NMR (400 MHz, CDCl3): δ 7.94-7.97 (dd, J = 
1.19 Hz, J = 8.22 Hz, 2H), 7.72 (s, 1H), 7.51-7.56 (tt, J = 7.41 Hz, 1H), 7.34-7.40 (m, 
4H), 6.97-7.03 (t, J = 8.70 Hz, 2H), 6.37 (d, J = 2.02 Hz, 1H), 6.08 (d, J = 2.00 Hz, 1H), 
5.27 (s, broad peak, 1H), 4.40-4.52 (m, 6H), 1.79-1.86 (m, 2H), 1.54 (dd, J = 4.33 Hz, J = 
6.73 Hz, 6H), 1.07 (t, J = 7.46 Hz, 3H). Anal. Calcd for C28H30FN3O3: C, 70.72; H, 6.36; 
N, 8.84. Found: C, 70.70; H, 6.57; N, 8.70.  
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2-(4-(2-nitrobenzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butyl benzoate 
(249p): 155 mg of a yellow solid (77%). Rf 0.67 (CH2Cl2/MeOH/NH4OH 100:10:0.1). 
MP = 210-215 oC. 1H NMR (400MHz, CDCl3): δ 8.08 (dd, J = 1.25 Hz, J = 8.13 Hz , 
1H), 7.91-7.93 (dd,  J = 1.07 Hz, J = 8.23 Hz, 2H), 7.76 (s, 1H), 7.71-7.73 (d, J = 7.32 
Hz, 1H), 7.47-7.55 (m, 2H), 7.36-7.39 (t, J = 7.83 Hz, 3H), 6.38 (d, J = 1.99 Hz, 1H), 
5.94 (d, J = 1.98 Hz, 1H), 5.63 (s, broad peak, 1H), 4.91 (s, 2H), 4.38-4.44 (m, 4H), 1.79-
1.82 (m, 2H), 1.55 (dd, J = 5.10 Hz, J = 6.69 Hz, 6H), 1.02 (t, J = 7.44 Hz, 3H). Anal. 
Calcd for C28H30N4O5. 0.1 % EtOAc: C, 66.70; H, 6.07; N, 10.96. Found: C, 66.91; H, 
6.01; N, 10.71. 
 
2-(4-(3-nitrobenzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy) butyl benzoate 
(249q): 160 mg  of a yellow solid (80%). Rf 0.70 (CH2Cl2/MeOH/NH4OH 100:10:0.1). 
MP = > 250 oC. 1H NMR (400 MHz, CDCl3): δ 8.26 (m, 1H), 8.09 (dd,  J = 1.8 Hz, J = 
7.8 Hz, 1H), 7.92-7.94 (dd, J = 1.3 Hz, J = 8.32 Hz, 2H), 7.76 (s, 1H), 7.73 (d, J = 8.02 
Hz, 1H), 7.54 (tt, J = 7.44 Hz, 1H), 7.43-7.46 (t, J = 7.92 Hz, 1H), 7.36-7.40 (t, J = 7.79 
Hz, 2H), 6.39 (d, J = 2.01 Hz, 1H), 6.01 (d, J = 1.99 Hz, 1H), 5.62 (s, broad peak, 1H), 
4.57 (s, 2H), 4.42-4.46 (m, 4H), 1.79-1.82 (m, 2H), 1.55 (dd, J = 4.86 Hz, J = 6.72 Hz, 
6H), 1.04 (t, J = 7.45 Hz, 3H). Anal. Calcd for C28H30N4O5. 0.225 %  H2O: C, 66.38; H, 
6.05; N, 11.06. Found: C, 66.44; H, 6.12; N, 10.73. (PJ-B-3-71-1) 
 
2-(4-(4-nitrobenzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butyl benzoate 
(249r): 170 mg of a yellow solid (80%). MP = 63-63.5 oC. Rf 0.71 
(CH2Cl2/MeOH/NH4OH 100:10:0.1). 1H NMR (400 MHz, CDCl3): δ 8.15 (d, J = 8.72 
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Hz,  2H), 7.92-7.94 (dd, J = 1.31 Hz, J = 8.35 Hz, 2H), 7.77 (s, 1H), 7.52-7.57 (m, 3H), 
7.36-7.40 (t, J = 7.79 Hz, 2H), 6.40 (d, J = 2.01 Hz, 1H), 5.97 (d, J = 2.01 Hz, 1H), 5.69 
(s, broad peak, 1H), 4.59 (s, 2H), 4.43-4.47 (m, 4H), 1.78-1.82 (m, 2H), 1.55 (dd, J = 
4.88 Hz, J = 6.73 Hz, 6H), 1.04 (t, J = 7.45 Hz, 3H). Anal. Calcd for C28H30N4O5: C, 
66.92; H, 6.02; N, 11.15. Found: C, 66.69; H, 5.97; N, 10.78.  
 
2-(4-(2-(trifluromethyl)benzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-
yloxy)butyl benzoate (249s): 160 mg of a white semisolid (61%). Rf 0.70 
(CH2Cl2/MeOH/NH4OH 100:10:0.1). 1H NMR (400 MHz, CDCl3): δ 7.92-7.94 (dd, J = 
1.29 Hz, J = 8.47 Hz, 2H), 7.74 (s, 1H), 7.66 (t, J = 7.73 Hz, 2H), 7.51-7.55 (tt, J = 7.43 
Hz, 1H), 7.30-7.45 (m, 4H), 6.37 (d, J = 2.04 Hz, 1H), 6.00 (d, J = 2.02 Hz, 1H), 5.45 (t, 
J = 5.88 Hz, 1H), 4.70 (d, J = 5.70 Hz, 2H), 4.40-4.45 (m, 4H), 1.77-1.81 (m, 2H), 1.54 
(dd, J = 3.99 Hz, J = 6.73 Hz, 6H), 1.02 (t, J = 7.45 Hz, 3H). Anal. Calcd for 
C29H30F3N3O3: C, 66.27; H, 5.75; N, 8.00. Found: C, 66.01; H, 5.94; N, 7.76.  
 
2-(4-(3-(trifluromethyl)benzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-
yloxy)butyl benzoate (249t): 155 mg of a white semisolid (59%). Rf 0.71 
(CH2Cl2/MeOH/NH4OH 100:10:0.1). 1H NMR (500 MHz, CDCl3): δ 7.95-7.97 (dd, J = 
1.31 Hz, J = 8.34 Hz, 2H), 7.74 (s, 1H), 7.68 (s, 1H), 7.60 (d, J = 7.63 Hz, 1H), 7.51-7.55 
(m, 2H), 7.43 (t, J = 7.73 Hz, 1H), 7.39 (m, 2H), 6.40 (d, J = 2.05 Hz, 1H), 6.08 (d, J = 
2.01 Hz, 1H), 5.35 (Broad s, 1H), 4.40-4.55 (m, 6H), 1.79-1.86 (m, 2H), 1.55 (dd, J = 
5.54 Hz, J = 6.69 Hz, 6H), 1.05 (t, J = 7.45 Hz, 3H). Anal. Calcd for C29H30F3N3O3: C, 
66.27; H, 5.75; N, 8.00. Found: C, 65.93; H, 5.89; N, 7.89.  
187 
2-(4-(4-(trifluromethyl)benzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-
yloxy)butyl benzoate (249u): 165 mg of an off-white solid (62%). Rf 0.71 
(CH2Cl2/MeOH/NH4OH 100:10:0.1). MP = 65-68 oC. 1H NMR (400 MHz, CDCl3): δ 
7.94-7.96 (dd, J = 1.21 Hz, J = 8.25 Hz, 2H), 7.74 (s, 1H), 7.50-56 (q, J = 8.38 Hz, J = 
20.61 Hz, 5H), 7.36-7.40 (t, J = 7.83 Hz, 2H), 6.38 (d, J = 2.01 Hz, 1H), 6.03 (d, J = 2.00 
Hz, 1H), 5.46 (broad s, 1H), 4.54 (d, J = 3.27 Hz, 2H), 4.40-4.47 (m, 4H), 1.78-1.82 (m, 
2H), 1.54 (dd, J = 4.56 Hz, J = 6.73 Hz, 6H), 1.02 (t, J = 7.45 Hz, 3H). Anal. Calcd for 
C29H30F3N3O3. 0.5 % H2O: C, 65.15; H, 5.84; N, 7.86. Found: C, 65.17; H, 5.80; N, 7.71.  
 
2-(1-isopropyl-4-(pyridin-2-ylmethylamino)-1H-benzo[d]imidazol-6-yloxy)butyl 
benzoate (249v): 160 mg of a yellow semisolid (94%). Rf 0.60 (CH2Cl2/MeOH/NH4OH 
100:10:0.1). 1H NMR (500 MHz, CDCl3): δ 8.59 (ddd, J = 0.9 Hz, J = 1.7 Hz, J = 4.8 Hz, 
1H), 7.94-7.97 (dd, J = 1.27 Hz, J = 8.38 Hz, 2H), 7.75 (s, 1H), 7.59 (dt, J = 1.81 Hz, J = 
7.70 Hz, 1H), 7.52-56 (ddd, J = 1.30 Hz, J = 2.59 Hz, J = 8.72 Hz, 1H), 7.37-7.41 (app t, 
J = 7.87 Hz, 3H), 7.15 (m, 1H), 6.38 (d, J = 2.06 Hz, 1H), 6.10 (d, J = 2.02 Hz, 1H), 5.79  
(t,  J = 5.64 Hz, 1H), 4.63 (d, J = 5.65 Hz, 2H), 4.44-4.55 (m, 4H), 1.80-1.85 (m, 2H), 
1.55 (dd, J = 5.10 Hz, J = 6.70 Hz, 6H), 1.06 (t, J = 7.45 Hz, 3H). Anal. Calcd for 
C27H30N4O3. 0.66 % H2O: C, 68.93; H, 6.71; N, 11.91. Found: C, 68.98; H, 6.78; N, 
11.69.  
 
2-(1-isopropyl-4-(pyridin-3-ylmethylamino)-1H-benzo[d]imidazol-6-yloxy)butyl 
benzoate (249w): 160 mg of a brown semisolid (88%). Rf 0.52(CH2Cl2/MeOH/NH4OH 
100:10:0.1). 1H NMR (400 MHz, MeOD-d4): δ 8.59 (d,  J =1.70 Hz, 1H), 8.41 (dd, J = 
188 
1.42 Hz, J = 4.93 Hz, 1H), 8.13 (s, 1H), 7.87 (d, J = 7.85 Hz, 1H), 7.79-7.82 (dd,  J = 
1.28 Hz, J = 8.37 Hz, 2H), 7.53-7.57 (t,  J = 7.48 Hz, 1H), 7.35 (m, 3H), 6.53 (d, J = 2.01 
Hz, 1H), 6.11 (d, J = 2.00 Hz, 1H), 4.50-4.60 (m, 4H),  4.45 (d, J = 5.26 Hz, 2H), 1.76-
1.83 (m, 2H), 1.52 (dd, J = 4.57 Hz, J = 6.70 Hz, 6H), 1.06 (t, J = 7.46 Hz, 3H).  Anal. 
Calcd for C27H30N4O3. 1.12 %  H2O: C, 67.73; H, 6.78; N, 11.70. Found: C, 67.75; H, 
6.67; N, 11.58.  
 
2-(1-isopropyl-4-(pyridin-4-ylmethylamino)-1H-benzo[d]imidazol-6-yloxy)butyl 
benzoate (249x): 75 mg of a yellow semisolid (47%). Rf 0.51(CH2Cl2/MeOH/NH4OH 
100:10:0.1). 1H NMR (500MHz, CDCl3): δ 8.53 (dd,  J = 1.63 Hz, J = 4.44Hz, 1H), 7.95 
(dd, J = 1.27 Hz, J = 8.41 Hz, 1H), 7.75 (s, 1H), 7.53 (m,  1H), 7.37-7.41 (dd, J = 7.55 
Hz, J = 8.14 Hz, 2H), 7.32 (dd, J = 1.57 Hz, 4.47 Hz, 1H), 6.40 (d, J = 2.05 Hz, 1H), 5.99 
(d, J = 1.99 Hz, 1H), 5.39  (t, J = 5.90 Hz, 1H), 4.51 (d, J = 6.11 Hz, 2H), 4.41-4.50(m, 
4H), 1.76-1.83 (m, 2H), 1.55 (dd, J = 6.00 Hz, J = 6.58 Hz, 6H), 1.04 (t, J = 7.45 Hz, 
3H). HRMS (EI) calcd for C27H30N4O3: 459.2391 [M+H+], Found 459.2376 [M+H+].  
 
4-((6-(1-(benzoyloxy)butan-2-yloxy)-1-isopropyl-1H-benzo[d]imidazol-4-
ylamino)methyl)benzoic acid (249z): 100 mg of a white solid (50%). Rf 0.15 
(CH2Cl2/MeOH/NH4OH 100:10:0.1). MP = 191.5-193.5 oC. 1H NMR (400 MHz, 
CDCl3): δ 8.00 (d, J = 1.35 Hz, 1H), 7.98 (d,  J = 1.31 Hz, 1H), 7.98 (s, 1H), 7.80 (d, J = 
8.33 Hz, 2H), 7.56 (m,1H), 7.46 (d, J = 8.42 Hz, 2H), 7.39-7.42  (t, J = 7.76 Hz, 2H), 
6.44 (d, J = 1.96 Hz, 1H), 6.31 (d, J = 1.96 Hz, 1H), 5.47 (bs, 1H), 4.45-4.60 (m, 5H), 
4.38 (s, 2H), 1.86-1.95 (dt, J = 7.56 Hz, J = 13.32 Hz, 2H), 1.58 (t, J = 6.51 Hz, 6H), 1.15 
189 
(t, J = 7.46 Hz, 3H). Anal. Calcd for C29H31N3O5: C, 69.44; H, 6.23; N, 8.38. Found: C, 
69.14; H, 6.19; N, 8.36.   
  
2-(4-(3-ethoxybenzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butyl 
benzoate(249y): 121.0 mg of a white solid (61%). Rf 0.65 (CH2Cl2/MeOH/NH4OH 
100:10:0.1). MP = 72 -78 oC. 1H NMR (400MHz, CDCl3): δ 7.96-7.99 (dd, J = 1.31 Hz, J 
= 8.34 Hz, 2H), 7.739 (s, 1H), 7.52-57 (m, 1H), 7.37-7.42 (t, J = 7.78 Hz, 2H), 7.23 (t, J 
= 7.82 Hz, 1H), 6.99 (d, J = 7.41 Hz, 2H), 6.81 (m, 1H), 6.36 (d, J = 2.04 Hz, 1H), 6.13 
(d, J = 2.03 Hz, 1H), 5.36 (bs, 1H), 4.40-4.55 (m, 6H), 4.06 (q, J = 6.99 Hz, 2H), 1.79-
1.85 (m, 2H), 1.55 (dd, J = 4.37 Hz, J = 6.73 Hz, 6H), 1.39 (t, J = 7.00 Hz, 3H) 1.07 (t, J 
= 7.46 Hz, 3H). HRMS (EI) calcd for C30H35N3O4: 502.2700 [M+H+], 524.2520 [M+ 
Na+], Found 502.2704 [M+H+], 524.2515 [M+ Na+].   
 
2-(4-(4-tert-butylbenzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butyl 
benzoate (249z’): 180 mg of a white fluffy solid (89%). Rf 0.70 (CH2Cl2/MeOH/NH4OH 
100:10:0.1).  MP =49.5- 52 oC. 1H NMR (400MHz, CDCl3): δ 7.96-7.98 (dd, J = 1.33 
Hz, J = 8.41 Hz, 2H), 7.72 (s, 1H), 7.53-56 (m, 1H), 7.36-7.41 (m, 2H), 7.35 (s, 4H), 6.36 
(d, J = 2.07 Hz, 1H), 6.03 (d, J = 2.00 Hz, 1H), 5.46 (bs, 1H), 4.40-4.55 (m, 6H), 1.81-
1.86 (m, 2H), 1.54 (dd, J = 4.09 Hz, J = 6.74 Hz, 6H), 1.32 (s, 9H), 1.07 (t, J = 7.47 Hz, 
3H). Anal. Calcd for C32H39N3O3. 0.44 % H2O: C, 73.67; H, 7.70; N, 8.05;. Found: C, 
73.68; H, 7.74; N, 8.05. 
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General procedure for synthesis of 2-(4-(substituted benzylamino)-1-isopropyl-1H-
benzo[d]imidazol-6-yloxy)butan-1-ol: 2-(4-(substituted benzylamino)-1-isopropyl-1H-
benzo[d]imidazol-6-yloxy)butyl benzoate) derivatives (249a- z’) were dissolved into 5.0 
mL of 5% KOH (MeOH) and the reaction mixture was stirred for 12 h. Completion of the 
reaction was determined by TLC. The reaction was quenched with 7.5 mL of NH4Cl (sat, 
aq) and extracted with three 10 mL portions of EtOAc. The combined EtOAc extracts 
were washed with three 5.0 mL portions of NaCl (sat aq) and dried (Na2SO4). The 
solution was decanted and removal of the solvent gave a residue, which was subjected to 
silica gel column chromatography (Hex: EtOAc; 1:1) to afford the desired products in 70-
99 % yield.  Treatment with HCl(g) in Et2O, gave the desired product as the 
hydrochloride salt of each 2-(4-(substituted benzylamino)-1-isopropyl-1H-
benzo[d]imidazol-6-yloxy)butan-1-ol 192. 
  
2-(1-isopropyl-4-(2-methylbenzylamino)-1H-benzo[d]imidazol-6-yloxy)butan-1-ol 
hydrochloride (192a): 91 mg of an off-white semisolid (73%). Rf 0.67 
(CH2Cl2/MeOH/NH4OH 100:10:0.1). 1H NMR (400 MHz, MeOD-d4): δ 9.21 (s, 1H), 
7.35-7.37 (d, J = 7.00 Hz, 2H), 7.18-7.24 (m, 3H), 6.71 (d, J = 1.94 Hz, 1H), 6.41 (d, J = 
1.91 Hz, 1H), 4.91 (m, 1H), 4.45 (s, 2H), 4.35-4.38 (m, 1H), 3.71-3.73 (dd, J = 1.94 Hz, J 
= 4.85 Hz, 2H), 2.96 (s, 3H), 1.70-1.76 (m, 2H), 1.68 (d, J = 6.71 Hz, 6H), 0.99 (t, J = 
7.48 Hz, 3H). Anal. Calcd for C22H30ClN3O2 . 0.25 % H2O: C, 64.68; H, 7.52; N, 10.28. 
Found: C, 64.71; H, 7.41; N, 10.09.  
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2-(1-isopropyl-4-(3-methylbenzylamino)-1H-benzo[d]imidazol-6-yloxy)butan-1-ol 
hydrochloride (192b): 80 mg  of an off-white semisolid (64%). Rf 0.65 
(CH2Cl2/MeOH/NH4OH 100:10:0.1). 1H NMR (400 MHz, CDCl3): δ 8.70 (s, broad peak, 
1H), 7.18-7.27 (m, 3H), 7.04 (d, J = 6.73 Hz, 1H), 6.27 (d, J = 1.75 Hz, 1H), 6.10 (d, J = 
1.76 Hz, 1H), 4.65 (bs, 1H),  4.52 (d, J = 2.21 Hz, 2H), 4.17 (m, 1H), 3.67-3.73 (dq, J = 
4.91 Hz, J = 12.05 Hz, 2H), 2.88 (s, 3H), 1.69 (d, J = 6.26 Hz, 6H), 1.59-1.67 (m, 2H), 
0.86 (t, J = 7.50 Hz, 3H). Anal. Calcd for C22H30ClN3O2. 0.21 % EtOAc: C, 64.93; H, 
7.56; N, 9.94. Found: C, 64.96; H, 7.55; N, 9.91. 
 
2-(1-isopropyl-4-(4-methylbenzylamino)-1H-benzo[d]imidazol-6-yloxy)butan-1-ol 
hydrochloride (192c): 90 mg  of an off-white semisolid (90%). Rf 0.68 
(CH2Cl2/MeOH/NH4OH 100:10:0.1). 1H NMR (400MHz, CDCl3): δ 8.75 (s, 1H), 7.32 
(d, J = 7.90 Hz, 2H), 7.12 (d, J = 8.01 Hz, 2H), 6.30 (s, 1H), 6.17 (s, 1H), 4.67 (m, 1H),  
4.52 (d, J = 1.99 Hz, 2H), 4.18 (m, 1H), 3.67-3.76 (ddd, J = 4.99 Hz, J = 11.88 Hz, J = 
18.28 Hz, 2H), 2.31 (s, 3H), 1.68 (d, J = 6.65 Hz, 6H), 1.60-1.66 (m, 2H), 0.90 (t, J = 
7.49 Hz, 3H). Anal. Calcd for C22H30ClN3O2. 0.33 % H2O: C, 64.46; H, 7.54; N, 10.25. 
Found: C, 64.47; H, 7.46; N, 10.19.  
 
2-(1-isopropyl-4-(2-methoxybenzylamino)-1H-benzo[d]imidazol-6-yloxy)butan-1-ol 
hydrochloride (192d) : 55 mg of an off white semisolid (59%). Rf 0.68 
(CH2Cl2/MeOH/NH4OH 100:10:0.1). 1H NMR (400 MHz, MeOD-d4): δ 9.19 (s, 1H), 
7.34-7.36 (dd, J = 1.61 Hz, J = 7.44 Hz,  1H), 7.29 (m, 1H), 7.02-7.04 (dd, J = 0.74 Hz, J 
= 8.21 Hz, 1H), 6.90-6.94 (dt, J = 1.03 Hz, J = 7.46 Hz, 1H), 6.68 (d, J = 1.95 Hz, 1H), 
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6.44 (d, J = 1.92 Hz, 1H), 4.87 (m, 1H), 4.47 (s, 2H), 4.32-4.35 (m, 1H), 3.90(s, 3H), 
3.70-3.72 (dd, J = 1.31 Hz, J = 4.86 Hz, 2H), 1.70-1.76 (m, 2H), 1.68 (d, J = 6.68 Hz, 
6H), 0.97 (t, J = 7.49 Hz, 3H). Anal. Calcd for C22H30ClN3O3: C, 62.92; H, 7.20; N, 
10.01. Found: C, 62.85; H, 7.17; N, 9.68. 
 
2-(1-isopropyl-4-(3-methoxybenzylamino)-1H-benzo[d]imidazol-6-yloxy)butan-1-ol 
hydrochloride (192e) : 55 mg  of a white solid (78%). Rf 0.70 (CH2Cl2/MeOH/NH4OH 
100:10:0.1). MP = 172-175 oC. 1H NMR (400 MHz, CDCl3): δ 8.53 (bs, 1H), 7.23 (t, J = 
8.19 Hz, 1H), 7.02 (d, J = 6.11 Hz, 2H), 6.79 (m, 1H), 6.27 (d, J = 0.95 Hz, 1H), 6.12 (d, 
J = 1.22 Hz, 1H), 4.66 (bs, 1H),  4.52 (m, 2H), 4.18 (m, 1H), 3.80 (s, 3H), 3.67-3.76 (dq, 
J = 4.91 Hz, J = 11.96 Hz, 2H), 1.69 (d, J = 6.34 Hz, 6H), 1.59-1.66 (m, 2H), 0.89 (t, J = 
7.49 Hz, 3H). Anal. Calcd for C22H30ClN3O3. 0.28 % H2O: C, 62.17; H, 7.24; N, 9.88. 
Found: C, 62.20; H, 7.26; N, 9.72.  
 
2-(4-(2-chlorobenzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butan-1-ol 
hydrochloride (192j): 70 mg of an off-white solid (68 %). Rf 0.65 
(CH2Cl2/MeOH/NH4OH 100:10:0.1). MP = 40-43 oC. 1H NMR (400 MHz, CDCl3): δ 
8.77 (s, 1H), 7.82 (bs, 1H), 7.51 (m, 1H), 7.39 (m, 1H), 7.19 (m, 2H), 6.31 (d, J = 1.86 
Hz, 1H), 6.05(d, J = 1.86 Hz, 1H), 4.66 (m, 3H), 4.23 (m, 1H), 3.71-3.75 (m, 2H), 1.82 
(s,broad peak, 1H), 1.71 (d, J = 6.71 Hz, 6H), 1.62-1.65 (m, 2H), 0.89 (t,  J = 7.51 Hz, 
3H). Anal. Calcd for C21H27Cl2N3O2. 0.37 % H2O: C, 58.52; H, 6.48; N, 9.75. Found: C, 
58.52; H, 6.45; N, 9.74. 
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2-(4-(4-chlorobenzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butan-1-ol 
hydrochloride (192l): 55 mg of an off-white solid (82 %). Rf 0.65 
(CH2Cl2/MeOH/NH4OH 100:10:0.1). MP = 130-135 oC. 1H NMR (400 MHz, CDCl3): δ 
8.93 (s, 1H), 7.81 (bs, 1H), 7.37 (d, J = 8.43 Hz, 2H), 7.28 (d, J = 8.13 Hz, 2H), 6.33 (d, J 
= 1.89 Hz, 1H), 6.04 (d, J = 1.86 Hz, 1H), 4.65-4.68 (m, 1H),  4.52 (d, J = 2.79 Hz, 2H), 
4.19 (m, 1H), 3.72-3.77 (m, 2H), 1.91 (bs, 1H), 1.70 (d, J = 6.68 Hz, 6H), 1.60-1.67 (m, 
2H), 0.89 (t, J = 7.50 Hz, 3H). Anal. Calcd for C21H27Cl2N3O2. 0.27 % H2O: C, 58.75; H, 
6.46; N, 9.78. Found: C, 58.75; H, 6.54; N, 9.85. 
 
2-(4-(2-fluorobenzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butan-1-ol 
hydrochloride (192m): 110 mg of an off-white solid (94%). Rf 0.69 
(CH2Cl2/MeOH/NH4OH 100:10:0.1). MP = 160-162 oC. 1H NMR (400MHz, MeOD-d4): 
δ 9.23 (s, 1H), 7.46-7.51 (dt, J = 1.77 Hz, J = 7.73 Hz, J = 7.47 Hz, 1H), 7.35 (m, 1H), 
7.13-7.19 (m, 2H), 6.72 (d, J = 1.94 Hz, 1H), 6.43 (d, J = 1.91 Hz, 1H), 4.90 (m, 1H), 
4.55 (s, 2H), 4.33-4.36 (m, 1H), 3.70-3.72 (dd, , J = 2.03 Hz, J = 4.82 Hz, 2H), 1.70-1.78 
(m, 2H), 1.67 (d, J = 6.71 Hz, 6H), 0.97 (t, J = 7.47 Hz, 3H). Anal. Calcd for 
C21H27ClFN3O2. 0.219 % H2O: C, 61.24; H, 6.71; N, 10.20. Found: C, 61.26; H, 6.78; N, 
10.12.  
 
2-(4-(3-fluorobenzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butan-1-ol 
hydrochloride (192n): 80 mg of an off-white solid (73%). Rf 0.68 
(CH2Cl2/MeOH/NH4OH 100:10:0.1). MP = 144-146 oC. 1H NMR (400 MHz, MeOD-d4): 
δ 9.26 (s, 1H), 7.36-7.42 (dt, J = 5.89 Hz, J = 7.94 Hz, J = 7.93 Hz, 1H), 7.25-7.28 (ddd, 
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J = 0.89 Hz, J = 1.50 Hz, J = 7.67 Hz, 1H), 7.16-7.20 (ddd, J = 1.68 Hz, J = 2.26 Hz, J = 
9.98 Hz, 1H), 7.00-7.06 (m, 1H), 6.73 (d, J = 1.94 Hz, 1H), 6.34 (d, J = 1.90 Hz, 1H), 
4.91 (m, 1H), 4.53 (s, 2H), 4.30-4.35 (m, 1H), 3.68-3.72 (dd, J = 2.48 Hz, J = 4.85 Hz, 
2H), 1.65-1.72 (m, 2H), 1.68 (d, J = 6.71 Hz, 6H), 0.95 (t, J = 7.49 Hz, 3H). Anal. Calcd 
for C21H27ClFN3O2: C, 61.83; H, 6.67; N, 10.30. Found: C, 61.44; H, 6.71; N, 10.06.  
 
2-(4-(4-fluorobenzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butan-1-ol 
hydrochloride (192o): 110 mg of a white solid (74%). Rf 0.70 (CH2Cl2/MeOH/NH4OH 
100:10:0.1). MP = 152-155 oC. 1H NMR (400 MHz, MeOD-d4): δ 9.23 (s, 1H), 7.45-7.48 
(dd, J = 5.29 Hz, J = 8.77 Hz, 2H), 7.08-7.12 (t, J = 8.80 Hz, 2H), 6.72 (d, J = 1.89 Hz, 
1H), 6.38 (d, J = 1.94 Hz, 1H), 4.92 (m, 1H), 4.47 (s, 2H), 4.30-4.35 (m, 1H), 3.69-3.71 
(dd, J = 2.28 Hz, J = 4.83 Hz, 2H), 1.70-1.79 (m, 2H), 1.68 (d, J = 6.71 Hz, 6H), 0.96 (t, 
J = 7.47 Hz, 3H). Anal. Calcd for C21H27ClFN3O2. 0.204 % H2O: C, 61.28; H, 6.71; N, 
10.20. Found: C, 61.31; H, 6.52; N, 9.96. 
 
2-(1-isopropyl-4-(4-nitrobenzylamino)-1H-benzo[d]imidazol-6-yloxy)butan-1-ol 
hydrochloride (192r):  15 mg of a yellow solid (~10 %). Rf 0.67 
(CH2Cl2/MeOH/NH4OH 100:10:0.1). MP = 128-130 oC. 1H NMR (400 MHz, MeOD-d4): 
δ 9.28 (s, 1H), 8.25 (d, J = 8.82 Hz, 2H), 7.69 (d, J = 8.85 Hz, 2H), 6.75 (d, J = 1.92 Hz, 
1H), 6.30 (d, J = 1.87 Hz, 1H), 4.85 (m, 1H), 4.67 (s, 2H), 4.32 (m, 1H), 3.68 (d, J = 3.62 
Hz, J = 4.81 Hz, 2H), 1.62-1.79 (m, 2H), 1.70 (d, J = 6.69 Hz, 6H), 0.94 (t, J = 7.49 Hz, 
3H). Anal. Calcd for C21H27N4O4Cl. 0.3356 % EtOH. 0.2 % HCl: C, 56.84; H, 6.43; N, 
12.23. Found: C, 56.91; H, 6.12; N, 12.03.  
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2-(1-isopropyl-4-(2-(trifluoromethyl)benzylamino)-1H-benzo[d]imidazol-6-
yloxy)butan-1-ol hydrochloride (192s): 65 mg of a white solid (63%). Rf 0.67 
(CH2Cl2/MeOH/NH4OH 100:10:0.1). MP = 193.5-195 oC. 1H NMR (400 MHz,  
MeOD-d4): δ 9.24 (s, 1H), 7.78 (d, J = 7.91 Hz, 1H), 7.69 (d, J = 7.57 Hz, 1H), 7.60 (t, J 
= 8.00 Hz, 1H), 7.50 (t, J = 7.50 Hz, 1H), 6.74 (d, J = 1.93 Hz, 1H), 6.25 (d, J = 1.88 Hz, 
1H), 4.91 (m, 1H), 4.70 (s, 2H), 4.29 (m, 1H), 3.68 (dd, J = 3.02 Hz, J = 4.81 Hz, 2H) 
1.64-1.79 (m, 2H), 1.68 (d, J = 6.70 Hz, 6H), 0.94 (t, J = 7.50 Hz, 3H). Anal. Calcd for 
C22H27ClF3N3O2: C, 57.70; H, 5.94; N, 9.18. Found: C, 57.56; H, 5.90; N, 9.02.  
 
2-(1-isopropyl-4-(3-(trifluoromethyl)benzylamino)-1H-benzo[d]imidazol-6-
yloxy)butan-1-ol hydrochloride (192t): 55 mg of a white solid (77%). Rf 0.68 
(CH2Cl2/MeOH/NH4OH 100:10:0.1). MP = 55-56 oC. 1H NMR (400 MHz, MeOD-d4): δ 
9.26 (s, 1H), 7.76 (s, 1H), 7.72 (d, J = 7.23 Hz, 1H), 7.57-7.61 (m, 2H), 6.74 (d, J = 1.89 
Hz, 1H), 6.35 (d, J = 1.78 Hz, 1H), 4.91 (m, 1H), 4.61 (s, 2H), 4.31 (m, 1H), 3.69 (dd, J = 
2.38 Hz, J = 4.81 Hz, 2H) 1.62-1.75 (m, 2H), 1.68 (d, J = 6.71 Hz, 6H), 0.94 (t, J = 7.48 
Hz, 3H). Anal. Calcd for C22H27ClF3N3O2. 0.344 % H2O: C, 56.93; H, 6.01; N, 9.05. 
Found: C, 56.97; H, 5.88; N, 8.73.  
 
2-(1-isopropyl-4-(4-(trifluoromethyl)benzylamino)-1H-benzo[d]imidazol-6-
yloxy)butan-1-ol hydrochloride (192u): 100 mg of a white solid (83%). Rf 0.69 
(CH2Cl2/MeOH/NH4OH 100:10:0.1). MP = 112-115 oC. 1H NMR (400 MHz, MeOD-d4): 
δ 9.26 (s, 1H), 7.66 (q,  J = 8.40 Hz, 4H), 6.74 (d, J = 1.95 Hz, 1H), 6.32 (d, J = 1.91 Hz, 
1H), 4.91 (m,1H), 4.61 (s, 2H), 4.30 (m, 1H), 3.68 (dd, J = 3.16 Hz, J = 4.82 Hz, 2H) 
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1.62-1.75 (m, 2H), 1.68 (d, J = 6.72 Hz, 6H), 0.94 (t, J = 7.48 Hz, 3H). Anal. Calcd for 
C22H27ClF3N3O2.0.26 % H2O: C, 57.12; H, 5.99; N, 9.08. Found: C, 57.15; H, 5.84; N, 
8.84.  
 
2-(1-isopropyl-4-(pyridin-2-ylmethylamino)-1H-benzo[d]imidazol-6-yloxy)butan-1-
ol hydrochloride (192v): 50 mg of yellow semisolid (51%). Rf 0.30 
(CH2Cl2/MeOH/NH4OH 100:10:0.1). 1H NMR (500 MHz, MeOD-d4): δ 9.37 (s, 1H), 
8.81 (ddd , J = 0.68 Hz, J = 1.52 Hz, J = 5.90 Hz, 1H), 8.59 (dt, J = 1.57 Hz, J = 7.92 Hz, 
1H), 8.15 (d, J = 7.89 Hz, 1H), 8.00 (t, J = 6.75 Hz, 1H), 6.86 (d, J = 1.85 Hz, 1H), 6.31 
(d, J = 1.85 Hz, 1H), 5.03 (s, 2H), 4.95 (td, J = 6.74 Hz, 13.48 Hz, 1H), 4.34-4.40 (m, 
1H), 3.64 (ddd, J = 4.82 Hz, J = 11.85 Hz, J = 17.38 Hz, 2H), 1.65-1.72 (m, 2H), 1.70 (d, 
J = 6.72 Hz, 6H), 0.95 (t, J = 7.47 Hz, 3H). Anal. Calcd for C20H28Cl2N4O2.0.64 % 
C2H5OH ·0.67 % HCl: C, 53.11; H, 6.80; N, 11.64. Found: C, 53.06; H, 7.06; N, 11.78.  
 
2-(1-isopropyl-4-(pyridin-3-ylmethylamino)-1H-benzo[d]imidazol-6-yloxy)butan-1-
ol hydrochloride (192w): 35 mg of yellow semisolid (47.3%). Rf 0.51 
(CH2Cl2/MeOH/NH4OH 100:10:0.1). 1H NMR (400 MHz, MeOD-d4): δ 9.35 (s, 1H), 
8.97 (s, 1H), 8.82 (d, J = 5.68 Hz , 1H), 8.75 (d, J = 8.24 Hz, 1H), 8.12 (dd, J = 5.86 Hz, 
8.06Hz, 1H), 6.81 (d, J = 1.80 Hz, 1H), 6.34 (d, J = 1.81 Hz, 1H), 4.93 (m, 1H), 4.86 (s, 
2H), 4.35-4.40 (m, 1H), 3.65-3.75 (dq,  J = 4.83 Hz, 11.84 Hz, 2H), 1.65-1.73 (m, 2H), 
1.70 (d, J = 6.68 Hz, 6H), 0.968 (t, J = 7.48 Hz, 3H). Anal. Calcd for C20H28Cl2N4O2 · 2.5 
% H2O: C, 50.85; H, 7.04;  N, 11.86. Found: C, 50.89; H, 6.89; N, 11.64.  
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2-(1-isopropyl-4-(pyridin-4-ylmethylamino)-1H-benzo[d]imidazol-6-yloxy)butan-1-
ol hydrochloride (192x): 30 mg of yellow semisolid (50%). Rf 0.51 
(CH2Cl2/MeOH/NH4OH 100:10:0.1). 1H NMR (500 MHz, MeOD-d4): δ 9.36 (s, 1H), 
8.82 (d, J = 6.85 Hz , 2H), 8.16 (d, J = 6.82 Hz, 2H), 6.81 (d, J = 1.87 Hz, 1H), 6.21 (d, J 
= 1.87 Hz, 1H), 4.91-4.96 (m, 3H), 4.31-4.37 (m, 1H), 3.64-3.75 (dq, J = 4.81 Hz, J = 
11.82 Hz, 2H), 1.65-1.74 (m, 2H), 1.70 (d, J = 6.66 Hz, 6H), 0.947 (t, J = 7.47 Hz, 3H). 
Anal. Calcd for C20H28Cl2N4O2· 0.46 % C2H5OH ·0.63 % HCl: C, 53.27; H, 6.70; N, 
11.89. Found: C, 53.25; H, 6.85; N, 11.97. HRMS (EI) calcd for C20H26N4O2: 355.2129 
[M+H+], found 355.2117 [M+H+].  
 
General procedure for debenzoylation to 2-(4-(substituted benzylamino)-1-
isopropyl-1H-benzo[d]imidazol-6-yloxy)butan-1-ol derivatives: The 2-(4-(substituted 
benzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butyl benzoate (249) was 
dissolved into 5.0 mL of 5% KOH in MeOH and the reaction mixture was stirred for 12 
h. Completion of the reaction was determined by TLC. The reaction was quenched with 
7.5 mL of NaCl (sat, aq) and extracted with three 10 mL portions of EtOAc. The 
combined EtOAc extracts were washed with three 5.0 mL portions of NaCl (sat aq) and 
then dried (Na2SO4).  The solvent was decanted and removal of the solvent under 
pressure gave a residue, which was subjected to silica gel column chromatography (Hex: 
EtOAc; 1:1) to afford the product in 70-99% yield. 
 
2-(1-isopropyl-4-(4-methoxybenzylamino)-1H-benzo[d]imidazol-6-yloxy)butan-1-ol 
(192f) : 80 mg of a yellow solid (95%). Rf 0.70 (CH2Cl2/MeOH/NH4OH 100:10:0.1). MP 
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= 125-126.5 oC. 1H NMR (400 MHz, CDCl3): δ 7.72(s, 1H), 7.34 (d, J = 8.53 Hz, 2H), 
6.87 (d, J = 8.64 Hz, 2H), 6.30 (d, J = 2.04 Hz, 1H), 6.03 (d, J = 2.04 Hz, 1H), 5.23 (t, J 
= 5.13 Hz, 1H), 4.48 (m, 1H),  4.40 (d, J = 5.37 Hz, 2H), 4.25 (m, 1H), 3.70-3.84 (m, 
5H), 2.31 (s, 3H), 1.98 (bs, 1H), 1.65-1.74 (m, 2H), 1.58 (dd, J = 1.45 Hz, J = 6.74 Hz , 
6H), 0.97 (t, J = 7.51Hz, 3H). Anal. Calcd for C22H29N3O3: C, 68.90; H, 7.62; N, 10.96. 
Found: C, 68.70; H, 7.71; N, 10.92.  
 
2-(1-isopropyl-4-(2-hydroxybenzylamino)-1H-benzo[d]imidazol-6-yloxy)butan-1-ol 
(192g) : 95 mg of a white solid (94%). Rf 0.62 (CH2Cl2/MeOH/NH4OH 100:10:0.1). MP 
= 69.1-74.0 oC. 1H NMR (400 MHz, CDCl3): δ 7.80 (s, 1H), 7.20 (m, 2H), 7.85-7.92 (m, 
2H), 6.42 (d, J = 1.92 Hz, 1H), 6.31 (d, J = 2.00 Hz, 1H), 5.19 (bs, 1H), 4.58 (s, 2H), 
4.45-4.55 (m, 1H), 4.24 (m, 1H), 3.71-3.83 (ddd, J = 4.85 Hz, J = 11.76 Hz, J = 18.13 
Hz, 2H), 1.70-1.79 (m, 2H), 1.59 (d, J = 6.73 Hz, 6H), 0.97 (t, J = 7.52 Hz, 3H). Anal. 
Calcd for C21H27N3O3. 0.38 % H2O: C, 67.01; H, 7.43; N, 11.16. Found: C, 67.05; H, 
7.05; N, 10.82. 
 
2-(1-isopropyl-4-(3-hydroxybenzylamino)-1H-benzo[d]imidazol-6-yloxy)butan-1-ol 
(192h): 95 mg of an off-white solid (87%). Rf 0.65 (CH2Cl2/MeOH/NH4OH 100:10:0.1). 
MP = 67.5 -71.1 oC. 1H NMR (400 MHz, CDCl3): δ  7.83 (s, 1H), 7.11 (t, J = 7.99 Hz, 
1H), 6.86 (m, 2H), 6.78 (m, 1H), 6.31 (d, J = 1.98 Hz, 1H), 6.15 (d, J = 1.96 Hz, 1H), 
5.49 (bs, 1H), 4.49-4.54 (m, 1H), 4.30 (s, 3H), 3.71-3.86 (ddd, J = 4.85 Hz, J = 11.72 Hz, 
J = 18.23 Hz, 2H), 1.71-1.80 (m, 2H), 1.61 (dd, J = 0.80 Hz, J = 6.75 Hz, 6H), 1.00 (t, J 
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= 7.51 Hz, 3H). Anal. Calcd for C21H27N3O3. 0.34 % H2O: C, 67.15; H, 7.42; N, 11.18. 
Found: C, 67.20; H, 7.23; N, 10.82.  
 
2-(1-isopropyl-4-(4-hydroxybenzylamino)-1H-benzo[d]imidazol-6-yloxy)butan-1-ol 
(192i): 70 mg of an off-white solid (67%). Rf 0.69 (CH2Cl2/MeOH/NH4OH 100:10:0.1). 
MP= 143.5-146 oC. 1H NMR (400 MHz, CDCl3): δ 7.82 (s, 1H), 7.14 (d, J = 8.47 Hz, 
2H), 6.75 (d, J = 8.43 Hz, 2H), 6.32 (d, J = 2.03 Hz, 1H), 6.19 (d, J = 2.00 Hz, 1H), 5.03 
(bs, 1H), 4.52 (m, 1H), 4.32 (m, 1H), 4.25 (d, J = 4.82 Hz, 2H), 3.77-3.85 (m, 2H), 1.96 
(bs, 1H), 1.68-1.80 (m, 2H), 1.60 (dd, J = 1.22 Hz, J = 6.71 Hz , 6H), 1.00 (t, J = 7.51 
Hz, 3H). Anal. Calcd for C21H27N3O3. 0.34 % H2O : C, 67.16; H, 7.42; N, 11.18. Found: 
C, 67.19; H, 7.36; N, 11.03.  
 
2-(1-isopropyl-4-(2-nitrobenzylamino)-1H-benzo[d]imidazol-6-yloxy)butan-1-ol 
(192p): 50 mg of an off-white solid (74%). Rf 0.65 (CH2Cl2/MeOH/NH4OH 100:10:0.1). 
MP = 73.5-76 oC. 1H NMR (500 MHz, CDCl3): 7.96 (s, 1H), 7.77-7.76 (td, J = 0.96 Hz, J 
= 0.96 Hz, J = 8.59 Hz, 1H), 7.64 (td, J = 0.89 Hz, J = 0.89 Hz, J = 8.82 Hz, 1H), 7.23-
7.26 (ddd, J = 1.02 Hz, J = 6.54 Hz, J = 8.93 Hz, 1H), 7.22 (d, J = 2.20 Hz, 1H), 7.11 (d, 
J = 2.21 Hz, 1H), 6.97 (ddd, J = 0.83 Hz, J = 6.58 Hz, J = 8.67 Hz, 1H), 4.62 (m, 1H), 
4.40 (m, 1H), 4.30 (s, 2H), 3.80-3.90 (ddd, J = 5.14 Hz, J = 11.83 Hz, J = 18.05 Hz, 2H), 
1.92 (s, broad peak, 1H), 1.72-1.83 (m, 2H), 1.66 (d, J = 6.81Hz, 6H), 1.03 (t, J = 7.52 
Hz, 3H). Anal. Calcd for C21H26N4O4 · 0.34 % C6H5CH3: C, 65.33; H, 6.73; N, 13.03. 
Found: C, 65.54; H, 6.56; N, 13.40.  
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2-(1-isopropyl-4-(3-nitrobenzylamino)-1H-benzo[d]imidazol-6-yloxy)butan-1-ol 
(192q):  70 mg of a yellow solid (68%). Rf 0.66 (CH2Cl2/MeOH/NH4OH 100:10:0.1). 
MP = 45.5-47 oC. 1H NMR (400 MHz, CDCl3): δ 8.28 (s, 1H), 8.12 (dd, J = 1.42 Hz, J = 
7.8 Hz, 1H), 7.92-7.94 (dd, J = 1.3 Hz, J = 8.32 Hz, 2H), 7.76 (s, 1H), 7.73 (d, J = 8.17 
Hz, 2H), 7.76 (d, J = 5.93 Hz, 2H), 7.51 (t, J = 7.93 Hz, 1H), 6.33 (d, J = 2.01 Hz, 1H), 
5.96 (d, J = 1.99 Hz, 1H), 5.52 (bs, 1H), 4.61 (d, J = 3.11 Hz, 2H), 4.48-4.51 (m, 1H), 
4.20-4.22 (m, 1H), 3.68-3.82 (ddd, J = 4.91 Hz, J = 11.74 Hz,  J = 18.21 Hz, 2H), 1.62-
1.73 (m, 2H), 1.60 (dd, J = 1.74 Hz, J = 6.74 Hz, 6H), 0.93 (t, J = 7.53 Hz, 3H). Anal. 
Calcd for C21H26N4O4 · 0.1 % CH3CO2C2H5: C, 63.10; H, 6.63; N, 13.75. Found: C, 
63.30; H, 6.47; N, 13.60. 
 
4-((6-(1-hydroxybutan-2-yloxy)-1-isopropyl-1H-benzo[d]imidazol-4-
ylamino)methyl)benzoic acid (192z): 40 mg of a white solid (58.8%). Rf 0.05 
(CH2Cl2/MeOH/NH4OH 100:10:0.1). MP = 241.5-243 oC. 1H NMR (500 MHz, DMSO-
d6): δ 12.78 (bs, 1H), 7.98 (s, 1H), 7.88 (d, J = 8.31 Hz, 2H), 7.48 (d, J = 8.33 Hz, 2H), 
6.42 (t, J = 6.39 Hz, 1H), 6.31 (d, J = 1.99 Hz, 1H), 5.74 (d, J = 2.01 Hz, 1H), 4.66 (t, J = 
5.60 Hz, 1H), 4.52-4.61 (m, 1H), 4.52 (d, J = 6.27 Hz, 2H), 4.05-4.10 (p, J = 5.4 Hz, 1H), 
3.40-3.53 (dtd, J = 5.29 Hz, J = 11.2 Hz,  J = 22.14 Hz, 2H), 1.42-1.50 (m, 1H), 1.55-
1.62 (m, 1H), 1.48 (d, J = 6.72 Hz, 6H), 0.84 (t, J = 7.47 Hz, 3H).  1H NMR (500 MHz, 
DMSO-d6) (D2O Exchange): δ 7.98 (s, 1H), 7.87 (d, J = 8.26 Hz , 2H), 7.47 (d, J = 8.34 
Hz, 2H), 6.30 (d, J = 1.97 Hz, 1H), 5.74 (d, J = 2.03 Hz, 1H), 4.52-4.58 (m, 1H), 4.52 (s, 
2H), 4.05-4.10 (p, J= 5.3Hz, 1H), 3.40-3.53 (m, 2H), 1.42-1.50 (m, 1H), 1.55-1.62(m, 
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1H), 1.48 (d, J = 6.70 Hz, 6H), 0.82 (t, J = 7.46 Hz, 3H). Anal. Calcd for C22H27N3O4 · 
0.5 % H2O: C, 65.00; H, 6.94; N, 10.33. Found: C, 65.00; H, 6.59; N, 10.24.  
 
2-(4-(3-ethoxybenzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butan-1-ol 
(192y): 65 mg of a white semisolid (84.1%). Rf 0.50 (CH2Cl2/MeOH/NH4OH 
100:10:0.1). 1H NMR (400 MHz, CDCl3): δ 7.75 (s, 1H), 7.24 (dd, J = 6.24Hz, J = 9.34 
Hz , 1H), 6.98-7.02 (dd, J = 5.25 Hz, J = 7.01 Hz, 2H), 6.80 (dd, J = 1.74 Hz, 8.22 Hz, 
1H), 6.30 (d, J = 2.04 Hz, 1H), 6.08 (d, J = 2.04 Hz, 1H), 5.41 (bs, 1H), 4.45-4.55 (m, 
3H), 4.21-4.26 (m, 1H), 4.03 (q, J= 6.98 Hz, 2H), 3.70-3.83 (ddd, J = 4.86 Hz, J = 11.72 
Hz,  J = 18.07 Hz, 2H), 1.62-1.78 (m, 2H), 1.59 (dd, J = 1.47 Hz, J = 6.73 Hz, 6H), 1.40 
(t, J = 6.99Hz, 3H), 0.96 (t, J = 7.52 Hz, 3H). Anal. Calcd for C23H32ClN3O3·0.5 % H2O: 
C, 62.34; H, 7.50; N, 9.48. Found: C, 62.37; H, 7.62; N, 9.38.  
 
2-(4-(4-tert-butylbenzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butan-1-ol 
(192z’): 110 mg of a off white solid (92.7%). Rf 0.60(CH2Cl2/MeOH/NH4OH 
100:10:0.1). MP = 59.5 – 61 oC. 1H NMR (400 MHz, CDCl3): δ 7.75 (s, 1H), 7.37 (s, 
4H), 6.31 (d, J = 2.07 Hz, 1H), 6.10 (d, J = 2.04 Hz, 1H), 5.33 (s, broad peak, 1H), 4.45-
4.51 (m, 1H), 4.46 (s, 2H),  4.22-4.28 (ddd, J= 3.28 Hz, 6.37 Hz, 12.32 Hz, 1H), 3.70-
3.86 (ddd, J = 4.86 Hz, J = 11.73 Hz,  J = 18.12 Hz, 2H), 1.62-1.78 (m, 2H), 1.60 (dd, J = 
1.45 Hz, J = 6.75 Hz, 6H), 1.33(s, 9H), 0.96 (t, J = 7.52 Hz, 3H). Anal. Calcd for 
C25H35N3O2 ·0.82 %  H2O: C, 70.76; H, 8.70; N, 9.90. Found: C, 70.77; H, 8.31; N, 9.75.  
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Series 5.2 : DISUBSTITUTED N4 BENZYL BENZIMIDAZOLE SERIES 
General procedure for synthesis of 2-(substituted 4-(disubstituted benzylamino)-1-
isopropyl-1H-benzo[d]imidazol-6-yloxy)butyl benzoate):  A 100 mL dry round bottom 
flask was charged with 2-(4-amino-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butyl 
benzoate hydrochloride  (248; 150 mg, 0.37 mmol), NaHB(OAc)3 (157.4 mg, 0.743 
mmol), the appropriate benzaldehyde (0.446 mmol, 1.2 equiv) and 4.0 mL of 1,2-
dichloroethane.  The mixture was stirred at 23 oC for 12 h. Completion of the reaction 
was determined by TLC.  The reaction mixture was quenched with the addition of 10 mL 
of NaHCO3 (sat., aq) (pH~ 9-10), the mixture was extracted with three 10 mL portions of 
EtOAc. The combined EtOAc extracts were washed with three 5 mL portions of NaCl
 
(sat, aq) and dried (Na2SO4). The solution was decanted and removal of the solvent in 
vacuo gave a residue, which was subjected to silica gel flash column chromatography 
(Hex/EtOAc; 1:1) to afford the products in approximately 50-88% yield typically as an 
oil.  
 
2-((4-((2,5-dimethylbenzyl)amino)-1-isopropyl-1H-benzo[d]imidazol-6-yl)oxy)butyl 
benzoate (251a): 170 mg of an off-white semisolid (94 %). Rf  0.75 
(CH2Cl2/MeOH/NH4OH 100:10:0.1). 1H NMR (400 MHz, CDCl3): δ 7.95-7.98 (dd, J = 
1.29 Hz, J = 8.31 Hz, 2H), 7.74 (s, 1H), 7.54 (t, J = 7.41 Hz, 1H), 7.39 (t, J = 7.82 Hz,  
2H), 7.19 (s, 1H),  7.14 (d, J = 8.64 Hz, 1H), 7.08 (d, J = 7.75 Hz, 1H), 6.36 (d, J = 2.00 
Hz, 1H), 6.17 (d, J = 2.03 Hz, 1H), 5.32 (bs, 1H), 4.46-4.53 (m, 3H), 4.42 (td, J = 6.82 
Hz, J = 13.66 Hz, 1H), 4.39 (s, 2H), 2.25 (s, 6H), 1.82-1.89 (m, 2H), 1.54 (dd, J = 5.43 
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Hz, J = 6.63 Hz, 6H), 1.08 (t, J = 7.45 Hz, 3H). Anal. Calcd for C30H35N3O3. 0.42 % H2O 
: C, 73.04; H, 7.32; N, 8.51. Found: C, 73.05; H, 7.22; N, 8.42.  
 
2-((4-((3,5-dimethylbenzyl)amino)-1-isopropyl-1H-benzo[d]imidazol-6-yl)oxy)butyl 
benzoate (251b): 115 mg of an off-white semisolid (64 %). Rf 0.75 
(CH2Cl2/MeOH/NH4OH 100:10:0.1). 1H NMR (500 MHz, CDCl3): δ 7.97 (dd, J = 1.34 
Hz, J = 8.27 Hz, 2H), 7.72 (s, 1H), 7.53-7.56 (t, J = 7.47 Hz, 1H), 7.39 (dd, J = 7.60 Hz, 
J = 8.07 Hz, 1H), 7.04 (s, 2H),  6.90 (s, 1H), 6.36 (d, J = 2.02 Hz, 1H), 6.16 (d, J = 2.01 
Hz, 1H), 5.23 (bs, 1H), 4.47-4.55 (m, 3H), 4.42 (td, J = 6.80 Hz, J = 13.57 Hz, 1H), 4.37 
(s, 2H), 2.03 (s, 6H), 1.81-1.89 (qd, J = 7.24 Hz, J = 6.96 Hz, J = 10.06 Hz, 2H), 1.54 
(dd, J = 5.40 Hz, J = 6.68 Hz, 6H), 1.09 (t, J = 7.48 Hz, 3H). Anal. Calcd for 
C30H35N3O3. 0.1 %  Hex : C, 74.38; H, 7.44; N, 8.47. Found: C, 74.61; H, 7.42; N, 8.68.  
 
2-((4-((2,4-dichlorobenzyl)amino)-1-isopropyl-1H-benzo[d]imidazol-6-yl)oxy)butyl 
benzoate (251c): 140 mg of a brown semisolid (70 %). Rf  0.75 (CH2Cl2/MeOH/NH4OH 
100:10:0.1). 1H NMR (500 MHz, CDCl3): δ 7.93-7.96 (dd, J = 1.36 Hz, J = 8.32 Hz, 2H), 
7.77 (s, 1H), 7.53-7.57 (t, J = 7.42 Hz, 1H), 7.37-7.42 (ddd, J = 2.71 Hz, J = 4.74 Hz, J = 
7.89 Hz, 4H),  7.14 (dd, J = 2.03 Hz, J = 8.32 Hz, 1H), 6.39 (d, J = 2.06 Hz, 1H), 6.01 (d, 
J = 2.01 Hz, 1H), 5.48 (bs, 1H), 4.55 (s, 2H), 4.40-4.52 (m, 4H), 1.79-1.85 (m, 2H), 1.55 
(dd, J = 5.03 Hz, J = 7.61 Hz, 6H), 1.06 (t, J = 7.48 Hz, 3H). Anal. Calcd for 
C28H29Cl2N3O3. 0.66 % H2O : C, 62.47; H, 5.67; N, 7.80. Found: C, 62.47; H, 5.45; N, 
7.66.  
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2-((4-((3,5-dichlorobenzyl)amino)-1-isopropyl-1H-benzo[d]imidazol-6-yl)oxy)butyl 
benzoate (251d) : 155 mg of an off-white semisolid (80 %). Rf 0.75 
(CH2Cl2/MeOH/NH4OH 100:10:0.1). 1H NMR (500 MHz, CDCl3): δ 7.95-7.97 (dd, J = 
1.32 Hz, J = 8.27 Hz, 2H), 7.75 (s, 1H), 7.55 (t, J = 7.43 Hz, 1H), 7.51 (d, J = 2.00 Hz, 
1H), 7.36-7.39 (dd, J = 7.83 Hz, J = 15.31 Hz, 3H),  7.23 (dd, J = 1.96 Hz, J = 8.23 Hz,  
1H), 6.39 (d, J = 1.98 Hz, 1H), 6.04 (d, J = 2.03 Hz, 1H), 5.41 (bs, 1H), 4.44-4.55 (m, 
6H), 1.80-1.85 (m, 2H), 1.55 (dd, J = 5.83 Hz, J = 6.61 Hz, 6H), 1.07 (t, J = 7.45 Hz, 
3H). Anal. Calcd for C28H29Cl2N3O3: C, 63.88; H, 5.55; N, 7.98. Found: C, 63.55; H, 
5.51; N, 7.81.  
 
2-((4-((3,5-dimethoxybenzyl)amino)-1-isopropyl-1H-benzo[d]imidazol-6-yl)oxy)butyl 
benzoate (251e): 35 mg of a brown semisolid (22.5 %). Rf 0.6 (CH2Cl2/MeOH/NH4OH 
100:10:0.1). 1H NMR (500MHz, CDCl3): δ 8.11 (s, 1H), 7.93-7.95 (dd, J = 1.27 Hz, J = 
8.39 Hz, 2H), 7.54 (t, J = 7.47 Hz, 1H), 7.39 (dd, J = 7.60 Hz, J = 8.07 Hz,  1H), 7.02 (d, 
J = 1.87 Hz, 1H),  6.94 (dd, J = 1.85 Hz, J = 8.17 Hz, 1H), 6.71 (d, J = 8.20 Hz, 1H), 
6.44 (bs, 1H), 6.29 (d, J = 1.89 Hz, 1H), 6.08 (d, J = 1.84 Hz, 1H), 4.34-4.55 (m, 6H), 
3.81 (s, 3H), 3.80 (s, 3H), 1.76-1.81 (m, 2H), 1.46 (dd, J = 5.27 Hz, J = 6.54 Hz, 6H), 
1.03 (t, J = 7.44 Hz, 3H). HRMS (EI) calcd for C30H35N3O5: 518.2610 [M+H+],  Found 
518.2649 [M+H]. 
 
General procedure for debenzoylation to 2-(4-(disubstituted benzylamino)-1-
isopropyl-1H-benzo[d]imidazol-6-yloxy)butan-1-ol derivatives: The 2-(4-
(disubstituted benzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butyl benzoate 
205 
was dissolved into 5.0 mL of 5% KOH (MeOH) and the reaction mixture was stirred for 
12 h. Completion of the reaction was determined by TLC. The reaction was quenched 
with 7.5 mL of NH4Cl (sat, aq) and extracted with three 10 mL portions of  EtOAc. The 
combined EtOAc extracts were washed with three 5.0 mL portions of NaCl (sat, aq) and 
then dried (Na2SO4).  The solution was decanted and removal of the solvent in vacuo 
gave a crude product, which was subjected to silica gel column chromatography (Hex: 
EtOAc; 1:1) to afford the product in 70-99 % yield. 
 
2-((4-((2,5-dimethylbenzyl)amino)-1-isopropyl-1H-benzo[d]imidazol-6-yl)oxy)butan-
1-ol (193a) : 110 mg of an off-white solid (93 %). Rf 0.50 (CH2Cl2/MeOH/NH4OH 
95:5:0.1). MP = 46 - 48 oC. 1H NMR (400MHz, CDCl3): δ 7.75 (s, 1H), 7.21 (s, 1H), 7.16 
(d, J = 7.68 Hz, 1H), 7.10 (d, J = 7.68 Hz, 1H), 6.30 (d, J = 1.98 Hz, 1H), 6.11 (d, J = 
1.95 Hz, 1H), 5.30 (bs, 1H), 4.49 (td, J = 6.72 Hz, J = 13.47 Hz, 1H),  4.41 (s, 2H), 4.26 
(ddd, J = 3.33 Hz, J = 6.53 Hz, J = 12.34 Hz, 1H), 3.70-3.84 (ddd, J = 4.86 Hz, J = 11.73 
Hz, J = 18.12 Hz, 2H), 2.26 (s, 6H), 1.62-1.74 (m, 3H), 1.59 (dd, J = 1.33 Hz, J = 6.72 
Hz , 6H), 0.97 (t, J = 7.50 Hz, 3H). Anal. Calcd for C23H31N3O2. 0.42 % H2O: C, 70.99; 
H, 8.24; N, 10.79. Found: C, 71.02; H, 8.09; N, 10.61.  
 
2-((4-((3,5-dimethylbenzyl)amino)-1-isopropyl-1H-benzo[d]imidazol-6-yl)oxy)butan-
1-ol (193b) : 75 mg of an off-white solid (100 %). Rf 0.50 (CH2Cl2/MeOH/NH4OH 
95:5:0.1). MP = 44 - 47 oC. 1H NMR (500 MHz, CDCl3): δ 7.76 (s, 1H), 7.06 (s, 2H), 
6.92 (s, 1H), 6.31 (d, J = 2.03 Hz, 1H), 6.11 (d, J = 2.04 Hz, 1H), 5.34 (bs, 1H), 4.50 
(sept, J = 8.80 Hz, 1H),  4.41 (s, 2H), 4.26 (ddd, J = 3.35 Hz, J = 6.42 Hz, J = 12.36 Hz, 
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1H), 3.8 (ddd, J = 4.86 Hz, J = 11.73 Hz, J = 18.09 Hz, 2H), 2.31 (s, 6H), 1.76 (dq, J = 
7.56 Hz, J = 13.31 Hz, 1H), 1.69 (dt, J = 7.15 Hz, J = 14.2 Hz, 1H), 1.60 (dd, J = 1.71 
Hz, J = 6.73 Hz , 6H), 0.97 (t, J = 7.52 Hz, 3H). Anal. Calcd for C23H31N3O2: C, 72.41; 
H, 8.19; N, 11.01. Found: C, 72.13; H, 8.10; N, 11.06.  
 
2-((4-((2,4-dichlorobenzyl)amino)-1-isopropyl-1H-benzo[d]imidazol-6-yl)oxy)butan-
1-ol (193c): 85 mg of an off-white solid (81.7 %). Rf 0.50 (CH2Cl2/MeOH/NH4OH 
95:5:0.1). MP = 55.5 - 58 oC. 1H NMR (500MHz, CDCl3): δ 7.77 (s, 1H), 7.42 (d, J = 
1.93 Hz, 1H), 7.41 (d, J = 8.03 Hz, 1H), 7.17 (dd, J = 2.10 Hz, J = 8.32 Hz, 1H), 6.33 (d, 
J = 2.00 Hz, 1H), 5.95 (d, J = 2.01 Hz, 1H), 5.47 (bs, 1H), 4.56 (d, J = 4.61 Hz, 2H), 4.50 
(td, J = 6.75 Hz, J = 13.50 Hz, 1H),  4.24 (ddd, J = 3.30 Hz, J = 6.40 Hz, J = 12.30 Hz,  
1H), 3.72-3.81 (ddd, J = 4.87 Hz, J = 11.73 Hz, J = 18.18 Hz, 2H), 1.63-1.75 (m, 2H), 
1.60 (dd, J = 2.27 Hz, J = 6.75 Hz, 6H), 0.95 (t, J = 7.52 Hz, 3H). Anal. Calcd for 
C21H25Cl2N3O2: C, 59.72; H, 5.97; N, 9.95. Found: C, 59.66; H, 6.05; N, 9.76.  
 
2-((4-((3,5-dichlorobenzyl)amino)-1-isopropyl-1H-benzo[d]imidazol-6-yl)oxy)butan-
1-ol (193d) : 115 mg of an off-white solid (100 %). Rf 0.50 (CH2Cl2/MeOH/NH4OH 
95:5:0.1). MP = 51.5 - 53 oC. 1H NMR (400 MHz, CDCl3): δ 7.79 (s, 1H), 7.53 (d, J = 
1.96 Hz, 1H), 7.41 (d, J = 8.25 Hz, 1H), 7.26 (dd, J = 2.08 Hz, J = 8.29 Hz, 1H), 6.34 (d, 
J = 2.03 Hz, 1H), 5.98 (d, J = 1.98 Hz, 1H), 5.45 (bs, 1H), 4.45-4.54 (m, 3H),  4.23 (ddd, 
J = 3.36 Hz, J = 6.52 Hz, J = 12.22 Hz, 1H), 3.73-3.84 (ddd, J = 4.95 Hz, J = 11.73 Hz, J 
= 18.27 Hz, 2H), 1.63-1.74 (m, 2H), 1.61 (dd, J = 1.95 Hz, J = 6.73 Hz , 6H), 0.95 (t, J = 
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7.51 Hz, 3H). Anal. Calcd for C21H25Cl2N3O2. 0.33 % H2O: C, 58.89; H, 6.03; N, 9.81. 
Found: C, 58.96; H, 6.12; N, 9.45.  
 
2-((4-((3,5-dimethoxybenzyl)amino)-1-isopropyl-1H-benzo[d]imidazol-6-
yl)oxy)butan-1-ol hydrochloride (193d): 22 mg of an off-white solid (86.2 %). Rf 0.50 
(CH2Cl2/MeOH/NH4OH 95:5:0.1). MP = 119.1 - 123 oC. 1H NMR (500 MHz, CDCl3): δ 
7.74 (s, 1H), 6.98 (d, J = 5.10 Hz, 2H), 6.85 (d, J = 8.63 Hz, 1H), 6.32 (d, J = 2.00 Hz, 
1H), 6.12 (d, J = 1.99 Hz, 1H), 5.25 (bs, 1H), 4.49 (td, J = 6.75 Hz, J = 13.50 Hz, 1H),  
4.42 (d, J = 5.10 Hz, 2H), 4.26 (dq, J = 3.39 Hz, J = 6.36 Hz, 1H), 3.89 (s, 3H),  3.88 (s, 
3H),  3.79 (ddd, J = 6.48 Hz, J = 13.51 Hz, J = 18.02 Hz,  2H), 1.99 (bs, 1H), 1.65-1.80 
(m, 2H), 1.60 (dd, J = 1.70 Hz, J = 6.74 Hz , 6H), 0.98 (t, J = 7.50 Hz, 3H). Anal. Calcd 
for C23H32N3O4Cl. 0.55 % HCl: C, 58.77; H, 6.98; N, 8.94. Found: C, 58.82; H, 6.92; N, 
8.65.  
 
Series 6: N4 PHENYL BENZIMIDAZOLE 
2-(1-isopropyl-4-(phenylamino)-1H-benzo[d]imidazol-6-yloxy)butan-1-ol (194a): An 
oven dried  50 mL round bottom flask was cooled under an Ar atmosphere and was 
charged with 2-(4-amino-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butyl benzoate 
hydrochloride (248; 100.97 mg, 0.25 mmol), Xantphos (14.5 mg, 0.025 mmol), Pd(dba)3 
(18.3 mg, 0.02 mmol), NaOtBu (72.0 mg, 0.75 mmol) and iodobenzene (0.14 mL, 1.25 
mmol). The flask was sealed with three way valve and evacuated and then back filled 
with Ar; this sequence was repeated two additional times. Toluene (3 mL) was 
subsequently added via syringe and vacuum/purge cycle was repeated three times. The 
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three way valve was replaced with air condenser under an Ar atmosphere. The mixture 
was heated at 60 °C (external temperature) for 48 h. After cooling, the reaction mixture 
was diluted with toluene (20 mL) and filtered through a pad of Celite. The pad was 
washed with 25 mL of EtOAc. The organic layer was washed with three 10 mL portions 
of NaCl (sat. aq.) and dried (Na2SO4). The organic layer was decanted and removal of the 
solvent in vacuo gave 190 mg of brown semisolid, which was subjected to silica gel 
column chromatography (1:2 hexane/EtOAc) to afford 30 mg of the product in 35 % 
yield. HCl (Et2O) was used to form the hydrochloride salt of the product. Rf 0.55 
(CH2Cl2:MeOH:NH4OH 95:5:0.1). MP = 185 -188 oC. 1H NMR (500 MHz, MeOD-d4): δ 
9.19 (s, 1H), 7.31 – 7.35 (dd, J = 7.5 Hz, J = 8.5 Hz, 2H), 7.12-7.15 (dd, J = 1.05 Hz, J = 
8.6 Hz, 2H), 7.00-7.04 (tt, J = 1.06 Hz, J = 7.53 Hz, 1H), 6.98 (dd, J =1.86 Hz, J = 9.15 
Hz, 2H), 4.92 (td, J = 6.69 Hz, J = 13.40 Hz, 1H), 4.36 (m, 1H), 3.72 (dq, J = 4.88 Hz, J 
=11.90 Hz, 2H), 1.70 – 1.81 (m, 2H), 1.7 (d, J = 6.71,  6H), 0.99 (t, J = 7.5 Hz, 3H). 
HRMS (EI) calcd for C20H25N3O2: 340.2020 [M+H+] found 340.2030.  
 
2-(4-(3-chlorophenylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butan-1-ol 
(194b): An oven dried  50 mL round bottom flask was placed under an Ar atmosphere 
and was charged with 2-(4-amino-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butyl 
benzoate hydrochloride (85 mg, 0.21 mmol), Xantphos (12.1 mg, 0.021 mmol), Pd(dba)3 
(15.3 mg, 0.017 mmol), NaOtBu (60.5 mg, 0.63 mmol) and 3-chloro-bromobenzene 
(0.123 mL, 1.05 mmol). The round bottom flask was sealed with three way valve and 
evacuated and then back filled with Ar. This sequence was repeated two additional times. 
Toluene (2 mL) was added via syringe and this vacuum purge cycle was repeated three 
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times. The three way valve was replaced with an air condenser under Ar atmosphere. The 
mixture was heated to 55 °C (external temperature) for 48 h. After cooling, the reaction 
mixture was diluted with toluene (20 mL) and then filtered through pad of Celite. The 
pad was washed with 25 mL of EtOAc. The organic layer was washed with three 10 mL 
portions of NaCl (sat. aq.) and dried (Na2SO4). The organic layer was decanted and 
removal of the solvent in vacuo gave 250 mg of a brown semisolid, which was subjected 
to silica gel column chromatography (1:2 hexane/EtOAc) to afford 50 mg of brown solid 
in 64% yield. Rf 0.50 (CH2Cl2:MeOH:NH4OH 95:5:0.1). MP = 55 - 57 oC. 1H NMR (500 
MHz, CDCl3): δ 7.77 (s, 1H), 7.28 (t,  J = 2.06 Hz, 1H), 7.22 (t,  J = 8.01 Hz, 1H), 7.13 
(ddd, J = 0.8 Hz, J = 2.14 Hz, J = 8.16 Hz, 1H), 6.98 (bs, 1H), 6.94 (ddd, J = 0.89 Hz, J = 
1.87 Hz, J = 7.88 Hz, 1H), 6.80 (d, J = 2.00 Hz, 1H), 6.95 (d, J = 2.03 Hz, 1H), 4.50 
(sept, J = 6.71 Hz, 1H), 4.28 (dq, J = 3.36 Hz, J = 6.43 Hz, 1H), 3.75-3.85 (ddd, J = 4.93 
Hz, J = 11.81 Hz, J = 18.26 Hz, 2H),  2.32 (bs, 1H (OH)), 1.65 – 1.81 (m, 2H), 1.6 (dd, J 
= 2.98 Hz, J = 6.75 Hz, 6H), 0.99 (t, J = 7.5 Hz, 3H). HRMS (EI) calcd for 
C20H24N3O2Cl: 374.1630 [M+H+] Found 374.1625.  
 
2-(1-isopropyl-4-(3-methoxyphenylamino)-1H-benzo[d]imidazol-6-yloxy)butan-1-ol 
(194c): An oven dried  50 mL round bottom flask was placed under an Ar atmosphere 
and  was charged with 2-(4-amino-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butyl 
benzoate hydrochloride (60 mg, 0.15 mmol), Xantphos (8.7 mg, 0.015 mmol), Pd(dba)3 
(11 mg, 0.012 mmol), NaOtBu (28.8 mg, 0.30 mmol) and 3-bromoanisole (0.048 mL, 
0.375 mmol). The round bottom flask was sealed with a three way valve, evacuated and 
then back filled with Ar; this sequence was repeated two additional times. Toluene (3 
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mL) was added via syringe and this vacuum purge cycle was repeated three times. The 
three way valve was replaced with an air condenser under Ar atmosphere. The mixture 
was heated to 64 °C (external temperature) for 48 h. After cooling, the reaction mixture 
was diluted with toluene (20 mL) and filtered through a pad of Celite. The pad was 
washed with 25 mL of EtOAc. The organic layer was washed with three 10 mL portions 
of NaCl (sat. aq.) and dried (Na2SO4). The organic layer was decanted and removal of the 
solvent in vacuo gave 65 mg of a brown semisolid, which was subjected to silica gel 
column chromatography (1:2 hexane/EtOAc) to afford 10 mg of brown semisolid in 
18.2% yield. Rf 0.6 (CH2Cl2:MeOH:NH4OH 95:5:0.1).  1H NMR (500 MHz, CDCl3): δ 
7.78 (s, 1H), 7.23 (d, J = 8.1 Hz, 1H), 6.92 (bs, 1H), 6.88-6.91 (ddd, J = 0.62 Hz, J = 2.07 
Hz, J = 9.4 Hz, 1H), 6.86 (dd, J = 2.19 Hz, J = 5.02 Hz, 2H), 6.56 (ddd, J = 0.79 Hz, J = 
2.46 Hz, J = 8.22 Hz, 1H), 6.50 (d, J = 2.05 Hz, 1H), 4.51 (td, J = 6.75 Hz, J = 13.51 Hz, 
1H), 4.27 (ddd, J = 3.40 Hz, J = 6.47 Hz, J = 12.34 Hz, 1H), 3.74-3.85 (ddd, J = 5.00 Hz, 
J =12.12 Hz, J = 18.13 Hz, 2H), 3.81 (s, 3H), 1.95 (bs, 1H), 1.65 – 1.81 (m, 2H), 1.6 (dd, 
J = 2.16 Hz, J = 6.74 Hz, 6H), 0.98 (t, J = 7.51 Hz, 3H). HRMS (EI) calcd for 
C21H27N3O3: 370.2125 [M+H+], 392.1945 [M+Na+] found 370.2140[M+H+], 392.1941 
[M+Na+].  
 
2-((4-((3-(benzyloxy)phenyl)amino)-1-isopropyl-1H-benzo[d]imidazol-6-
yl)oxy)butan-1-ol (194d): An oven dried  50 mL round bottom flask was placed under 
Ar atmosphere and  was charged with 2-(4-amino-1-isopropyl-1H-benzo[d]imidazol-6-
yloxy)butyl benzoate hydrochloride (248; 85 mg, 0.21 mmol), Xantphos (12.15 mg, 
0.021 mmol), Pd(dba)3 (15.5 mg, 0.017 mmol), NaOtBu (60.5 mg, 0.63 mmol) and 1-
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(benzyloxy)-3-bromobenzene (165.77 mg, 0.63 mmol). The round bottom flask was 
sealed with a three way valve, evacuated and then back filled with Ar; this sequence was 
repeated two additional times. Toluene (5 mL) was added via syringe and then vacuum 
purge cycle was repeated three times. The three-way valve was replaced with an air 
condenser under Ar atmosphere. The mixture was heated to 65-70 °C (external 
temperature) for 48 h. After cooling, the reaction mixture was diluted with H2O (5 mL) 
and filtered through a pad of Celite. The pad was washed with 25 mL of EtOAc. The 
organic layer was washed with three 10 mL portions of NaCl (sat. aq.) and dried 
(Na2SO4). The organic layer was decanted and removal of the solvent in vacuo gave 220 
mg of a brown semisolid, which was subjected to silica gel column chromatography (2:1 
hex/EtOAc) to afford 50 mg of brown semisolid in 65% yield. Rf 0.55 
(CH2Cl2:MeOH:NH4OH 95:5:0.1). 1H NMR (500 MHz, CDCl3): δ 7.78 (s, 1H), 7.44 (dd, 
J = 0.91 Hz,  J = 7.86 Hz, 2H), 7.38 (t, J = 7.46 Hz, 2H), 7.32 (tt, J = 4.45 Hz, J = 8.5 Hz, 
1H ), 7.23 (t, J = 8.08 Hz, 1H), 6.89-6.95 (m, 3H),  6.85 (d, J = 2.00 Hz, 1H), 6.63 (ddd, J 
= 0.62 Hz, J = 2.38 Hz, J = 8.19 Hz, 1H), 6.45 (d, J = 2.05 Hz, 1H), 5.07 (s, 2H), 4.51 
(pd, J = 6.61 Hz, J =13.3 Hz, 1H), 4.27 (ddd, J = 3.36 Hz, J = 6.43 Hz, J = 12.41 Hz, 
1H), 3.74-3.85 (m, 2H), 1.99 (bs, 1H), 1.66 – 1.81 (m, 2H), 1.6 (dd, J = 2.37 Hz, J = 6.74 
Hz, 6H), 0.98 (t, J = 7.52 Hz, 3H). 
 
3-((6-((1-hydroxybutan-2-yl)oxy)-1-isopropyl-1H-benzo[d]imidazol-4-
yl)amino)phenol : 2-((4-((3-(benzyloxy)phenyl)amino)-1-isopropyl-1H-
benzo[d]imidazol-6-yl)oxy)butan-1-ol (194d; 40 mg, 0.09 mmol) was dissolved in 30 mL 
of  EtOH and added to a Parr hydrogenation flask containing 30 mg of 10% Pd/C.  The 
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hydrogenation flask was evacuated and then backfilled with hydrogen 3 times, and then 
shaken under 50 psi of a H2 atmosphere for 48 h.  The mixture was filtered through a pad 
of Celite, and the pad was washed with 20 mL of EtOH.  The solvent was removed in 
vacuo to provid 35 mg of the product, which was subjected to silica gel column 
chromatography using Hex/EtOAc (5% hexane in EtOAc) to provide white solid (15 mg) 
in 50% yield.  Rf = 0.5 (CH2Cl2/MeOH/ NH4OH 95:5:0.1). MP = 144.5 – 146 oC. 1H 
NMR (500 MHz, CDCl3): δ 7.84 (s, 1H), 7.17 (t, J = 8.00 Hz, 1H), 6.89 (bs, 1H),  6.87 
(d, J = 2.02 Hz, 1H), 6.81-6.85 (m, 2H), 6.51 (ddd, J = 0.75 Hz, J = 2.38 Hz, J = 8.23 Hz, 
1H), 6.48 (d, J = 2.06 Hz, 1H), 4.53 (qd, J = 6.58 Hz, J =13.2 Hz, 1H), 4.30 (dq,  J =3.34 
Hz, J = 6.37 Hz, J = 6.47 Hz, 1H), 3.81 (ddd, J = 4.91 Hz, J =11.81 Hz, J =18.23 Hz, 
2H), 1.68 – 1.81 (m, 2H), 1.62 (dd, J = 1.95 Hz, J = 6.74 Hz, 6H), 1.00 (t, J = 7.52 Hz, 
3H). HRMS (EI) calcd for C20H25N3O3: 356.1969 [M+H+] found 356.1979.  
 
1-isopropyl-6-methoxy-N-phenyl-1H-benzo[d]imidazol-4-amine (258): A dry 2 mL 
disposable microwave reactor tube was charged with 1-isopropyl-6-methoxy-1H-
benzo[d]imidazol-4-amine hydrochloride (220; 47 mg, 0.19 mmol), Xantphos (11 mg, 
0.019 mmol), Pd(dba)3 (14.1 mg, 0.0155 mmol) and NaOtBu (55.7 mg, 0.58 mmol). The 
tube was sealed with a plastic microwave septum, evacuated and then back filled with Ar; 
this sequence was repeated two additional times. Toluene (1 mL) and iodobenzene (0.1 
mL, 0.97 mmol) were subsequently added via syringe. The mixture was subjected to 
microwave irradiation at 65 °C for 4 h. Thin layer chromatography (TLC) showed the 
presence of starting material.  After cooling, the reaction mixture was diluted with 
toluene (5 mL) and filtered through a pad of Celite and the pad was washed with 25 mL 
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of EtOAc. The organic layers were washed with three 10 mL portions of NaCl (sat. aq.) 
and dried (Na2SO4). Evaporation of the solvent in vacuo gave 120 mg of brown 
semisolid, which was subjected to silica gel column chromatography (1:2 Hex/EtOAc) to 
afford 20 mg of product in 20 % yield. HCl (Et2O) was used to form the hydrochloride 
salt form of product.  Rf 0.6 (CH2Cl2:MeOH:NH4OH 95:5:0.1). MP = 194.5 – 196 oC.  1H 
NMR (500 MHz, MeOD-d4): δ 9.31 (s, 1H), 7.33 (dd, J =7.44 Hz, J = 8.51 Hz, 2H), 7.12 
(dd, J = 1.05 Hz, J = 8.59 Hz, 2H), 7.03 (tt, J = 1.04 Hz, J = 7.52 Hz, 1H), 6.94 (d, J = 
2.05 Hz, 1H), 6.90 (d, J = 2.06 Hz, 1H), 4.98 (pd, J = 6.63 Hz, J =13.4 Hz, 1H), 3.88 (s, 
3H), 1.7 (d, J = 6.73 Hz, 6H). HRMS (EI) calcd for C17H19N3O: 282.1601 [M+H+] Found 
282.1605.  
 
1-Cyclopentyl-6-methoxy-4-nitro-1H-benzo[d]imidazole (219): A 500 mL one neck 
flask was charged with 5-methoxy-3-nitrobenzene-1,2-diamine (211; 3.67 g, 20.0 mmol), 
NaBH(OAc)3 (12.71 g, 60.0 mmol), THF (60 mL), cyclopentanone (8.95 mL, 100.0 
mmol) and formic acid (2.26 mL, 60.0 mmol).  The mixture was stirred at 23 oC for 12 h.  
The solvent was removed in vacuo, and the dark red residue was dissolved in formic acid 
(60 mL).  BHT (20 mg) was added, and the mixture was cooled to 0 °C.  Then 
concentrated 80 mL of HCl was added, and the mixture was brought to reflux with a 
heating mantle.  After refluxing for 25 min, the solvent was removed in vacuo at 80 °C.  
The residue was neutralized with K2CO3 (sat, aq) to pH = 8 and extracted with three 50 
mL portions of EtOAc.  The combined organic extracts were washed with three 10 mL 
portions of NaCl (sat, aq) and dried (Na2SO4).  The solvent was decanted and removal of 
the solvent under reduced pressure gave a brown solid, which was subjected to silica gel 
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column chromatography (Hex/EtOAc 1:1) to afford 2.1 g (40%) of the desired product as 
a yellow solid.  Rf 0.32 (CH2Cl2/MeOH/NH4OH 100:10:0.1). MP = 107-108 °C.  1H 
NMR (400 MHz, CDCl3): δ 8.08 (s, 1H), 7.79 (d, J = 2.32 Hz, 1H), 7.23 (d, J = 2.3 Hz, 
1H), 4.68 – 4.75 (m, 1H), 3.95 (s, 3H), 2.35-2.30 (m, 2H), 1.83-2.05 (m, 6H). Anal. 
Calcd for C13H15N3O3: C, 59.76; H, 5.79; N, 16.08; O, 18.37. Found: C,59.88; H, 5.84; 
N, 16.27. 
 
1-Cyclopentyl -4-nitro-1H-benzo[d]imidazol-6-ol (226a): A 50 mL microwave reactor 
tube was charged with 1-cyclopentyl-6-methoxy-4-nitro-1H-benzo[d]imidazole (219; 500 
mg, 1.91 mmol) and 10 mL of 48% HBr (aq) and was subjected to microwave irradiation 
at 120 ºC for 2.5 h. The solvent was removed in vacuo.  The resulting yellow solid was 
dissolved in minimum amount of water.  NaHCO3 (sat, aq) was added in small portions 
until the pH = 6.  The resultant yellow precipitate was collected on a #1 Whatman filter 
paper. The collected yellow solid was washed with 10 mL of H2O and dried in vacuo to 
afford 470 mg of the product in 97 % yield.  Rf 0.36 (CH2Cl2/MeOH/NH4OH 
100:10:0.1). MP = 118 -121 oC. 1H NMR (400 MHz, DMSO-d6): δ 10.12 (s, 1H), 8.40 (s, 
1H), 7.51 (d, J = 2.17 Hz, 1H), 7.38 (d, J = 2.21 Hz, 1H), 4.81 - 4.87 (m, 1H), 2.15 - 2.21 
(m, 2H), 1.70 - 1.96 (m, 6H). Anal. Calcd for C12H13N3O3. 1.18 %  HBr: C, 42.09; H, 
4.17; N, 12.27.  Found: C, 42.13; H, 4.33; N, 12.12.  
2-(1-cyclopentyl-4-nitro-1H-benzo[d]imidazol-6-yloxy) butyl benzoate (261): 
A dry one-neck 25 mL round bottom flask was charged with 1-cyclopentyl-4-nitro-1H-
benzo[d]imidazol-6-ol (226a; 420 mg, 1.7 mmol), 2-hydroxybutyl benzoate (237a; 875 
mg, 4.25 mmol), triphenyl phosphine (1.11 g, 4.25 mmol), and 5 mL of anhydrous DMF.  
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This solution was cooled to 0 oC.  Neat DIAD (0.5 mL, 4.0 mmol) was added with 
dropwise addition to the reaction mixture.  After 30 min at 0 oC, the ice-bath was 
removed and the reaction was stirred for an additional 2 h at 23 oC.  The reaction was 
then cooled to 0 oC and an additional quantity of DIAD (0.5 mL, 4.0 mmol) was added at 
0 oC.  The reaction was stirred for 30 min at 0 oC then at 23 oC for 12 h. Completion of 
reaction was determined by TLC. The reaction mixture was then poured into 25 mL of 
EtOAc and 25 mL of K2CO3 (sat, aq) (pH = 9).  The reaction mixture was extracted with 
three 25 mL portions of EtOAc and the combined organic extracts were washed with 
three 10 mL portions of NaCl (sat, aq) and dried (Na2SO4).  The organic layer was 
decanted and the solvent was removed under reduced pressure.  The resultant brown 
crude material was subjected to silica gel flash column chromatography (Hex: EtOAc 
1:1) to afford 1.1 g of desired product, which was then subjected to recrystallization 
(Hex:EtOAc 1: 0.5)  to give 560 mg of  a bright yellow color solid in 77 % yield.  Rf 0.6 
(CH2Cl2/MeOH/NH4OH 100:10:0.1). MP = 90-92 ºC. 1H NMR (500 MHz, CDCl3): δ 
8.07 (s, 1H), 7.92 (dd, J = 2.57 Hz, J = 5.75 Hz, 3H), 7.53 (m, 1H), 7.37-7.39 (dd, J = 
4.87 Hz, J = 9.22 Hz, 3H), 4.50-4.70 (m, 4H), 2.25 (m, 2H), 1.80-2.00 (m, 8H), 1.14 (t, J 
= 7.45 Hz, 3H). Anal. Calcd for  C23H25N3O5: C, 65.24; H, 5.95; N, 9.92. Found: C, 
65.24; H, 5.91; N, 9.53.  
2-(4-amino-1-cyclopentyl-1H-benzo[d]imidazol-6-yloxy)butyl benzoate 
hydrochloride (254): 2-(1-cyclopentyl-4-nitro-1H-benzo[d]imidazol-6-yloxy)butyl 
benzoate (261; 550 mg, 1.30 mmol) was dissolved into 30 mL of EtOH and added to a 
Parr hydrogenation vessel previously charged with 65 mg of Pd/C (10 % w/w).  After 3 
vacuum/purge cycles with H2, the vessel was charged to 50 psi with H2 and shaken for 12 
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h on a Parr hydrogenation apparatus and reaction progression was followed by TLC.  The 
mixture was filtered through a pad of Celite, washed with an additional 10 mL of EtOH, 
and then the solvent was removed under reduced pressure. The resultant brown oil was 
then dissolved in 10 mL of Et2O and HCl(g) (Et2O) was added. A white precipitate was 
obtained.  Recrystallization from hot EtOH gave the 500 mg of the desired product as an 
off white solid in 90% yield. Rf 0.52 (CH2Cl2/MeOH/NH4OH 100:10:0.1). MP = 234 -
238 ºC. 1H NMR (500 MHz, MeOD-d4): δ 9.18 (s, 1H), 7.87 (dd, J = 1.25 Hz, J = 8.26 
Hz, 2H), 7.57 (t, J = 7.41 Hz, 1H), 7.40 (t, J = 7.83 Hz, 2H), 6.75 (d, J = 1.99 Hz, 1H), 
6.57 (d, J = 1.98 Hz, 1H), 4.74-4.79 (m, 2H), 4.54 (d, J = 5.20 Hz, 2H), 2.32-2.36 (m, 
2H), 1.85-1.91 (m, 8H), 1.12 (t, J = 7.43 Hz, 3H). Anal. Calcd for C23H28ClN3O3: C, 
62.70; H, 6.48; N, 9.41. Found: C, 62.77; H, 6.23; N, 9.07. 
 
1-cyclopentyl-6-methoxy-N-phenyl-1H-benzo[d]imidazol-4-amine (257): 
An oven dried  50 mL round bottom flask was placed under Ar atmosphere and  was 
charged with 2-(4-amino-1-cyclopentyl-1H-benzo[d]imidazol-6-yloxy)butyl benzoate 
hydrochloride (150 mg, 0.56 mmol), Xantphos (19.5 mg, 0.033 mmol), Pd(dba)3 (20.5 
mg, 0.022 mmol), Cs2CO3 (547 mg, 1.68 mmol), iodobenzene (75 µL, 0.672 mmol) and 3 
mL of anhydrous anisole. The round bottom flask was sealed with three way valve, 
evacuated and then back filled with Ar; this sequence was repeated two additional times. 
The three-way valve was replaced with an air condenser under an Ar atmosphere. The 
mixture was heated to 80 °C (outside temperature) for 65 h. After cooling, the reaction 
mixture was diluted with 20 mL of anisole and filtered through a pad of Celite. The 
Celite pad was washed with 25 mL of EtOAc. The organic layer was washed with 10 mL 
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of NaCl (sat, aq) and dried (Na2SO4). The solvent was decanted and removal of the 
solvent in vacuo gave 140 mg of brown semisolid, which was subjected to silica gel 
column chromatography (1:2 hex/EtOAc) twice to afford 50 mg of desired product in 
30% yield. Rf 0.65 (CH2Cl2:MeOH:NH4OH 95:5:0.1). MP = 100-110 oC. 1H NMR (500 
MHz, CDCl3): δ 7.78 (s, 1H), 7.34-7.42 (m, 4H), 7.00-7.04 (m, 1H), 6.99 (bs, 1H), 6.82 
(d, J = 2.09 Hz, 1H), 6.39 (d, J = 2.08 Hz, 1H), 4.66 (p, J = 7.1 Hz, 1H), 3.86 (s, 1H), 
2.29 (dq,  J = 1.3Hz,  J = 7.4Hz, 2H), 2.06 (m, 2H), 1.95(m, 2H), 1.85 (m, 2H). Anal. 
Calcd for C19H21N3O: C, 74.24; H, 6.89; N, 13.67; O, 5.20. Found: C,74.54; H, 6.72; N, 
13.45.  
 
2-(1-cyclopentyl-4-(phenylamino)-1H-benzo[d]imidazol-6-yloxy)butan-1-ol (195a): 
An oven dried  50 mL round bottom flask was placed under an Ar atmosphere and  was 
charged with 2-(4-amino-1-cyclopentyl-1H-benzo[d]imidazol-6-yloxy)butyl benzoate 
hydrochloride (56 mg, 0.13 mmol), Xantphos (7.5 mg, 0.013 mmol), Pd(dba)3 (9.5 mg, 
0.01 mmol), NaOtBu (37.5 mg, 0.39 mmol) and iodobenzene (31.2 µL, 0.28 mmol). The 
round bottom flask was sealed with three way valve, evacuated and then back filled with 
Ar; this sequence was repeated two additional times. Toluene (3 mL) was subsequently 
added via syringe and vacuum purge cycle was repeated an additional three times. The 
three-way valve was replaced with an air condenser under an Ar atmosphere. The mixture 
was heated to 60 °C (external temperature) for 52 h. After cooling, the reaction mixture 
was diluted with 20 mL of toluene and filtered through a pad of Celite. The Celite pad 
was washed with 25 ml of EtOAc. The organic layer was washed with three 10 mL 
portions of NaCl (sat, aq) and dried (Na2SO4). The solvent was decanted and removal of 
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the solvent in vacuo gave 140 mg of a brown semisolid, which was subjected to silica gel 
column chromatography (1:2 hex/EtOAc) to afford 25 mg of product in 52.6% yield. Rf 
0.6 (CH2Cl2:MeOH:NH4OH 95:5:0.1). MP = 196 – 198.5 oC.1H NMR (500 MHz, 
CDCl3): δ 7.78 (s, 1H), 7.33 (td, J = 7.9 Hz, J = 8.54 Hz, 4H), 7.02 (t, J = 7.15 Hz, 1H), 
6.95 (bs, 1H), 6.84 (d, J = 1.99 Hz, 1H), 6.48 (d, J = 2.01 Hz, 1H), 4.64 (p, J = 7.1 Hz, 
1H), 4.30(dq,  J = 3.4 Hz, J = 6.4 Hz, 1H), 3.81 (ddd, J = 4.75 Hz, J = 11.75 Hz, J = 
18.20 Hz, 2H), 2.25-2.30 (ddd, J = 6.68 Hz, J =13.01 Hz, J =12.65 Hz, 2H), 2.00-2.09 
(m, 2H), 1.70 –1.90 (m, 6H), 1.00 (t, J = 7.52 Hz, 3H). HRMS (EI) calcd for 
C22H27N3O2: 366.2176 [M+H+] Found 366.2208.  
 
2-(4-(3-chlorophenylamino)-1-cyclopentyl-1H-benzo[d]imidazol-6-yloxy)butan-1-ol 
(195b): An oven dried  50 mL round bottom flask was placed under an Ar atmosphere 
and  was charged with 2-(4-amino-1-cyclopentyl-1H-benzo[d]imidazol-6-yloxy)butyl 
benzoate hydrochloride (56 mg, 0.13 mmol), Xantphos (7.5 mg, 0.013 mmol, 0. 1 equiv), 
Pd(dba)3 (9.5 mg, 0.01 mmol), NaOtBu (37.5 mg, 0.39 mmol, 3.0 equiv) and 3-
bromochlorobenzene (32.88 µL, 0.28 mmol). The round bottom flask was sealed with 
three way valve, evacuated and then back filled with Ar; this sequence was repeated two 
additional times. Toluene (3 mL) was added via syringe and the vacuum purge cycle was 
repeated an additional three times. The three-way valve was replaced with an air 
condenser under an Ar atmosphere. The mixture was heated to 60 °C (external 
temperature) for 24 h. Additional 3-bromochlorobenzene (45.8 µL, 0.39 mmol) was 
added to the reaction mixture and mixture was heated at 60 °C for additional 30 h. After 
cooling, the reaction mixture was diluted with 20 mL of toluene and filtered through a 
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pad of Celite. The Celite pad was washed with 25 ml of EtOAc. The organic layer was 
washed with three 10 mL portions of NaCl (sat. aq) and dried (Na2SO4). The solvent was 
decanted and removal of the solvent in vacuo gave a brown semisolid, which was 
subjected to silica gel column chromatography (1:2 Hex/EtOAc) to afford 22 mg of the 
product in 42.3% yield. Rf 0.7 (CH2Cl2:MeOH:NH4OH 95:5:0.1). MP = 115 – 119.5 oC. 
1H NMR (500 MHz, CDCl3): δ 7.79 (s, 1H), 7.31 (t, J = 2.06 Hz, 1H), 7.25 (t, J = 8.02 
Hz, 1H), 7.15 (ddd, J = 0.8 Hz, J = 2.15 Hz, J = 8.19 Hz, 1H), 6.98 (dd, J = 0.82 Hz, J = 
1.89 Hz, 1H), 6.96 (d, J = 0.77 Hz, 1H), 6.84 (d, J = 2.02 Hz, 1H), 6.53(d, J = 2.02 Hz, 
1H), 4.65 (p, J = 7.1 Hz, 1H), 4.30 (ddd, J = 3.33 Hz, J = 6.54 Hz, J = 12.38 Hz, 1H), 
3.84 (ddd, J = 4.90 Hz, J =11.78 Hz, J =18.28 Hz, 2H), 2.25-2.32 (ddd, J = 6.23 Hz, J = 
12.36 Hz, J =12.47 Hz, 2H), 2.00-2.09 (m, 2H), 1.90-2.00 (m, 1H), 1.70 – 1.85 (m, 4H), 
1.02 (t, J = 7.53 Hz, 3H). HRMS (EI) calcd for C22H26N3O2Cl: 400.1786 [M+H+] found 
400.1802.   
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Series 7 : N1 Methyl Benzimidazole Series  
 
6-methoxy-1-methyl-4-nitro-1H-benzo[d]imidazole (213):  A 20 mL microwave tube 
was charged with 6-methoxy-4-nitro-1H-benzo[d]imidazole (212; 386.36 mg, 2.0 mmol), 
Na2CO3 (423.9 mg, 4.0 mmol), CH3I (0.62 mL, 10.0 mmol) and 5.5 mL of NMP. The 
mixture was subjected to microwave irradiation (350 Watt) to maintain an internal 
temperature of 60 ºC for 1 h. After cooling, 10 mL of H2O was added to quench the 
reaction and the mixture was extracted with three 10 mL portions of CH2Cl2. The 
combined organic extracts were washed with three 10 mL portions of NaCl (sat, aq) and 
dried (Mg2SO4). The mixture was filtered and evaporated in vacuo to provide yellow 
solid, which was subjected to silica gel flash column chromatography (EtOAc) to afford 
225 mg a yellow-brown solid in 54% yield. Rf 0.3 (CH2Cl2/MeOH/NH4OH 100:5:0.1). 
MP = 225-227 oC. 1H NMR (500 MHz, CDCl3): δ 8.08 (s, 1H), 7.84 (d, J = 2.25 Hz, 1H), 
7.21 (d, J = 2.26 Hz, 1H), 3.98 (s, 3H), 3.91 (s, 3H). Anal. Calcd for C9H9N3O3: C, 51.82; 
H, 4.38; N, 20.28. Found: C, 51.82; H, 4.23; N, 20.30. 
 
1-Methyl-4-nitro-1H-benzo[d]imidazol-6-ol (259): 1-Methyl-6-methoxy-4-nitro-1H-
benzo[d]imidazole (213; 350 mg, 1.69 mmol) and 20 mL of 48% HBr were added to a 20 
mL microwave tube. The mixture was subjected to microwave irradiation (350 Watt) to 
maintain an internal temperature of 120 ºC for 2 h. After cooling to 23 oC, the solvent 
was removed in vacuo. The resulting yellow solid was dissolved in minimum amount of 
H2O. NaHCO3 (sat, aq) was added with dropwise addition until the pH was equivalent to 
6. The yellow solid was collected on a #1 Whatman filter paper and washed with 10 mL 
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of H2O and then dried under high vacuum (150 micron) to afford 320 mg (98%) of the 
yellow solid. Rf 0.25 (CH2Cl2/MeOH/NH4OH 100:10:0.1). MP = 250 °C (decomposed).  
1H NMR (500 MHz, DMSO-d6): δ 10.16 (bs, 1H), 8.28 (s, 1H), 7.53 (d, J = 2.18 Hz, 1H), 
7.35 (d, J = 2.19 Hz, 1H), 3.51 (s, 3H). Anal. Calcd for C8H7N3O3.0.72 % HBr .0.11 % 
EtOAc: C, 38.81; H, 3.32; N, 16.05. Found: C, 38.79; H, 3.51; N, 16.09. 
 
2-((4-(benzylamino)-1-methyl-1H-benzo[d]imidazol-6-yl)oxy)butan-1-ol (197b): A 
dry one-neck 25 mL round bottom flask was charged with 1-methyl-4-nitro-1H-
benzo[d]imidazol-6-ol (213; 300 mg, 1.55 mmol), 2-hydroxybutyl benzoate (752.6 mg, 
3.87 mmol), Ph3P (1.01 g, 3.87 mmol), and 10 mL of anhydrous DMF.  This solution was 
cooled to 0 oC.  Neat DIAD (0.41 mL, 1.8 mmol) was added with dropwise addition over 
5 min.  The solution was stirred for 30 min at 0 oC. The ice-bath was removed and the 
reaction was stirred for an additional 2 h at 23 oC.  The reaction was then cooled to 0 oC 
and an additional quantity of DIAD (0.41 mL, 1.8 mmol) was added at 0 oC.  The 
reaction was stirred for 30 min at 0 oC then at 23 oC for 12 h. Completion of reaction was 
determined by TLC. The reaction mixture was poured into a mixture of 10 mL of EtOAc 
and 10 mL of NaHCO3 (sat, aq) (pH>9).  This mixture was extracted with three 10 mL 
portions of EtOAc and the combined organic extracts were washed with three 10 mL 
portions of NaCl
 
(sat, aq) and dried (Na2SO4).  The extract was decanted and the solvent 
was removed in vacuo.  The brown colored crude material (600 mg) was subjected to 
silica gel flash column chromatography (EtOAc) to afford 220 mg of a yellow colored 
solid in 38.5% yield. Rf 0.55 (CH2Cl2/MeOH/NH4OH 100:10:0.1). MP =115.5-116.5 ºC 
1HNMR (500 MHz, CDCl3): δ 8.00 (s, 1H), 7.95 (d, J = 1.22 Hz, 1H), 7.93 (m, 2H), 
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7.54-7.57 (ddd, J = 1.29 Hz, J = 2.56 Hz, J = 7.70 Hz, 1H), 7.38- 7.42 (ddd, J = 1.48 Hz, 
J = 5.37 Hz, J = 7.67 Hz, 2H), 7.35 (d, J = 2.26 Hz, 1H), 4.60-4.69 (qq, J = 4.4 Hz, J = 
8.48 Hz, 1H), 4.57 (ddd, J = 5.31 Hz, J = 11.68 Hz, J = 15.70 Hz, 2H), 3.80 (s, 3H), 1.92 
(tq, J = 7.45 Hz, J = 14.83 Hz, 2H), 1.14 (t, J = 7.46 Hz, 3H).  
2-(1-methyl-4-nitro-1H-benzo[d]imidazol-6-yloxy)butyl benzoate (200 mg, 0.54 mmol) 
was dissolved into 30 mL of EtOH and added to a Parr hydrogenation vessel previously 
charged with 30 mg of Pd/C (10 % w/w).  After three vacuum/purge cycles with H2, the 
vessel was charged to 50 psi with H2 and shaken for 12 h on a Parr hydrogenation 
apparatus.  The mixture was filtered through a pad of Celite, the pad was washed with an 
additional 10 mL of EtOH, and then the solvent was removed in vacuo.  The resultant oil 
was dissolved into 10 ml of Et2O and HCl(g)(Et2O) was added. A white precipitate was 
resulted. The solid was collected on a #1 Whatman filter paper as red solid in 95% yield.  
Rf 0.45 (CH2Cl2/MeOH/NH4OH 100:10:0.1). MP = 155-160 ºC. 1H NMR (500 MHz, 
CDCl3): δ 9.17 (s, 1H), 7.96 (d,  J = 7.34 Hz, 2H), 7.57 (t, J = 7.40 Hz, 1H), 7.42 (t, J = 
7.69 Hz, 2H), 6.41 (s, 2H), 5.52 (bs, 2H), 4.55 (dd, J = 4.36 Hz, J = 11.52 Hz, 2H), 4.47 
(dd, J = 6.85 Hz, J = 13.65 Hz,1H), 3.92 (s, 3H), 1.85 (tt, J = 7.23 Hz, J = 14.39 Hz, 2H), 
1.09 (t, J = 7.42 Hz, 3H).  
A dry 100 mL round bottom flask was charged with 2-((4-amino-1-methyl-1H-
benzo[d]imidazol-6-yl)oxy)butyl benzoate hydrochloride (200 mg, 0.54 mmol), 
NaBH(OAc)3 (228.9 mg, 1.08 mmol), benzaldehyde (61 µL, 0.60 mmol) and 5 mL of 
1,2-dichloroethane. The mixture was stirred at 23 oC for 12 h. After quenching with 2 mL 
of deionized H2O and 2 mL of NaHCO3 (sat, aq), the mixture was extracted with three 10 
mL portions of EtOAc. The combined extracts were washed with three 5 mL portions of 
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NaCl (sat, aq) and dried (Mg2SO4). The mixture was filtered and evaporated in vacuo to 
provide a brown solid, which was subjected to silica gel flash column chromatography 
(Hex/EtOAc 1:1) to afford 100 mg of a yellow solid product  (43 % yield). The obtained 
yellow compound was carried to the next step without further purification. Rf 0.6 
(CH2Cl2/MeOH/NH4OH 100:5:0.1). 2-((4-(benzylamino)-1-methyl-1H-
benzo[d]imidazol-6-yl)oxy)butyl benzoate (90 mg, 0.20 mmol) dissolved into 3.0 mL of 
5% KOH in MeOH and the reaction mixture was stirred for 12 h. Completion of the 
reaction was determined by TLC. The reaction was quenched with 7.5 mL of NH4Cl (sat 
aq) and extracted with three 10 mL portions of EtOAc. The combined EtOAc extracts 
were washed with three 5.0 mL of NaCl (sat aq) and dried (Na2SO4). The mixture was 
filtered and evaporation of the solvent gave 65 mg of brown solid (98 %). Rf 0.3 
(CH2Cl2/MeOH/NH4OH 100:5:0.1). MP = 118-120 oC. 1H NMR (500 MHz, CDCl3): δ 
7.63 (s, 1H), 7.43 (dd, J = 0.45 Hz, J = 7.48 Hz, 2H), 7.35 (dd, J = 4.77 Hz, J = 10.16 Hz, 
2H), 7.28 (m, 1H), 6.28 (d, J = 2.05 Hz, 1H ), 6.10 (d, J = 2.03 Hz, 1H), 5.30 (t, J = 6.34 
Hz, 1H), 4.50 (d, J = 5.08 Hz, 2H), 4.26 (ddd, J = 3.33 Hz, J = 6.39 Hz, J = 12.48 Hz, 
1H), 3.75 (s, 3H), 3.70-3.81 (m, 2H), 1.92 (bs, 1H), 1.65-1.75 (m, 2H), 0.96 (t, J = 7.52 
Hz, 3H). Anal. Calcd for C19H23N3O2: C, 70.13; H, 7.12; N, 12.91. Found: C, 69.95; H, 
7.18; N, 12.65. 
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Series 8: AMINOTHIAZOLE SERIES 
 
tert-Butyl thiazol-2-ylcarbamate (125): A 250 mL round bottom flask was charged with  
2-aminothiazole (2.0 g, 20 mmol), Boc anhydride (4.80 g, 22.0 mmol), DMAP (160 mg, 
1.32 mmol) and 25 mL of THF. The reaction mixture was stirred at 23 oC for 12 h. The 
solvent was removed in vacuo. The crude off-white solid was dissolved into CH2Cl2 and 
washed with three 10 mL portions of 1 N HCl, two 10 mL portions of H2O and  three 10 
mL portions of NaCl (sat, aq) and then dried (Na2SO4). The solution was decanted and 
removal of the solvent in vacuo gave a light brown solid, which was subjected to silica 
gel column chromatography (Hex/EtOAc 10:1) to afford the desired product as a white 
solid in 55 % yield. Rf 0.55 (5% EtOAc in Hex). MP =181-183 oC. 1HNMR (500 MHz, 
CDCl3): δ 12.23 (bs, 1H), 7.40 (d, J = 3.63 Hz, 1H), 6.91 (d, J = 3.59 Hz, 1H), 1.61 (s, 
9H).  
 
tert-Butyl (5-(hydroxy(phenyl)methyl)thiazol-2-yl)carbamate (271a): n-Butyl lithium 
(2.0 M (titrated), 1.1 mL) was slowly added to a solution of tert-butyl thiazol-2-
ylcarbamate (125; 200.2 mg, 1.0 mmol) in 2 mL of anhydrous THF at -78 oC under an Ar 
atmosphere. A solution of benzaldehyde (0.1 mL, 1.0 mmol) in 0.5 mL of THF was then 
added dropwise at -78 oC. The mixture was warmed slowly 23 oC and then stirred for 12 
h. The reaction mixture was then quenched with a 20 mL of NH4Cl (sat. aq). The aqueous 
layer was extracted three times with 10 mL portions of EtOAc and the combined organic 
layers were washed with three 10 mL portions of NaCl (sat, aq), dried (Na2SO4), 
decanted, and concentrated in vacuo. The crude solid was subjected to silica gel column 
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chromatography using 1:1 Hex: EtOAc to provide 155 mg of desired product in 51 % 
yield. Rf 0.5 (CH2Cl2/MeOH/ NH4OH 95:5:0.1). MP = 170-171.5 oC. 1HNMR (500 MHz, 
DMSO- d6): δ 11.26 (bs, 1H), 7.40 (dd, J = 1.0 Hz, J = 8.1 Hz, 2H), 7.35 (t, J = 7.62 Hz, 
2H), 7.26 (t, J = 7.26 Hz, 1H), 6.13 (d, J = 4.24 Hz, 1H), 5.88 (d, J = 4.0 Hz, 1H), 1.45 (s, 
9H). Anal. Calcd for C15H18N2O3S: C, 58.80; H, 5.92; N, 9.14; O, 15.67. Found: C, 
58.76; H, 6.01; N, 8.96.  
 
5-benzylthiazol-2-amine (272a): 2-tert-butoxycarbonylamino-5-[hydroxyl-(phenyl)-
methyl]-thiazole (271a; 150 mg, 0.49 mmol) was dissolved in mixture of CH2Cl2 (5 mL) 
and TFA (0.2 mL, 2.5 mmol). Triethylsilane (0.118 mL, 0.74 mmol) was added slowly to 
the reaction mixture at 23 oC. The resultant solution was stirred at 23 oC for 15 h. The 
solvent was removed under reduced pressure and 10 mL of H2O was added. The resultant 
white solid was collected on #1 Whatman filter paper and washed with 10 mL of H2O. 
The white solid was dissolved into 25 mL of EtOAc, then washed with three 5 mL 
portions of NaHCO3 (sat, aq), NaCl (sat, aq) and dried (Na2SO4).  The solution was 
decanted and removal of the solvent in vacuo provided 80 mg of white solid as the 
product in 86 % yield. Rf 0.55 (CH2Cl2/MeOH/ NH4OH 95:5:0.1). MP = 92.5 - 95 oC. 
1HNMR (500 MHz, CDCl3): δ 7.34 (t, J = 7.32 Hz, 2H), 7.27 (td, J = 1.7Hz, J = 4.2Hz, 
1H), 7.24 (d, J = 6.87 MHz, 2H), 6.81 (s, 1H), 5.29 (bs, 2H), 3.98 (s, 2H).  
 
N-(5-benzylthiazol-2-yl)-2-phenylacetamide (198f): 2-amino-5-benzyl thiazole (272a; 
75 mg, 0.4 mmol) was dissolved into 5 mL of CH2Cl2. Powdered NaHCO3 (84.8 mg, 0.8 
mmol), phenacyl chloride (66 µL, 0.5 mmol) and catalytic 4-dimethylaminopyridine 
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(DMAP) (5 mg, 0.04 mmol) were added to the reaction mixture. The reaction mixture 
was stirred at 23 oC for 12 h. The reaction mixture was quenched with the addition of 10 
mL of H2O and extracted three times with 10 mL portions of CH2Cl2. The combined 
organic layers were washed with three 10 mL portions of NaCl (sat, aq) and dried 
(Na2SO4). The solvent was decanted and removed in vacuo and then was subjected to 
silica gel column chromatography (3:1 Hex: EtOAc) to afford 70 mg of the desired 
product in 57% yield. Rf 0.7 (CH2Cl2/MeOH/ NH4OH 95:5:0.1) MP = 136.8 -139 oC 
1HNMR (500 MHz, CDCl3): δ 9.51 (bs, 1H), 7.29-7.41 (m, 7H), 7.23-7.27 (m, 3H), 7.10 
(s, 1H), 4.07 (s, 2H), 3.81 (s, 2H). Anal. Calcd for C18H16N2OS.0.11% CH2Cl2: C, 68.32; 
H, 5.13; N, 8.79. Found: C,68.32; H, 4.97; N, 8.90.  
 
tert-butyl (5-(hydroxy(pyridin-3-yl)methyl)thiazol-2-yl)carbamate (282a): n-Butyl 
lithium (titrated 2.0 M, 2.2 mL) was slowly added to a solution of tert-butyl thiazol-2-
ylcarbamate (125; 400.4 mg, 2.0 mmol) in 4 mL of anhydrous THF at -78 oC under an Ar 
atmosphere. A solution of 4-pyridinecarboxaldehyde (0.19 mL, 2.0 mmol) in 0.5 mL of 
THF was added with dropwise addition at -78 oC. The mixture was warmed slowly to 23 
oC and stirred for an additional 12 h at 23 oC. The reaction mixture was quenched with 20 
mL of NH4Cl (sat, aq). The aqueous layer was extracted three times with 10 mL portions 
of  CH2Cl2/ MeOH (1:1) mixture and the combined organic layers were washed three 
times with 10 mL portions of  NaCl (sat, aq) and  then concentrated in vacuo. The crude 
solid was recrystallized (EtOH) to provide 280 mg of white solid in 44.5% yield. Rf 0.3 
(CH2Cl2/MeOH/ NH4OH 95:5:0.1) MP = 200 oC. 1HNMR (500 MHz, DMSO- d6): δ 
11.35 (bs, 1H), 7.54 (dd, J = 1.62 Hz, J = 4.44 Hz, 2H), 7.39 (dd, J = 1.43 Hz, J = 4.67 
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Hz, 2H), 7.21 (s, 1H), 6.37 (d, J = 4.06Hz, 1H), 5.93 (d, J = 3.71 Hz, 1H), 1.45 (s, 9H). 
Anal. Calcd for C14H17N3O3S.0.19% CH2Cl2: C, 52.76; H, 5.42; N, 13.01. Found: 
C,52.85; H, 5.42; N, 12.77.  
 
tert-butyl (5-(hydroxy(pyridin-4-yl)methyl)thiazol-2-yl)carbamate (282b): The 
general procedure for synthesis of tert-butyl (5-(hydroxy(pyridin-4-yl)methyl)thiazol-2-
yl)carbamate is same as described above. Recystallization from EtOH provided 350 mg 
of white solid in 57% yield. Rf 0.2 (CH2Cl2/MeOH/ NH4OH 95:5:0.1). MP = 198.5-199.2 
oC. 1HNMR (500MHz, DMSO-d6): δ 11.36 (bs, 1H), 8.59 (d, J = 1.42 Hz, 1H), 8.47 (dd, 
J = 1.46 Hz, J = 4.71 Hz, 1H), 7.77 (dd, J = 1.65 Hz, J = 7.76 Hz, 1H), 7.37 (dd, J = 4.79 
Hz, J = 7.81 Hz, 1H), 7.09 (bs, 1H), 6.25 (bs, 1H), 5.94 (s, 1H), 1.43 (s, 9H). Anal. Calcd 
for C14H17N3O3S. 0.32 % CH2Cl2: C, 51.39; H, 5.31; N, 12.55. Found: C,51.44; H, 5.44; 
N, 12.39. 
 
tert-Butyl (5-(hydroxy(4-nitrophenyl)methyl)thiazol-2-yl)carbamate (271b): 
n-Butyl lithium (2.0 M titrated, 3.3 mL) was slowly added to a solution of tert-butyl 
thiazol-2-ylcarbamate (125; 600.75 mg, 3.0 mmol) in 5 mL of anhydrous THF at -78 oC 
under an Ar atmosphere. A solution of 4-nitrophenylbenzaldehyde (544.0 mg, 3.6 mmol) 
in 3 mL of THF was then added dropwise at -78 oC. The mixture was warmed slowly to 
23 oC and stirred for an additional 12 h at 23 oC. The reaction mixture was quenched with 
20 mL of NH4Cl (sat, aq). The aqueous layer was then extracted three times with 10 mL 
portions of EtOAc and the combined organic layers were washed twice with 10 mL of 
NaCl (sat, aq), dried (Na2SO4), decanted and concentrated in vacuo. The crude solid (1.7 
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g) was subjected to silica gel gradient column chromatography using Hex: EtOAc (1:1 to 
100% EtOAc) to provide 190 mg of yellow solid (estimated purity 90 % pure) in 54% 
yield. Recrystallization (2:98 Hex: EtOH) provided 150 mg of an orange colored solid 
(15 % yield). Rf 0.5 (CH2Cl2/MeOH/ NH4OH 95:5:0.1). MP = 192.5 – 193 oC. 1HNMR 
(400 MHz, CDCl3): δ 10.43 (bs, 1H), 8.25 (d, J = 8.61 Hz, 2H), 7.66 (d, J = 8.94 Hz, 
2H), 7.17 (s, 1H), 6.14 (s, 1H), 1.52 (s, 9H). HRMS (EI) calcd for C15H17N3O5S: 
352.0962 [M+H+] found 352.0959. 
 
5-(4-nitrobenzyl)thiazol-2-amine (272b): 2-tert-butoxycarbonylamino-5-[hydroxyl-(4-
nitrophenyl)-methyl]-thiazole (271b; 100 mg, 0.28 mmol) was dissolved into a mixture 
of CH2Cl2 (2 mL) and TFA (62 µL, 0.85 mmol). Triethylsilane (67 µL, 0.42 mmol) was 
added slowly to the reaction mixture at 23 oC. The resultant solution was stirred at 23 oC 
for 15 h. The solvent was removed under reduced pressure. The reaction was followed by 
TLC. The reaction mixture was then dissolved into 1 mL of TFA and triethylsilane (0.134 
mL, 0.84 mmol). The resultant solution was stirred at 23 oC for 12 h. The solvent was 
evaporated in vacuo and residual H2O was removed with azeotropic distillation with three 
10 mL portions of toluene. Recrystallization (EtOH) provided 55 mg of yellow solid in 
60% yield. Rf 0.45 (CH2Cl2/MeOH/ NH4OH 95:5:0.1). MP = 158.5-160 oC. 1HNMR (500 
MHz, MeOD-d4): δ 8.33 (d, J = 8.89 Hz, 2H), 7.59 (d, J = 8.72 Hz, 2H), 7.07 (t, J = 2.29 
Hz, 1H), 4.99 (d, J = 2.36 Hz, 2H). HRMS (EI) calcd for C15H17N3O5S: 236.0494 
[M+H+] found 236.0496. 
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N-(5-(4-nitrobenzyl)thiazol-2-yl)-2-phenylacetamide (198i): 2-amino-5-(4-nitrobenzyl) 
thiazole (272b; 93 mg, 0.28 mmol) was dissolved into 5 mL of CH2Cl2 in a 100 mL 
round bottom flask. Powdered NaHCO3 (57.2 mg, 0.54 mmol), phenacyl chloride (41 µL, 
0.31 mmol) and 4-dimethylaminopyridine (DMAP) (5 mg, 0.04 mmol) were added to the 
reaction mixture. The reaction mixture was stirred at 23 oC for 12 h. The reaction mixture 
was quenched with 2 mL of H2O and extracted with three 10 mL portions of CH2Cl2. The 
combined organic layers were washed with three 10 mL portions of NaHCO3 (sat, aq), 
NaCl (sat, aq) and dried (Na2SO4). The solvent was evaporated in vacuo and was 
subjected to silica gel column chromatography (1:1 Hex: EtOAc) to afford 75 mg of the 
product in 57% yield. Recrystallization (10:90 Et2O: EtOH) provided 55 mg of orange 
crystals. Rf 0.75 (CH2Cl2/MeOH/ NH4OH 95:5:0.1). MP =188.9-189.5 oC. 1HNMR (500 
MHz, CDCl3): δ 9.26 (bs, 1H), 8.18 (d, J = 8.73, 2H), 7.35-7.42 (m, 5H), 7.31 (dd, J = 
4.86 Hz, J = 6.43 Hz, 2H), 7.16 (s, 1H), 4.19 (s, 2H), 3.83 (s, 2H). Anal. Calcd for 
C18H15N3O3S. 0.15 % Et2O: C, 61.28; H, 4.56; N, 11.52. Found: C,61.54; H, 4.24; N, 
11.33.  
 
N-(5-(4-aminobenzyl)thiazol-2-yl)-2-phenylacetamide (198l): N-(5-(4-
nitrobenzyl)thiazol-2-yl)-2-phenylacetamide (198i; 50 mg, 0.14 mmol) was dissolved 
into 20 mL of EtOH and 5 mL of CHCl3 and added to a 250 mL Parr hydrogenation 
vessel previously charged with 9.5 mg of 10% Pd/C.  The hydrogenation vessel was 
evacuated and backfilled with H2 three times, and then shaken under 50 psi of a H2 for 12 
h. The mixture was filtered through pad of Celite, and the pad was then washed with an 
additional 10 mL of EtOH.  Evaporation of the solvent provided 50 mg of the product as 
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off-white solid (quantitative yield).  Rf 0.45 (CH2Cl2/MeOH/ NH4OH 95:5:0.1). MP 
=185-190 oC. 1H NMR (500 MHz, DMSO-d6): δ 12.24 (bs, 1H, 2-NH, exch), 10.02 (bs, 
2H, 4’-NH2, exch), 7.23 − 7.37 (m, 10H), 4.10 (s, 2H), 6.55 (s, 1H), 3.72 (s, 2H). Anal. 
Calcd for C18H18ClN3OS. 0.44 % CHCl3: C, 53.67; H, 4.50; N, 10.18. Found: C, 53.70; 
H, 4.36; N, 10.13.  
 
Benzyl 4-((2-((tert-butoxycarbonyl)amino)thiazol-5-yl)(hydroxy)methyl)piperidine-
1-carboxylate (278): The general procedure for synthesis of Benzyl 4-((2-((tert-
butoxycarbonyl)amino)thiazol-5-yl)(hydroxy)methyl)piperidine-1-carboxylate is same as 
described above. Silica gel column chromatography (Hex:EtOAc 1:1) provided 430 mg 
of a white fluffy solid in 32% yield. Rf 0.65 (CH2Cl2/MeOH/ NH4OH 95:5:0.1). MP = 60 
oC. 1H NMR (500 MHz, CDCl3): δ 10.07 (bs, 1H, 2-NH, exch), 7.36-7.38 (m, 5H), 7.02 
(s, 1H), 5.14 (s, 2H), 4.60 (d, J = 7.80 MHz, 1H), 4.22 (bs, 2H), 2.79 (bs, 2H), 2.00 (bs, 
1H), 1.86 (m, 2H), 1.55-1.59 (m, 2H), 1.58 (s, 9H). 13CNMR (CDCl3, 100 MHz): δ 
161.74, 155.34, 155.25, 152.91, 136.82, 136.78, 133.84, 133.53, 128.47, 127.96, 127.83, 
72.16, 67.31, 67.06, 43.88, 43.76, 43.46, 38.61, 26.28.  Anal. Calcd for C22H29N3O5S.1.0 
% THF: C, 60.13; H, 7.20; N, 8.03. Found: C, 60.44; H, 7.03; N, 8.18.  
 
Benzyl 4-((2-aminothiazol-5-yl)methyl)piperidine-1-carboxylate (279): 
Benzyl 4-((2-((tert-butoxycarbonyl)amino)thiazol-5-yl)(hydroxy)methyl)piperidine-1-
carboxylate (278; 140 mg, 0.31 mmol) was dissolved in mixture of 20 mL of CH2Cl2 and 
3 mL of TFA. Triethylsilane (0.5 mL, 3.13 mmol) was added slowly to the reaction 
mixture at 23 oC. The resultant solution was stirred at 23 oC for 15 h. This reaction 
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mixture was neutralized to pH = 8 using NaHCO3 (sat, aq) and extracted with three 10 
mL portions of CH2Cl2. The combined organic layers were washed with three 5 mL 
portions of NaCl (sat, aq) and dried (Na2SO4). The solution was decanted and solvent was 
evaporated in vacuo to provide 120 mg of a white solid, which was subjected to silica gel 
column chromatography (99:1 EtOAc : TEA) to provide 50 mg of product in 48.32 % 
yield. Rf 0.5 (CH2Cl2/MeOH/ NH4OH 95:5:0.1). MP = 142.8-143.5 oC. 1HNMR (500 
MHz, CDCl3): δ 7.32-7.40 (m, 5H), 6.73 (s, 1H), 6.54 (bs, 2H), 5.14 (s, 2H), 4.21 (bs, 
2H), 2.77 (bs, 2H), 2.58 (d, J = 6.98 Hz, 2H), 1.72 (d, J = 9.82 Hz, 2H), 1.60 -1.65 (m, 
1H), 1.17 (d, J = 9.67 Hz, 2H). HRMS (EI) calcd for C17H21N3O2S: 332.1427 [M+H+] 
found 332.1420.   
 
Benzyl 4-((2-(2-phenylacetamido)thiazol-5-yl)methyl)piperidine-1-carboxylate (281): 
Benzyl 4-((2-aminothiazol-5-yl)methyl)piperidine-1-carboxylate (279; 50 mg, 0.15 
mmol) was dissolved into 3 mL of CH2Cl2 in a 100 mL of round bottom flask. Powdered 
NaHCO3 (84 mg, 0.75 mmol), phenacyl chloride (280; 60 µL, 0.45 mmol) and a catalytic 
quantity of 4-dimethylaminopyridine (DMAP) (10 mg, 0.08 mmol) were added to the 
reaction mixture. The reaction mixture was stirred at 23 oC for 12 h. The reaction mixture 
was quenched with 5 mL of H2O and extracted with three 10 mL portions of CH2Cl2. The 
combined organic layer were washed with three 10 mL portions of NaHCO3(sat, aq), 
three 10 mL portions of NaCl (sat, aq) and dried (Na2SO4). The solvent was decanted and 
removal of solvent in vacuo provided crude material, which was subjected to silica gel 
column chromatography (Hex: EtOAc 90:10) to afford the 26 mg of product in 41.5 % 
yield. Recrystallization (Et2O) provided an off white solid. Rf 0.6 (CH2Cl2/MeOH/ 
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NH4OH 95:5:0.1). MP =152.1-154 oC. 1HNMR (400 MHz, CDCl3): δ 9.17 (bs, 1H), 
7.34-7.40 (m, 5H), 7.06 (s, 1H), 5.13 (s, 2H), 4.23 (bs, 2H), 3.83 (s, 2H), 2.75 (bs, 2H), 
2.69 (d, J = 6.69 Hz, 2H), 1.67-1.73 (m, 3H), 1.57 (bs, 2H). Anal. Calcd for 
C25H27N3O3S. 0.21 % CH2Cl2: C, 64.74; H, 5.91; N, 8.98. Found: C,64.78; H, 5.71; N, 
8.83.  
 
3-(pyridin-3-yl)propanal (291): An oven dried 100 mL round bottom flask was charged 
with oxalyl chloride (1.88 mL, 22 mmol) and CH2Cl2 (25 mL) under an Ar atmosphere. 
The reaction mixture was cooled down to -78 oC and internal temperature was maintained 
at -78 oC.  A solution of DMSO (3.12 mL, 44 mmol) in 25 mL of CH2Cl2 was added with 
dropwise addition at 23 oC while maintaining the internal reaction temperature below -65 
oC. The resultant solution was stirred at -78 oC for 20 min.  A solution of 3-
pyridylpropanol (290; 2.58 mL, 20 mmol) in 5 mL of CH2Cl2 was added with dropwise 
addition at -78 oC. The reaction solution was stirred at -78 oC for 45 min. Finally, TEA 
(14 mL, 100 mmol) was added to the solution at -78 oC. The reaction mixture was slowly 
warmed up to the 23 oC over 30 min. Upon completion of the oxidation (TLC) 20 mL of 
H2O was added and the aqueous layer was then extracted with three 20 mL portions of 
CH2Cl2. The organic layer was collected and the combined organic layers were washed 
with three 10 mL portions of NaCl (sat, aq) and dried (Na2SO4), deacanted and removal 
of solvent in vacuo provided 1.8 g of product as yellow oil in 70% yield. Rf =0.5 
(CH2Cl2/MeOH/ NH4OH 95:5:0.1) (2,4-DNP positive) 1HNMR (400 MHz, CDCl3): δ 
9.77 (s, 1H), 8.43 (s, 2H), 7.48 (s, 1H), 7.17 (s, 1H), 2.9 (bs, 2H), 2.77(d, J = 6.27 Hz, 
2H).  
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5-(pyridin-3-ylmethyl)thiazol-2-amine (283): A solution of 3-(pyridin-3-yl)propanal 
(291; 1.8 g, 13.0 mmol) in 15 mL of AcOH was cooled to 5 oC. The reaction mixture was 
then treated with 33% HBr in AcOH (0.86 mL, 15 mmol) at 5 oC. After 5 min, a solution 
of Br2 (0.38 mL, 15 mmol) in 5 mL of AcOH was added with dropwise addition to the 
reaction mixture. The reaction mixture was then warmed to the 23 oC and then stirred for 
another 2.5 h. After completion of the reaction (TLC), the mixture was concentrated in 
vacuo, redissolved into 10 mL of CH2Cl2 and concentrated in vacuo. This crude orange 
solid was carried on to the next step without further purification. Rf =0.5 (CH2Cl2/MeOH/ 
NH4OH 95:5:0.1) (2,4-DNP positive) The orange colored crude material (3.5 g) was 
dissolved into 50 mL of EtOH and then thiourea (1.5 g, 19.7 mmol) was added in one 
portion. The suspension was brought to reflux for 3.5 h, and then allowed to cool to 23 oC 
over 12 h. The resultant white precipitate was collected on #1 Whatman filter paper. The 
solid obtained (1.5 g) was treated with NaHCO3 (sat, aq) and extracted with three 20 mL 
portions of EtOAc. The combined organic layers were washed with NaCl (sat, aq), dried 
(Na2SO4) and concentrated in vacuo to provide 1.2 g of an off-white product in 50% 
yield. Rf =0.35 (20% EtOH in EtOAc). MP= 127.5-131 oC. 1HNMR (400 MHz, DMSO-
d6): δ 8.46 (d, J = 1.46 Hz, 1H), 8.43 (dd, J = 1.2 Hz, J = 4.7 Hz, 1H), 7.62 (d, J = 7.84 
Hz, 1H), 7.33 (dd, J = 4.77 Hz, J = 7.79 Hz, 1H), 6.76 (bs, 2H), 6.72 (d, J = 0.92 Hz, 
1H), 3.92 (s, 2H). 13CNMR (100 MHz, DMSO-d6): δ 170.16, 148.49, 146.90, 136.85, 
136.68, 134.70, 124.50, 123.91, 29.66. Anal. Calcd for C9H9N3S. 0.22 % CH3COOH: C, 
55.44; H, 4.87; N, 20.53. Found: C,55.33; H, 4.58; N, 20.59.  
 
234 
2-phenyl-N-(5-(pyridin-3-ylmethyl)thiazol-2-yl)acetamide (198k): 5-(pyridin-3-
ylmethyl)thiazol-2-amine (283; 382.5 mg, 2.0 mmol) was suspended in 20 mL of CH2Cl2. 
Solid NaHCO3 (1.05 g, 10 mmol) was added to the reaction mixture, and the 5-(pyridin-
3-ylmethyl)thiazol-2-amine dissolved into the CH2Cl2. DMAP (20 mg, 0.1 mmol) and 
then phenacyl chloride (280; 0.4 mL, 3.0 mmol, 1.5 equiv) were added and the resultant 
mixture was stirred at 23 oC for 12 h. The reaction was quenched with the addition of 10 
mL of H2O and extracted with three 10 mL portions of CH2Cl2. The combined organic 
layers were washed with three 10 mL portions of NaCl (sat, aq) and dried (Na2SO4). The 
solvent was decanted and removed in vacuo to provide 700 mg of an off-white solid, 
which was subjected to recrystallization (EtOAc) to obtain 400 mg of a white solid in 66 
% yield. The mother liquor was subjected to column chromatography using 2:1 
Hex/EtOAc to provide an additional 200 mg of product (combined 98% yield). Rf =0.6 
(20% EtOH/ EtOAc). MP= 176.5-180 oC. 1HNMR (400 MHz, CDCl3): δ 10.71 (bs, 1H), 
8.54 (d, J = 1.95 Hz, 1H), 8.51 (dd, J = 1.38 Hz, 4.79 Hz, 1H), 7.54 (d, J = 7.81 Hz, 1H), 
7.37 (ddd, J = 1.8 Hz, J = 5.6 Hz, J = 6.0 Hz, 3H), 7.31 (dd, J = 5.7 Hz, J = 7.2 Hz, 2H), 
7.25 (dd, J = 4.8 Hz, J = 7.8 Hz, 1H), 7.12 (s, 1H), 4.10 (s, 2H), 3.82 (s, 2H). Anal. Calcd 
for C17H15N3OS. 0.55 % H2O: C, 63.95; H, 5.08; N, 13.16. Found: C,63.94; H, 4.73; N, 
13.08.  
 
N-methoxy-N-methylisonicotinamide (285): Isonicotinic acid (284; 1.85 g, 15.0 mmol) 
was dissolved into 50 mL of DMF and solution was cooled to 0 °C. To this solution, 
EDCI (4.3 g, 22.5 mmol), HOBt (2.02 g, 15.0 mmol), N,O-dimethylhydroxylamine 
hydrochloride (2.2 g, 22.5 mmol) and N-methylmorpholine (8.2 mL, 75 mmol) were 
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added. The mixture was stirred at 23 oC for 12 h. The reaction mixture was diluted with 
30 mL of EtOAc and washed with three 10 mL portions of 1N HCl. The aqueous layer 
was then basified with solid Na2CO3 to pH = 9-10.Then the aqueous layer was extracted 
three times with EtOAc. The combined organic layers were washed with 10 mL portions 
of NaCl (sat, aq) and dried (Na2SO4). The solvent was decanted and evaporated in vacuo 
to provide 1.1 g of Weinreb amide in 44 % yield as an oil. The crude was carried to next 
step without further purification. Rf =0.7 (CH2Cl2/MeOH/ NH4OH 95:5:0.1) 1HNMR 
(500 MHz, CDCl3): δ 8.71 (dd, J = 1.57 Hz, J = 4.42 Hz, 2H), 7.53 (dd, J = 1.47 Hz, J = 
4.49 Hz, 2H), 3.54 (s, 3H), 3.37 (s, 3H).  
 
tert-Butyl (5-isonicotinoylthiazol-2-yl)carbamate (286): n-Butyl lithium (2.0 M, 
titrated, 3.65 mL, 7.33 mmol) was slowly added to a solution of tert-butyl thiazol-2-
ylcarbamate (125; 666.8 mg, 3.3 mmol) in 8 mL of anhydrous THF  at -78 oC under an 
Ar atmosphere. A solution of N-methoxy-N-methylisonicotinamide (285; 665 mg, 4.0 
mmol) in 1.5 mL of THF was then added with dropwise addition at -78 oC. The mixture 
was warmed slowly to 23 oC and then stirred for 12 h. The reaction mixture was 
concentrated in vacuo. The resultant white solid was suspended in 100 mL of EtOAc, and 
washed with three 10 mL portions of NaCl (sat, aq) and then dried (Na2SO4). The organic 
layer was decanted and concentrated in vacuo. The crude solid was subjected to silica gel 
column chromatography with 5% EtOH in EtOAc as the eluant to provide 120 mg of 
product in 49 % yield. Rf 0.2 (CH2Cl2/MeOH/ NH4OH 95:5:0.1). MP = 193.5-195 oC. 
1HNMR (500 MHz, DMSO-d6): δ 12.21 (bs, 1H), 8.78 (dd, J = 1.68 Hz, J = 4.34 Hz, 
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2H), 8.04 (s, 1H), 7.69 (dd, J = 1.66 Hz, J = 4.34 Hz, 2H), 1.50 (s, 9H). Anal. Calcd for 
C14H15N3O3S: C, 55.07; H, 4.95; N, 13.76.  Found: C,55.03; H, 4.89; N, 13.53.  
 
(2-aminothiazol-5-yl)(pyridin-4-yl)methanone (288): tert-Butyl (5-
isonicotinoylthiazol-2-yl)carbamate (286; 55 mg, 0.18 mmol) was dissolved into 1N HCl 
in EtOH (5 mL, prepared from conc. HCl (aq)) and then stirred at 23 oC. After 1 h, a drop 
of TFA was added to reduce the pH of the solution. The reaction mixture stirred at 23 oC 
for another 1 h. After completion of the reaction (TLC), solvent was removed in vacuo 
and the crude was basified with solid K2CO3 and then extracted three times with 10 mL 
portions of EtOAc. The combined organic layers were washed with NaCl (sat, aq) and 
dried over Na2SO4. The resultant white solid (45 mg, quantitative yield) was carried out 
to the next reaction step without further purification. Rf 0.3 (CH2Cl2/MeOH/ NH4OH 
95:5:0.1). MP = 242.5-244 oC. 1HNMR (500 MHz, MeOD-d4): δ 8.89 (d, J = 4.96 Hz, 
2H), 8.03 (dd, J = 1.44 Hz, J = 4.88 Hz, 2H), 7.72 (s, 1H). Anal. Calcd for C9H7N3OS. 
0.03 % TFA.0.04 % EtOAc: C, 52.22; H, 3.50; N, 19.77. Found: C,52.32; H, 3.11; N, 
19.66.  
 
N-(5-isonicotinoylthiazol-2-yl)-2-phenylacetamide (289): (2-aminothiazol-5-
yl)(pyridin-4-yl)methanone (288; 38 mg, 0.18 mmol) was dissolved into 3 mL of CH2Cl2. 
Powdered NaHCO3 (42.4 mg, 0.4 mmol) was added to the reaction mixture. DMAP (2 
mg, 0.01 mmol) and phenacyl chloride (44 µL, 0.46 mmol) were added and the reaction 
mixture was stirred at 23 oC for 12 h. The reaction mixture was quenched with 10 mL of 
H2O and extracted with three 5 mL portions of CH2Cl2. The combined organic layers 
237 
were washed with three 10 mL portions of NaCl (sat, aq) and then dried (Na2SO4). The 
solvent was decanted and evaporated in vacuo to provide 58 mg of an off-white solid, 
which was subjected to silica gel column chromatography (EtOAc: 0.1 % TEA) to obtain 
30 mg of white solid as a product. Recrystallization of 30 mg of the solid (EtOAc: Hex) 
provided 25 mg of white solid in 52% yield.  Rf =0.75 (CH2Cl2/MeOH/ NH4OH 95:5:0.1) 
MP = 204.2-205 oC. 1HNMR (500 MHz, CDCl3): δ 9.29 (bs, 1H), 8.83 (dd, J = 1.48 Hz, 
J = 4.46 Hz, 2H), 7.88 (s, 1H), 7.61 (dd, J = 1.62 Hz, J = 4.39 Hz, 2H), 7.36 – 7.44 (m, 
3H), 7.32 (d , J = 1.60 Hz, 1H), 7.31 (bs, 1H), 3.90 (s, 2H). Anal. Calcd for 
C17H13N3O2S.0.12 % H2O: C, 62.73; H, 4.09; N, 12.91. Found: C, 62.74; H, 3.89; N, 
12.75.  
 
Series 9: DIKETOPIPERAZINE DERIVATIVE 
 
(R)-methyl 2-((S)-2-((tert-butoxycarbonyl)amino)-3-methylbutanamido)-3-
phenylpropanoate (302b): In a 250 mL round bottom flask, (S)-2-((tert-
butoxycarbonyl)amino)-3-methylbutanoic acid (Boc L-valine, 2.01 g, 9.27 mmol) and 
(R)-methyl 2-amino-3-phenylpropanoate (2.0 g, 9.27 mmol) were dissolved into 25 mL 
of THF. Solid HOBt (125.2 mg, 0.927 mmol), DIEA (3.23 mL, 18.5 mmol) and EDCI 
(2.04 g, 10.66 mmol) were added sequentially to the reaction mixture using an external 
water bath to maintain the reaction temperature at 23 oC. A 10 mL portion of DMF was 
added slowly to make a homogeneous mixture and resultant solution was stirred at 23 oC 
for 3 h. After completion of reaction (TLC), the solvent was removed in vacuo. The 
resultant crude oily mixture was dissolved into 30 mL of Et2O and the organic layer was 
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washed with five 10 mL portions of H2O to remove DMF, then with three 10 mL portions 
of  NaCl (sat, aq) and dried (Na2SO4).  The solvent was decanted and the solvent was 
removed in vacuo to afford 3.4 g of a white solid (97% yield). Rf 0.65 (CH2Cl2/MeOH/ 
NH4OH 95:5:0.1). MP = 94.5 - 96.5 oC. 1HNMR (500 MHz, CDCl3): δ 7.25 -7.35 (m, 
3H), 7.13 (d, J = 6.78 Hz, 2H), 6.37 (d, J = 7.94 Hz, 1H), 4.94 (bs, 1H), 4.91 (dd, J = 
6.21 Hz, J = 14.03 Hz, 1H), 3.98 (bs, 1H), 3.74 (s, 3H),  3.13 (dq, J = 6.18 Hz, J = 13.99 
Hz, 2H), 2.15 (qd, J = 6.79 Hz, J = 13.43 Hz, 1H), 1.45 (s, 9H), 0.90 (m, 3H), 0.83 (d, J = 
6.88 Hz, 3H). Anal. Calcd for C20H30N2O5. 0.19 % H2O: C, 62.87; H, 8.01; N, 7.33.   
Found: C,62.84; H, 7.75; N, 7.51.   
 
(3R, 6S)-3-benzyl-6-isopropylpiperazine-2,5-dione (200b): (R)-methyl 2-((S)-2-((tert-
butoxycarbonyl)amino)-3-methylbutanamido)-3-phenylpropanoate (302b; 1.13 g, 3.0 
mmol) was dissolved into 15 mL of TFA at 0 oC. After 15 min, the solution was brought 
to 23 oC and stirred at 23 oC for an additional 2 h. After completion of the Boc 
deprotection (TLC), the reaction mixture was refluxed for 3 h. The TFA was removed in 
vacuo and the resultant crude solid was treated with 50 mL of NaHCO3 (sat, aq) to 
neutrality. The aqueous solution was stored in a refrigerator for 8 h. The resultant white 
precipitate was resuspended in 50 mL of EtOAc and organic layer was removed in vacuo 
to give 450 mg of a crude white solid. This was recrystallized (EtOH) to provide 235 mg 
of white needles (32 % yield). Rf 0.5 (CH2Cl2/MeOH/ NH4OH  95:5:0.1). MP = 279-280 
oC 1HNMR (500 MHz, DMSO-d6): δ 8.11 (bs, 1H), 7.93 (bs, 1H), 7.20-7.30 (m, 5H), 
4.17 (t, J = 4.22 Hz, 1H), 3.11 (dd, J = 4.01 Hz, J = 13.54 Hz, 1H), 2.97 (t, J = 2.06 Hz, 
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1H), 2.89 (dd, J = 4.88 Hz, J = 13.56 Hz, 1H), 2.05 (dtd, J = 3.3 Hz, J = 6.9 Hz, J =13.8 
Hz, 1H), 0.80 (dd, J = 6.97 Hz, J = 34.36 Hz, 6H).  
 
(R)-methyl 2-((R)-2-((tert-butoxycarbonyl)amino)-3-methylbutanamido)-3-
phenylpropanoate (302c): A 250 mL round bottom flask was charged with (R)-2-((tert-
butoxycarbonyl)amino)-3-methylbutanoic acid (Boc D- valine, 2.01 g, 9.27 mmol) and 
(R)-methyl 2-amino-3-phenylpropanoate (2.0 g, 9.27 mmol) were dissolved into 20 mL 
of THF. Solid HOBt (125.2 mg, 0.927 mmol), DIEA (3.23 mL, 18.5 mmol) and EDCI 
(2.04 g, 10.66 mmol) were added sequentially to the reaction mixture using external 
water bath to maintain the reaction temperature at 23 oC. A 10 mL portion of DMF was 
added slowly to make a homogeneous mixture and the resultant solution was stirred at 23 
oC for 3 h.  After completion of the reaction (TLC), the solvent was removed in vacuo. 
The crude oily mixture was dissolved into 30 mL of Et2O, and the organic layer was 
washed with five 10 mL portions of H2O to remove the DMF and then with three 10 mL 
portions of  NaCl (sat, aq) and then dried (Na2SO4). The solvent was removed in vacuo to 
afford 3.2 g of a white solid (91% yield). Rf 0.65(CH2Cl2/MeOH/NH4OH  95:5:0.1). MP 
= 94 - 96.5 oC. 1HNMR (500 MHz, CDCl3): δ 7.25-7.35 (m, 3H), 7.13 (d, J = 6.79 Hz, 
2H), 6.27 (bs, 1H), 5.00 (bs, 1H), 4.89 (td, J = 5.94 Hz, J = 7.66 Hz, 1H), 3.90 (dd, J = 
8.66 Hz, J = 15.43 Hz, 1H), 3.73 (s, 3H), 3.10-3.25 (m, 2H), 2.11 (dd, J = 6.56 Hz, J = 
13.11 Hz, 1H), 1.47 (s, 9H), 0.95-1.05 (dd, J = 6.69 Hz, J = 45.77 Hz,  6H). Anal. Calcd 
for C20H30N2O5: C, 63.47; H, 7.99; N, 7.40. Found: C,63.43; H, 7.70; N, 7.61.   
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(3R, 6R)-3-benzyl-6-isopropylpiperazine-2,5-dione (200c): (R)-methyl 2-((S)-2-((tert-
butoxycarbonyl)amino)-3-methylbutanamido)-3-phenylpropanoate (302c; 1.13 g, 3.0 
mmol) was dissolved into 15 mL of TFA at 0 oC. After 15 min, the solution was brought 
to 23 oC and stirred at 23 oC for an additonal 2 h. After completion of the Boc 
deprotection (TLC), the reaction mixture was maintained at reflux (~ 100 oC) for 3 h. The 
TFA was removed in vacuo and crude solid was treated with 50 mL of NaHCO3 (sat, aq) 
to neutrality. The aqueous solution was stored in a refrigerator at 6 oC for 8 h. The 
resulting white precipitate was suspended in 50 mL of EtOAc and organic layer was 
removed in vacuo. The 730 mg of crude white solid was recrystallized (EtOH) to provide 
220 mg of white needles (30 % yield). Rf 0.5 (CH2Cl2/MeOH/NH4OH  95:5:0.1). MP = 
222.5-224 oC. 1HNMR (500 MHz, DMSO-d6): δ 8.08 (bs, 1H), 7.89 (bs, 1H), 7.15-7.25 
(m, 5H), 4.21 (ddd, J = 1.76 Hz, J = 4.82 Hz, J = 6.38 Hz, 1H), 3.53 (td, J = 1.91 Hz, J = 
3.69 Hz, 1H), 3.15 (dd, J = 4.38 Hz, J = 13.46 Hz, 1H), 2.88 (dd, J = 5.03 Hz, J = 13.52 
Hz, 1H), 1.70 (dtd, J =3.73 Hz, J =6.85 Hz, J =13.86 Hz, 1H), 0.65 (d, J = 7.12 Hz, 3H), 
0.28 (d, J = 6.84 Hz, 3H). Anal. Calcd for C14H18N2O2: C, 68.27; H, 7.37; N, 11.37.  
Found: C,67.92; H, 7.30; N, 11.15.  
 
(S)-methyl 2-((R)-2-((tert-butoxycarbonyl)amino)-3-methylbutanamido)-3-
phenylpropanoate (302d) : A 250 mL round bottom flask was charged with (R)-2-((tert-
butoxycarbonyl)amino)-3-methylbutanoic acid (Boc D-valine, 2.01 g, 9.27 mmol) and 
(S)-methyl 2-amino-3-phenylpropanoate (2.0 g, 9.27 mmol). The solids were dissolved 
into 15 mL of THF. Solid HOBt (125.2 mg, 0.927 mmol), DIEA (3.23 mL, 18.5 mmol) 
and EDCI (2.04 g, 10.66 mmol) were added sequentially to the reaction mixture using an 
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external water bath to maintain the reaction temperature at 23 oC. A 15 mL portion of 
DMF was added slowly to make a homogeneous solution and resultant solution was 
stirred at 23 oC for 3 h. After completion of reaction (TLC), the solvent was removed in 
vacuo. The crude oily mixture was dissolved into 30 mL of Et2O and the organic layer 
was washed with five 10 mL portions of H2O to remove the DMF, then with two 10 mL 
portions of  NaCl (sat, aq) and dried (Na2SO4). The solvent was removed in vacuo to 
afford 2.8 g of white solid (81% yield). Rf = 0.6(CH2Cl2/MeOH/NH4OH 95:5:0.1). MP = 
90-94 oC. 1HNMR (500 MHz, CDCl3): δ 7.26 -7.32 (m, 3H), 7.14 (dd, J = 3.20 Hz, J = 
5.09 Hz, 2H), 6.37 (d, J = 7.90 Hz, 1H), 4.94 (bs, 1H), 4.91 (dd, J = 6.32 Hz, J = 13.92 
Hz, 1H), 3.99 (bs, 1H), 3.74 (s, 3H), 3.13 (dq, J = 6.21 Hz, J = 14.00 Hz, 2H), 2.15 (dt, J 
= 6.56 Hz, J = 13.30 Hz, 1H), 1.46 (s, 9H), 0.91 (m, 3H), 0.83 (d, J = 6.87 Hz, 3H). Anal. 
Calcd for C20H30N2O5: C, 63.47; H, 7.99; N, 7.40. Found: C, 63.49; H, 7.87; N, 7.50.   
 
(3S, 6R)-3-benzyl-6-isopropylpiperazine-2,5-dione (200d): (S)-methyl 2-((R)-2-((tert-
butoxycarbonyl)amino)-3-methylbutanamido)-3-phenylpropanoate (302d; 1.13 g, 3.0 
mmol) was dissolved into 15 mL of TFA at 0 oC. After 15 min, the solution was brought 
to the 23 oC and stirred at 23 oC for an additional 2 h. After completion of the Boc 
deprotection (TLC), the reaction mixture was brought to reflux for 3 h.  The TFA was 
removed in vacuo and crude solid was treated with 50 mL of NaHCO3 (sat, aq) to acheive 
neutrality. The aqueous solution was stored in refrigerator at 6 oC for 8 h. The resultant 
white precipitate was suspended in 50 mL of EtOAc and the organic layer was removed 
in vacuo. The 850 mg of crude white solid was recrystallized (EtOH) to provide 430 mg 
of white needles (58 % yield). Rf 0.5 (CH2Cl2/MeOH/NH4OH  95:5:0.1). MP = 269-270 
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oC. 1HNMR (500 MHz, DMSO-d6): δ 8.11 (bs, 1H), 7.93 (bs, 1H), 7.20-7.26 (m, 5H), 
4.17 (t, J = 4.20 Hz, 1H), 3.15 (dd, J = 4.00 Hz, J = 13.62 Hz, 1H), 3.97 (ddd, J = 0.8 Hz, 
J = 2.14 Hz, J = 3.00 Hz, 1H), 2.89 (dd, J = 4.96 Hz, J = 13.61 Hz, 1H), 2.04 (dtd, J 
=3.34 Hz, J =7.07 Hz, J =14.13 Hz, 1H), 0.84 (d, J = 7.09 Hz, 3H), 0.77 (d, J = 6.85 Hz, 
3H).   
 
(3S, 6S)-3-benzyl-6-isopropylpiperazine-2,5-dione (200a) (TAR-1-18): 
Recrystallization to clean up Anal. Calcd for C14H18N2O2. 0.45 %  EtOH. 1.17 % TFA: 
C, 51.68; H, 5.50; N, 6.98. Found: C,51.69; H, 5.48; N, 6.96. 
 
6-benzyl-3-isopropylpyrazin-2(1H)-one (200e) (TAR-1-27) : MP = 168-172 oC, Anal. 
Calcd for C14H16N2O. 0.355 % H2O : C, 71.64; H, 7.17; N, 11.93.   Found: C,71.70; H, 
7.02; N, 11.55. 
 
 
 
243 
CHAPTER  FIVE  
 
SUMMARY 
In summary, this work represents the exploration of benzimidazoles, aminothiazoles and 
diketopiperazines as potential agents for inhibiting CDK5/p25. This research has resulted 
in the synthesis of 65 novel target compounds and 90 novel synthetic intermediates. A 
novel synthetic route was developed for the synthesis of 1,4,6-trisubstituted 
benzimidazoles; this enabled previously intractable synthesis to be reduced to practical 
utility. Eighteen previously reported compounds were synthesized and characterized as 
intermediates or to be used as standards for biological evaluation studies. The biological 
evaluation of the benzimidazoles synthesized as a part of this project revealed that the 
compounds displayed moderate potency compared to their purine analogs. This loss of 
potency was offset by a gain in selectivity for CDK5/p25 over other kinases and could 
represent a significant therapeutic advantage. Most significantly, this work provided the 
innovative application of 1,4,6-trisubstituted benzimidazole as novel adenosine mimics at 
ATP utilizing kinases; development of methodology enabled this innovation. The 
biological activities of the tested compounds are presented in the Appendix. Biological 
evaluation of the aminothiazole and diketopiperazine compounds presented in this 
dissertation was currently underway at the time of writing of this dissertation and will be 
presented in due course in publications. This research work has resulted in six peer-
reviewed publications at the time of writing of this dissertation. An additional literature 
review has been published. 
5.1 Benzimdazole Scaffold:  
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5.1.1 List of Novel Compounds 
 
1. 1.N-benzyl-1-isopropyl-6-(1-methoxybutan-2-yloxy)-1H-benzo[d]imidazol-4-amine 
hydrochloride (190b) 
2. 2-(4-(benzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)ethanol (190c) 
3. 1-((4-(benzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yl)oxy)butan-2-ol 
hydrochloride (190d) 
4. (R)-2-(4-(benzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-ylamino)propan-1-ol 
(189b) 
5. (S)-2-(4-(benzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-ylamino)propan-1-ol 
(189c) 
6. N-benzyl-6-benzyl-1-isopropyl-1H-benzo[d]imidazol-4-amine (191a) 
7. N-benzyl-6-(4-Fluorobenzyl)-1-isopropyl-1H-benzo[d]imidazol-4-amine (191c) 
8. N-benzyl-6-(4-Methoxybenzyl)-1-isopropyl-1H-benzo[d]imidazol-4-amine (191b) 
9. N-benzyl-6-benzyl-1-cyclopentyl-1H-benzo[d]imidazol-4-amine(191d) 
10. 2-(4-(benzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butyl benzoate 
(249aa) 
11. 2-(1-isopropyl-4-(2-methylbenzylamino)-1H-benzo[d]imidazol-6-yloxy)butan-1-ol 
hydrochloride (192a) 
12. 2-(1-isopropyl-4-(3-methylbenzylamino)-1H-benzo[d]imidazol-6-yloxy)butan-1-ol 
hydrochloride (192b)  
13. 2-(1-isopropyl-4-(4-methylbenzylamino)-1H-benzo[d]imidazol-6-yloxy)butan-1-ol 
hydrochloride (192c) 
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14. 2-(1-isopropyl-4-(2-methoxybenzylamino)-1H-benzo[d]imidazol-6-yloxy)butan-1-ol 
hydrochloride (192d) 
15. 2-(1-isopropyl-4-(3-methoxybenzylamino)-1H-benzo[d]imidazol-6-yloxy)butan-1-ol 
hydrochloride (192e) 
16. 2-(4-(2-chlorobenzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butan-1-ol 
hydrochloride (192j) 
17. 2-(4-(4-chlorobenzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butan-1-ol 
hydrochloride (192l) 
18. 2-(4-(2-fluorobenzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butan-1-ol 
hydrochloride (192m) 
19. 2-(4-(3-fluorobenzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butan-1-ol 
hydrochloride (192n) 
20. 2-(4-(4-fluorobenzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butan-1-ol 
hydrochloride (192o) 
21. 2-(1-isopropyl-4-(4-nitrobenzylamino)-1H-benzo[d]imidazol-6-yloxy)butan-1-ol 
hydrochloride (192r) 
22. 2-(1-isopropyl-4-(2-(trifluoromethyl)benzylamino)-1H-benzo[d]imidazol-6-
yloxy)butan-1-ol hydrochloride (192s) 
23. 2-(1-isopropyl-4-(3-(trifluoromethyl)benzylamino)-1H-benzo[d]imidazol-6-
yloxy)butan-1-ol hydrochloride (192t) 
24. 2-(1-isopropyl-4-(4-(trifluoromethyl)benzylamino)-1H-benzo[d]imidazol-6-
yloxy)butan-1-ol hydrochloride (192u) 
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25. 2-(1-isopropyl-4-(pyridin-2-ylmethylamino)-1H-benzo[d]imidazol-6-yloxy)butan-1-
ol hydrochloride (192v) 
26. 2-(1-isopropyl-4-(pyridin-3-ylmethylamino)-1H-benzo[d]imidazol-6-yloxy)butan-1-
ol hydrochloride (192w) 
27. 2-(1-isopropyl-4-(pyridin-4-ylmethylamino)-1H-benzo[d]imidazol-6-yloxy)butan-1-
ol hydrochloride (192x) 
28. 2-(1-isopropyl-4-(4-methoxybenzylamino)-1H-benzo[d]imidazol-6-yloxy)butan-1-ol 
(192f) 
29. 2-(1-isopropyl-4-(2-hydroxybenzylamino)-1H-benzo[d]imidazol-6-yloxy)butan-1-ol 
(192g) 
30. 2-(1-isopropyl-4-(3-hydroxybenzylamino)-1H-benzo[d]imidazol-6-yloxy)butan-1-ol 
(192h) 
31. 2-(1-isopropyl-4-(4-hydroxybenzylamino)-1H-benzo[d]imidazol-6-yloxy)butan-1-ol 
(192i) 
32. 2-(1-isopropyl-4-(2-nitrobenzylamino)-1H-benzo[d]imidazol-6-yloxy)butan-1-ol 
(192p) 
33. 2-(1-isopropyl-4-(3-nitrobenzylamino)-1H-benzo[d]imidazol-6-yloxy)butan-1-ol 
(192q) 
34. 4-((6-(1-hydroxybutan-2-yloxy)-1-isopropyl-1H-benzo[d]imidazol-4-
ylamino)methyl)benzoic acid (192z) 
35. 2-(4-(3-ethoxybenzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butan-1-ol 
(192y) 
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36. 2-(4-(4-tert-butylbenzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butan-1-ol 
(192z’) 
37. 2-((4-((2,5-dimethylbenzyl)amino)-1-isopropyl-1H-benzo[d]imidazol-6-
yl)oxy)butan-1-ol (193a) 
38. 2-((4-((3,5-dimethylbenzyl)amino)-1-isopropyl-1H-benzo[d]imidazol-6-
yl)oxy)butan-1-ol (193b) 
39. 2-((4-((2,4-dichlorobenzyl)amino)-1-isopropyl-1H-benzo[d]imidazol-6-yl)oxy)butan-
1-ol (193c) 
40. 2-((4-((3,5-dichlorobenzyl)amino)-1-isopropyl-1H-benzo[d]imidazol-6-yl)oxy)butan-
1-ol (193d) 
41. 2-((4-((3,5-dimethoxybenzyl)amino)-1-isopropyl-1H-benzo[d]imidazol-6-
yl)oxy)butan-1-ol hydrochloride (193d) 
42. 2-(1-isopropyl-4-(phenylamino)-1H-benzo[d]imidazol-6-yloxy)butan-1-ol (194a) 
43. 2-(4-(3-chlorophenylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butan-1-ol 
(194b) 
44. 2-(1-isopropyl-4-(3-methoxyphenylamino)-1H-benzo[d]imidazol-6-yloxy)butan-1-ol 
(194c) 
45. 2-((4-((3-(benzyloxy)phenyl)amino)-1-isopropyl-1H-benzo[d]imidazol-6-
yl)oxy)butan-1-ol (194d) 
46. 3-((6-((1-hydroxybutan-2-yl)oxy)-1-isopropyl-1H-benzo[d]imidazol-4-
yl)amino)phenol (194e) 
47. 1-isopropyl-6-methoxy-N-phenyl-1H-benzo[d]imidazol-4-amine (258) 
48. 1-cyclopentyl-6-methoxy-N-phenyl-1H-benzo[d]imidazol-4-amine (257) 
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49. 2-(1-cyclopentyl-4-(phenylamino)-1H-benzo[d]imidazol-6-yloxy)butan-1-ol (195a) 
50. 2-(4-(3-chlorophenylamino)-1-cyclopentyl-1H-benzo[d]imidazol-6-yloxy)butan-1-ol 
(195b) 
51. 2-((4-(benzylamino)-1-methyl-1H-benzo[d]imidazol-6-yl)oxy)butan-1-ol (197b) 
52. N2, N4-dibenzyl-1-isopropyl-6-methoxy-1H-benzo[d]imidazole-2,4-diamine (196a) 
53. N2, N4-dibenzyl-1-cyclopentyl-6-methoxy-1H-benzo[d]imidazole-2,4-diamine 
(196b) 
54. N,N-dibenzyl-1-isopropyl-6-methoxy-1H-benzo[d]imidazol-4-amine (222a) 
55. N-Benzyl-1-isopropyl-6-methoxy-1H-benzo[d]imidazol-4-amine (222) 
 
5.1.2 List of Novel intermediates 
1. 1-Isopropyl-6-methoxy-4-nitro-1H-benzo[d]imidazole (214) 
2. 1-Isopropyl-4-nitro-1H-benzo[d]imidazol-6-ol (226) 
3. 1-isopropyl-6-(1-methoxybutan-2-yloxy)-4-nitro-1H-benzo[d]imidazole (234b) 
4. 1-isopropyl-6-(1-methoxybutan-2-yloxy)-1H-benzo[d]imidazol-4-amine (235b) 
5. 2-(1-isopropyl-4-nitro-1H-benzo[d]imidazol-6-yloxy)ethyl benzoate (234c) 
6. 2-(4-amino-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)ethyl benzoate (235c) 
7. 2-(4-(benzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)ethyl benzoate (190c’) 
8. 1-((1-isopropyl-4-nitro-1H-benzo[d]imidazol-6-yl)oxy)butan-2-yl benzoate (234d) 
9. 1-((4-amino-1-isopropyl-1H-benzo[d]imidazol-6-yl)oxy)butan-2-yl benzoate (235d) 
10. 1-((4-(benzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yl)oxy)butan-2-yl benzoate 
(190d’) 
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11. (R)-benzyl 2-(N-(4-(benzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yl)-2,2,2-
trifluoroacetamido)propanoate (245a) 
12. (S)-methyl 2-(N-(4-(benzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yl)-2,2,2-
trifluoroacetamido)propanoate (245b) 
13. 1-Isopropyl-4-nitro-1H-benzo[d]imidazol-6-yl trifluoromethanesulfonate (227) 
14. 6-benzyl-1-isopropyl-4-nitro-1H-benzo[d]imidazole (229a) 
15. 6-benzyl-1-isopropyl-1H-benzo[d]imidazol-4-aminium chloride (230a) 
16. 6-(4-Fluorobenzyl)-1-isopropyl-4-nitro-1H-benzo[d]imidazole (229c) 
17. 6-(4-Fluorobenzyl)-1-isopropyl-1H-benzo[d]imidazol-4-amine (230c) 
18. 6-(4-Methoxy benzyl)-1-isopropyl-4-nitro-1H-benzo[d]imidazole (229b) 
19. 6-(4-Methoxybenzyl)-1-isopropyl-1H-benzo[d]imidazol-4-amine (230b) 
20. 1-Cyclopentyl-6-methoxy-4-nitro-1H-benzo[d]imidazole (219) 
21. 1-Cyclopentyl -4-nitro-1H-benzo[d]imidazol-6-ol hydrobromide (226a) 
22. 1-Cyclopentyl-4-nitro-1H-benzo[d]imidazol-6-yl trifluoromethanesulfonate (227a) 
23. 6-benzyl-1-cyclopentyl-4-nitro-1H-benzo[d]imidazole (229d) 
24. 6-benzyl-1-cyclopentyl-1H-benzo[d]imidazol-4-aminium chloride (230d) 
25. 2-(1-isopropyl-4-nitro-1H-benzo[d]imidazol-6-yloxy)butyl benzoate (246) 
26. 2-(4-amino-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butyl benzoate hydrochloride 
(248) 
27. 2-(1-isopropyl-4-(2-methylbenzylamino)-1H-benzo[d]imidazol-6-yloxy)butyl 
benzoate (249a) 
28. 2-(1-isopropyl-4-(3-methylbenzylamino)-1H-benzo[d]imidazol-6-yloxy)butyl 
benzoate (249b) 
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29. 2-(1-isopropyl-4-(4-methylbenzylamino)-1H-benzo[d]imidazol-6-yloxy)butyl 
benzoate (249c) 
30. 2-(1-isopropyl-4-(2-methoxybenzylamino)-1H-benzo[d]imidazol-6-yloxy)butyl 
benzoate (249d) 
31. 2-(1-isopropyl-4-(3-methoxybenzylamino)-1H-benzo[d]imidazol-6-yloxy)butyl 
benzoate (249e) 
32. 2-(1-isopropyl-4-(4-methoxybenzylamino)-1H-benzo[d]imidazol-6-yloxy)butyl 
benzoate (249f) 
33. 2-(4-(2-hydroxybenzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butyl 
benzoate (249g) 
34. 2-(4-(3-hydroxybenzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butyl 
benzoate (249h) 
35. 2-(4-(4-hydroxybenzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butyl 
benzoate (249i) 
36. 2-(4-(2-chlorobenzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butyl 
benzoate (249j) 
37. 2-(4-(4-chlorobenzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butyl 
benzoate (249l) 
38. 2-(4-(2-fluorobenzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butyl 
benzoate (249m) 
39. 2-(4-(3-fluorobenzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butyl 
benzoate (249n) 
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40. 2-(4-(4-fluorobenzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butyl 
benzoate (249o) 
41. 2-(4-(2-nitrobenzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butyl benzoate 
(249p) 
42. 2-(4-(3-nitrobenzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy) butyl benzoate 
(249q) 
43. 2-(4-(4-nitrobenzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butyl benzoate 
(249r) 
44. 2-(4-(2-(trifluromethyl)benzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-
yloxy)butyl benzoate (249s) 
45. 2-(4-(3-(trifluromethyl)benzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-
yloxy)butyl benzoate (249t) 
46. 2-(4-(4-(trifluromethyl)benzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-
yloxy)butyl benzoate (249u) 
47. 2-(1-isopropyl-4-(pyridin-2-ylmethylamino)-1H-benzo[d]imidazol-6-yloxy)butyl 
benzoate (249v) 
48. 2-(1-isopropyl-4-(pyridin-3-ylmethylamino)-1H-benzo[d]imidazol-6-yloxy)butyl 
benzoate (249w) 
49. 2-(1-isopropyl-4-(pyridin-4-ylmethylamino)-1H-benzo[d]imidazol-6-yloxy)butyl 
benzoate (249x) 
50. 4-((6-(1-(benzoyloxy)butan-2-yloxy)-1-isopropyl-1H-benzo[d]imidazol-4-
ylamino)methyl)benzoic acid (249z) 
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51. 2-(4-(3-ethoxybenzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butyl 
benzoate (249y) 
52. 2-(4-(4-tert-butylbenzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butyl 
benzoate (249z’) 
53. 2-((4-((2,5-dimethylbenzyl)amino)-1-isopropyl-1H-benzo[d]imidazol-6-yl)oxy)butyl 
benzoate (251a) 
54. 2-((4-((3,5-dimethylbenzyl)amino)-1-isopropyl-1H-benzo[d]imidazol-6-yl)oxy)butyl 
benzoate (251b) 
55. 2-((4-((2,4-dichlorobenzyl)amino)-1-isopropyl-1H-benzo[d]imidazol-6-yl)oxy)butyl 
benzoate (251c) 
56. 2-((4-((3,5-dichlorobenzyl)amino)-1-isopropyl-1H-benzo[d]imidazol-6-yl)oxy)butyl 
benzoate (251d) 
57. 2-((4-((3,5-dimethoxybenzyl)amino)-1-isopropyl-1H-benzo[d]imidazol-6-
yl)oxy)butyl benzoate (251e) 
58. 2-(1-cyclopentyl-4-nitro-1H-benzo[d]imidazol-6-yloxy) butyl benzoate (261) 
59. 2-(4-amino-1-cyclopentyl-1H-benzo[d]imidazol-6-yloxy)butyl benzoate 
hydrochloride (254) 
60. 1-Methyl-4-nitro-1H-benzo[d]imidazol-6-ol (259) 
61. 1-isopropyl-4-nitro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-
benzo[d]imidazole (305) 
62. (1-isopropyl-4-nitro-1H-benzo[d]imidazol-6-yl)boronic acid (306) 
63. 2-bromo-1-isopropyl-6-methoxy-4-nitro-1H-benzo[d]imidazole (307) 
64. N-benzyl-1-isopropyl-6-methoxy-4-nitro-1H-benzo[d]imidazol-2-amine (308) 
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65. N2-benzyl-1-isopropyl-6-methoxy-1H-benzo[d]imidazole-2,4-diamine 
hydrochloride(309) 
66. 2-Bromo-1-cyclopentyl-6-methoxy-4-nitro-1H-benzo[d]imidazole (310) 
67. N-benzyl-1-cyclopentyl-6-methoxy-4-nitro-1H-benzo[d]imidazol-2-amine (311) 
68. N2-benzyl-1-cyclopentyl-6-methoxy-1H-benzo[d]imidazole-2,4-diamine 
hydrochloride (312) 
69. 1-isopropyl-6-methoxy-1H-benzo[d]imidazol-4-amine (220) 
70. 1-isopropyl-6-methoxy-1H-benzo[d]imidazol-4-amine hydrochloride (220a) 
71. 1-cyclopentyl-6-methoxy-1H-benzo[d]imidazol-4-amine hydrochloride (254) 
72. 4-bromo-1-cyclopentyl-6-methoxy-1H-benzo[d]imidazole (256) 
 
5.1.3 List of partially characterized compounds in literature 
1. 6-methoxy-1-methyl-4-nitro-1H-benzo[d]imidazole (213) 
2. 5-methoxy-7-nitro-1H-benzo[d]imidazole (212) 
 
5.1.4 Crystal structure of 214 to confirm the N-1 alkylation of benzimidazole core was 
obtained by Dr. Michael Moore.  
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5.2 Aminothiazole Scaffold: 
 
5.2.1 List of novel compounds 
1. N-(5-benzylthiazol-2-yl)-2-phenylacetamide (198f) 
2. N-(5-(4-nitrobenzyl)thiazol-2-yl)-2-phenylacetamide (198i) 
3. N-(5-(4-aminobenzyl)thiazol-2-yl)-2-phenylacetamide (198l) 
4. Benzyl 4-((2-(2-phenylacetamido)thiazol-5-yl)methyl)piperidine-1-carboxylate (281) 
5. 2-phenyl-N-(5-(pyridin-3-ylmethyl)thiazol-2-yl)acetamide (198k) 
6. N-(5-isonicotinoylthiazol-2-yl)-2-phenylacetamide (289) 
 
 
5.2.2 List of novel intermediates 
1. tert-Butyl (5-(hydroxy(phenyl)methyl)thiazol-2-yl)carbamate (271a) 
2. tert-butyl (5-(hydroxy(pyridin-3-yl)methyl)thiazol-2-yl)carbamate (282a) 
3. tert-butyl (5-(hydroxy(pyridin-4-yl)methyl)thiazol-2-yl)carbamate (282b) 
4. tert-Butyl (5-(hydroxy(4-nitrophenyl)methyl)thiazol-2-yl)carbamate (271b) 
5. 5-(4-nitrobenzyl)thiazol-2-amine (272b) 
6. Benzyl 4-((2-((tert-butoxycarbonyl)amino)thiazol-5-yl)(hydroxy)methyl)piperidine-
1-carboxylate (278) 
7. Benzyl 4-((2-aminothiazol-5-yl)methyl)piperidine-1-carboxylate (279) 
8. tert-Butyl (5-isonicotinoylthiazol-2-yl)carbamate (286) 
9. (2-aminothiazol-5-yl)(pyridin-4-yl)methanone (288) 
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5.2.3 List of known but partially characterized compounds 
1. tert-Butyl thiazol-2-ylcarbamate (125) 
2. 5-benzylthiazol-2-amine (272a) 
3. 3-(pyridin-3-yl)propanal (291) 
4. 5-(pyridin-3-ylmethyl)thiazol-2-amine (283) 
5. N-methoxy-N-methylisonicotinamide (285) 
6. N-(5-cyclopentylthiazol-2-yl)-2-phenylacetamide (266) 
7. N-(5-isopropylthiazol-2-yl)-2-phenylacetamide (266a) 
8. 5-phenylthiazol-2-amine (296) 
9. 4-phenylthiazol-2-amine (133) 
10. 2-phenyl-N-(4-phenylthiazol-2-yl)acetamide (298) 
11. 2-phenyl-N-(5-phenylthiazol-2-yl)acetamide (297) 
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5.3 Diketopiperazine Scaffold 
 
5.3.1 List of partially characterized compounds 
1. (R)-methyl 2-((S)-2-((tert-butoxycarbonyl)amino)-3-methylbutanamido)-3-
phenylpropanoate (302b) 
2. (3R, 6S)-3-benzyl-6-isopropylpiperazine-2,5-dione (200b) 
3. (R)-methyl 2-((R)-2-((tert-butoxycarbonyl)amino)-3-methylbutanamido)-3-
phenylpropanoate (302c) 
4. (3R, 6R)-3-benzyl-6-isopropylpiperazine-2,5-dione (200c) 
5. (S)-methyl 2-((R)-2-((tert-butoxycarbonyl)amino)-3-methylbutanamido)-3-
phenylpropanoate (302d) 
6. (3S, 6R)-3-benzyl-6-isopropylpiperazine-2,5-dione (200d) 
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CHAPTER SEVEN 
 
Appendix 
7.1 Biological Evaluation 
The biological testing of benzimidazole series of compounds was conducted in the 
laboratory of Dr. Laurent Meijer (CNRS Station Biologique, Roscoff, France).  
Activities of CDK1, CDK2, CDK5, GSK3β, CK1, DyrK1A and ERK2 were assayed in 
25 mM Mops Buffer (pH 7.2) with 60 mM β-glycerophosphate, 5 mM EDTA, 15 mM 
MgCl2, and 1 mM DTT.1  
CDK5/p25 Assay protocol1: A brief description of the primary assay is presented below. 
The mammalian CDK5 and p25 utilized in this assay have both been cloned and stably 
co-expressed as GST (Glutathione-S-transferase) fusion proteins.  The vectors were 
developed by Dr. J. H. Wang (Harvard Medical School – Department of Pathology) and 
used with his permission. Isolation of the expressed proteins will utilize a glutathione-
agarose affinity column chromatography. Kinase activity will be assayed in 25 mM Mops 
Buffer (pH 7.2) with 60 mM β-glycerophosphate, 5 mM EGTA, 15 mM MgCl2, and 1 
mM DTT. 
The protein histone H1 (Sigma; 1 mg/mL) was used as the substrate, in the presence of 
15 µm [γ-
33
P] ATP (3,000 Ci/mmol; 1 mCi/ml) to a final volume of 30 µL. After a 10 
minute incubation period at 30 °C, 25 µL aliquots of supernatant were removed and 
spotted onto 2.5 x 3 cm pieces of Whatman P81 phosphocellulose paper. After 20 
seconds the filter paper was washed five times (for at least 5 min. each time) with a 
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solution of 10 ml phosphoric acid/liter of water. The wet filter paper was then counted in 
the presence of 1 ml ACS (Amersham) scintillation fluid to determine the degree of 
substrate phosphorylation. 
 
7.1.1 Biological Data 
Series 1: C6-O linked benzimidazole compounds2 
 
 
 
Compound 
Number R 
CDK1   
IC50(µM)  
CDK5  
IC50(µM)  
GSK3 
IC50(µM)  
CDK2A  
IC50(µM)  
CK1  
IC50(µM)  
222 
 
>10   >10   >10   >10   >10   
 190a 
 
13 13 >10   10 >10   
 190b 
 
>10   >10   >10   >10   >10   
190c 
 
>10   >10   >10   >10   >10   
190d 
 
>10   >10   >10   >10   >10   
 (R)-
roscovitine  0.45 0.16  130 0.7 2.3 
 
Series 2: C6-C benzimdazole compounds 
N
N
R
HN
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This series of compounds were inactive against CDK5/p25 assay. 
Series 3: C6-N linked benzimidazole compounds 
 
 
 
Comp. No. R CDK5/p25 (µM) 
189a (R,S)-Ethyl 23 
189b (R)-Methyl   -  
189c (S)-Methyl  - 
189d  (R)-Benzyl >100 
189e (R)-iButyl >100 
189f (S)-cHexyl >100 
 (R)-roscovitine - 0.16 
 
 
 
Series 4: N4-Benzyl  benzimdazole compounds 
 
N
N
NH
O
OH
R
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7.1.2 Dilution Curves for 192e and 192h: 
 
 
 
 
Comp. No. R CDK5/p25(µM) 
 192a 2-Me 60 
 192b 3-Me 35 
 192c 4-Me 25 
 192d 2-OMe 93 
 192e 3-OMe 24 
 192f 4-OMe 31 
 192g 2-OH Nd 
 192h 3-OH 11 
 192i 4-OH 36 
 192j 2-Cl 24 
 192k 3-Cl 22 
192l 4-Cl 33 
 192m 2-F 70 
 192n 3-F 35 
Comp. No.
 
R
 
CDK5/p25 (µM)
 
192o
 
4-F
 
70
 
192p
 
2-NO2 >10 
192q
 
3-NO2 12 
192r
 
4-NO2 >10 
192s
 
2-CF3 >10 
192t
 
3-CF3 15 
192u
 
4-CF3 22 
192v
 
2-Pyrido
 
>10
 
192w
 
3-Pyrido
 
15
 
192x
 
4-Pyrido
 
>10
 
192y
 
3-Ethoxy
 
20
 
192z
 
4-COOH
 
>10
 
192z’
 
4-t-Bu
 
>10
 
PJ-B-3-33-1 (2009/0358) CDK5 IC50 = 24µM
50
100
Ki
n
as
e 
ac
tiv
ity
 
(%
 
o
f a
v
er
ag
e 
m
ax
im
al
 
ac
tiv
ity
)
270 
 
 
 
 
 
 
 
 
 
 
 
Fig. 62 Log serial dilution curves for 192e and 192h  
Serial dilution curves (Fig. 62) obtained during the testing of 192e and 192h indicate IC50 
values of 24 µM and 11 µM against CDK5/p25 respectively.  
Compounds beloging to Series 4.2 (N4-dibenzyl substituted benzimidazoles), Series 5 
(N4-phenyl benzimidazoles), Series 6 (N2-benzimidazoles), Series 7 (N1-
benzimidazoles), Series 8 (Aminothiazoles), and Series 9 (Diketopiperazines) are 
currently undergoing biological evaluation. The results from these studies will be 
reported in future publications. 
PJ-B-3-74-1 (2009/0492) CDK5 IC50 = 11µM
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7.2 Experimental 
7.2.1 Synthesis of benzimidazole boronic acid (307) 
NO2
TfO N
N
NO2
B N
N
O
O
O
B
O
B
O
O
KOAc, Dioxane
PdCl2(dppf) CH2Cl2
MW 30 min
306, 60%227
.
N
N
NO2
BHO
HO
2 N HCl, CH3CN
23 oC, 12 h
307, ~95%
 
1-isopropyl-4-nitro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-
benzo[d]imidazole (306): A 10 mL dry microwave tube with a stir bar was charged with 
1-isopropyl-4-nitro-1H-benzo[d]imidazol-6-yl trifluoromethanesulfonate (160.0 mg, 0.45 
mmol), pinacol diborane (172.52 mg, 0.68 mmol), KOAc (133.37 mg, 1.36 mmol) and 
PdCl2(dppf)·CH2Cl2 (74.48 mg, 0.09 mmol). The microwave tube was capped with a 
rubber septum and underwent three vacuum/ N2 purge cycles. 5 mL of dioxane was 
added via syringe. The rubber septum was quickly removed and replaced with a 
microwave tube cap. The mixture was subjected to microwave irradiation at 250Watt to 
maintain a reaction temperature at 110 ºC for 0.5 h.  After cooling to 23 oC, the mixture 
was filtered through a pad of Celite. The filtrate was extracted with three 10 mL portions 
of EtOAc. The combined organic extracts were washed with three 5 mL portions of H2O, 
three 5 mL portions of NaCl (sat, aq) and dried (MgSO4). The solvent was decanted and 
evaporation of the solvent under reduced pressure gave a brown solid, which was 
subjected to silica gel column chromatography (Hex/EtOAc 1:1) to afford 90.0 mg of the 
desired product in 60% yield. Rf 0.7 (EtOH: EtOAc 1:10). MP= 172-174.5 oC. 1H NMR 
(500 MHz, CDCl3): δ 8.60 (s, 1H), 8.26 (s, 1H), 8.17 (s, 1H), 4.79 (Sept,  J = 6.63 Hz, 
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1H), 1.69 (d, J = 6.70 Hz, 6H), 1.40 (s, 12H). Anal. Calcd for C16H22BN3O4: C, 58.03; H, 
6.70; N, 12.69. Found: C, 58.14; H, 6.78; N, 12.64.   
(1-isopropyl-4-nitro-1H-benzo[d]imidazol-6-yl)boronic acid (307): 1-isopropyl-4-
nitro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzo[d]imidazole (174.0 mg, 
0.52 mmol) was dissolved in 10 mL of  acetonitrile and  10 mL of 2N HCl(aq). The 
resultant solution was stirred at 23 oC for 12 h. The reaction was monitored on TLC. 
After completion, solvent was removed in vacuo and resultant 180 mg of white solid was 
obtained. Recrystallization from hot EtOH provided 120 mg of desired compound as a 
white solid in 92 % yield. Rf 0.1 (EtOH: EtOAc 1:10). MP= 200.5-202 oC. 1H NMR (400 
MHz, DMSO-d6): δ 9.18 (s, 1H), 8.62 (s, 1H), 8.60 (s, 1H), 4.97 (td, J = 6.98 Hz, J = 
13.78 Hz, 1H), 1.61 (d, J = 6.73 Hz, 6H), 1.40 (s, 12H). Anal. Calcd for C10H12BN3O4.1.7 
% H2O. 1.0 % HCl: C, 37.70; H, 5.21; N, 13.18. Found: C, 37.70; H, 5.21; N, 13.19.   
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7.2.2 Synthesis of 196a 
Series 7: N2 Amino Benzimidazole 
N
N
NO2
O N
N
NO2
O
Br
N
N
NO2
O
NH
N
N
NH2.HCl
O
NH
N
N
NH
O
NH
LiHMDS, 0 oC
CBr4, DCM
NH2
23 oC, 2 h
H2, 50 psi, Pd/C
EtOH, CHCl3
O
NaBH(OAc)3
H
DCE, 12 h, 23 oC
214 308 309
310 196a
 
2-bromo-1-isopropyl-6-methoxy-4-nitro-1H-benzo[d]imidazole (308):  
Preparation of LiHMDS: A 20 mL oven dried vial was charged with 2.12 mL of 
hexamethyldisilane (HMDS) in 5 mL of THF. The solution was cooled to -78 oC and 5 
mL of (2.0 M, titrated) n-BuLi was added maintaining the internal temperature below -70 
oC. The reaction mixture was stirred at -78 oC for an additional 5 min. A 100 mL of oven-
dried round bottom flask was charged with 1-isopropyl-6-methoxy-4-nitro-1H-
benzo[d]imidazole (225.35 mg, 1.0 mmol) in 2 mL of THF. The mixture was stirred at -
78 °C for 15 min. A 1 M solution of LiHMDS (1.2 mL, 1.2 mmol), prepared as described 
above, was added slowly to the reaction mixture to maintain internal temperature below -
65 °C. The resulting suspension was stirred at -78 °C for another 1 h. Finally a CBr4 
(333.6 mg, 1.0 mmol) solution in 1 mL of THF was added and reaction mixture stirred at 
-78°C for an additional 1 h. After 1 h, the greenish reaction mixture was warmed up to 23 
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oC. This reaction mixture was immediately quenched with 5 mL of NH4Cl (sat, aq) and 
extracted with three 10 mL portions of EtOAc. The combined organic layers were 
washed with three 5 mL portions of NaCl (sat, aq) and dried (Na2SO4). Filtration and 
then removal of the solvent under reduced pressure provided 390 mg of an oil, which was 
directly carried onto the next step without further purification (quantitative yield). Rf 0.8 
(CH2Cl2/MeOH/NH4OH 100:10:0.1).  1H NMR (400 MHz, CDCl3): δ 7.74 (d, J = 2.31 
Hz, 1H), 7.35 (d,  J = 2.3 Hz, 1H), 5.00 (sept,  J = 7.03 Hz, 1H), 3.96  (s, 3H), 1.69 (d,  J 
= 7.02 Hz, 6H). 
 
N-benzyl-1-isopropyl-6-methoxy-4-nitro-1H-benzo[d]imidazol-2-amine (309): 
A 50 mL one neck flask was charged with 2-bromo-1-isopropyl-6-methoxy-4-nitro-1H-
benzo[d]imidazole (390 mg, 1.0 mmol) and cooled down to 0 °C. Ice cold benzylamine 
(5 mL, excess) was added to the reaction mixture at 0 °C. The resulting solution was 
stirred at 0 °C for 30 min and then warmed to 23 oC for an additional 2 h. Progress of 
reaction was followed by TLC. The reaction mixture was extracted with three 10 mL 
portions of Et2O. The combined organic extracts were washed with three 10 mL portions 
of NaCl (sat, aq) and dried (Na2SO4). Filtration and removal of the solvent in vacuo gave 
brown oil, which was subjected to silica gel column chromatography to afford 210 mg 
(61%) of a greenish solid. Recrystallization (Hex/EtOAc) provided approximately 100 
mg of a greenish solid. Rf 0.6 (CH2Cl2/MeOH/NH4OH 100:10:0.1). MP = 100.5 – 102 oC 
1H NMR (400 MHz, CDCl3): δ 7.51 (d, J = 2.31 Hz, 1H), 7.45 (d, J = 6.95 Hz, 2H), 7.39 
(m, 2H), 7.33 (m, 1H),  7.06 (d, J = 2.29 Hz, 1H), 4.84 (d, J = 5.17 Hz, 2H), 4.47 (t, J = 
5.06 Hz, 1H), 4.34 (m, 1H), 3.89 (s, 3H), 1.57 (d, J = 6.98 Hz, 6H). 
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N2-benzyl-1-isopropyl-6-methoxy-1H-benzo[d]imidazole-2,4-diamine hydrochloride 
(310): A mixture of  N-benzyl-1-isopropyl-6-methoxy-4-nitro-1H-benzo[d]imidazol-2-
amine (100 mg, 0.29 mmol), 25 mL of EtOH and 3 mL of CHCl3 was added to 15 mg of 
10% Pd/C in  Parr hydrogenation vessel. The flask was evacuated then backfilled with H2 
three times, and then shaken under 50 psi of a H2 for 5 h.  The reaction mixture was 
filtered through a pad of Celite, and then washed with an additional 10 mL of EtOH. 
Removal of the solvent in vacuo provided 220 mg of the red colored product in 
quantitative yield. Rf 0.4 (CH2Cl2/MeOH/NH4OH 100:10:0.1). The crude was carried 
onto the next step without further purification. 
 
N2, N4-dibenzyl-1-isopropyl-6-methoxy-1H-benzo[d]imidazole-2,4-diamine(196a): 
A dry round bottom flask was charged with N2-benzyl-1-isopropyl-6-methoxy-1H-
benzo[d]imidazole-2,4-diamine hydrochloride (220 mg, 0.29 mmol), NaHB(OAc)3 
(124.5 mg, 0.587 mmol), benzaldehyde (29 µL, 0.29 mmol) and 3 mL of 1,2-
dichloroethane.  This mixture was stirred at 23 oC for 12 h. After completion (TLC), the 
reaction was quenched with 5 mL of NaHCO3 (sat, aq), and extracted with three 10 mL 
portions of EtOAc.  The combined organic extracts were washed with three 10 mL 
portions of NaCl (sat, aq) and dried (Mg2SO4).  Filtration and then removal of the solvent 
under reduced pressure provided brown oil, which was subjected to silica gel flash 
column chromatography (Hex/EtOAc 2:1) to afford 50 mg of material, which was 
subjected to a second silica gel column chromatography (Hex/EtOAc 2:1) to afford 25 
mg of the brown solid in 20% yield.  Rf 0.6 (CH2Cl2/MeOH/NH4OH 100:10:0.1). MP = 
103.5 - 105 °C.  1H NMR (500 MHz, CDCl3): δ 7.43 (d, J = 7.01 Hz, 4H), 7.30 – 7.38 
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(m, 5H), 7.23 -7.26 (m, 1H), 6.21 (d, J = 1.99 Hz, 1H), 6.00 (d, J = 2.09 Hz, 1H), 5.00 
(bs, 1H), 4.66 (d, J = 4.23 Hz, 2H), 4.47 (s, 1H), 4.33 (sept,  J = 6.95 Hz, 1H), 3.96 (bs, 
1H), 3.76 (s, 3H), 1.557 (d, J = 6.96 Hz, 6H). Anal. Calcd for C25H28N4O. 0.36 % H2O: 
C, 73.75; H, 7.11; N, 13.76.  Found: C, 73.81; H, 7.03; N, 13.45. 
 
7.2.3: Synthesis of 196a' 
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2-Bromo-1-cyclopentyl-6-methoxy-4-nitro-1H-benzo[d]imidazole (311):  
Preparation of LiHMDS: A 20 mL oven dried vial was charged with 2.12 mL of 
hexamethyldisilane (HMDS) in 5 mL of THF. This solution was cooled to -78 oC and 5 
mL of n-BuLi (2.0 M, titrated) was added maintaining the internal temperature below -70 
oC. The reaction mixture was stirred at -78 oC for an additional 5 min. A 50 mL of oven-
dried round-bottom flask was charged with 1-cyclopentyl-6-methoxy-4-nitro-1H-
benzo[d]imidazole (100 mg, 0.38 mmol) and 1 mL of THF under an Ar atmosphere. The 
mixture was stirred at -78 °C for 15 min. A 1 M solution of LiHMDS (0.41 mL, 0.41 
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mmol), prepared as described above, was added slowly to the reaction mixture to 
maintain an internal temperature below -65 °C. The resulting brown suspension was 
stirred at -78 °C for an additional 1 h. Then CBr4 (126 mg, 0.38 mmol) solution in 1 mL 
of THF was added and reaction mixture stirred at -78 °C for an additional 1 h. The 
resultant greenish reaction mixture was permitted to warm to 23 oC.  After reaching 23 
oC, the reaction mixture was immediately quenched with 5 mL of NH4Cl (sat, aq) and 
extracted three 10 mL portions of EtOAc. The combined organic layers were washed 
with three 5 mL portions of NaCl (sat, aq) and dried (Na2SO4). Evaporation of solvent 
provided a 170 mg of brown oil (quantitative yield), which was directly carried onto the 
next step without further purification. Rf 0.8 (CH2Cl2/MeOH/NH4OH 100:10:0.1).  1H 
NMR (500 MHz, CDCl3): δ 7.74 (d, J = 2.32 Hz, 1H), 7. 24 (d, J = 2.30 Hz, 1H), 5.10 (p, 
J = 8.99 Hz, 1H), 3.96 (s, 3H),  2.15 - 2.25 (m, 4H),  2.03-2.10 (m, 2H), 1.82-1.90 (m, 
2H). 
 
N-benzyl-1-cyclopentyl-6-methoxy-4-nitro-1H-benzo[d]imidazol-2-amine (312): 
In a 50 mL one neck flask, 2-bromo-1-cyclopentyl-6-methoxy-4-nitro-1H-
benzo[d]imidazole (170 mg, 0.38 mmol) was cooled down to 0 °C. A 10 mL portion of 
benzylamine (excess) chilled to 0 oC and was added to the reaction mixture at 0 °C. The 
resulting solution was stirred at 0 °C for 30 min, and then warmed to 23 oC for another 3 
h. Progression of reaction was judged by TLC. The reaction mixture was then diluted 
with 10 mL of H2O and extracted in three 10 mL portions of EtOAc. The combined 
organic extracts were washed with three 5 mL portions of NaCl (sat, aq) and dried 
(Na2SO4). Filtration and removal of the solvent under reduced pressure gave brown oil 
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(220 mg), which was subjected to silica gel column chromatography twice to afford 60 
mg of the product. Recrystallization from Hex/EtOAc provided 50 mg of orange crystals 
in 35% yield. Rf 0.5 (CH2Cl2/MeOH/NH4OH 100:10:0.1).  MP 156.2-157 °C.  1H NMR 
(500 MHz, CDCl3): δ 7.54 (d, J = 2.28 Hz, 1H), 7.47 (d, J = 7.04 Hz, 2H), 7.41 (t, J = 
7.04 Hz, 2H), 7.36 (t, J = 7.26 Hz, 1H), 7.00 (d, J = 2.31 Hz, 1H), 4.87 (d, J = 5.24 Hz, 
2H), 4.5 (m, 1H), 4.45 (td, J = 8.81 Hz, J = 17.59 Hz, 1H), 3.91 (s, 3H), 2.09 - 2.15 (m, 
4H), 1.94-2.02 (m, 2H), 1.75-1.82 (m, 2H). Anal. Calcd for C20H22N4O3: C, 65.56; H, 
6.05; N, 15.29.  Found: C, 65.81; H, 5.75; N, 14.98. 
 
N2-benzyl-1-cyclopentyl-6-methoxy-1H-benzo[d]imidazole-2,4-diamine 
hydrochloride (313): N-benzyl-1-cyclopentyl-6-methoxy-4-nitro-1H-benzo[d]imidazol-
2-amine (40 mg, 0.10 mmol) was dissolved into 10 mL of EtOH and 1 mL of CHCl3 and  
added to a Parr hydrogenation flask with 10 mg of 10% Pd/C.  The hydrogenation flask 
was evacuated and then backfilled with H2 three times, and then shaken under 52 psi of a 
H2 for 5 h.  The mixture was filtered through a pad of Celite, and the pad was washed 
with an additional 10 mL of EtOH. The filtrate was collected and removal of the solvent 
in vacuo provided 30 mg of a red solid in quantitative yield.  The crude was carried to the 
next step without further purification. 
N2, N4-dibenzyl-1-cyclopentyl-6-methoxy-1H-benzo[d]imidazole-2,4-diamine (196a') 
A dry round bottom flask was charged N2-benzyl-1- cyclopentyl -6-methoxy-1H-
benzo[d]imidazole-2,4-diamine hydrochloride (30 mg, 0.10 mmol), NaHB(OAc)3 (46.2 
mg, 0.218 mmol), benzaldehyde (11 µL, 0.10 mmol) and 2 mL of 1,2-dichloroethane.  
The mixture was stirred at 23 oC for 12 h.  After completion (TLC), the reaction was 
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quenched with 5 mL of NaHCO3 (sat, aq), and extracted with three 10 mL portions of 
EtOAc.  The combined organic extracts were washed with three 10 mL portions of NaCl 
(sat, aq) and dried (MgSO4).  Filtration and removal of the solvent in vacuo provided 
brown oil, which was subjected to silica gel flash column chromatography (Hex/EtOAc 
2:1) to afford 12 mg of yellow solid in 28 % yield. Rf 0.65 (CH2Cl2/MeOH/NH4OH 
100:10:0.1).  MP = 93-95 °C. 1H NMR (500 MHz, CDCl3): δ 7.46 (m, 4H), 7.30-7.40 (m, 
5H), 7.25 (m, 1H), 6.18 (d, J = 2.12 Hz, 1H), 6.03 (d, J = 2.12 Hz, 1H), 5.05 (bs, 1H), 
4.67 (d, J = 5.63 Hz, 2H), 4.49 (s, 2H), 4.45 (m, 1H), 3.96 (t, J = 5.75 Hz, 1H), 3.78 (s, 
3H), 2.12 - 2.20 (m, 2H), 2.00-2.09 (m, 2H), 1.90-2.00 (m, 2H), 1.70-1.80 (m, 2H). Anal. 
Calcd for C27H30N4O.0.14 % EtOAc: C, 75.41; H, 7.14; N, 12.76.  Found: C, 75.50; H, 
6.98; N, 12.59. 
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7.3 MacMillan Catalyst (322)3 
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MacMillan reagent 322 was synthesized using the reported synthetic procedure to 
synthesize the desired compound in a gram scale.  
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7.4 Molecular Modeling and Computational Studies 
The X-ray crystal structure of CDK5/p25 at 2.20Å resolution was obtained from the 
protein database (PDB ID 1UNL)4. This crystal structure contains CDK5/p25 in complex 
with a (R)-roscovitine. Docking studies were performed using the docking suite of 
Molecular Operating Environment software (MOE 2008.10)5. After addition of hydrogen 
atoms, the protein was then “prepared” using the LigX function in MOE. LigX is a 
graphical interface and collection of procedures for conducting interactive ligand 
modification and energy minimization in the active site of a flexible receptor. In LigX 
calculations, the enzyme atoms far from the ligand are constrained and not allowed to 
move while enzyme atoms in the active site of the protein are allowed to move. This 
procedure was performed with the default settings. Ligands were built using the molecule 
builder function in MOE and were energy minimized to its local minima using the 
MMF94X forcefield to a constant energy variation of 0.05 kcal/mol. Ligands were 
docked into the ATP binding site of the prepared protein using the docking suite as 
implemented in MOE. The docking was restricted to the active site pocket residues using 
alpha triangle placement method. Refinement of the docked poses was carried out using 
the Forcefield refinement scheme and scored using Affinity dG scoring system.  Atleast 
30 poses were returned for each compound at the end of each docking run. The docked 
poses were manually examined in the binding pocket to ensure quality of docking and to 
confirm absence of steric clashes with the amino acid residues of the binding pocket.  
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The selection of compounds was based on the following criteria: 1) Reasonable binding 
conformation; this was analyzed by conformational analysis of the ligand free from the 
enzyme and analysis of strain energy as a function of dihedral angle. 2) Reasonable 
interaction (both polar and non-polar) with the enzyme surface. These compounds were 
scored with a published principal component scoring algorithm developed by the Madura 
lab. 3) Uniqueness of structure. These compounds were clustered into families. 4) The 
possibility of reasonable pharmacokinetic properties.  
 
7.4.1 Molecular modeling studies for 4-phenyl benzimidazole series: In order to assay 
the ribose binding pocket with new ligands derived from purvalanol, a computer-assisted 
analog design approach was selected. The CDK2/cyclin A/ purvalanol B trimeric 
structure was obtained (PDB ID 1CKP).6 The purvalanol A structure was energy 
minimized, aligned with the reported ligand and docked in crystal structure of 
CDK2/cyclin A (1CKP) using MOE 2008.10. In a parallel manner the designed ligands 
were energy minimized and docked using MOE 2008.10 into the putative ATP binding 
site on the X-ray crystal structure of CDK5/p25/roscovitne (1UNL). The receptor/ ligand 
complex was brought to an overall local energy minimum retaining the backbone 
conformation of 1UNL using the above described method. Ligands were inspected for 
reasonable interactions with the enzyme surface. 
  
283 
 
 
 
 
 
 
 
Fig 63 Crystal structure of CDK2/cyclin A  bound with ligand in the ATP site (1CKP) 
 
      
Fig 64: Purvalanol A docked into the structure of CDK5/p25 (Based on 1UNL) 
 
N
N
NH
N
N
Ligand
Cl
N
N
NH
N
N
Purvalanol A
Cl
N
H
OH
284 
     
Fig 65: Benzimidazole analog 194b docked in to the structure of CDK5/p25 
  
NH
N
N
194b
Cl
O
OH
285 
References for Appendix: 
 (1) Patrick, G. N.; Zukerberg, L.; Nikolic, M.; de la Monte, S.; Dikkes, P.; Tsai, L.-H. 
Nature 1999, 402, 615. 
 (2) Jain, P.; Flaherty, P. T.; Yi, S.; Chopra, I.; Bleasdell, G.; Lipay, J.; Ferandin, Y.; 
Meijer, L.; Madura, J. D. Bioorg Med Chem 2011, 19, 359. 
 (3) Graham, T. H.; Horning, B. D.; MacMillan, D. W. C. Org. Synth. 2011, 88, 42  
 (4) Mapelli, M.; Massimiliano, L.; Crovace, C.; Seeliger, M. A.; Tsai, L. H.; Meijer, 
L.; Musacchio, A. J Med Chem 2005, 48, 671. 
 (5) MOE; 2008.2011 ed.; Chemical Computing Group Inc.: Montreal, Quebec, 
Canada, 2008.2011. 
 (6) Gray, N. S.; Wodicka, L.; Thunnissen, A. M.; Norman, T. C.; Kwon, S.; 
Espinoza, F. H.; Morgan, D. O.; Barnes, G.; LeClerc, S.; Meijer, L.; Kim, S. H.; 
Lockhart, D. J.; Schultz, P. G. Science 1998, 281, 533. 
 
 
 
 
